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Abstract 
 
Polyketides are chemically diverse bioactive natural products that often harbor desirable 
therapeutic characteristics. As such, the biological machinery used to synthesize these 
compounds are valuable targets for metabolic and protein engineering studies. A key 
characteristic of polyketide synthase (PKS) catalysis is the selective installation of many stereo- 
and regiocenters. To reach the full potential of PKS as a source of novel therapeutics and 
commodity chemicals, a molecular understanding of selective filters of each catalytic domain 
must be established. This thesis investigates the stereospecificity and regioselectivity of 
dehydratase (DH) domains from the pikromycin, curacin A, tylosin and gephyronic acid PKS 
pathways using a combination of biochemical assays and x-ray crystallography. These 
experiments establish new roles for PKS DH domains as stereoselective filters for substrate 
chiral centers distal from the site of catalysis, uncover previously unobserved dehydration 
consistent with vinylogous elimination, and establish the molecular basis for secondary 
isomerization. Results from these experiments facilitated the design of a novel DH/isomerase 
from an isomerase-inactive DH from the curacin A pathway, representing the first successful 
gain-of-function engineering of a PKS DH domain. 
Fatty acid biosynthesis is a cornerstone of metabolism in cells. Fatty acids are involved in 
energy storage and production, membrane construction, temperature response, and biosynthesis 
of many secondary metabolites. An enigmatic facet of fatty acid biosynthesis in E. coli is the 
presence of two functionally distinct DHs, FabA and FabZ. FabA catalyzes a secondary 
isomerization reaction that is the source of all unsaturated fatty acids in E. coli, while FabZ 
 xxi 
harbors only dehydratase function. This thesis establishes the molecular basis for the puzzling 
functional discrepancies between FabA and FabZ using functional crosslinking technology, x-ray 
crystallography, and molecular dynamics (MD) simulations. A high-resolution crystal structure 
of FabZ in complex with six AcpP subunits loaded with a C6 substrate was determined. This 
model facilitated MD simulations that demonstrated differential substrate preferences in 
agreement with published biochemical data, as well as differences in preferred substrate binding 
geometry such that FabZ catalyzes dehydration only whereas FabA can catalyze dehydration and 
subsequent isomerization. 
The data presented in this thesis further our understanding of PKS and will aid in future 
experiments to capitalize on the promise of PKS as a biological machine for the synthesis of 
designer polyketides and commodity chemicals. The results the from E. coli fatty acid synthase 
experiments answer a decades old mechanistic question and may facilitate efforts to develop 
antibiotics specific to bacterial fatty acid synthase. 
 
 1 
Chapter 1. Introduction 
 
Natural products and fatty acids 
Natural products represent a broad array of biologically synthesized molecules, ranging 
from relatively simple alkyl esters and acids to chemically complex compounds such as 
polyketides and non-ribosomal peptides. Fatty acids are an essential metabolite for all life1-2, 7, 
and their biosynthesis is closely related to that of polyketides. The producing organisms 
synthesize these polyketides and fatty acids for purposes as diverse as the chemistry of the 
compounds themselves, including cell membrane homeostasis, signaling, and biological warfare. 
As 65% of FDA-approved small molecule therapeutics are in some way derived from natural 
products, these have significant clinical relevance. In addition to understanding the 
pharmacological properties of natural products, much work has been done to characterize the 
biosynthetic machinery that generates these compounds8. 
Natural product and fatty acid biosynthesis 
A theme amongst many natural product biosynthesis pathways is the use of common 
cellular metabolites such as acyl-CoAs or amino acids as building blocks. By varying the order 
of building block addition and modification, the producing organisms achieve a staggering level 
of chemical diversity from otherwise simple starting materials. Even with modern methods, 
many natural products remain out of reach of total synthesis. In the case of polyketide natural 
products, the linear architecture and assembly-line logic of the biosynthetic pathways has led to 
 2 
the hypothesis that pathway engineering efforts may be a viable alternative to total synthesis to 
access novel natural products, or to generate useful commodity chemicals1. 
PKS and FAS share many of the same chemical steps, and both covalently attach their 
nascent products to small carrier proteins10-11.  However, there are considerable differences 
between the bacterial and metazoan FAS reactions, most specifically in the generation of 
unsaturated fatty acids4. In order to maintain membrane fluidity, organisms must adjust the ratio 
of saturated to unsaturated fatty acids in response to their environment. While higher eukaryotes 
synthesize unsaturated fatty acids via dedicated desaturases12, bacteria such as E. coli create 
unsaturation during fatty acid biosynthesis13. The distinctions between these two schemes have 
led to the hypothesis that bacterial fatty acid biosynthesis may represent a viable antibiotic 
target6, 14.  
Thus, a mechanistic and molecular understanding of the machinery responsible for the 
biosynthesis of natural products and fatty acids represents a goal of great importance for 
medicinal chemistry, microbiology, and metabolic engineering. 
Type II FAS mechanism 
Fatty acid biosynthesis remains one or the best understood pathways in primary 
metabolism. Significant effort has been made in the past few decades in characterizing the 
molecular machines involved in the biosynthesis of fatty acids both biochemically and 
structurally. Fatty acids are universally generated from acetyl- and malonyl- CoA (Fig. 1.1). All 
intermediates are tethered to a small highly acidic acyl carrier protein (ACP) that adopts a 4-
helix bundle structure. The ACP and nascent fatty acid are linked via a 4`-phosphopantetheine 
(Ppant) moiety that is attached via a phosphoester linkage to a conserved serine on the ACP. In 
E. coli FAS, the ACP (AcpP) is initially charged with a malonyl starter unit by malonyl-
 3 
CoA:ACP transacylase (FabD). Once charged, the ACP must interact with each of the catalytic 
domains of fatty acid synthase (FAS) to successfully generate a product.   
The first step in the elongation of a fatty acid is catalyzed by the 3-ketoacyl-ACP synthase (KS). 
The KS extends the fatty acid via a decarboxylative Claisen condensation between the acyl 
moiety from ACP and an acetyl group, forming a 3-ketoacyl-ACP product, which serves as the 
substrate for the subsequent reactions to reduce the 3-ketoacyl-ACP to its fully saturated form. 
An NADPH-dependent ketoreductase (KR) converts 3-ketoacyl-ACP to 3-hydroxyacyl-ACP, a 
dehydratase (DH) converts 3-hydroxyacyl-ACP to trans-2,3-enoyl-ACP via a β-elimination of 
the 3-hydroxy group as water, and finally an NADPH-dependent enyolreductase (ER) reduces 
the trans-2,3-enoyl-ACP to a fully saturated acyl-ACP. This cycle continues until the fatty acid 
Each cycle of catalysis utilizes a malonyl extender unit to grow the nascent fatty acid by two carbons via a Claisen 
condensation reaction at the KS. The KR then reduces the 3-ketoacyl-ACP to a 3-hydroxyacyl-ACP, the DH 
eliminates the 3-hydroxyl group as water, forming a 2,3-enoyl-ACP, and finally the ER reduces the 2,3-enoyl-ACP 
to its fully saturated alkane form. This cycle continues until the fatty acid reaches a C16 or C18 length. 
 
 
 
Figure 1.1 The FAS catalytic cycle 
 4 
reaches a C16 or C18 length, at which point a thioesterase (TE) will cleave the mature fatty acid, 
which will be utilized elsewhere in the cell such as for the biosynthesis of phospholipids.  
Biosynthesis of unsaturated fatty acids 
In E. coli, unsaturated fatty acids are synthesized via a branchpoint in the catalytic 
cycle15. A specific DH (FabA) harbors a secondary isomerization function, in which the typical 
trans-2,3-enyol-ACP is converted to cis-3,4-enoyl-ACP. Interestingly, this activity occurs only 
for acyl-ACPs of C10 chain length16. This cis unsaturated intermediate cannot be processed by 
the ER (FabI), or the normal KS (FabB) for another round of extension. Instead, a secondary KS 
(FabB) is used to extend the monounsaturated C10 intermediate, which can then undergo further 
rounds of reduction and extension until reaching a final C16 or C18 length. 
Type I polyketide synthase 
While the catalytic domains of FAS are conserved across all branches of life, their 
arrangement differs. Bacteria, such as E. coli, encode each enzyme in a separate gene, as well as 
the ACP, as a discrete soluble unit– this is referred to as a Type II system. In metazoan FAS, the 
entire set of elongation and reduction domains along with the ACP are domains within a single 
monolithic polypeptide – referred to as a Type I system. Type I FAS and Type I modular 
polyketide synthase (PKS) share many of the same catalytic domains, are similar in that all of 
their catalytic machines reside within a single polypeptide, and likely share a common ancestor 
(Fig. 1.2).  
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Type I polyketide synthase mechanism 
The strategy used by FAS is highly efficient at generating saturated and monounsaturated 
carbon chains around C16 in length, but the iterative biosynthetic logic, single starter acyl unit, 
and limited set of reductive domains is poorly suited to attain the chemical diversity found in the 
polyketide family of natural products. Type I modular PKS are able to access more diverse 
chemistry than FAS by establishing slightly different catalytic rules (Figs. 1.2, 1.3). The 
biosynthetic pathway is modular, with each module containing a unique set of elongation and 
modification domains, which each act only once. A module ACP carries the intermediate 
between domains, and hands off the product of one module to the KS of the next module in the 
pathway. In addition to this assembly-line style catalysis, Type I modular PKS may contain extra 
The modular AT first loads module 2 ACP with a malonyl acyl unit. The ACP then travels to the KS domain, where the 
polyketide intermediate from module 1 has been delivered by ACP1. The KS then catalyzes a decarboxylative Claisen 
condensation, extending the polyketide chain by two carbons and eliminating CO2. Next, the ACP travels to the C-MT, 
where a methyl group at the C2 position is installed using the methyl donor SAM as a cofactor. The ACP then moves to 
the KR domain, which reduces the C3 keto group to a hydroxyl with an NADPH cofactor. Finally, the ACP visits the 
DH, where the C3 hydroxyl is eliminated as water, generating an (S,E)-2,4,6-trimethylhepta-2,5-dienoyl-ACP. This 
intermediate is then passed on to module 4. 
Figure 1.3 Catalytic cycle of GphF module 2 
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catalytic domains, such as O- and C-methyltransferases (OMT, CMT), and may be coupled with 
non-PKS enzymes, such as non-ribosomal peptide synthetase (NRPS) modules.  
Stereochemistry in polyketides 
An additional feature that differentiates polyketides from fatty acids are chiral centers. In 
FAS, each chiral hydroxyl is reduced to either an olefin or alkane. A PKS module may install a 
variety of stereocenters that will remain through biosynthesis of a natural product, depending on 
the composition of the module’s catalytic domains. Of note are the hydroxyl modifications 
installed by the PKS KR domains. This step is the first in which an intermediate gains chirality, 
generating either a (3R)- or (3S)-hydroxyacyl-ACP from an achiral 3-ketoacyl-ACP substrate. 
Interestingly, sequence motifs distinguish KRs that produce (R)-hydroxyacyl-ACP from those 
that produce (S)-hydroxyacyl-ACP. These motifs have been used to classify A-type KRs as those 
which generate (S)-hydroxyacyl-ACP and B-type KRs as those which generate (R)-hydroxyacyl-
ACP. Any modification domains that act after the KR are directly impacted by the 
stereochemistry of the hydroxyl group.  
DH mechanism and structure 
In general, both FAS and PKS DHs utilize a conserved His-Asp dyad to catalyze a syn-β-
elimination reaction, at the substrate C3-hydroxyl to form an (E)-2,3-olefin (Fig. 1.3A). DHs are 
the first domains within a PKS/FAS that are presented with chiral substrate, adding an extra layer 
of complexity to the molecular clockwork of PKS and FAS. Not only must a DH select the 
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proper substrate stereocenter, but it also must select the proper regiochemistry of the resultant 
olefin. In modules lacking an ER, the olefin DH product will be retained through subsequent 
elongation and modification reactions, altering both the chemical characteristics and potential 
bioactivities of the natural product. Although the stereospecificity of PKS KR domains can be 
inferred from their sequences, no such motifs exist in DHs. While the structures of several PKS 
DHs have been solved27, 32-33 (Fig. 1.3B), each exhibiting a canonical double-hotdog fold in 
which a “bun” of β-strands wraps around two central α-helical “hotdogs”. The overall structures 
of these DHs are quite similar (RMSD ~2Å) and, taken alone, reveal little regarding substrate 
specificity or product selectivity. As generating authentic substrate mimics synthetically remains 
A 
B 
A. The catalytic mechanism of dehydration by PKS and FAS DH domains. The catalytic His deprotonates at 
C2, causing the Asp to act as a proton donor in the elimination of the C3 hydroxyl as water. B. The structures 
of several PKS DHs and native substrates, substrate binding pockets shown as transparent surface, binding 
pocket entrances indicated with arrows, catalytic residues shown in ball-and-stick. This comparison highlights 
the overall structural similarity of these domains, even though their substrates and binding pockets are quite 
different. PDBids 3EL6, 3KG7, 3KG8, 3KG9. 
Figure 1.4 Mechanism and structure of PKS DHs 
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challenging, the stereospecificity of DHs is a poorly explored area, leaving a critical gap in the 
understanding of the molecular processing of PKS.  
Cis and trans unsaturation in polyketides 
There are examples of both cis and trans unsaturated polyketides generated from modules 
which contain DHs. Initially, the regiochemistry of the unsaturated product of a DH was 
hypothesized to be correlated to the stereochemistry of the hydroxyl substrate4. (R)-hydroxy 
substrates (generated by a B-type KR) were associated with trans-unsaturated DH products, 
while (S)-hydroxy substrates (generated by an A-type KR) were associated with cis-unsaturated 
DH products. This classification has fallen out of favor as more PKS pathways have been 
sequenced and annotated, as many do not fit this model40-41.  
Olefin rearrangement by PKS and FAS DHs 
Of the DHs characterized to date, several have been shown to catalyze secondary 
reactions. A recently reported DH from the ambruticin biosynthetic pathway (AmbDH4) was 
shown to harbor secondary isomerization functionality in addition to the standard dehydration 
function43 (Fig. 1.5). Several other annotated PKS modules seem to generate 3,4-enoyl (odd-to-
even) intermediates as opposed to the usual 2,3-enoyl (even-to-odd) intermediates – often in 
The His-Asp dyad are required for both reactions. The initial dehydrated intermediate contains an (E)-2,3-olefin, while 
the final product contains a (Z)-3,4-olefin. The molecular basis for this secondary function remains unclear. 
Figure 1.5 Sequential dehydration and isomerization by FabA 
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modules containing a DH40, 44-45, and many polyketides whose pathways have not been annotated 
contain odd-to-even olefins. There are no reported structures of DHs harboring secondary 
isomerization, and although the ambruticin DH/isomerase has been characterized biochemically, 
the molecular basis for secondary function is poorly understood. In E. coli FAS, FabA exhibits 
secondary isomerization functionality after dehydration, generating a cis-3,4-enoyl-ACP (Figs. 
1.5, 1.6). The molecular basis for the dual FabA dehydration and isomerization activity, and the 
FabZ can only dehydration only activity has remained an enigma for decades.  
  
Cyclization by PKS DHs 
Some DHs have been shown catalyze secondary reactions beyond olefin rearrangement. 
Another DH from the ambruticin biosynthetic pathway (AmbDH3) was recently reported to 
catalyze the formation of a tetrahydropyran moiety from the 2,3-enoyl intermediate of 
Figure 1.6 The reaction courses of characterized multifunctional 
DHs from PKS and FAS 
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dehydration1(Fig. 1.6). In the structure of this DH, an amino acid adjacent to the catalytic His-
Asp dyad was implicated (V173) in the secondary pyran cyclase function. In typical PKS DHs, 
this position is occupied by a well conserved Tyr. Mutagenesis experiments demonstrated that 
when V173 was substituted by a Tyr, cyclization activity was lost, while dehydration remained 
unchanged. These experiments hint that secondary functionality in PKS DHs may derive from 
subtle alterations to the substrate binding pocket, which are not immediately obvious at the 
sequence level.  
Epimerization by PKS DHs 
Another secondary function that has been attributed to DHs is methyl epimerization. As 
mentioned above, AmbDH4 has been shown to epimerize the C4 position of its substrate during 
catalysis (Fig 1.6). Additionally, “orphan” DHs are found in some modules with KR domains 
predicted to be redox-inactive3-4. Of these, both NanDH1 and NanDH5 from the nanchangmycin 
biosynthetic pathway were shown to harbor cryptic epimerase activity of C2-methyl groups on 
truncated substrate mimics. A more intriguing result from these studies showed the EryDH4 
from the erythromycin biosynthetic pathway and NanDH2 from nanchangmycin biosynthesis, 
two DHs found in modules with active KRs, also exhibited C2-methyl epimerase activity. The 
structure of EryDH4 is known, but there are no distinguishing features in the active site that 
explain this unexpected C2 epimerase function.  
 
ACP-DH interactions in PKS and FAS 
In addition to understanding the stereoselectivity and regiospecificity of DHs, 
characterization of ACP-DH interactions is a critically underexplored area in both PKS and FAS. 
These experiments pose significant technical challenges due to the transient nature of the ACP – 
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DH interaction, along with difficulties designing 
minimal systems suitable for assay. While the ACP and 
DH must interact, the ACP is only a carrier for the real 
substrate – the hydroxylated nascent polyketide or fatty 
acid. Thus, a truly native complex will likely be 
dependent not only on protein-protein interactions, but 
also protein-substrate interactions between the DH and 
the hydroxyacyl-Ppant. Recent advancements in 
synthetic probe design have led to the development of 
mechanistic crosslinking compounds that can be loaded 
directly onto ACP, facilitating the trapping of a complex 
representative of that formed during fatty acid 
biosynthesis.  
The crosslinking probes were used to trap a stable 1:1 complex of AcpP and FabA from 
E. coli FAS (AcpP=FabA), facilitating the determination of the crystal structure of the complex 
at atomic resolution7-8 (Fig. 1.7). These studies gave critical insight into the binding mode of 
AcpP with a FAS catalytic domain, but in the absence of a complementary structure of the AcpP-
FabZ complex, it remains unclear what drives the distinct mechanistic differences between these 
two FAS DHs. 
 
 
FabA shown in pale and dark green, AcpP 
shown in magenta. Crosslinking probe and 
catalytic His-Asp dyad shown as sticks. 
PDBid 4KEH 
Figure 1.7 Crystal structure of the 
crosslinked AcpP=FabA complex solved 
to 1.9-Å 
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Thesis overview 
This thesis further establishes the molecular basis of catalysis, stereospecificity, regioselectivity, 
and non-canonical function of DH domains in PKS. DHs from the pikyromycin, tylosin, curacin, 
and gephryonic acid PKS pathways are studied by mass spectrometry-based assays and x-ray 
crystallography. Libraries of chiral substrate mimics established previously unknown sensitivity 
to the chirality of positions distal from the C3 site of elimination in the pikromycin and tylosin 
systems. Studies on DHs from the curacin A pathway uncover an unusual C5 dehydration 
consistent with vinylogous elimination by the CurH and CurJ DHs and facilitated the trapping of 
a substrate fragment in the CurJ DH, visualized in a crystal structure. Biochemical and structural 
studies of GphF DH1 from the gephryonic acid pathway elucidated the molecular requirements 
for secondary isomerization function in PKS DHs. The results from the GphF DH1 experiments 
facilitated the rational engineering of a dual function dehydratase-isomerase from the isomerase-
inactive CurK DH – the first successful gain-of-function engineering experiment of a PKS DH.  
 This thesis also investigates the protein-protein interactions between the E. coli FAS DH 
FabZ and its carrier protein AcpP. A novel fusion construct was designed to generate milligram 
quantities of FabZ, a previously insoluble protein. In combination with an optimized crosslinking 
protocol, a stable 1:1 complex of AcpP=FabZ facilitated crystallization. A high-resolution crystal 
structure of the complex served as the foundation for molecular dynamics simulations that 
identified key differences in the preferred conformations of a variety of substrates in FabA and 
FabZ. Taken together, the results for the first time establish the molecular differences between 
FabA and FabZ catalysis that lead to the FabA secondary isomerization function. 
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Chapter 2. Functional characterization of a dehydratase domain from the pikromycin 
polyketide synthase 
 
This chapter is published: Li, Y., Dodge, G. J., Fiers, W. D., Fecik, R. A., Smith, J. L., & 
Aldrich, C. C. Functional characterization of a dehydratase domain from the pikromycin 
polyketide synthase. J Am Chem Soc 137, 7003-7006 (2015). 
Summary 
Metabolic engineering of polyketide synthase (PKS) pathways represents a promising 
approach to natural products discovery. The dehydratase (DH) domains of PKSs, which generate 
an α,β-unsaturated bond through a dehydration reaction, have been poorly studied compared to 
other domains, likely due to the simple nature of the chemical reaction they catalyze and lack of 
a convenient assay to measure substrate turnover. Herein we report the first steady-state kinetic 
analysis of a PKS DH domain employing LC-MS/MS analysis for product quantitation. PikDH2 
was selected as a model DH domain. Its substrate specificity and mechanism were interrogated 
with a systematic series of synthetic triketide substrates containing a nonhydrolyzable thioether 
linkage as well as by site-directed mutagenesis, evaluation of the pH dependence of catalytic 
efficiency (Vmax/KM), and through kinetic characterization of a mechanism-based inhibitor. These 
studies revealed PikDH2 converts d-alcohol substrates to trans-olefin products. The reaction was 
reversible with equilibrium constants ranging from 1.2–2. Moreover, the enzyme activity was 
robust and PikDH2 was used on a preparative scale for the chemoenzymatic synthesis of 
unsaturated triketide products. PikDH2 was shown to possess remarkably strict substrate 
specificity and was unable to turnover substrates epimeric at the β, γ or δ-positions. We also 
demonstrated PikDH2 has a key ionizable group with a pKa of 7.0 and can be irreversibly 
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inactivated through covalent modification by a mechanism-based inhibitor, which provides a 
foundation for future structural studies to elucidate substrate–protein interactions. 
 
 
Introduction 
Polyketides derived from modular type I polyketide synthases (PKSs) have drawn 
enormous attention and interest from chemists for decades due to their intricate structures, 
stereochemical complexity and diverse pharmacological activities. Sharing the same 
evolutionary history with fatty acid synthases (FASs)1-2, modular type I PKSs employ similar 
assembly-line molecular machinery wherein the chain intermediates remain covalently attached 
to acyl carrier protein (ACP) domains during biosynthesis. Unlike FASs, the presence of the 
three processing domains in PKSs: ketoreductase (KR), dehydratase (DH) and enoylreductase 
(ER), are varied in each module, leading to a fully reduced, partially reduced or unreduced 
segment on the polyketide chain. Owing to its assembly-line attribute and varying combination 
of processing domains, PKSs have been exploited through combinatorial biosynthesis and 
metabolic engineering to provide large libraries of polyketide analogs3-5.  
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Many polyketides such as the archetypical macrolide antibiotic pikromycin, the 
antifungal polyene amphotericin B, the linear polyketide discodermolide, and the mixed 
nonribosomal peptide-polyketide curacin, contain one or more double bonds that serve as 
conformational constraints and are essential for biological activity (Figure 2.1)6-7. The double 
bonds are formed by DH domains through abstraction of the α-proton and concomitant 
protonation of the β-hydroxyl group of the nascent β-hydroxyacyl-ACP polyketide intermediate, 
resulting in loss of one water molecule. As observed in FAS DHs, the characteristic double 
hotdog fold is also found in PKS DHs to form the active site with two catalytic residues, aspartic 
acid and histidine8-12. The olefin geometry of DH products cannot be predicted through a 
signature fingerprint as in the KRs13 since the active site residues appear quite similar in both cis- 
and trans-olefin generating DHs11,14. Initial evidence suggested the geometry of a double bond 
was exclusively dependent on the stereochemistry of the DH substrate, provided by the upstream 
KR module wherein A-type KR products (l-alcohols) lead to cis-double bonds while trans-
olefins arise from B-type KR products (d-alcohols);15 although exceptions have recently been 
observed12,16-17. Post-PKS tailoring enzymes such as enoyl reductases or isomerases can further 
obscure the original olefin geometry12,16-17,18.  
Steady-state kinetic analysis using simple diffusible N-acetylcysteamine (NAC) thioester 
precursors, successfully employed to interrogate the substrate specificity of other PKS domains 
and modules19-24, has thus far been ineffective for studying isolated DH domains. This is likely 
due to the extremely low activity of the excised DH domains, which necessitates overnight 
incubations to generate sufficient product for detection. Moreover, the simple nature and ready 
reversibility of the dehydration reaction cannot be easily monitored by conventional radio-TLC 
or spectrophotometric assays. Cane and co-workers have also shown, at least in one example,  
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Figure 2.1 Structures of pikromycin, amphotericin B, discodermolide and 
curacin A 
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that a NAC thioester substrate was not properly delivered to a DH active site resulting in reversal 
of diastereospecificity12. This result highlights the potential importance of the ACP for 
chaperoning the polyketide intermediate for proper recognition and processing by DHs. Despite 
these aforementioned challenges, significant progress has been made in PKS functional 
characterization using NAC and ACP-bound substrates, which has provided useful insight into 
the substrate specificity and compelling evidence that (E)-unsaturated polyketide intermediates 
involve a stereospecific syn-elimination12, 16-17,25-27. To further advance our understanding of DH 
domains, we report herein the first detailed steady-state kinetic characterization of an individual 
DH domain through monitoring reaction progress by liquid chromatography-tandem mass 
spectrometry (LC-MS/MS). The substrate specificity was studied with a systematic series of 
synthetic triketide analogs to probe the impact of both vicinal and distal stereochemistry and 
through mutagenesis of active-site residues. The ability to monitor reaction progress also 
permitted the study of pH dependence on catalytic activity and kinetic characterization of a 
mechanism-based irreversible inhibitor designed to facilitate co-crystallization and elucidation of 
substrate-protein interactions. 
Methods 
General biology procedures. 
  All chemical reagents were purchased from Sigma-Aldrich and were used directly without 
further purification. E. coli BL21(DE3) cells were from New England BioLabs. IPTG was 
acquired through Gold Biotechnology. His60 Ni Superflow resin was purchased from Clontech 
Laboratories, Inc. OD600 was measured on an Eppendorf BioPhotometer. Sonication was carried 
out by Branson Sonifier 450. Gel filtration purification was performed on HiLoad 16/600 Superdex 
200 pg column (GE). The protein mass spectra data was obtained by Bruker BioTOF II mass 
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spectrometer. LC–MS/MS was conducted with AB Sciex QTRAP 5500 mass spectrometer and 
Shimadzu LC system. 
Cloning and mutagenesis.  
The PikKR2-DH2 didomain was cloned from the cosmid pLZ51 into the expression vector 
pMCSG77 using ligation independent cloning (LIC). PikKR2-DH2 forward primer: 5'-
TACTTCCAATCCAATGCCAGCCGCGTCGGCGGG-3'; PikKR2-DH2 reverse primer: 5'-
TTATCCACTTCCAATGCTACGGCCGGGCCCGG-3' (LIC-overhangs in bold; inserted stop 
codon underlined). The insert was confirmed via sequencing.  Primers for the F3746L, F3750L, 
and F3750Y variants were designed via the QuikChange primer design tool website (Agilent) 
(Table 2.1). Mutagenesis was run using the standard protocol provided with the QuikChange 
Lightning Site Directed Mutagenesis kit (Agilent). Mutated codons are underlined below. All 
mutations were confirmed via sequencing. 
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Table 2.1 Primers of mutants F3746L, F3750L, and F3750Y. 
Mutant Primers (5' – 3') 
F3746L 
gaacagcggacctaaggcgaggccgtt 
aacggcctcgccttaggtccgctgttc 
F3750L 
cagcccctgtaacagcggaccgaagg 
ccttcggtccgctgttacaggggctg 
F3750Y 
gcgttcagcccctgatacagcggaccgaag 
cttcggtccgctgtatcaggggctgaacgc 
 
Protein expression and purification. 
  Competent E. coli BL21 (DE3) cells were transformed with pMCSG7 containing PikKR2-
DH2 and grown in Terrific Broth (TB) media with 100 µg/mL ampicillin at 37 °C until OD600 
reached to 1.2. The cultures were cooled to 20 °C and 200 µM IPTG was added to induce protein 
expression. After overnight expression, cells were harvested by centrifugation at 6,000g and 4 °C 
for 10 min. The resulting cell pellet was frozen at –80 C for 10 min, resuspended in lysis buffer 
(50 mM HEPES, 300 mM NaCl, 10 mM imidazole, pH 8.0) and lysed by sonication. After 
centrifuging at 50,000g and 4 °C for 10 min, the cleared lysate was incubated with His-60 Ni 
superflow resin (2 mL) at 4 °C for 1 h and then loaded onto a gravity column. The column was 
washed with 14 mL of wash buffer (10 mM imidazole, 50 mM HEPES, 300 mM NaCl, pH 8.0) 
and eluted with 2.5 mL elution buffer (500 mM imidazole, 50 mM HEPES, 300 mM NaCl, pH 
8.0). The protein was further purified via size exclusion chromatography on a Superdex 16/600 
200pg gel filtration column eluting at 0.5 mL min-1 with 50 mM sodium phosphate (pH 7.1) and 
150 mM NaCl. Purified protein was stored in storage buffer (50 mM Tris, 150 mM NaCl, 10% 
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(v/v) glycerol, pH 8.0) at –80 °C. Protein concentration was determined using the Bio-Rad protein 
assay kit with bovine serum albumin as the standard. Exact molecular weight of the purified 
monomeric protein was determined by ESI mass spectrometry. All the mutants were expressed 
and purified in an analogous way (Fig. 2.2 and Table 2.2). 
 
 
Table 2.2 Characterization of PikKR2-DH2 and mutants; including calculated molecular 
weight, monomeric molecular weight (ESI mass spectrometry), and overexpression yield. 
Protein Calculated MW (Da) Monomeric MW (Da) Yield (mg/L) 
Wild-type 83009 83012 36 
F3746L 82975 82975 66 
Figure 2.2 SDS-PAGE gel electrophoresis of purified PikDH2-KR2 and mutants on 
BIO-RAD precast gels (Mini-PROTEAN® TGXTM gels) stained by Bio-SafeTM 
Coomassie G-250 Stain 
Lane 1 was loaded with PikDH2-KR2 wild type; Lane 2 was loaded with PikDH2-KR2 F3746L; Lane 3 was loaded 
with PikDH2-KR2 F3750L; Land 4 was loaded with PikDH2-KR2 F3750Y. Lane 5 was loaded with Kaleidoscope 
Precision Plus Protein Standards (BIO-RAD). 
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F3750Y 83025 83028 29 
F3750L 82975 82978 46 
 
Determination of initial velocity conditions. (Data generated by Yang Li)  
Substrate 2a (6 mM) was incubated with PikDH2-KR2 (1.25–10 µM) and reaction buffer 
(50 mM Tris, 150 mM NaCl, pH 8.0) in a total volume of 50 µL at 25 °C. At 2, 5, 10, 20 and 40 
min time points, 5 µL of the reaction mixture was added to 495 µL of 1:1 MeCN–reaction buffer 
(100-fold dilution) to quench the reaction. The resulting solution was vortexed, centrifuged. 60 µL 
of the diluted reaction solution was added to a HPLC vial with 10 µL of internal standard 3 (320 
nM) and analyzed by LC-MS/MS (Table 2.3) employing a Kinetix reverse-phase C18 column (50 
mm  2.1 mm, 2.6 µm, Phenomenex) operated at 0.4 mL min-1 with a gradient between mobile 
phase A (15 mM ammonium acetate in H2O) and mobile phase B (MeCN). The gradient program 
was 0 min, 5% B; 2 min, 5% B; 7 min, 55% B; 8 min, 95% B; 9 min, 95% B; 9.5 min, 5% B; 12 
min, 5% B. Standard curve of enzymatic product 4 was generated by injecting the authentic 
standard at varying concentrations with a fixed concentration of an internal standard 3. The amount 
of enzymatic product formation at each time point was calculated by plotting the area ratio 
(analyte/internal standard) into the standard curve. Each reaction was performed in duplicate. The 
progress curve at varying enzyme concentrations was generated and the initial velocity at each 
enzyme concentration was obtained (Figure 2.3). 
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(A) Progress curve of PikDH2 dehydration reaction at varying enzyme concentrations (1.25–10 µM); (B) Plot of 
initial velocity vs. enzyme concentration. 
 
Figure 2.3 Measurement of initial velocity. 
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Table 2.3 LC-MS/MS analysis of analytes 1a, 2a, 3 and 4. 
Analyte 
HPLC retention 
time (min) 
Transition Internal standard 
1a 4.69 314→198 2a 
2a 4.45, 4.98 328→212 1a 
3 4.73 274→216 4 
4 5.00 288→120 3 
 
Reversibility of the dehydration reaction. (Data generated by Yang Li) 
Compounds 1a, 2a, 3 and 4 (1 mM) were individually added to the reaction buffer (50 mM Tris, 
150 mM NaCl, pH 8.0) with PikDH2-KR2 (10 µM) in a total volume of 100 µL, respectively. 
After 20 h incubation, 5 µL of the reaction mixture was quenched by adding to 495 µL of 1:1 
MeCN–reaction buffer (100-fold dilution). 10 µL of the diluted reaction mixture was added to 90 
µL of 1:1 MeCN–reaction buffer (10-fold dilution, total 1000-fold dilution). The identities of the 
enzymatic products were determined by co-injection of authentic standards (Figs. 2.4, 2.5) and 
total amount was calculated by standard curve with internal standard added in. Each reaction was 
performed in duplicate. 
Kinetic analysis of dehydration reaction by LC-MS/MS. 
 The enzymatic reactions were carried out in a total volume of 50 µL under initial velocity 
conditions containing PikDH2-KR2 (5 µM), reaction buffer (50 mM Tris, 150 mM NaCl, pH 8.0) 
and substrates 1a or 2a at variable concentrations (0.25, 0.5, 1, 2, 3, 4, 6 mM). The final DMSO 
concentration was held constant at 3%. After incubation at 25 °C for 15 min, 5 µL of the reaction 
mixture was added to 495 µL of 1:1 MeCN–reaction buffer (100-fold dilution). The resulting 
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solution was vortexed, centrifuged and analyzed by LC-MS/MS as described above. Control 
reactions for each concentration of substrate were performed without the addition of enzyme. Each  
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Figure 2.5 LC-MS/MS analysis of standards. 
(A)1a (MRM m/z 314→198); (B) 2a (MRM m/z 328→212); (C) 3 (MRM 
m/z 274→216); (D) 4 (MRM m/z 288→120) 
Figure 2.4 LC-MS/MS traces for hydration reactions of substrates 3 (A) and 
substrate 4 (B) by pikKR2-DH2 
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reaction was performed in duplicate. Apparent steady-state kinetic parameters were determined by 
fitting the normalized v0 vs [S] plots to the Michaelis–Menten equation by nonlinear regression 
analysis using GraphPad Prism 5.0 (Fig. 2.6). Kinetic parameters of PikDH2-KR2 mutants were 
acquired in an analogous way except in some cases saturation was not achieved and the curve was 
fit by linear regression to provide specificity constants (Fig. 2.8).  
 
  
Figure 2.6 Michaelis-Menten curves of PikDH2. 
(A) with substrates 1a; (B) with substrates 2a. 
Figure 2.7 Michaelis-Menten and linear curves of PikDH2 mutants with substrate 2a 
(A) F3746L; (B) F3750L; (C) F3750Y. 
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Homology model of PikDH2.  
The PikDH2 homology model (residues 1-293 of the PikKR2-DH2 didomain) was built in 
LOMETS8 using the CurK dehydratase from the curacin pathway as a template (PDB 3KG9) (Fig. 
2.8)9. The PikDH2 model has an RMSD of 0.290 Å compared to the template, with a Z-score of 
27.3 and 22% sequence identity. 
 
pH dependency profile of PikDH2. (Data generated by Yang Li) 
 The effect of pH on kinetic parameters was obtained by using HEPES (pH 6.6–7.5), Tris (pH 8.0), 
and bicine (pH 8.5–9.0). At desired pH values, enzymatic reactions were conducted with substrate 
2a (0–3 mM) under the conditions described above. Kinetic parameters Vmax/KM at different pH 
were obtained via fitting the v0 vs [S] plots to by linear regression analysis. The pKa value of the 
ionizable group was obtained through fitting Vmax/KM to eq 1:  
log⁡
𝑉max
𝐾M
= log⁡
𝐶
1−[H]+/𝐾a
                                                           (1) 
Figure 2.8 Active site of PikDH2 homology 
model. 
Catalytic residues Asp3800 and His3611 as well as 
hydrophobic residues Phe3746 and Phe3750 have been 
depicted in detail. 
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where, C is the pH-independent plateau value, [H]+ is the hydrogen ion concentration, and Ka is 
the dissociation constant of the acid.10 
 
Inhibition assay with mechanism-based inhibitor 6. (Data generated by Yang Li) 
Inhibitor 6 (10–40 µM) was incubated with substrate 2a (5 mM), PikDH2-KR2 (5 µM), reaction 
buffer (50 mM Tris, 150 mM NaCl, pH 8.0) in a total volume of 50 µL at 25 °C. At 2, 4, 8, 16 min 
time points, 5 µL of the reaction mixture was added to 495 µL of 1:1 MeCN–reaction buffer (100-
fold dilution). The resulting solution was vortexed, centrifuged and analyzed by LC-MS/MS to 
detect the enzymatic product formation. Each reaction was conducted in duplicate. Inhibitor 6 
showed time-dependent inhibition of PikDH2. The progress curve was fit to eq 2 and eq 3 for tight 
binding time-dependent inhibition: 
[𝑃] = 𝑣s𝑡 +
(1−𝛾)(𝑣i−𝑣s)
𝛾𝑘obs
ln
1−exp(−𝑘obs𝑡)
1−𝛾
                                         (2) 
𝛾 =
[𝐸]
[𝐼]
(1 −
𝑣s
𝑣i
)
2
                                                                       (3) 
where [P] is the concentration of enzymatic product, t is the reaction time, vi is the initial velocity, 
vs is the steady state velocity, and kobs is the observed rate constant of inhibition. Since mechanism-
based inhibition is irreversible, the vs value is equal to 0, thus the γ value is equal to the ratio of 
enzyme concentration to inhibitor concentration. The secondary plot of 1/kobs versus 1/[I] was fit 
to a Kitz and Wilson plot to provide KI,app and kinact values. The true KI value was deduced from eq 
4: 
KI,app =
KI
1+[S] KM⁄
                                                                 (4) 
where [S] is the substrate concentration, and KM is the Michaelis-Menten constant for the substrate. 
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General chemistry procedures.  
(All synthesis protocols run by Yang Li) 
All commercial reagents were used as provided unless otherwise indicated. Substrate analogs 1a5, 
2a5, intermediates S11,2, S23,4, S95 and S145,6 were prepared by the published procedures. THF 
and CH2Cl2 were purified by passage through alumina columns. All reactions were performed 
under an inert atmosphere of dry N2 in oven-dried (150 ºC) glassware. Flash chromatography was 
conducted on silica gel (230–400 mesh) using the indicated solvent systems. TLC was performed 
on 250 µm, F254 silica gel plates, and visualized by UV and p-anisaldehyde stain. Optical rotations 
were determined on a Rudolph Autopol III polarimeter using the sodium D line ( = 589 nm) at 
the temperature indicated and are reported as follows: [α]
temp
D , concentration (c = g/100 mL), and 
solvent. 1H and 13C NMR spectra were recorded on a Bruker 400 spectrometer at 400 Hz for 1H 
NMR and at 100 Hz for 13C NMR. Chemical shifts are reported in ppm from an internal standard 
of residual CHCl3 (7.26 ppm for 
1H NMR and 77.00 for 13C NMR). Proton chemical data are 
reported as follows: chemical shift (ppm), multiplicity (s = singlet, d = doublet, t = triplet, q = 
quartet, quin = quintet, sext = sextet, m = multiplet, br = broad), coupling constant (Hz), and 
integration. High resolution mass spectra were obtained on a Bruker BioTOF II ESI-TOF/MS 
using either PEG or PPG standards as high resolution calibrants. 
 (3S,4S,5R)-5-[(tert-Butyldimethylsilyl)oxy]-3-hydroxy-1-[(R)-4-isopropyl-2-thioxothiazolidin-
3-yl]-4-methylheptan-1-one (S3).  
To a solution of thiazolidinethione S2 (172 mg, 0.846 mmol, 1.60 
equiv) in CH2Cl2 (4.2 mL) at –40 °C was added TiCl4 (99 µL, 0.90 
mmol, 1.7 equiv). An aliquot of i-Pr2NEt (0.16 mL, 0.90 mmol, 1.7 
equiv) was added after stirring at –40 °C for 30 min. The reaction mixture was stirred at –40 °C 
 35 
an additional 2 h, and then cooled to –78 °C. Aldehyde S1 (122 mg, 0.529 mmol, 1.00 equiv) was 
added and rinsed with CH2Cl2 (3 × 0.3 mL). The reaction was stirred at –78 °C for 80 min, 
quenched by addition of saturated aqueous NH4Cl (20 mL) and allowed to warm to room 
temperature. The organics were extracted with CH2Cl2 (3 × 20 mL), dried (Na2SO4), filtered and 
concentrated under reduced pressure. Purification by flash chromatography (20% EtOAc/hexanes) 
afforded the title compound (140 mg, 61%) as a yellow oil: Rf = 0.34 (20% EtOAc/hexanes); [α]
22
D 
= –258 (c 1.00, CHCl3); 1H NMR (CDCl3, 400 MHz) δ 5.16 (t, J = 6.8 Hz 1H), 4.19–4.11 (m, 1H), 
3.75 (q, J = 6.0 Hz, 1H), 3.64 (dd, J = 17.7, 2.0 Hz, 1H), 3.51 (dd, J = 11.5, 8.0 Hz, 1H), 3.15 (dd, 
J = 17.7, 9.9 Hz, 1H), 3.02 (d, J = 11.5 Hz, 1H), 2.36 (dq, J = 13.5, 6.8 Hz, 1H), 1.85 (sext, J = 
7.0 Hz, 1H), 1.58–1.40 (m, 2H), 1.06 (d, J = 6.8 Hz, 3H), 0.97 (d, J = 6.9 Hz, 3H), 0.93–0.83 (m, 
15H), 0.06 (s, 3H), 0.05 (s, 3H); 13C NMR (CDCl3, 100 MHz) δ 203.0, 173.4, 75.1, 71.4, 69.4, 
43.0, 42.5, 30.8, 30.6, 25.9, 25.6, 19.1, 18.1, 17.8, 11.4, 9.2, -4.4, -4.6; HRMS (ESI-TOF) m/z: [M 
+ Na]+ calcd for C20H39NO3S2SiNa 456.2033, found 456.2057. 
 (3S,4R,5R)-3,5-Dihydroxy-N-methoxy-N,4-dimethylheptanamide (S5).  
To a solution of thiazolidinethione S3 (136 mg, 0.314 mmol, 1.00 equiv) 
in CH2Cl2 (5 mL) at room temperature was added N,O-
dimethylhydroxylamine hydrochloride (123 mg, 1.26 mmol, 4.00 equiv) 
and imidazole (171  mg, 2.51 mmol, 8.00 equiv), followed by the addition of DMAP (7.7 mg, 
0.063 mmol, 0.20 equiv).  The reaction mixture was stirred at room temperature until the bright 
yellow color faded (24 h), then quenched with water. The layers were separated, and the aqueous 
layer was extracted with CH2Cl2 (3 × 10 mL). The combined organic layers were washed with 
saturated aqueous NaCl (20 mL), dried (Na2SO4), filtered and concentrated under reduced pressure 
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to afford the crude S4 as a colorless oil, which was used directly in the next reaction without further 
purification. Rf = 0.41 (30% EtOAc/hexanes). 
To a solution of silyl ether S4 prepared above (105 mg, 0.314 mmol, 1.00 equiv) in THF (10 
mL) at 0 °C was added TBAF (1.0 M in THF, 0.94 mL, 0.94 mmol, 3.0 equiv). The reaction 
mixture was stirred at 0 °C for 7 h, then quenched by addition of saturated aqueous NH4Cl (10 
mL). The reaction mixture was extracted with EtOAc (3 × 10 mL), and the combined organic 
layers were washed with saturated aqueous NaCl (20 mL), dried (Na2SO4), filtered, and 
concentrated under reduced pressure. Purification by flash chromatography (5% MeOH/CH2Cl2) 
afforded the title compound (60 mg, 87% over 2 steps) as a colorless oil: Rf = 0.30 (5% 
MeOH/CH2Cl2); [α]
21
D  = –43.4 (c  0.650, CHCl3); 
1H NMR (CDCl3, 400 MHz) δ 4.07–3.99 (m, 
1H), 3.69 (s, 3H), 3.59 (td, J = 7.9, 2.9 Hz, 1H), 3.19 (s, 3H), 2.80 (d, J = 16.5 Hz, 1H), 2.51 (dd, 
J = 16.5, 9.8 Hz, 1H), 1.71–1.60 (m, 2H), 1.41 (dquin, J = 14.7, 7.4 Hz, 1H), 0.97 (t, J = 7.4 Hz, 
3H), 0.82 (d, J = 6.9 Hz, 3H); 13C NMR (CDCl3, 100 MHz) δ 173.9, 76.3, 72.9, 61.3, 42.8, 36.0, 
31.9, 27.1, 12.9, 9.3; HRMS (ESI-TOF) m/z: [M + Na]+ calcd for C10H21NO4Na 242.1363, found 
242.1368. 
(3S,4R,5R)-N-Methoxy-N,4-dimethyl-3,5-bis[(triethylsilyl)oxy]heptanamide (S6).  
To a solution of alcohol S5 (54 mg, 0.25 mmol, 1.0 equiv) in CH2Cl2 
(10 mL) at 0 °C was added i-Pr2NEt (0.15 mL, 0.89 mmol, 3.6 equiv) 
and TESOTf (0.18 mL, 0.79 mmol, 3.2 equiv). After stirring at 0 °C 
for 60 min, the reaction mixture was quenched by the addition of saturated aqueous NaHCO3 (20 
mL). The layers were separated, and the aqueous layer was extracted with CH2Cl2 (3 × 10 mL). 
The combined organic layers were washed with saturated aqueous NaCl (50 mL), dried (Na2SO4), 
filtered and concentrated under reduced pressure. Purification by flash chromatography (10% 
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EtOAc/hexanes) afforded the title compound (73 mg, 66%) as a colorless oil: Rf = 0.44 (10% 
EtOAc/hexanes); [α]
22
D
 = –31.0 (c 1.50, CHCl3); 1H NMR (CDCl3, 400 MHz) δ 4.50–4.43 (m, 1H), 
3.68 (s, 3H), 3.60 (q, J = 5.7 Hz, 1H), 3.16 (s, 3H), 2.76–2.65 (m, 1H), 2.36 (dd, J = 15.0, 2.9 Hz, 
1H), 1.85–1.77 (m, 1H), 1.58–1.44 (m, 2H), 0.99–0.83 (m, 24H), 0.64–0.52 (m, 12H); 13C NMR 
(CDCl3, 100 MHz) δ 173.1, 74.5, 69.5, 61.2, 43.7, 35.5, 32.0, 26.4, 10.3, 8.8, 7.0, 6.9, 5.2, 5.0; 
HRMS (ESI-TOF) m/z: [M + Na]+ calcd for C22H49NO4Si2Na 470.3092, found 470.3097. 
 (5S,6R,7R)-6-Methyl-5,7-bis[(triethylsilyl)oxy]non-1-en-3-one (S7).  
To a solution of Weinreb amide S6 (73 mg, 0.16 mmol, 1.0 equiv) in THF 
(5 mL) at 0 °C was added vinyl magnesium bromide (1.0 M in THF, 0.48 
mL, 0.48 mmol, 3.0 equiv). After stirring at 0 °C for 55 min, the reaction 
mixture was quenched by the addition of saturated aqueous NH4Cl (5 mL). The layers were 
separated, and the aqueous layer was extracted with EtOAc (3 × 10 mL). The combined organic 
layers were washed with saturated aqueous NaCl (20 mL), dried (Na2SO4) and concentrated under 
reduced pressure. Purification by flash chromatography (10% EtOAc/hexanes) afforded the title 
compound (45 mg, 66%) as a colorless oil: Rf = 0.60 (10% EtOAc/hexanes); [α]
21
D
 = –34.6 (c 0.800, 
CHCl3); 
1H NMR (CDCl3, 400 MHz) δ 6.38 (dd, J = 17.6, 10.5 Hz, 1H), 6.20 (dd, J = 17.6, 1.0 
Hz, 1H), 5.79 (dd, J = 10.5, 1.1 Hz, 1H), 4.51–4.45 (m, 1H), 3.58 (q, J = 5.3 Hz, 1H), 2.77 (q, J = 
8.8 Hz, 1H), 2.59 (dd, J = 15.5, 2.9 Hz, 1H), 1.84–1.76 (m, 1H), 1.57–1.45 (m, 2H), 1.00–0.82 (m, 
24H), 0.57 (app. dq, J = 19.0, 7.8 Hz, 12H); 13C NMR (CDCl3, 100 MHz) δ 200.0, 137.5, 127.8, 
74.6, 69.1, 43.52, 43.46, 26.5, 10.3, 8.6, 7.0, 6.9, 5.2, 5.0; HRMS (ESI-TOF) m/z: [M + Na]+ calcd 
for C22H46O3Si2Na 437.2878, found 437.2854. 
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 (5S,6R,7S)-5,7-Dihydroxy-6-methyl-1-[N-(2-acetamidoethyl)thio]nonan-3-one (2c).  
To a solution of vinyl 
ketone S7 (32 mg, 0.078 
mmol, 1.0 equiv) in THF (5 mL) was added N-acetylcysteamine (12 µL, 0.12 mmol, 1.5 equiv) 
and a catalytic amount of Cs2CO3. The reaction was stirred at room temperature for 40 min, before 
quenching with saturated aqueous NH4Cl (5 mL). The layers were separated, and the aqueous layer 
was extracted with EtOAc (3 × 10 mL). The combined organic layers were washed with saturated 
aqueous NaCl (40 mL), dried (Na2SO4), filtered and concentrated under reduced pressure to yield 
crude S8 (35 mg) as a colorless oil, which was used in the next reaction without further 
purification: Rf = 0.36 (5% MeOH/CH2Cl2). 
To a solution of silyl ether S8 prepared above (35 mg, 0.066 mmol, 1.0 equiv) in THF (6 mL) 
at 0 °C was added a solution of 70% HF-pyridine:pyridine:THF (1:2:8, 3 mL). The reaction was 
stirred at 0 °C for 3.5 h, then quenched with saturated aqueous NaHCO3 to bring the reaction to 
pH 7, and extracted with EtOAc (3 × 10 mL). The combined organic layers were washed with 
saturated aqueous NaCl (40 mL), dried (Na2SO4), filtered and concentrated under reduced 
pressure. Purification by flash chromatography (5% MeOH/CH2Cl2) afforded the title compound 
(17 mg, 72% over 2 steps) as a colorless oil: Rf = 0.20 (5% MeOH/CH2Cl2); [α]
21
D = 41.1 (c 1.00, 
CHCl3); 
1H NMR (CDCl3, 400 MHz) δ 6.10 (s, 1H), 4.98 (s, 1H), 3.97–3.85 (m, 1H), 3.75–3.68 
(m, 1H), 3.50–3.36 (m, 3H), 2.78–2.61 (m, 4H), 2.04–1.96 (m, 4H), 1.90–1.81 (m, 2H), 1.71–1.59 
(m, 2H), 1.50–1.32 (m, 2H), 0.96–0.90 (m, 6H); 13C NMR (CDCl3, 100 MHz) δ 170.4, 97.1, 70.4, 
70.2, 41.4, 39.9, 38.3 (overlap), 31.5, 25.4, 25.0, 23.2, 13.9, 9.3; HRMS (ESI-TOF) m/z: [M + 
Na]+ calcd for C14H27NO4SNa 328.1553, found 328.1551. 
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 (3S,4R,5S)-5-[(tert-Butyldimethylsilyl)oxy]-3-hydroxy-1-[(R)-4-isopropyl-2-thioxothiazolidin-
3-yl]-4-methylheptan-1-one (diastereomer-S3).  
The title compound was prepared using otherwise identical conditions 
as described for the preparation of aldol product S3 except for the use 
of aldehyde (+)–S1 (157 mg, 0.771 mmol, 1.00 equiv). Purification by 
flash chromatography (20% EtOAc/hexanes) afforded the title compound (129 mg, 62%) as a 
yellow oil: Rf = 0.46 (20% EtOAc/hexanes); [α]
21
D  = –211 (c 2.00, CHCl3); 
1H NMR (CDCl3, 400 
MHz) δ 5.19–5.13 (m, 1H), 4.66 (d, J = 9.4 Hz, 1H), 3.72–3.65 (m, 2H), 3.51 (dd, J = 11.4, 8.0 
Hz, 1H), 3.42 (dd, J = 17.1, 9.3 Hz, 1H), 3.27 (dd, J = 17.1, 2.0 Hz, 1H), 3.01 (d, J = 11.5 Hz, 1H), 
2.40 (dq, J = 13.5, 6.7 Hz, 1H), 1.82–1.59 (m, 3H), 1.06 (d, J = 6.8 Hz, 3H), 1.01 (d, J = 7.1 Hz, 
3H), 0.98 (d, J = 7.0 Hz, 3H), 0.88 (s, 9H), 0.87 (t, J = 7.5 Hz), 0.093 (s, 3H), 0.085 (s, 3H); 13C 
NMR (CDCl3, 100 MHz) δ 203.0, 172.2, 79.3, 71.6, 66.7, 43.8, 38.0, 30.9, 30.5, 27.5, 25.8, 19.1, 
17.9, 17.7, 11.7, 9.5, -4.4, -4.9; HRMS (ESI-TOF) m/z: [M + Na]+ calcd for C20H39NO3S2SiNa 
456.2033, found 456.2052.  
 (3S,4S,5S)-3,5-Dihydroxy-N-methoxy-N,4-dimethylheptanamide (diastereomer-S5).  
Identical reaction conditions employed for the synthesis of weinreb 
amide S4 were used, except for the use of thiazolidinethione 
diastereomer-S3 (129 mg, 0.297 mmol, 1.00 equiv). The crude product 
was used to carry out the next reaction without further purification: Rf = 0.34 (30% 
EtOAc/hexanes). 
The title compound was prepared using otherwise identical conditions as described for the 
preparation of diol S5, except for the use of silyl ether diastereomer-S4 prepared above (99 mg, 
0.297 mmol, 1.00 equiv). Purification by flash chromatography (5% MeOH/CH2Cl2) afforded the 
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title compound (45 mg, 69% over 2 steps) as a colorless oil: Rf = 0.29 (5% MeOH/CH2Cl2); [α]
22
D  
= –40.4 (c  1.00, CHCl3); 1H NMR (CDCl3, 400 MHz) δ 4.39 (dt, J = 9.8, 2.8 Hz, 1H), 3.69 (s, 
4H), 3.55–3.48 (m, 1H), 3.22–3.14 (m, 4H), 2.68–2.49 (m, 2H), 1.72–1.65 (m, 1H), 1.63–1.44 (m, 
2H), 1.00–0.91 (m, 6H); 13C NMR (CDCl3, 100 MHz) δ 173.9, 76.1, 69.4, 61.3, 40.6, 34.7, 31.9, 
28.1, 11.9, 9.8; HRMS (ESI-TOF) m/z: [M + Na]+ calcd for C10H21NO4Na 242.1363, found 
242.1366. 
 (3S,4S,5S)-N-Methoxy-N,4-dimethyl-3,5-bis[(triethylsilyl)oxy]heptanamide (diastereomer-S6).  
The title compound was prepared using otherwise identical conditions 
as described for the preparation of silylether S6, except for the use of 
alcohol diastereomer-S5 (42 mg, 0.19 mmol, 1.0 equiv). Purification 
by flash chromatography (10% EtOAc/hexanes) afforded the title compound (57 mg, 66%) as a 
colorless oil: Rf = 0.45 (10% EtOAc/hexanes); [α]
21
D
 = –26.3 (c 1.00, CHCl3); 1H NMR (CDCl3, 
400 MHz) δ 4.25 (q, J = 5.6 Hz, 1H), 3.68 (s, 3H), 3.57 (dt, J = 7.9, 3.6 Hz, 1H), 3.16 (s, 3H), 2.66 
(dd, J = 15.0, 6.7 Hz, 1H), 2.57 (dd, J = 15.0, 5.6 Hz, 1H), 1.73–1.65 (m, 1H), 1.55–1.44 (m, 1H), 
1.43–1.35 (m, 1H), 1.00–0.85 (m, 24H), 0.60 (app. dq, J = 7.9, 3.5 Hz, 12H); 13C NMR (CDCl3, 
100 MHz) δ 172.4, 75.9, 70.8, 61.2, 45.0, 38.8, 32.0, 25.5, 10.4, 9.6, 7.0, 5.2; HRMS (ESI-TOF) 
m/z: [M + Na]+ calcd for C22H49NO4Si2Na 470.3092, found 470.3088. 
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 (5S,6S,7S)-6-Methyl-5,7-bis[(triethylsilyl)oxy]non-1-en-3-one (diastereomer-S7).  
The title compound was prepared using otherwise identical conditions as 
described for the preparation of enone S7, except for the use Weinreb amide 
diastereomer-S6 (42 mg, 0.094 mmol, 1.0 equiv). Purification by flash 
chromatography (5% EtOAc/hexanes) afforded the title compound (28 mg, 72%) as a colorless 
oil: Rf = 0.68 (10% EtOAc/hexanes); [α]
21
D
 = –27.0 (c 0.650, CHCl3); 1H NMR (CDCl3, 400 MHz) 
δ 6.37 (dd, J = 17.6, 10.5 Hz, 1H), 6.21 (d, J = 17.6 Hz, 1H), 5.83 (d, J = 10.5 Hz, 1H), 4.28 (q, J 
= 5.7 Hz, 1H), 3.55 (dt, J = 7.8, 4.0 Hz, 1H), 2.84–2.70 (m, 2H), 1.69–1.61 (m, 1H), 1.53–1.34 
(m, 2H), 0.99–0.84 (m, 24H), 0.58 (app. dq, J = 7.9, 4.0 Hz, 12H); 13C NMR (CDCl3, 100 MHz) 
δ 199.1, 137.1, 128.3, 75.6, 70.2, 46.5, 44.9, 25.6, 10.1, 9.7, 7.00, 5.2; HRMS (ESI-TOF) m/z: [M 
+ Na]+ calcd for C22H46O3Si2Na 437.2878, found 437.2847.  
 
(5S,6S,7S)-5,7-Dihydroxy-6-methyl-1-[N-(2-acetamidoethyl)thio]nonan-3-one (2d).  
Identical reaction 
conditions as reported for 
the synthesis of thioether 
S8 were employed, except for the use of vinyl ketone diastereomer-S7 (14 mg, 0.034 mmol, 1.0 
equiv). The crude product diastereomer-S8 was used to carry out the next reaction without further 
purification: Rf = 0.45 (5% MeOH/CH2Cl2). 
The title compound was prepared using otherwise identical conditions as described for the 
preparation of thioether 2c, except for the use of silyl ether diastereomer-S8 prepared above (18 
mg, 0.034 mmol, 1.0 equiv). Purification by flash chromatography (5% MeOH/CH2Cl2) afforded 
the title compound (5.8 mg, 56% over 2 steps) as a colorless oil: Rf = 0.27 (5% MeOH/CH2Cl2); 
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Due to the instability of the compound the optical rotation could not be obtained; 1H NMR (CDCl3, 
400 MHz, approximately 3:17 mixture of A:B where the integrations have been normalized) δ 6.03 
(s, 0.15H), 5.89 (s, 0.85H), 4.45 (dt, J = 10.1, 2.4 Hz, 0.15H), 3.69 (dt, J = 10.7, 4.8 Hz, 0.85H), 
3.54–3.36 (m, 3.15H), 3.20 (s, 0.85H), 2.83–2.62 (m, 4.45H), 2.46 (dd, J = 16.4, 2.7 Hz, 0.15H), 
2.11 (dd, J = 12.3, 4.8 Hz, 0.85H), 1.99 (s, 3H), 1.95–1.89 (m, 1.7H), 1.76–1.68 (m, 1H), 1.46–
1.30 (m, 1.85H), 1.28–1.21 (m, 1H), 1.01–0.87 (m, 6H); 13C NMR (CDCl3, 100 MHz, major 
isomer B) δ 170.2, 97.3, 74.6, 70.0, 43.2, 43.0, 41.1, 38.2, 31.4, 25.3, 25.2, 23.3, 12.6, 9.6; HRMS 
(ESI-TOF) m/z: [M + Na]+ calcd for C14H27NO4SNa 328.1553, found 328.1560. 
 (3S,4S,5S)-3-Hydroxy-N-methoxy-N,4-dimethyl-5-[(triethylsilyl)oxy]heptanamide (S10).  
To a solution of freshly distilled i-Pr2NH (0.21 mL, 1.5 mmol, 1.5 
equiv) in THF (30 mL) at –78 °C was added n-BuLi (1.2 M in THF, 
1.2 mL, 1.4 mmol, 1.4 equiv). After stirring at –78 °C for 30 min, N-methoxy-N-methylacetamide 
(0.15 mL, 1.4 mmol, 1.4 equiv) was added. The reaction mixture was stirred at –78 °C for an 
additional 30 min, followed by the dropwise addition of a solution of aldehyde S9 (233 mg, 1.01 
mmol, 1.00 equiv) in THF (0.5 mL). The reaction mixture was stirred at –78 °C for an additional 
1 h, then quenched by the addition of saturated aqueous NH4Cl (20 mL). The layers were separated 
and the aqueous layer was extracted with EtOAc (3 × 20 mL). The combined organic layers were 
dried (Na2SO4), filtered and concentrated under reduced pressure. Purification by flash 
chromatography (40% EtOAc/hexanes) afforded the title compound S10 (169 mg, 50%) as a 
colorless oil (total yield = 75%, dr = 2: 1): [α]
22
D = –32.2 (c 1.00, CHCl3); 
1H NMR (CDCl3, 400 
MHz) δ 4.16 (d, J = 2.9 Hz, 1H), 4.01 (tt, J = 9.0, 3.0 Hz, 1H), 3.95 (dt, J = 6.8, 2.2 Hz, 1H), 3.70 
(s, 3H), 3.20 (s, 3H), 2.66 (d, J = 14.3 Hz, 1H), 2.52 (dd, J = 15.7, 9.2 Hz, 1H), 1.74–1.63 (m, 1H), 
1.60–1.46 (m, 2H), 0.96 (t, J = 7.9 Hz, 9H), 0.87 (t, J = 7.5 Hz, 3H), 0.81 (d, J = 7.0 Hz, 3H), 0.62 
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(q, J = 7.9 Hz, 6H); 13C NMR (CDCl3, 100 MHz) δ 173.7, 75.1, 70.0, 61.2, 41.8, 36.9, 31.9, 26.6, 
10.7, 10.6, 6.9, 5.2; HRMS (ESI-TOF) m/z: [M + Na]+ calcd for C16H35NO4SiNa 356.2228, found 
356.2226. 
 (3S,4R,5S)-N-Methoxy-N,4-dimethyl-3,5-bis[(triethylsilyl)oxy]heptanamide (S11).  
To a solution of alcohol S10 (122 mg, 0.366 mmol, 1.00 equiv) in 
CH2Cl2 (10 mL) at 0 °C was added i-Pr2NEt (0.11 mL, 0.66 mmol, 1.8 
equiv) and TESOTf (0.13 mL, 0.59 mmol, 1.6 equiv). After stirring at 
0 °C for 1 h, the reaction mixture was quenched by the addition of saturated aqueous NaHCO3 (10 
mL). The layers were separated, and the aqueous layer was extracted with CH2Cl2 (3 × 10 mL). 
The combined organic layers were washed with saturated aqueous NaCl (20 mL), dried (Na2SO4), 
filtered and concentrated under reduced pressure. Purification by flash chromatography (20% 
EtOAc/hexanes) afforded the title compound (155 mg, 95%) as a colorless oil: Rf = 0.65 (20% 
EtOAc/hexanes); [α]
22
D
 = –28.2 (c 1.00, CHCl3); 1H NMR (CDCl3, 400 MHz) δ 4.30 (dt, J = 9.7, 
3.0 Hz, 1H), 3.70 (s, 3H), 3.52 (q, J = 5.6 Hz, 1H), 3.17 (s, 3H), 2.87–2.72 (m, 1H), 2.20 (dd, J = 
14.9, 2.0 Hz, 1H), 1.86–1.74 (m, 1H), 1.61–1.49 (m, 2H), 0.98–0.85 (m, 24H), 0.63–0.54 (m, 
12H); 13C NMR (CDCl3, 100 MHz) δ 173.1, 75.2, 71.1, 61.2, 42.9, 34.8, 32.0, 27.7, 8.9, 8.8, 7.0, 
6.8, 5.4, 4.9; HRMS (ESI-TOF) m/z: [M + Na]+ calcd for C22H49NO4Si2Na 470.3092, found 
470.3093. 
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 (5S,6R,7S)-6-Methyl-5,7-bis[(triethylsilyl)oxy]non-1-en-3-one (S12).  
To a solution of Weinreb amide S11 (155 mg, 0.346 mmol, 1.00 equiv) in 
THF (15 mL) at 0 °C was added vinyl magnesium bromide (1.0 M in THF, 
1.04 mL, 1.04 mmol, 3.00 equiv). The reaction mixture was stirred at 0 °C 
for 70 min, quenched by the addition of saturated aqueous NH4Cl (10 mL), and allowed to warm 
up to room temperature. The layers were separated, and the aqueous layer was extracted with 
EtOAc (3 × 20 mL). The combined organic layers were washed with saturated aqueous NaCl (30 
mL), dried (Na2SO4), and concentrated under reduced pressure. Purification by flash 
chromatography (10% EtOAc/hexanes) afforded the title compound (77 mg, 53%) as a colorless 
oil: Rf = 0.64 (10% EtOAc/hexanes); [α]
23
D
 = –34.8 (c 1.00, CHCl3); 1H NMR (CDCl3, 400 MHz) δ 
6.36 (dd, J = 17.6, 10.5 Hz, 1H), 6.20 (dd, J = 17.6, 1.1 Hz, 1H), 5.81 (dd, J = 10.5, 1.1 Hz, 1H), 
4.30 (ddd, J = 9.2, 3.5, 2.3 Hz, 1H), 3.58–3.50 (m, 1H), 2.86 (dd, J = 15.6, 9.3 Hz, 1H), 2.49 (dd, 
J = 15.6, 2.3 Hz, 1H), 1.83–1.73 (m, 1H), 1.57–1.47 (m, 2H), 0.99–0.84 (m, 24H), 0.57 (q, J = 7.8 
Hz, 6H), 0.54 (q, J = 7.8 Hz, 6H); 13C NMR (CDCl3, 100 MHz) δ 200.2, 137.6, 128.1, 75.3, 71.1, 
42.82, 42.77, 27.8, 9.2, 8.3, 7.0, 6.9, 5.4, 5.0; HRMS (ESI-TOF) m/z: [M + Na]+ calcd for 
C22H46O3Si2Na 437.2878, found 437.2868. 
 (5S,6R,7S)-6-Methyl-1-[N-(2-acetamidoethyl)thio]-5,7-bis[(triethylsilyl)oxy]nonan-3-one (S13).  
To a solution of vinyl ketone S12 (42 mg, 0.10 mmol, 1.0 equiv) in 
THF (8 mL) was added N-acetylcysteamine (16 µL, 0.15 mmol, 1.5 
equiv) and a catalytic amount of Cs2CO3. The reaction was stirred 
at room temperature for 1.5 h, then quenched by the addition of saturated aqueous NH4Cl (10 mL). 
The layers were separated and the aqueous layer was extracted with EtOAc (3 × 10 mL). The 
combined organic layers were washed with saturated aqueous NaCl (40 mL), dried (Na2SO4), 
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filtered and concentrated under reduced pressure. Purification by flash chromatography (5% 
MeOH/CH2Cl2) afforded the title compound (38 mg, 70%) as a colorless oil: Rf = 0.37 (5% 
MeOH/CH2Cl2); [α]
23
D
 = –28.4 (c 1.00, CHCl3); 1H NMR (CDCl3, 400 MHz) δ 6.07 (s, 1H), 4.31–
4.20 (m, 1H), 3.54–3.43 (m, 3H), 2.83–2.58 (m, 7H), 2.40 (dd, J = 15.5, 1.9 Hz, 1H), 2.01 (s, 3H), 
1.78–1.70 (m, 1H), 1.57–1.42 (m, 2H), 1.01–0.81 (m, 24H), 0.56 (app. quin, J = 8.0 Hz, 12H); 13C 
NMR (CDCl3, 100 MHz) δ 208.3, 170.1, 75.2, 71.3, 46.1, 44.4, 42.5, 38.4, 32.3, 27.7, 25.0, 23.2, 
9.2, 8.0, 7.0, 6.9, 5.4, 5.0; HRMS (ESI-TOF) m/z: [M + Na]+ calcd for C26H55NO3SSi2Na 
556.3283, found 556.3291. 
(5S,6R,7S)-5,7-Dihydroxy-6-methyl-1-[N-(2-acetamidoethyl)thio]nonan-3-one (2e).  
To a solution of silyl ether S13 (44 mg, 0.082 mmol, 1.0 equiv) in THF (6 mL) at 0 °C was added 
a solution of 70% HF-pyridine:pyridine:THF (1:2:8, 3 mL). The reaction was stirred at 0 °C for 
4.5 h, then quenched by the addition of saturated aqueous NaHCO3 to bring the reaction to pH 7, 
and extracted with n-butanol (5 × 20 mL). The combined organic layers were washed with 
saturated aqueous NaCl (40 mL), dried (Na2SO4), filtered, and concentrated under reduced 
pressure. Purification by flash chromatography (10% MeOH/EtOAc) afforded the title compound 
(16 mg, 64%) as a colorless oil: Rf = 0.36 (10% MeOH/EtOAc); [α]
22
D
 = –35.5 (c 0.52, CHCl3); 1H 
NMR (CDCl3, 400 MHz, approximately 6:6:1 mixture of A:B:C where the integrations have been 
normalized) δ 6.61 (s, 0.08H), 6.08 (s, 0.46H), 5.98 (s, 0.46H), 4.20 (dt, J = 11.9, 4.8 Hz, 0.46H), 
4.17–4.08 (m, 0.46H), 4.07–4.03 (m, 0.08H), 3.85–3.77 (m, 1H), 3.75–3.69 (m, 0.16H), 3.53–3.34 
(m, 1.84H), 3.22–3.13 (m, 0.32H), 2.86–2.58 (m, 5.52H), 2.00–1.98 (m, 3H), 1.95–1.84 (m, 
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1.38H), 1.81 (dd, J =4.8, 12.5 Hz, 0.46H), 1.65–1.34 (m, 3H), 1.09 (d, J = 7.2 Hz, 0.24H), 1.05 (t, 
J = 7.3 Hz, 0.24H), 0.98–0.87 (m, 4.14H), 0.80 (d, J = 6.9 Hz, 1.38H); 13C NMR (CDCl3, 100 
MHz, major isomers A and B) δ 209.9, 170.4, 170.3, 97.5, 73.8, 72.9, 71.6, 67.5, 48.1, 43.4, 41.5, 
41.3, 38.6, 38.3, 37.3, 37.1, 31.9, 31.4, 26.7, 25.2, 25.1, 25.0, 23.23, 23.21, 10.9, 10.8, 10.3, 3.6; 
HRMS (ESI-TOF) m/z: [M + Na]+ calcd for C14H27NO4SNa 328.1553, found 328.1560. 
 (±)-3-Hydroxy-1-(2-thioxothiazolidin-3-yl)pentan-1-one [(±)-S15].  
To a solution of thiazolidinethione S14 (1.06 g, 6.55 mmol, 1.00 equiv) in 
CH2Cl2 (30 mL) at –40 °C was added TiCl4 (0.79 mL, 7.2 mmol, 1.1 equiv). 
Hünig’s base (i-Pr2Net) (1.37 mL, 7.86 mmol, 1.20 equiv) was added after 
stirring at –40 °C for 30 min. The reaction mixture was stirred at –40 °C for another 2 h, and then 
cooled to –78 °C. Freshly distilled propionaldehyde (0.851 mL, 11.8 mmol, 1.80 equiv) was added. 
The reaction was stirred at –78 °C for 3 h, quenched by addition of saturated aqueous NH4Cl (40 
mL) and allowed to warm up to room temperature. The organics were extracted with CH2Cl2 (3 × 
40 mL), dried (Na2SO4), filtered, and concentrated under reduced pressure. Purification by flash 
chromatography (40% EtOAc/hexanes) afforded the title compound (825 mg, 57%) as a yellow 
oil: Rf = 0.14 (30% EtOAc/hexanes); 
1H NMR (CDCl3, 400 MHz) δ 4.66–4.55 (m, 2H), 4.08–3.95 
(m, 1H), 3.53 (dd, J = 17.6, 2.3 Hz, 1H), 3.35–3.24 (m, 3H), 2.87 (d, J = 3.9 Hz, 1H), 1.66–1.49 
(m, 2H), 0.98 (t, J = 7.4 Hz, 3H); 13C NMR (CDCl3, 100 MHz) δ 201.9, 174.3, 69.5, 55.7, 45.4, 
29.4, 28.3, 9.9; HRMS (ESI-TOF) m/z: [M + Na]+ calcd for C8H13NO2S2Na 242.0280, found 
242.0281. 
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 (±)-S-(2-Acetamidoethyl)-3-hydroxypentanethioate [(±)-5].  
To a solution of thiazolidinethione (±)-S15 (821 mg, 3.74 mmol, 1.00 equiv) 
in CH2Cl2 (30 mL) at room temperature was added imidazole (763 mg, 11.2 
mmol, 3.00 equiv) and N-acetylcysteamine (0.44 mL, 4.1 mmol, 1.1 equiv). The reaction was 
stirred at room temperature for 12 h, then quenched by the addition of saturated aqueous NH4Cl 
(30 mL), and extracted with CH2Cl2 (3 × 20 mL). The combined organic layers were washed with 
saturated aqueous NaCl (40 mL), dried (Na2SO4), filtered, and concentrated under reduced 
pressure. Purification by flash chromatography (5% MeOH/CH2Cl2) afforded the title compound 
(566 mg, 69%) as a colorless oil: Rf = 0.24 (5% MeOH/CH2Cl2); 
1H NMR (CDCl3, 400 MHz) δ 
5.79 (s, 1H), 4.04–3.96 (m, 1H), 3.53–3.40 (m, 2H), 3.11–2.98 (m, 2H), 2.77 (dd, J = 15.4, 3.3 Hz, 
1H), 2.68 (dd, J = 15.4, 8.7 Hz, 1H), 2.61 (s, 1H), 1.97 (s, 3H), 1.61–1.45 (m, 2H), 0.97 (t, J = 7.4 
Hz, 3H); 13C NMR (CDCl3, 100 MHz) δ 199.6, 170.4, 70.1, 50.6, 39.3, 29.6, 28.9, 23.2, 9.8; 
HRMS (ESI-TOF) m/z: [M + Na]+ calcd for C9H17NO3SNa 242.0821, found 242.0827. 
 (5R,6R,E)-6-Hydroxy-5-methyl-1-[N-(2-acetamidoethyl)thio]oct-3-en-2-one (3).  
The enzymatic reaction was carried out with 4 mM diol 1a 
(5.8 mg, 0.020 mmol, 1.0 equiv, dissolved in 200 µL 1: 1 
DMSO: H2O) in 10% glycerol, 1.5 M NaCl, 0.5 M Tris (pH 8.0) and 40 µM PikKR2-DH2 (16.6 
mg, 0.2 µmol, 1 mol%) in a volume of 5 mL. The reaction mixture was shaken at room temperature 
at a speed of 150 rpm for 24 h and then extracted with EtOAc (5 × 10 mL). The organic layers 
were combined, washed with saturated aqueous NaCl (20 mL), dried (Na2SO4), filtered, and 
concentrated under reduced pressure. Since the enzymatic product and starting material had the 
same Rf values, separation of enzymatic product was accomplished by converting the starting 
material to its acetonide. The enzymatic reaction residue was dissolved in CH2Cl2 (2 mL) and O,O-
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dimethoxypropane (25 µL) and PPTS (cat.) were added. After stirring at room temperature for 3 
h, the reaction was quenched by the addition of saturated aqueous NH4Cl (2 mL). The layers were 
separated, and the aqueous layer was extracted with CH2Cl2 (3 × 5 mL). The combined organic 
layers were washed with saturated aqueous NaCl (10 mL), dried (Na2SO4), filtered and 
concentrated under reduced pressure. Purification by flash chromatography (5% MeOH/CH2Cl2) 
afforded the title compound (2.8 mg, 51%) as colorless oil: Rf = 0.23 (5% MeOH/CH2Cl2); [α]
22
D
 = 
20.0 (c 0.0900, CHCl3); 
1H NMR (CDCl3, 400 MHz) δ 6.97 (dd, J = 15.9, 7.6 Hz, 1H), 6.28 (dd, J 
= 15.9, 1.3 Hz, 1H), 6.04 (s, 1H), 3.58–3.51 (m, 1H), 3.48–3.36 (m, 4H), 2.66 (t, J = 6.3 Hz, 2H), 
2.55–2.42 (m, 1H), 1.99 (s, 3H), 1.73 (s, 1H), 1.57–1.49 (m, 1H), 1.48–1.38 (m, 1H), 1.11 (d, J = 
6.8 Hz, 3H), 0.98 (t, J = 7.4 Hz, 3H); 13C NMR (CDCl3, 100 MHz) δ 194.8, 170.2, 151.7, 127.9, 
75.8, 42.4, 39.0, 38.4, 32.2, 27.4, 23.3, 13.6, 10.4; HRMS (ESI-TOF) m/z: [M + Na]+ calcd for 
C13H23NO3SNa 296.1291, found 296.1292. 
 (6R,7R,E)-7-Hydroxy-6-methyl-1-[N-(2-acetamidoethyl)thio]non-4-en-3-one (4).  
The enzymatic reaction was carried out with 4 mM diol 2a 
(6.1 mg, 0.020 mmol, 1.0 equiv, dissolved in 200 µL 1: 1 
DMSO: H2O) in 10% glycerol, 1.5 M NaCl, 0.5 M Tris (pH 8.0) and 40 µM PikKR2-DH2 (16.6 
mg, 0.2 µmol, 1 mol%) in a volume of 5 mL. The reaction mixture was shaken at room temperature 
at a speed of 150 rpm for 24 h. The enzymatic product was extracted with EtOAc (5 × 10 mL) and 
the combined organic layers were washed with saturated aqueous NaCl (20 mL), dried (Na2SO4), 
filtered, and concentrated under reduced pressure. Purification by flash chromatography (5% 
MeOH/CH2Cl2) afforded the title compound (3.3 mg, 58%) as colorless oil: Rf = 0.21 (5% 
MeOH/CH2Cl2); [α]
22
D
 = 22.0 (c 0.100, CHCl3); 
1H NMR (CDCl3, 400 MHz) δ 6.94 (dd, J = 16.1, 
7.6 Hz, 1H), 6.13 (dd, J = 16.1, 1.2 Hz, 1H), 6.02 (s, 1H), 3.58–3.50 (m, 1H), 3.45 (q, J = 6.3 Hz, 
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2H), 2.93–2.87 (m, 2H), 2.84–2.78 (m, 2H), 2.67 (t, J = 6.5 Hz, 2H), 2.47 (sext, J = 6.9 Hz, 1H), 
2.02–1.97 (m, 4H), 1.59–1.47 (m, 1H), 1.46–1.35 (m, 1H), 1.09 (d, J = 6.8 Hz, 3H), 0.98 (t, J = 
7.4 Hz, 3H); 13C NMR (CDCl3, 100 MHz) δ 198.5, 170.4, 150.7, 129.8, 75.8, 42.3, 39.7, 38.7, 
31.9, 27.3, 25.8, 23.3, 13.5, 10.4; HRMS (ESI-TOF) m/z: [M + Na]+ calcd for C14H25NO3SNa 
310.1447, found 310.1438. 
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Results 
The pikromycin biosynthetic pathway is one of the most well-explored type I PKSs and 
has served as a model system for fundamental investigations of PKS catalysis22-24, 28-31. We 
selected the DH domain from pikromycin PKS module 2 (PikDH2) for our studies since it is 
responsible for the trans-olefin in pikromycin (Fig. 2.1) and Cane et al. revealed that the cryptic 
β-hydroxy stereochemistry of the triketide substrate possesses the d-configuration24,32. We 
predicted a larger, multi-domain portion of the PKS would create a more native context for in 
vitro analysis32. The region of pikAI encoding the PikKR2-DH2 didomain comprising residues  
 
3579–4365 was cloned into a pMCSG7 expression vector and the resulting protein was 
overexpressed and purified using standard methods. Substrate mimics 1a and 2a for PikDH2 are 
based on its natural substrate (Fig. 2.9)32. While maintaining the same stereochemistry on the 
triketide moiety, they possess two major modifications compared to the natural substrate 
including replacement of the ACP-phosphopantetheinyl arm with N-acetylcysteamine (NAC) 
Figure 2.9 Rational design of PikDH2 substrate mimics 1a and 2a and the 
corresponding enzymatic products 3 and 4 
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and insertion of one or two methylene spacers between the carbonyl and sulfur atom to avoid 
undesired, intramolecular lactonization while not significantly perturbing the pKa of the α-
protons33. These two modifications were tolerated by PikKR2, instilling confidence the 
downstream DH would accept these substrates32. Overnight incubation of substrates 1a and 2a 
with PikKR2-DH2 didomain in relatively large scale generated the corresponding enzymatic 
products 3 and 4, respectively, in slightly more than 50 isolated yield (Scheme 2.1). The 
structures of 3 and 4 were unambiguously confirmed by NMR spectroscopy and exhibited 
diagnostic 13C chemical shifts at 150 and 130 ppm and a 3JHH coupling of 16 Hz for the vinyl 
protons. These results are consistent with the empirical rule that d-alcohols provide trans-olefins. 
 
Additionally, we investigated the reason for incomplete reaction. Since most FAS DHs 
conduct the reverse hydration reactions, enones 3 and 4 were incubated with PikKR2-DH2 to test 
the reversibility of the enzymatic reaction. We observed PikKR2-DH2 stereoselectively 
converted 3 and 4 exclusively to their hydrated products 1a and 2a, respectively, whose identities 
were confirmed by LC-MS/MS with authentic synthetic standards (Figs. 2.4, 2.5). When 
equilibrium was reached, the ratio of 1a to 3 was 1:1.2 and the ratio of 2a to 4 was 1:2, slightly 
favoring the dehydration products in both cases. In the biosynthetic pathway, this equilibrium is 
pushed towards dehydration, driven by downstream module activities. 
Scheme 2.1 Chemoenzymatic synthesis of enones 3 and 4 in Tris 
buffer (pH 8.0) at 25 °C. 
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To interrogate the stereospecificity of PikDH2, we altered the β-stereocenter of substrates 
1a and 2a as well as every stereogenic center in 2a through chemical synthesis (Schemes 2.2 – 
2.4 ) resulting in substrate stereoisomers 1b and 2b–e (Table 2.4)32. As LC-MS/MS showed high 
sensitivity and selectivity for detection of KR products32, we continued using this technique to 
examine the formation of DH products by their unique fragmentation patterns and/or retention 
times. Initial velocity was linear up to 40 min with 10 μM PikKR2-DH2 didomain (Fig. 2.3), 
thus we chose an end-point quench after 15 min incubation for our kinetic studies. The kinetic 
parameters of all substrates were obtained by fitting the saturation curves to the Michaelis-
Menten equation (Table 2.4). Substrates 1a and 2a, maintaining the native stereochemistry, were 
accepted and processed rapidly by the enzyme. The KM (6.9 ± 1.7 mM and 5.7 ± 1.4 mM) and 
kcat values (0.67 ± 0.11 min
−1 and 1.28 ± 0.19 min−1) were comparable, suggesting the methylene 
spacer does not adversely impact active site binding and catalysis. Substrate 1b and 2b, epimeric 
at the β-position were not processed. This strict substrate specificity has been similarly observed 
with other DHs12, 16, 26. 
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Anti-aldol product (–)-S1, synthesized using Masamune’s chiral auxiliary,1,2 was submitted to an acetate aldol reaction 
with thiazolidinethione S23,4 to yield alcohol S3 as the major diastereomer.  The thiazolidinethione was displaced with 
N,O-dimethylhydroxylamine to afford Weinreb amide S4.  The TBS protecting group stable in the previous aldol reaction 
was ultimately problematic in the final deprotection and was therefore replaced with a TES protecting group to facilitate 
its later removal. This was accomplished by treatment of S4 with TBAF to furnish S5 and subsequent silylation with 
TESOTf provided  S6.  Grinard reaction and Michael addition furnished the NAC-analog S8. A final deprotection under 
mild conditions furnished the substrate analog 2c. Substrate analog 2d was also synthesized in an analogous way by using 
aldehyde (+)-S1 
Scheme 2.2 Synthesis of substrate analogs 2c and 2d. 
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Scheme 2.3 Synthesis of substrate analog 2e 
The synthetic route commenced with the acetate aldol reaction of aldehyde S95 and N-methoxy-N-methylacetamide to 
give Weinreb amide S10 as the major diastereomer (dr = 2:1, separated by chromatography). TES protection provided 
S11 that was converted to vinyl ketone S12 through Grignard addition of vinylmagnesium bromide. Sequential Michael 
addition of N-acetylcysteamine and silyl deprotection provided substrate analog 2e. 
 
Scheme 2.4 Synthesis of substrate analog (±)-5. 
Thiazolidinethione S145,6 was subjected to an acetate aldol reaction with propionaldehyde to provide a 
racemic mixture of S15, followed by displacement with N-acetylcysteamine to afford NAC thioester 
(±)–5. 
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Table 2.4 Structures of Substrate Analogues 1a, 1b,  
2a-e, and 5 and Their Steady-State Kinetic Parameters 
To inspect the sensitivity of PikDH2 
to changes in distal stereochemistry, 
we next investigated substrates 2c and 
2d, epimeric at the γ- and δ-position 
as well as 2e wherein both the γ- and 
δ-positions are inverted. Enzymatic 
products of 2c–e were not detected by 
LC-MS/MS, indicating an 
unprecedented degree of 
discrimination of these distal 
stereocenters. Moreover, racemic 
diketide 5, similar to widely used 
diketide substrates to study other 
DHs12, 16, was unexpectedly not converted to the corresponding dehydration product. 
To study the chemical mechanism of PikDH2, the pH dependence of catalytic efficiency 
(Vmax/KM) with substrate 2a was obtained from pH 6.6 to 9.0 (Table 2.5). The hyperbolic curve 
implicates at least one key ionizable group responsible for binding and catalysis (from either the 
free enzyme or the free substrate)34 with a pKa value of 7.0 ± 0.1 (Fig. 2.10A). The protonation 
of this ionizable group at low pH values abolished the enzyme activity. The pKa values for the 
two hydroxyl groups of substrate 2a are expected to be ~14–16. Thus we expect the observed 
ionizable group is a general base in the enzyme, presumably the conserved histidine residue  
No. Substrate Structure KM (mM) kcat (min-1) 
kcat/KM, 
min-1 M-1 
1a  
 
6.9 ± 1.7 0.67 ± 0.11 98 ± 39 
1b  
 
> 8 <0.01 <1 
2a  
 
5.7 ± 1.4 1.28 ± 0.19 225 ± 88 
2b  
 
> 8 <0.01 <1 
2c  
 
> 8 <0.01 <1 
2d  
 
 
> 8 <0.01 <1 
2e  
 
> 8 <0.01 <1 
(±)-5 
 
 
> 8 <0.01 <1 
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Table 2.5 Vmax/KM values at varying hydrogen ion concentrations. 
pH Vmax/KM (×10-3min-1) 
6.6 0.2606 ± 0.0157 
6.7 0.4571 ± 0.0276 
7.0 0.6014 ± 0.0147 
7.2 0.6675 ± 0.0504 
7.5 0.9206 ±0.0345 
8.0 0.9154 ± 0.0376 
8.5 0.9479 ± 0.0413 
9.0 1.112 ± 0.0428 
  
Figure 2.10 (A) pH dependence of log(Vmax/KM). (B) Mechanism and key 
residues involved in dehydration reaction 
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(His3611), which abstracts the α-proton. An aspartic acid residue protonates the β-hydroxyl 
group to facilitate the loss of a water molecule (Fig. 2.10B)8-12. The slightly perturbed pKa of 7.0 
for the catalytic histidine, compared to pKa of 6.0 for the free amino acid, indicates the influence 
of adjacent residues to form a slightly negatively charged cavity35.  
In order to understand the basis for the remarkable selectivity of PikDH2 we next aligned 
the amino acid sequence of PikDH2 with other DHs of known 3D structure10-12. Two catalytic 
residues, the histidine (His3611) in an HXXGXXXP motif and the aspartic acid (Asp3800) in an 
HPALLD motif, are also found in PikDH2. However, the tyrosine in a YGP motif (observed in 
most DHs), whose role was proposed to assist the protonation of the β-hydroxyl group14, is 
absent in this DH. Instead, a phenylalanine (Phe3746, FGP motif) is located only 3.8 Å from the 
catalytic histidine in a PikDH2 homology model (Fig. 2.8), suggesting that this residue could 
impact substrate binding at the active site. The F3746L point mutant was generated and tested 
with substrate surrogate 2a to verify this possibility. The specificity constant dropped to 1/40 of 
the wild type, indicating the important role this phenylalanine plays for substrate binding (Table 
2.6). Another phenylalanine, residue 3750, conserved in most DHs, is also near the catalytic 
residues (3.2 Å from the aspartic acid) in the homology model. Mutants F3750Y and F3750L  
Table 2.6 Kinetic Parameters of PikDH2 Mutants 
 
had similar KM values to the wild type, but 15–30-fold decreased kcat values, demonstrating that 
change of Phe3750 hampers the catalytic activity of PikDH2. We hypothesize that the two 
Mutant KM (mM) kcat (min-1) kcat/KM, min-1 M-1 
WT 5.7 ± 1.4 1.28 ± 0.19 225 ± 88 
F3746L >40 N/A 5.2 ± 0.3 
F3750Y 4.14 ± 1.4 0.086 ± 0.013 21 ± 9 
F3750L 7.1 ± 2.6 0.046 ± 0.011 6.5 ± 3.9 
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phenylalanine residues (F3746 and F3750) may shape a hydrophobic pocket at the active site to 
position the substrate as well as maintain the catalytically active state. 
Co-crystallography of PKSs is particularly challenging since substrate affinity is often 
low due to the intramolecular nature of substrate presentation. With the hope of aiding structural 
studies and potentially allowing visualization of protein interfaces between ACP and DH 
domains36-37, we set out to screen for a suitable PikDH2 suicide substrate that would covalently 
react within the enzyme active site. 3-Decynoyl-N-acetylcysteamine (6) developed by Bloch was 
the first described mechanism-based inhibitor for any enzyme, which coincidentally inactivates 
FAS DHs38. Burkart and co-workers recently developed second-generation DH probes with 
improved chemical stability and demonstrated these could inactivate functionally and structurally 
related PKS DHs36-37. Therefore, we evaluated the ability of 6 to irreversibly inhibit PikDH2 
using our discontinuous assay monitoring the dehydration of substrate 2a by LC-MS/MS. 
Compound 6 was shown to exhibit time-dependent inhibition and the kinetic constants for 
inactivation were determined using the Kitz–Wilson method39. The kinetic parameters KI and 
kinact were 156 ± 34 μM and 0.36 ± 0.06 min−1 (Figs. 2.11A-C). Enzyme activity could not be 
recovered by dialysis and substrate protected PikDH2 from inactivation. Consequently, we 
expect 6 covalently labels PikDH2 in analogy to FAS DHs through abstraction of an α-proton by 
the catalytic histidine residue of the enzyme to form a reactive allene via propargylic 
rearrangement, which subsequently undergoes nucleophilic attack by the catalytic histidine (Fig. 
2.11A)40-41. 
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Discussion 
In summary, we have performed the first steady-state kinetic analysis of a PKS DH 
domain by using LC-MS/MS analysis for product quantitation. PikDH2 was found to process 
only d-alcohols to furnish trans-olefin products. The enzyme showed an unforeseen extremely 
high stereospecificity at the β-, γ- and δ-positions of the substrate, potentially revealing a 
challenge for future metabolic engineering efforts. The pH dependence of kcat/KM identified a 
general base with a pKa of 7.0 critical for substrate binding and catalysis, which we assign to 
Figure 2.11 (A) Mechanism of DH domain inactivation by 3-decynoyl-N-
acetylcysteamine (6). (B) Time course of the inactivation of PikDH2 with 10–40 
μM 6. 
Symbols represent the mean ± SD from duplicate experiments. (C) Kitz–Wilson plot19 of the 
inhibition data (1/kobs vs 1/[I]). 
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histidine (His3611). Mutagenesis and kinetic studies uncovered a critical hydrophobic region 
shaped by two phenylalanine residues that is essential for substrate binding as well as catalytic 
activity and suggest the tyrosine in a YGP motif (observed in most DHs) implicated in DH 
catalysis is not required for activity. In the search for a co-crystallography candidate for PikDH2, 
we demonstrated that an alkyne-based probe irreversibly modified this non-iterative type I PKS 
DH. These studies provide a foundation for future efforts aimed to uncover the protein-substrate 
interactions that govern binding and catalysis. Our findings further reinforce the utility of 
diffusible NAC substrate mimics containing a ketone isostere in place of the labile thioester for 
studying intrinsically unstable PKS chain intermediates. 
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Chapter 3. Tylosin polyketide synthase module 3: stereospecificity, stereoselectivity and 
steady-state kinetic analysis of β-processing domains via diffusible, synthetic substrates 
 
This chapter is published: Fiers, W. D., Dodge, G. J., Li, Y., Smith, J. L., Fecik, R. A., & 
Aldrich, C. C. Tylosin polyketide synthase module 3: stereospecificity, stereoselectivity and 
steady-state kinetic analysis of β-processing domains via diffusible, synthetic substrates. Chem 
Sci 6, 5027-5033 (2015). 
Summary 
Polyketide synthase (PKS) β-processing domains are responsible for much of the 
stereochemical complexity of polyketide natural products. Although the importance of β-
processing domains has been well noted and significantly explored, key stereochemical details 
pertaining to cryptic stereochemistry and the impact of remote stereogenic centers have yet to be 
fully discerned. To uncover the inner workings of ketoreductases (KR) and dehydratases (DH) 
from the tylosin pathway a didomain composed of TylDH3-KR3 was recombinantly expressed 
and interrogated with full-length tetraketide substrates to probe the impact of vicinal and distal 
stereochemistry. In vitro product isolation analysis revealed the products of the cryptic KR as d-
alcohols and of the DH as trans-olefins. Steady-state kinetic analysis of the dehydration reaction 
demonstrated a strict stereochemical tolerance at the β-position as d-configured substrates were 
processed more than 100 times more efficiently than l-alcohols. Unexpectedly, the k cat/K M 
values were diminished 14- to 45-fold upon inversion of remote ε- and ζ-stereocenters. This 
stereochemical discrimination is predicted to be driven by a combination of allylic A1,3 strain that 
likely disfavors binding of the ε-epimer and a loss of electrostatic interactions with the ζ-epimer. 
Our results strongly suggest that dehydratases may play a role in refining the stereochemical 
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outcomes of preceding modules through their substrate stereospecificity, honing the 
configurational purity of the final PKS product. 
Introduction 
Polyketides, polyoxygenated secondary metabolites isolated from fungal, plant and 
bacterial producing organisms, represent an incredibly diverse natural product family with 
manifold bioactivites1-3. Constituents of this natural product class are thought to serve as 
defensive and cell–cell signaling agents arising from billions of years of evolution. The complex 
and varied structural characteristics of polyketides are derived from their highly tunable, 
assembly line-like biosynthesis. Modular type I polyketide synthases (PKSs) are characterized by 
multi-functional proteins equipped with numerous catalytic domains, each responsible for a 
unique enzymatic reaction in the biosynthetic pathway4. A minimal module consists of acyl 
carrier protein (ACP), ketosynthase (KS) and acyl transferase (AT) domains. Additionally, 
polyketide modules often carry out varying degrees of β-carbon processing by successive action 
of ketoreductase (KR), dehydratase (DH), and enoyl reductase (ER) domains. These catalytic 
domains transform the β-keto moiety produced from the ACP, KS, and AT domains into 
hydroxyl, olefin, and saturated alkane products depending on their presence in the biosynthetic 
pathway. The β-processing domains create stereogenic centers and set the olefin geometry 
present in the final natural product with extremely stringent fidelity5-8. 
The stereochemical and/or geometric outcome of β-processing domains is often 
concealed or obscured through subsequent, downstream catalytic events. These instances of 
hidden domain action can fall into two broad categories: cryptic ketoreductase stereochemistry 
and cryptic dehydratase geometry. Cryptic KR reductions arise from presence of a subsequent 
DH domain, catalytically eliminating water and, in so doing, removing both α- and β-stereogenic 
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centers. trans-Olefin configuration arises from the elimination of d-alcohols while cis-olefins 
emanate from enzyme-mediated isomerization events.9-10 Despite recent, compelling evidence 
suggesting that, in phoslactomycin biosynthesis, PKS DH domain-catalyzed generation of Z-
olefins occurs from l-alcohols, in vitro validation has yet to be obtained.11-12 Olefin geometry 
may be rendered cryptic through successive reduction by an ER domain, potentially yielding a 
new α-stereogenic center in the process. Cryptic reductions have received a significant amount of 
attention over the last decade resulting in several novel approaches to their study.13-14 
Bioinformatic analysis has shown promise in predicting stereogenic centers based on amino acid 
sequence of the KR domain in question9, 15-16 . 
Tylosin (1), a 16-membered macrolactone product of Streptomyces fradiae, was chosen 
as a model system for our initial cryptic domain studies. The tylosin polyketide synthase includes 
one loading module and seven extension modules terminating in a thioesterase (TE) domain 
affording the aglycone tylactone (2) (Fig. 3.1)17. By virtue of their DH domains, modules 2, 3, 
and 5 have cryptic KR stereochemistry. Additionally, module 5 housing an ER domain 
constitutes a complete reductive sequence further obscuring the geometry of the precursor olefin. 
Prior methods to study cryptic KRs and DHs using synthetic substrates have generally been 
limited to diketides. Truncated substrates, while synthetically more accessible, are often poorly 
tolerated resulting in low conversion and exhibit loose stereochemical discrimination8, 18. As a 
result, the inferred substrate specificity obtained using truncated substrates remains dubious 
given their significant deviation from the native chain intermediates. Cane et al. overcame this 
limitation through the in situ chemoenzymatic synthesis of a triketide from a diketide substrate 
using a KS-AT didomain and excised ACP domain from the DEBS pathway19. However, we 
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anticipated this strategy would be difficult to implement for tetraketides as this would require the 
use of two complete modules in tandem. 
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The truncated region of the native substrate serving as 
the basis for substrates 4 and 5 is highlighted in blue. 
Figure 3.2 Native and synthetic TylKR3 
substrates and their possible β-processing 
products. 
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As part of ongoing studies in our laboratories, we are interested in the development and use of 
small molecule tools for exploring innate reactivity within polyketide synthase modules. In the 
present study we sought to probe the enzyme catalyzed turnover of full-length tetraketide 
substrates 4, 6a and 6b by TylKR3 and TylDH3 via LC-MS/MS detection (Fig. 3.2). One virtue 
of our chosen tetraketides is that they uniformly lack a δ-hydroxyl moiety which has been shown 
to spontaneously lactonize onto the thioester.18-20 Our previous strategy utilized stable full-length 
polyketide intermediate mimics that are resistant to spontaneous intramolecular lactonization 
through replacement of the labile thioester linkage with a stable thioether moiety14, 21. In light of 
these results, we sought to validate the use of thioether analogs 5, 7a and 7b for direct 
comparison with the aforementioned thioester substrates. This would constitute the first steady-
state analysis of a polyketide dehydratase domain using native substrates, uncover the cryptic 
stereochemistry of TylKR3, and would offer a unique, more native context to discover innate 
substrate biases. The use of a natural full-length tetraketide chain intermediates and epimers at 
each stereogenic center would also allow us to evaluate the impact of vicinal and distal 
stereochemistry on KR and DH substrate processing. 
Methods 
General chemistry procedures.  
(All synthesis protocols were run by Will Fiers) 
All chemical reagents were used as provided unless explicitly indicated otherwise. 
Tetrahydrofuran (THF) and dichloromethane (CH2Cl2) were purified via passage through alumina 
columns. All reactions were performed under anhydrous argon atmosphere using oven-dried (150 
C) glassware. Reaction mixtures were stirred magnetically using oven-dried magnetic stir bars. 
Compound purification via flash chromatography utilized silica gel (300–400 mesh) in the 
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indicated solvent system. TLC was performed using 250 µm, F254 silica gel plates and visualized 
UV and para-anisaldehyde stain. A Rudolph Autopol III polarimeter at the indicated temperature 
using the sodium D line (λ = 589 nm) unless otherwise specified and reported as follows: []temp
D
= 
rotation (c g/100 mL, solvent). 1H and 13C NMR spectra were recorded on a Bruker 400 
spectrometer at 400 Hz for 1H NMR and at 100 Hz for 13C NMR. Chemical shifts are reported in 
ppm based on an internal standard of residual CHCl3 (7.26 ppm in 
1H NMR and 77.16 in 13C 
NMR). Proton chemical data are reported in the following format: chemical shift (ppm) 
(multiplicity (s = singlet, d= doublet, t = triplet, q = quartet, quin = quintet, sextet = sextet, sept = 
septet, m = multiplet, br = broad peak), J = coupling constant (Hz), integration). High-resolution 
mass spectra (HRMS) were obtained on a Bruker BioTOF II ESI-TOF/MS using either PEG or 
PPG standards as high resolution calibrants.  
 
(S)-3-((4S,5R,E)-5-hydroxy-2,4-dimethylhept-2-enoyl)-4-isopropyloxazolidin-2-one (12). 
 An oven-dried round bottom flask (250 mL) equipped with magnetic 
stir bar charged with freshly distilled propionaldehyde22 (4.93 mL, 
68.3 mmol, 2 equiv.) in anhydrous dichloromethane (120 mL) was 
placed in dry ice-acetone bath (-78 C) and allowed to equilibrate.  To the cooled solution was 
added titanium(IV) chloride (3.77 mL, 34.2 mmol, 1 equiv.).  To the resulting yellow reaction 
mixture was slowly added the vinylketene silyl N,O-acetal 1123 (11.60 g, 34.2 mmol, 1 equiv.) as 
a solution in CH2Cl2 (45 mL, anhydrous).  The reaction quickly adopted a dark red hue.  
Following completion of addition the reaction mixture was transferred to dry ice-acetonitrile bath 
(-40 C) and stirred for 21 hours.  The reaction mixture was quenched upon treatment with 
saturated Rochelle’s salt (aq.) followed by saturated sodium bicarbonate (aq.) solutions at -40 
O
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C.  The cloudy, white solution was allowed to warm to room temperature and stirred for 1 hour.  
The resulting biphasic solution was separated, and the aqueous layer was extracted with 
dichloromethane (3 x 75 mL) and ethyl acetate (3 x 75 mL).  The combined organic solutions 
were dried over anhydrous Na2SO4, filtered, and concentrated under vacuum.  The resulting 
crude oil was dry-loaded onto silica column and purified via flash chromatography (30% 
EtOAc/hexanes) yielding the title compound (12) (8.76 g, 30.9 mmol, 90%) as a viscous, slightly 
yellow oil. Rf = 0.20 (20% EtOAc/hexanes); []23
D
= 28.3 (c 1.00, CHCl3); 
1H NMR (CDCl3, 400 
MHz) δ 5.82 (d, J = 10.4 Hz, 1H), 4.58 (dt, J = 8.8, 4.8 Hz, 1H), 4.34 (t, J = 8.8 Hz, 1H), 4.18 
(dd,  J  = 7.2, 7.6 Hz, 1H), 3.32–3.25 (m, 1H), 3.08 (br, 1H), 2.63–2.52 (m, 1H), 2.38–2.28 (m, 
1H), 1.94 (s, 3H), 1.76–1.64 (m, 1H), 1.44 (app sept, J = 7.6 Hz, 1H), 1.01 (t, J = 7.2 Hz, 3H), 
0.98 (d, J = 7.2 Hz, 3H), 0.95–0.89 (m, 6H); 13C NMR (CDCl3, 100 MHz) δ 171.7, 154.7, 142.5, 
131.2, 76.7, 63.6, 58.3, 39.9, 28.6, 26.8, 18.0, 16.3, 15.4, 14.1, 10.1; HRMS (ESI-TOF) m/z: [M 
+ Na]+ Calcd for C15H24NO4Na 306.1676; Found 306.1673. 
  
 
 (S)-3-((4S,5R,E)-2,4-dimethyl-5-((triisopropylsilyl)oxy)-hept-2-enoyl)-4-isopropyloxazolidin-2-
one (13).  
A solution containing the aldol adduct 12 (889 mg, 3.14 mmol, 1 
equiv.) in dichloromethane (24 mL, anhydrous) was cooled via ice-
water bath. To the chilled, colorless solution was added 
diisopropylethylamine (0.655 mL, 3.76 mmol, 1.2 equiv.) followed by triisopropylsilyl 
trifluoromethylsulfonate (1.01 mL, 3.76 mmol, 1.2 equiv.). The resulting solution was stirred at 
0° C (1 h) and transferred to refrigerator (3-5° C, 24 h). The yellow, clear reaction solution was 
O
N
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quenched upon addition of saturated sodium bicarbonate (aq.) solution at 0° C and allowed to 
warm to room temperature (20 min). The biphasic mixture was separated, and the aqueous layer 
was extracted with dichloromethane (4 x 20 mL). The combined organic layers were dried over 
Na2SO4, filtered, and concentrated under vacuum. The product residue was purified by flash 
chromatography (10% EtOAc/hexanes) affording the silyl ether 13 (1.3805 g, 3.14 mmol, quant.) 
as a transparent, colorless oil. Rf = 0.68 (20% EtOAc/hexanes); []21
D
 = 29.5 (c 1.00, CHCl3); 
1H 
NMR (CDCl3, 400 MHz) δ 6.19 (dd, J = 9.6, 1.2 Hz, 1H), 4.50 (ddd, J = 9.2, 5.6, 4.4, 1H), 4.29 
(t, J = 8.8), 4.14 (dd, J = 6.0, 9.2 Hz, 1H), 3.73(ddd, J = 5.2, 2.4, 7.6, 1H), 2.72 (ddq, 9.6, 6.8, 2.4 
Hz, 1H), 2.42-2.30 (m, 1H), 1.92 (d, J = 1.2 Hz, 3H), 1.63-1.48 (m, 2H), 1.10-1.04 (m, 24H), 
0.90 (t, J = 7.2 Hz, 6H), 0.86 (t, J = 7.6 Hz, 3H); 13C NMR (CDCl3, 100 MHz) δ 172.4, 153.8, 
141.1, 130.6, 77.8, 63.4, 58.4, 37.0, 28.3, 18.5, 18.4, 18.0, 16.7, 15.1, 13.7, 13.2, 10.5; HRMS 
(ESI-TOF) m/z: [M + Na]+ Calcd for C24H45NO4Na 462.3010; Found 462.3019. 
 
 (4S,5R,E)-2,4-dimethyl-5-((triisopropylsilyl)oxy)hept-2-enal (14).  
A solution of imide 13 (3.185 g, 7.24 mmol, 1 equiv.) in anhydrous 
dichloromethane (229 mL) was equilibrated in dry ice-acetone bath (-78 
°C) under argon atmosphere. To the stirred solution was added  
diisobutylaluminum hydride (1.49 M in toluene, 9.73 mL, 14.5 mmol, 2 equiv.) in a dropwise 
fashion over two minutes. The reaction mixture was allowed to stir at -78 °C for 14 minutes then 
quenched upon successive addition of methanol (15 mL) and saturated, aqueous sodium 
potassium tartrate (15 mL). The resulting mixture was allowed to warm to room temperature and 
stirred vigorously overnight (14 h). The biphasic solution was separated, and the aqueous layer 
was extracted with dichloromethane (3 x 100 mL). Combined organic extracts were dried over 
O
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sodium sulfate, filtered and concentrated under vacuum. The resulting toluene solution was 
directly loaded onto flash silica column and purified (10% EtOAc/hexanes) furnishing enal 14 
(1.983 g, 6.34 mmol, 88%) as a clear, colorless oil. Rf = 0.52 (10% EtOAc/hexanes); []22
D
 = -4.3 
(c 1.00, CHCl3); 
1H NMR (CDCl3, 400 MHz) δ 9.40 (s, 1H), 6.59 (d, J = 10.0 Hz, 1H), 3.78 
(app. quin, J = 4 Hz, 1H),  2.89 (ddq, J = 10.0, 6.8, 3.2 Hz, 1H), 1.76 (s, 3H), 1.65-1.54 (m, 1H), 
1.41 (app. sept, J = 7.6, 1H), 1.12 (d, J = 7.2 Hz, 3H), 1.08 (s, 21H), 0.86 (t, J = 7.6 Hz, 3H); 13C 
NMR (CDCl3, 100 MHz) δ 195.8, 156.8, 139.1, 77.4, 37.7, 28.6, 18.4, 16.9, 13.1, 9.9, 9.6; 
HRMS (ESI-TOF) m/z: [M + Na]+ Calcd for C18H36O2SiNa 335.2377; Found 335.2372. 
 
 (3S,6S,7R,E)-3-hydroxy-1-((R)-4-isopropyl-2-thioxo-thiazolidin-3-yl)-4,6-dimethyl-7-
((triisopropylsilyl)-oxy)non-4-en-1-one (16).  
A dichloromethane (anhydrous, 19.56 mL) solution of acetyl 
thiazolidinone 15 (1.07 g, 5.26 mmol, 1.7 equiv.) was cooled to -
40 °C (dry ice-acetonitrile bath) under inert, argon atmosphere. 
To the chilled, yellow solution was added titanium (IV) chloride (0.611 mL, 5.57 mmol, 1.8 
equiv.) resulting in a sudden color change to bright orange. The reaction mixture was stirred for 
30 minutes.  Slow addition of freshly distilled diisopropylethylamine22 (0.970 mL, 5.57 mmol, 
1.8 equiv.) over three minutes caused a dramatic color change to blood red. The enolate solution 
was stirred for 2h 12 m while maintaining an external temperature of -40 °C. The reaction was 
cooled to -78 °C and aldehyde 14 (0.967 g, 3.09 mmol, 1 equiv.) was slowly added over the 
course of one minute as a solution in dichloromethane (anhydrous, 3.87 mL) and stirred for 5 h. 
The resulting red-orange mixture was quenched via addition of saturated, aqueous ammonium 
chloride (10 mL) at -78 °C. The biphasic solution was allowed to warm to room temperature and 
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the layers were separated. The aqueous layer was extracted with dichloromethane (3 x 15 mL) 
and the combined organic layers were dried over sodium sulfate, filtered and concentrated under 
vacuum. The resulting clear, golden oil was wet-loaded onto silica column and purified via flash 
chromatography (20% EtOAc/hexanes) affording the title compound 16 as a bright yellow, 
viscous oil (1.29 g, 2.50 mmol, 81%). Rf = 0.29 (20% EtOAc/hexanes); []22
D
 = -219.0 (c 1.00, 
CHCl3); 
1H NMR (400 MHz, CDCl3) δ 5.51 (d, J = 9.6 Hz, 1H), 5.15 (app. t, J = 6.8 Hz, 1H), 
4.58 (dd, J = 8.8, 3.2 Hz, 1H), 3.66 (td, J = 6.4, 3.2 Hz, 1H), 3.56–3.44 (m, 3H), 3.03 (d, J = 11.6 
Hz, 1H), 2.63–2.55 (m, 1H), 2.38 (app. sextet, J = 7.2 Hz, 1H), 1.68 (s, 3H), 1.52–1.40 (m, 2H), 
1.07 (s, 24H), 0.99 (d, J = 2.4, 3H), 0.98 (d, J = 2.4, 3H), 0.85 (t, J = 7.2 Hz, 3H); 13C NMR 
(CDCl3, 100 MHz) δ 203.1, 173.0, 135.2, 129.1, 77.7, 73.4, 71.7, 44.3, 36.6, 31.0, 30.8, 27.6, 
19.3, 18.5, 17.9, 16.9, 13.2, 12.6, 10.5; HRMS (ESI-TOF) m/z: [M + Na]+ Calcd for 
C26H49NO3S2SiNa 538.2815; Found 538.2815. 
 
 (3S,6S,7R,E)-3-hydroxy-N-methoxy-N,4,6-trimethyl-7-((triisopropylsilyl)oxy)non-4-enamide 
(17).  
To a bright yellow dichloromethane (anhydrous, 2 mL) solution 
of acyl thiazolidinone 16 (203 mg, 0.39 mmol, 1 equiv.) was 
added imidazole (133 mg, 1.95 mmol, 5 equiv.) followed by methylmethoxyamine hydrochloride 
(95.0 mg, 0.98 mmol, 2.50 equiv). A catalytic amount of 4-dimethylaminopyridine (one crystal) 
was added to the final mixture. The reaction was stirred 20 h at room temperature and quenched 
via addition of saturated aqueous ammonium chloride (2 mL). The biphasic mixture was 
separated, and the aqueous layer was extracted with dichloromethane (4 x 10 mL). The combined 
organic layers were dried over sodium sulfate, filtered and concentrated under vacuum. The 
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crude residue was purified by flash chromatography (30% EtOAc/hexanes) providing a slightly 
yellow, clear, viscous oil (155 mg, 0.372 mmol, 96%). Rf = 0.34 (40% EtOAc/hexanes); []
21
D
 = 
-35.1 (c 1.00, CHCl3); 1H NMR (400 MHz, CDCl3) δ 5.49 (d, J = 9.6 Hz, 1H), 4.45 (dd, J = 8.0, 
4.4 Hz, 1H), 3.69 (s, 3H), 3.68–3.63 (m, 1H), 3.20 (s, 3H), 2.68 – 2.56 (m, 3H), 1.69 (s, 1H), 
1.47 (dq, J = 7.6, 6.8 Hz, 2H), 1.07 (s, 21H), 0.99 (d, J = 6.8 Hz, 3H), 0.85 (t, J = 7.6 Hz, 3H); 
13C NMR (CDCl3, 100 MHz) δ 173.9, 135.4, 128.5, 77.8, 73.4, 61.4, 37.2, 36.6, 32.0, 27.4, 
18.4, 16.8, 13.1, 12.6, 10.5; HRMS (ESI-TOF) m/z: [M + Na]+ Calcd for C22H45NO4SiNa 
438.3010; Found 438.3009. 
 
 (3S,6S,7R,E)-N-methoxy-N,4,6-trimethyl-3-((tri-ethylsilyl)oxy)-7-((triisopropylsilyl)oxy)non-4-
enamide (18).   
To a reaction flask containing β-hydroxy amide 17 (345 mg, 
0.829 mmol, 1.00 equiv.) dissolved in anhydrous 
dichloromethane (15 mL) in ice-water bath (0 °C) was added 2,6-lutidine (0.387 mL, 3.32 mmol, 
4.00 equiv.). The resulting basic solution was supplemented with triethylsilyl 
trifluoromethanesulfonate (0.375 mL, 1.66 mmol, 2.00 equiv.) and stirred for 1.5 h. The reaction 
was terminated via the sequential addition of methanol (3 mL) followed by saturated aqueous 
sodium bicarbonate (5 mL) at 0 °C. The biphasic mixture was warmed to room temperature, 
separated, and the aqueous fractions were extracted with dichloromethane (4 x 10 mL). The 
combined organic fractions were dried over anhydrous sodium sulfate, filtered and concentrated 
under vacuum. The resulting crude oil was wet-loaded onto silica column and purified via flash 
chromatography (10% EtOAc/hexanes) affording a clear, slightly yellow oil (410.6 mg, 0.776 
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mmol, 94%). Rf = 0.61 (20% EtOAc/hexanes); []
23
D
 = -20.6 (c 1.00, CHCl3); 1H NMR (400 
MHz) δ 5.45 (d, J = 9.6 Hz, 1H), 4.58 (dd, J = 8.8, 4.4 Hz, 1H), 3.70 (s, 3H), 3.65 (td, J = 6.8, 2.8 
Hz, 1H), 3.17 (s, 3H), 2.94–2.80 (m, 1H), 2.56 (dqd, J = 9.6, 6.8, 2.8 Hz, 1H), 2.31 (dd, J = 14.0, 
4.4 Hz, 1H), 1.64 (s, 3H), 1.52 – 1.39 (m, 2H), 1.08 (s, 21H), 0.96 (d, J = 6.8 Hz, 3H), 0.91 (t, J 
= 8.0 Hz, 9H), 0.85 (t, J = 7.6 Hz, 3H), 0.56 (q, J = 8.0 Hz, 6H); 13C NMR (CDCl3, 100 MHz) δ 
172.3, 136.8, 128.0, 78.0, 75.5, 61.5, 39.7, 36.6, 32.1, 27.6, 18.4, 16.7, 13.1, 11.7, 10.8, 7.0, 4.9; 
HRMS (ESI-TOF) m/z: [M + Na]+ Calcd for C28H59NO4Si2Na 552.3875; Found 552.3882. 
 
 (5S,8S,9R,E)-6,8-dimethyl-5-((triethylsilyl)oxy)-9-((triiso-propylsilyl)oxy)undeca-1,6-dien-3-
one (19).  
A reaction vessel containing weinreb amide 18 (237 mg, 0.448 
mmol, 1 equiv.) in anhydrous tetrahydrofuran (32 mL) was placed in 
ice-water bath (0 °C) and allowed to equilibrate. To the chilled, clear solution was added solution 
of vinylmagnesium bromide (1.0 M in THF, 1.44 mL, 1.44 mmol, 3.20 equiv.). The reaction 
mixture was stirred at 0 °C for 4 h. An additional aliquot of vinylmagnesium bromide (0.450 mL, 
0.450 mmol, 1.00 equiv.) was added and the reaction mixture was stirred for 1 h prior to 
quenching with saturated, aqueous ammonium chloride (10 mL). The biphasic mixture was 
allowed to warm to room temperature, separated and the aqueous layer was extracted with 
dichloromethane (3 x 15 mL). The combined organic layers were dried over sodium sulfate, 
filtered and concentrated under vacuum. The resulting crude oil was wet-loaded onto silica 
column and purified via flash chromatography (5% EtOAc/hexanes) yielding the desired enone 
as a clear, colorless oil (192 mg, 0.387 mmol, 86%). Rf = 0.38 (5% EtOAc/hexanes); []22
D
 = -
20.7 (c 0.978, CHCl3); 
1H NMR (400 MHz) δ 6.36 (dd, J = 17.6, 10.8 Hz, 1H), 6.20 (d, J = 17.6 
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Hz, 1H), 5.82 (d, J = 10.8 Hz, 1H), 5.43 (d, J = 9.2 Hz, 1H), 4.54 (dd, J = 8.4, 4.4 Hz, 1H), 3.64 
(td, J = 6.9, 2.6 Hz, 1H), 2.94 (dd, J = 14.0, 8.5 Hz, 1H), 2.63–2.42 (m, 2H), 1.63 (s, 3H), 1.52–
1.35 (m, 2H), 1.08 (s, 21H), 0.95 (d, J = 6.8, 3H), 0.89 (t, J = 8.0 Hz, 9H), 0.85, (t, J = 7.4 Hz, 
3H), 0.54 (q, J = 8.0 Hz, 6H); 13C NMR (CDCl3, 100 MHz) δ 199.6, 137.6, 136.5, 128.5, 128.1, 
77.9, 75.6, 47.0, 36.6, 27.6, 18.4, 13.1, 11.6, 10.8, 7.0, 6.0, 4.9; HRMS (ESI-TOF) m/z: [M + 
Na]+ Calcd for C28H56O3Si2Na 519.3660; Found 519.3647. 
 
 (5S,8S,9R,E)-5,9-dihydroxy-6,8-dimethylundeca-1,6-dien-3-one (20).  
To a polypropylene tube (15 mL, BD FalconTM) containing silylether 
19 (29.8 mg, 0.0600 mmol, 1 equiv.) was added acetonitrile (3.0 mL) 
and magnetic stir bar. The mixture was stirred in ice-water bath (0 °C) until a homogenous 
solution was obtained. A solution of 48% aqueous hydrofluoric acid and acetonitrile (11:89, 8.36 
mL) was slowly added to the reaction vessel. The resulting clear solution was stirred vigorously 
for 1 h and placed in a refrigerator (4 °C) for 15 h. The reaction was quenched at 0 °C via 
dropwise addition of a saturated aqueous sodium bicarbonate solution until the pH was 7. The 
neutralized solution was extracted with ethyl acetate (4 x 15 mL). All organic fractions were 
combined, dried over sodium sulfate, filtered and concentrated under vacuum. The crude residue 
was wet-loaded onto silica column and purified via flash column chromatography (5% 
MeOH/dichloromethane) affording the diol as a clear, colorless oil (13.3 mg, 0.586 mmol, 98%). 
Rf = 0.30 (5% MeOH/dichloromethane); []21
D
 = -37.2 (c 0.26, CHCl3); 1H NMR (400 MHz) δ 
6.37 (dd, J = 17.6, 10.3 Hz, 1H), 6.26 (dd, J = 17.7, 1.0 Hz, 1H), 5.90 (dd, J = 11.4, 1.0 Hz, 1H), 
5.38 (d, J = 9.9 Hz, 1H), 4.52 (dd, J = 7.3, 4.7 Hz, 1H), 3.32 (ddd, J = 8.4, 6.4, 3.6 Hz, 1H), 2.99 
(br, 1H), 2.86–2.80 (m, 2H), 2.53– 2.41(m, 1H), 1.69 (d, J = 1.2 Hz, 3H), 1.62–1.53 (m, 2H), 
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1.45–1.33 (m, 1H), 0.97 (t, J = 7.4 Hz, 3H), 0.96 (d, J = 6.8 Hz, 3H); 13C NMR (CDCl3, 100 
MHz) δ 201.0, 137.6, 136.9, 129.5, 128.4, 77.0, 73.0, 44.6, 38.1, 27.1, 17.2, 13.0, 10.2; HRMS 
(ESI-TOF) m/z: [M + Na]+ Calcd for C13H22O3Na 249.1461; Found 249.1466. 
 
N-(2-(((5S,8S,9R,E)-5,9-dihydroxy-6,8-dimethyl-3-oxoundec-6-en-1-yl)thio)ethyl)acetamide 
(7b).  
A reaction flask containing vinyl ketone 20 (3.9 mg) in 
anhydrous tetrahydrofuran (5 mL) was supplemented with 
N-acetylcysteamine (2.0 μL, 0.019 mmol, 1.1 equiv.). To the resulting clear solution was added a 
catalytic amount of cesium carbonate and the resulting reaction mixture was stirred for 5 hr at 
ambient temperature under argon atmosphere and quenched upon addition of a saturated, 
aqueous ammonium chloride solution (5 mL). The biphasic mixture was separated, and the 
aqueous layer was extracted with ethyl acetate (8 x 10 mL). The combined organic fractions 
were dried over sodium sulfate, filtered and concentrated under vacuum. The crude residue was 
wet-loaded onto silica flash column with a small copper(II) sulfate-impregnated silica gel plug (2 
cm thick) and purified (eluent = 10% MeOH/dichloromethane) furnishing the desired thioether 
as a colorless, translucent oil (5.9 mg, 0.017 mmol, quant.). Rf = 0.13 (5% 
MeOH/dichloromethane); []22
D
 = -24.9 (c 0.38, CHCl3); 
1H NMR (400 MHz) δ 6.11 (s, 1H), 
5.36 (d, J = 9.9 Hz, 1H), 4.48 (dd, J = 8.5, 3.4 Hz, 1H), 3.43 (app. q, J = 6.1 Hz, 2H), 3.37–3.24 
(m, 1H), 2.86–2.58 (m, 8H), 2.49–2.39 (m, 1H), 1.99 (s, 3H), 1.66 (d, J = 1.0 Hz, 3H), 1.61–1.52 
(m, 1H), 1.44–1.32 (m, 1H), 0.99–0.93 (m, 6H); 13C NMR (CDCl3, 100 MHz) δ 209.4, 170.5, 
137.5, 128.4, 77.1, 73.1, 48.2, 43.8, 38.7, 38.0, 32.2, 27.2, 25.2, 23.4, 17.2, 13.0, 10.2; HRMS 
(ESI-TOF) m/z: [M + Na]+ Calcd for C17H31NO4SNa 368.1866; Found 368.1872. 
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 (5S,8S,9R,E)-5-hydroxy-6,8-dimethyl-9-((triisopropylsilyl)-oxy)undeca-1,6-dien-3-one (21).  
To a reaction vessel containing disilylether 19 (39.3 mg, 0.0792 
mmol) in a mixture of tetrahydrofuran (1.98 mL) and deionized water 
(0.296 mL) was added trifluoroacetic acid (15.6 μL, 0.210 mmol, 2.65 equiv.). The acidic 
solution was stirred for 2.5 hr at ambient temperature and carefully neutralized upon addition of 
a saturated, aqueous sodium bicarbonate solution. The biphasic solution was separated, and the 
aqueous layer repeatedly extracted with ethyl acetate (4 x 7 mL). The combined organic layers 
were dried over sodium sulfate, filtered and concentrated under vacuum. The crude product was 
wet-loaded onto silica column and purified via flash column chromatography (10% 
EtOAc/hexanes) producing a light yellow, clear oil (29.5 mg, 0.0771 mmol, 97%). Rf = 0.25 
(10% EtOAc/hexanes); []24
D
 = -23.0 (c 1.00, CHCl3);
 1H NMR (400 MHz) δ 6.37 (dd, J = 17.7, 
10.4 Hz, 1H), 6.25 (d, J = 16.6 Hz, 1H), 5.89 (d, J = 10.4 Hz, 1H), 5.48 (d, J = 9.6 Hz, 1H), 4.52 
(dd, J = 9.1, 2.8 Hz, 1H), 3.65 (td, J = 6.2, 3.3 Hz, 1H), 2.87 (dd, J = 16.8, 9.2 Hz, 1H), 2.75 (dd, 
J = 16.8, 3.1 Hz, 1H), 2.62–2.54 (m, 1H), 1.68 (d, J = 1.3 Hz, 3H), 1.54 – 1.40 (m, 2H), 1.07 (s, 
21H), 0.97 (d, J = 6.9 Hz, 3H), 0.85 (t, J = 7.5 Hz, 3H); 13C NMR (CDCl3, 100 MHz) δ 201.1, 
136.9, 135.3, 129.2, 128.9, 77.8, 73.3, 44.8, 36.6, 27.6, 18.5, 16.9, 13.2, 12.5, 10.5; HRMS (ESI-
TOF) m/z: [M + Na]+ Calcd for C22H42O3SiNa 405.2795, Found 405.2795. 
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 (8S,9R,E)-6,8-dimethyl-9-((triisopropylsilyl)oxy)undeca-1,6-diene-3,5-dione (22).  
To a small flask containing β-hydroxy ketone 21 (80.0 mg, 0.209 
mmol) in ethyl acetate (10 mL) was added 2-iodoxybenzoic acid (390 
mg, 0.627 mmol, 3.00 equiv., 45% wt/wt). The white, cloudy solution was rapidly stirred and 
heated at reflux for 2 h. The slightly yellow solution was cooled to ambient temperature and 
concentrated under vacuum. The resulting concentrated solution was directly loaded onto silica 
flash column and purified (5% EtOAc/hexanes) yielding a red-orange oil (72.4 mg, 0.190 mmol, 
92%). Rf = 0.36 (5% EtOAc/hexanes); []21
D
 = -47.2 (c 1.00, CHCl3); 
1H NMR (400 MHz) δ 
15.46 (s, 1H), 6.71 (dd, J = 9.9, 1.0 Hz, 1H), 6.25 (dd, J = 17.2, 2.0 Hz, 1H), 6.17 (dd, J = 9.9, 
17.2 Hz, 1H), 5.89 (s, 1H), 5.64 (dd, J = 9.9, 2.0 Hz, 1H), 3.75 (ddd, J = 7.8, 4.6, 3.6 Hz, 1H), 
2.81–2.72 (m, 1H), 1.87 (d, J = 1.1 Hz, 3H), 1.63–1.52 (m, 1H), 1.49–1.37 (m, J = 14.9, 7.4 Hz, 
1H), 1.09–1.07 (m, 24H), 0.86 (t, J = 7.5 Hz, 3H); 13C NMR (CDCl3, 100 MHz) δ 193.1, 176.5, 
143.0, 134.4, 133.3, 124.5, 96.6, 77.6, 37.8, 28.4, 18.4, 16.9, 13.2, 11.9, 10.0; HRMS (ESI-TOF) 
m/z: [M + Na]+ Calcd for C22H40O3SiNa 403.2639, Found 403.2646. 
 
 (8S,9R,E)-9-hydroxy-6,8-dimethylundeca-1,6-diene-3,5-dione (23).  
To a polypropylene tube (15 mL, BD FalconTM) containing silylether 
22 (72.4 mg, 0.140 mmol) was added acetonitrile (1.23 mL). The clear 
solution was equilibrated in ice-water bath (0 °C) for 10 minutes. A pre-chilled solution of 48% 
aqueous hydrogen fluoride and acetonitrile (11:89, 9.84 mL) was slowly added to the rapidly 
stirred solution. The resulting slightly yellow solution was placed in refrigerator (4 °C) for 40 h. 
The reaction mixture was quenched via slow neutralization with aqueous, saturated sodium 
bicarbonate solution at 0 °C. The aqueous layer was extracted with ethyl acetate (5 x 20 mL) and 
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the combined organic layers were concentrated under vacuum. The product was placed under 
high vacuum for 2 h furnishing the desired alcohol 23 as a viscous, yellow oil (42.6 mg, 0.190 
mmol, quant.). Rf = 0.20 (20% EtOAc/hexanes); []22
D
 = -51.2 (c 1.00, CHCl3); (Compound 23 
was found to exist entirely in the enol form (not drawn)) 1H NMR (400 MHz) δ 15.54 (br, 1H), 
6.59 (dd, J = 10.0, 0.96 Hz, 1H), 6.28 (dd, J = 17.2, 2.4 Hz, 1H), 6.21 (dd, J = 17.2, 9.5 Hz, 1H) 
5.90 (s, 1H), 5.66 (dd, J = 9.5, 2.4 Hz, 1H), 3.49 (dt, J = 8.8, 4.6 Hz, 1H), 2.73–2.60 (m, 1H), 
1.89 (d, J = 1.0 Hz, 3H), 1.60–1.49 (m, 1H), 1.43 (dq, J = 14.2, 7.5 Hz, 1H), 1.08 (d, J = 6.7 Hz, 
3H), 0.97 (t, J = 7.4 Hz, 3H); 13C NMR (CDCl3, 100 MHz) δ 192.1, 177.7, 141.6, 135.1, 133.3, 
125.0, 96.9, 76.9, 39.2, 27.9, 16.8, 12.2, 10.2; HRMS (ESI-TOF) m/z: [M + Na]+ Calcd for 
C13H20O3Na 247.1305, Found 247.1310. 
 
 
N-(2-(((8S,9R,E)-9-hydroxy-6,8-dimethyl-3,5-dioxoundec-6-en-1-yl)thio)ethyl)acet-amide (5).  
To a round bottom flask containing vinyl ketone (12.3 mg, 0.055 mmol) in anhydrous 
tetrahydrofuran (10 mL) was added N-acetylcysteamine (6.4 μL, 0.060 mmol, 1.1 equiv.) as a 
solution in anhydrous THF (64 μL). The reaction mixture was supplemented with a catalytic 
amount of cesium carbonate and stirred at ambient temperature for 4.5 h. The bright yellow, 
transparent solution was quenched via addition of aqueous, saturated ammonium chloride 
solution (5 mL) and the resulting biphasic solution was separated. The aqueous layer was 
repeatedly extracted with ethyl acetate (5 x 10 mL). Combined organic fractions were dried over 
anhydrous sodium sulfate, filtered and concentrated under vacuum. The crude residue was 
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purified by via flash column chromatography (5% MeOH/dichloromethane) providing the 
desired thioether 5 as a viscous, bright orange oil (7.2 mg, 0.021 mmol, 38%). Rf = 0.30 (5% 
MeOH/dichloromethane); []21
D
 = -30.0 (c 0.46, CHCl3); (Compound 5 existed in a ~3:1 mixture 
of enol (B) and keto (A) tautomers, respectively) 1H NMR (400 MHz) δ 15.58 (s, 0.75H), 6.66–
6.56 (m, 1H), 6.09 (br, 0.25H), 5.96 br, 0.75H), 5.80 (br, 0.75H), 3.96 (d, J = 14.7 Hz, 0.25H), 
3.79 (d, J = 14.7 Hz, 0.25H), 3.61–3.36 (m, 3H), 2.87–2.80 (m, 2H), 2.80 – 2.74 (m, 0.50H), 
2.72–2.62 (m, 4.5H), 1.98–2.02 (m, 3H), 1.85 (d, J = 1.2 Hz, 2.25H), 1.81 (d, J = 1.2 Hz, 0.75H), 
1.60–1.48 (m, 1H), 1.47–1.37 (m, 1H), 1.09 (d, J = 6.9 Hz, 0.75H), 1.06 (dd, J = 6.8 Hz, 2.25H), 
1.00–0.93 (m, 3H); (Only the major (enol) tautomer B carbon shifts are recorded) 13C NMR 
(CDCl3, 100 MHz) δ 194.8, 183.7, 170.4, 141.2, 132.2, 96.6, 76.9, 39.7, 39.1, 38.6, 32.2, 27.9, 
27.2, 23.4, 16.8, 12.4, 10.2; HRMS (ESI-TOF) m/z: [M + Na]+ Calcd for C17H29NO4SSi 
366.1710, Found 366.1716. 
 
S-(2-acetamidoethyl) (3S,6S,7R,E)-3-hydroxy-4,6-di-methyl-7-((triisopropylsilyl)oxy)non-4-
enethioate (24).  
A reaction vessel containing thiazoldinethione 16 (0.142 g, 
0.276 mmol) in anhydrous dichloromethane (2 mL) under argon 
atmosphere was added imidazole (56.4 mg, 0.828 mmol, 3.00 equiv.). To the clear, yellow 
solution was added N-acetylcysteamine (32.3 μL, 0.304 mmol, 1.10 equiv.) and the resulting 
reaction mixture was stirred for 14 hr at ambient temperature. The crude reaction mixture was 
wet-loaded onto silica column and purified by flash chromatography (5% 
MeOH/dichloromethane) affording the desired thioester 24 as a transparent, slightly yellow oil 
(0.119 g, 0.251 mmol, 91%). Rf = 0.32 (5% MeOH/dichloromethane); []22
D
 = -15.0 (c 1.00, 
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CHCl3); 
1H NMR (400 MHz) δ 5.82 (s, 1H), 5.49 (d, J = 9.7 Hz, 1H), 4.49 (d, J = 8.4 Hz, 1H), 
3.65 (br, 1H), 3.45 (q, J = 5.9 Hz, 2H), 3.05 (t, J = 6.2 Hz, 2H), 2.85 (dd, J = 15.0, 9.2 Hz, 1H), 
2.79 – 2.64 (m, 1H), 2.63–2.51 (m, 1H), 2.34 (br, 1H), 1.97 (s, 3H), 1.65 (s, 3H), 1.54–1.36 (m, 
2H), 1.07 (s, 21H), 0.96 (d, J = 6.9 Hz, 3H), 0.84 (t, J = 7.3 Hz, 3H); 13C NMR (CDCl3, 100 
MHz) δ 199.1, 170.5, 134.9, 129.6, 77.7, 74.4, 49.8, 39.6, 36.6, 29.0, 27.6, 23.4, 18.5, 17.0, 13.2, 
12.2, 10.4; HRMS (ESI-TOF) m/z: [M + Na]+ Calcd for C24H47NO4SSiNa 496.2887, Found 
494.2896. 
 
S-(2-acetamidoethyl) (3S,6S,7R,E)-3,7-dihydroxy-4,6-dimethylnon-4-enethioate (6b).  
A solution of silylether 25 (33.4 mg, 0.0706 mmol) in acetonitrile 
(3.55 mL) in a polypropylene tube (15 mL, BD FalconTM) was 
cooled in ice-water bath (0 °C). To the reaction mixture was 
added a chilled solution of 48% hydrofluoric acid in acetonitrile (11:89, 10.6 mL) and the 
resulting combined solution was transferred to the refrigerator overnight (15 h). The reaction 
mixture was neutralized via slow addition of a saturated, aqueous sodium bicarbonate solution at 
0 °C. The clear solution was extracted with ethyl acetate (3 x 25 mL). The combined organic 
layers were dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. Flash 
column chromatography (10% MeOH/dichloromethane) of the crude residue furnished the title 
diol as a colorless, clear oil (14.1 mg, 0.0445 mmol, 63%). Rf = 0.44 (10% 
MeOH/dichloromethane); [] 22
365
 = -6.0 (c 0.51, CHCl3); 
1H NMR (400 MHz) δ 6.16 (br, 1H), 
5.38 (d, J = 9.9 Hz, 1H), 4.46 (br, 1H), 3.52–3.35 (m, 2H), 3.33–3.22 (m, 1H), 3.11–2.96 (m, 
3H), 2.87 (dd, J = 14.7, 7.5 Hz 1H), 2.79 (dd, J = 14.5, 4.0 Hz 1H), 2.49–2.39 (m, 1H), 1.96 (s, 
3H), 1.67 (s, 3H), 1.62–1.53 (m, 1H), 1.45–1.31 (m, 1H), 1.01–0.88 (m, 6H); 13C NMR (CDCl3, 
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100 MHz) δ⁡199.0, 170.7, 137.2, 128.9, 77.1, 74.0, 49.3, 39.3, 38.1, 29.3, 27.2, 23.3, 17.2, 13.1, 
10.1; HRMS (ESI-TOF) m/z: [M + Na]+ Calcd for C15H27NO4SNa 340.1553, Found 340.1565. 
 
S-(2-acetamidoethyl) (6S,7R,E)-4,6-dimethyl-3-oxo-7-((triisopropylsilyl)oxy)non-4-enethioate 
(25).  
To a small round bottom flask was added β-hydroxythioester 24 
(20.7 mmol, 0.0437 mmol) as an ethyl acetate solution (2 mL). 
The colorless solution was diluted with additional ethyl acetate (3 mL) and a superstoichiometric 
amount of 2-iodoxybenzoic acid (81.8 mg, 0.131 mmol, 3.00 equiv., 45% wt/wt) was added. The 
white suspension was refluxed for 1 h. After cooling to ambient temperature the reaction mixture 
was filtered through celite pad (3 cm thick) and concentrated under vacuum affording the crude 
β-ketothioester 25 as a yellow oil which was taken to the next step without further purification. 
Rf = 0.45 (5% MeOH/dichloromethane). 
 
 
S-(2-acetamidoethyl) (6S,7R,E)-7-hydroxy-4,6-dimethyl-3-oxonon-4-enethioate (4).  
The crude silylether 25 (20.6 mg, 0.0437 mmol) was transferred as an acetonitrile solution (0.200 
mL) to a polypropylene tube (15 mL, BD FalconTM)⁡and cooled via ice-water bath (0 °C). To the 
pre-chilled solution was added a 48% hydrofluoric acid solution diluted in acetonitrile (11:89, 
2.50 mL). The reaction mixture was placed in refrigerator (4 °C) for 24 h. TLC analysis of the 
reaction mixture indicated incomplete conversion and an addition portion of hydrofluoric acid 
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solution (freshly prepared and identical to above, 1 mL) was added to the reaction mixture at 0 
°C.  After an additional 12 h at 4 °C, the reaction mixture was neutralized at 0 °C via addition of 
aqueous, saturated sodium bicarbonate solution. The reaction mixture was extracted with ethyl 
acetate (4 x 25 mL). The combined organic fractions were dried over anhydrous sodium sulfate, 
filtered and concentrated under vacuum. Crude product was purified by flash column 
chromatography (5% MeOH/dichloromethane) yielding a slightly yellow oil (11.8 mg, 0.0374 
mmol, 86% from 24). Rf = 0.25 (5% MeOH/dichloromethane); []21
D
 = -35.8 (c 0.79, CHCl3); 
(Compound 26 exists as in equilibrium of A and B (~3:1)) 1H NMR (400 MHz) δ 12.71 (br, 
0.25H), 6.65 (d, J = 9.8 Hz, 0.75H), 6.58 (d, J = 10.1 Hz, 0.25H), 6.24 (s, 0.75H), 6.05 (s, 
0.25H), 5.66 (s, 0.25H), 4.08 (d, J = 15.0 Hz, 0.75H), 3.90 (d, J = 15.0 Hz, 0.75H), 3.59–3.33 
(m, 3H), 3.13–3.00 (m, 2H), 2.74–2.59 (m, 1H), 2.02–1.91 (m, 3H), 1.85–1.78 (s, 3H), 1.58–1.34 
(m, 2H), 1.09 (d, J = 6.8 Hz, 2.25H), 1.04 (d, J = 6.8 Hz, 0.75H), 1.00–0.90 (m, 3H); (Carbon 
shifts only given for major tautomer) 13C NMR (CDCl3, 100 MHz) δ 193.8, 193.5, 170.9, 147.7, 
137.3, 76.9, 53.2, 39.5, 39.2, 29.5, 28.3, 23.2, 16.8, 11.7, 10.3; HRMS (ESI-TOF) m/z: [M + 
Na]+ Calcd for C15H25NO4SSi 338.1397, Found 338.1398. 
 
 (3R,6S,7R,E)-3-hydroxy-1-((S)-4-isopropyl-2-thioxo-thiazolidin-3-yl)-4,6-dimethyl-7-
((triisopropylsilyl)-oxy)non-4-en-1-one (S1).  
A reaction vessel containing thiazolidinethione ent-15 (91.9 mg, 
0.452 mmol, 1.50 equiv.) in anhydrous dichloromethane (3.00 
mL) was cooled in ice-water bath (0 °C). To the chilled, bright 
yellow solution was added titanium(IV) chloride (55.0 μL, 0.503 mmol, 1.67 equiv.) resulting in 
a color change to red orange. The reaction was stirred for 5 min, then placed in dry ice-acetone 
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bath (-78 °C) and allowed to equilibrate. To the chilled reaction mixture was added freshly 
distilled diisopropylethylamine22 (87.6 μL, 0.503 mmol, 1.67 equiv.) dropwise over 4 min 
causing a sudden color change to blood red. The solution was stirred at -78 °C for 2 h. To the 
enolate solution was added aldehyde 14 (94 mg, 0.301 mmol, 1.00 equiv.) as a solution in 
anhydrous dichloromethane (1 mL) over the course of 6 min. The reaction mixture was stirred at 
-78 °C for an additional 6 hours and quenched upon addition of saturated, aqueous ammonium 
chloride solution (5 mL). The biphasic solution was warmed to ambient temperature, separated 
and the aqueous layer extracted with dichloromethane (4 x 10 mL). The combined, organic 
fractions were dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. 
Purification by silica gel chromatography (20% EtOAc/hexanes) provided the desired aldol 
adduct as a yellow, viscous oil (0.106 mg, 0.205 mmol, 68%). Rf = 0.31 (20% EtOAc/hexanes); 
[]22
D
 = 217.2 (c 1.00, CHCl3); 
1H NMR (400 MHz) δ 5.51 (d, J = 9.5 Hz, 1H), 5.15 (t, J = 6.5 
Hz, 1H), 4.58 (d, J = 9.3 Hz, 1H), 3.65 (br, 1H), 3.56 – 3.38 (m, 3H), 3.03 (d, J = 11.5 Hz, 1H), 
2.58 (br, 1H), 2.45 – 2.32 (m, 1H), 1.67 (s, 3H), 1.54–1.35 (m, 2H), 1.07 (app. s, 24H), 0.97 (t, J 
= 6.0 Hz, 6H), 0.84 (t, J = 7.0 Hz, 3H); 13C NMR (CDCl3, 100 MHz) δ 203.1, 173.0, 135.1, 
129.3, 77.7, 77.4, 73.5, 71.7, 44.2, 36.6, 31.0, 27.7, 19.3, 18.5, 18.0, 17.0, 13.2, 12.4, 10.4; 
HRMS (ESI-TOF) m/z: [M + Na]+ Calcd for C26H49NO3S2SiNa 538.2815, Found 538.2821. 
 
S-(2-acetamidoethyl) (3R,6S,7R,E)-3-hydroxy-4,6-di-methyl-7-((triisopropylsilyl)oxy)non-4-
enethioate (S2).  
To a reaction vessel containing acyl thiazolidinethione S1 (66.0 
mg, 0.128 mmol) in anhydrous dichloromethane (2 mL) was 
sequentially added imidazole (26.0 mg, 0.384 mmol, 3.00 equiv.) and N-acetylcysteamine (16.0 
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μL, 0.154 mmol, 1.20 equiv.). The transparent, yellow solution was vigorously stirred under 
argon atmosphere for 15 hr at ambient temperature. The reaction was quenched upon addition of 
an aqueous, saturated ammonium chloride solution (3 mL) and the biphasic solution was 
separated. The aqueous layer was extracted with dichloromethane (3 x 10 mL). The combined 
organic layers were dried over anhydrous sodium sulfate, filtered, concentrated under vacuum 
and purified via silica column flash chromatography (5% MeOH/dichloromethane) using a small 
plug of copper(II) sulfate impregnated silica gel (1 cm on top) furnished the title compound as a 
colorless oil (59.0 mg, 0.125 mmol, 97%). Rf = 0.35 (5% MeOH/dichloromethane); []22
D
 = -7.4 
(c 1.00, CHCl3); 
1H NMR (400 MHz) δ⁡5.94 (br, 1H), 5.48 (d, J = 9.7 Hz, 1H), 4.49 (dd, J = 9.2, 
3.4 Hz, 1H), 3.71–3.56 (m, 1H), 3.44 (q, J = 6.1 Hz, 2H), 3.13–2.94 (m, 2H), 2.85 (dd, J = 15.0, 
9.2 Hz, 1H), 2.71 (dd, J = 14.9, 3.6 Hz, 1H), 2.55 (ddd, J = 9.9, 6.8, 3.2 Hz, 1H), 2.47 (br, 1H), 
1.96 (s, 3H), 1.64 (d, J = 1.1 Hz, 3H), 1.52–1.30 (m, 2H), 1.06 (s, 21H), 0.98 (d, J = 6.9 Hz, 3H), 
0.82 (t, J = 7.4 Hz, 3H); 13C NMR (CDCl3, 100 MHz) δ 199.0, 170.6, 134.9, 129.7, 77.7, 74.5, 
49.8, 39.5, 36.5, 28.9, 27.7, 23.3, 18.4, 17.0, 13.1, 12.0, 10.4; HRMS (ESI-TOF) m/z: [M + Na]+ 
Calcd for C24H47NO4SSiNa 496.2887, Found 496.2881. 
 
 S-(2-acetamidoethyl) (3R,6S,7R,E)-3,7-dihydroxy-4,6-dimethylnon-4-enethioate (6a).  
The silylether S2 (40.0 mg, 0.0845 mmol) was deprotected in a 
manner analogous to the production of diol 6b affording the 
desired product as a clear, colorless oil (21.5 mg, 0.678 mmol, 
80%). Rf = 0.43 (10% MeOH/dichloromethane); []22
D
 = 18.2 (c 1.00, CHCl3); 
1H NMR (400 
MHz) δ⁡6.19 (br, 1H), 5.34 (d, J = 10.0 Hz, 1H), 4.50 (t, J = 6.6 Hz, 1H), 3.48 (app. dq, J = 12.4, 
6.2 Hz, 1H), 3.42–3.31 (m, 1H), 3.30–3.24 (m, 1H), 3.04 (t, J = 6.2 Hz, 2H), 2.83 (dd, J = 6.6, 
OH
Me Me Me
OHO
NACS
 89 
3.1 Hz, 2H), 2.62 (br, 1H), 2.49–2.39 (m, 1H), 1.96 (s, 3H), 1.69 (d, J = 1.1 Hz 3H), 1.63–1.52 
(m, 1H), 1.43–1.31 (m, 1H), 0.96 (t, J = 7.3 Hz, 3H), 0.96 (d, J = 6.7 Hz, 3H); 13C NMR (CDCl3, 
100 MHz) δ 198.6, 170.7, 137.2, 129.9, 77.1, 74.5, 49.7, 39.4, 38.2, 29.3, 27.2, 23.3, 17.2, 12.2, 
10.1; HRMS (ESI-TOF) m/z: [M + Na]+ Calcd for C15H27NO4SiNa 340.1553, Found 340.1554. 
 
  (3R,6S,7R,E)-3-hydroxy-N-methoxy-N,4,6-tri-methyl-7-((triisopropylsilyl)oxy)non-4-enamide 
(S3).  
To a reaction vessel containing acyl thiazolidinethione S1 
(0.298 g, 0.578 mmol) in anhydrous dichloromethane (3 mL) 
was sequentially added imidazole (0.197 g, 2.89 mmol, 5.00 equiv.) and N,O-
dimethylhydroxylamine hydrochloride (0.141 g, 1.45 mmol, 2.50 equiv.). The reaction mixture 
was stirred at ambient temperature under argon atmosphere for 16 h and quenched upon addition 
of a saturated, aqueous ammonium chloride solution (4 mL). The biphasic solution was 
separated, and the aqueous layer was extracted with dichloromethane. Combined organic 
fractions were dried over anhydrous sodium sulfate, filtered, concentrated under vacuum and 
purified via silica flash column chromatography (40% EtOAc/hexanes) yielding the desired 
amide as a slightly yellow, clear oil (0.208 g, 0.501 mmol, 87%). Rf = 0.37 (40% 
EtOAc/hexanes); []23
D
 = 26.3 (c 1.00, CHCl3); 
1H NMR (400 MHz) δ⁡5.48 (d, J = 9.6 Hz, 1H), 
4.47–4.41 (m, 1H), 3.67 (s, 3H), 3.66–3.60 (m, 2H), 3.19 (s, 3H), 2.69–2.51 (m, 3H), 1.67 (s, 
3H), 1.52–1.36 (m, 2H), 1.06 (s, 21H), 0.99 (d, J = 6.9 Hz, 3H), 0.84 (t, J = 7.4 Hz, 3H); 13C 
NMR (CDCl3, 100 MHz) δ 173.9, 135.4, 129.8, 77.8, 73.6, 61.4, 37.3, 36.6, 32.0, 27.6, 18.4, 
17.0, 13.1, 12.3, 10.4; HRMS (ESI-TOF) m/z: [M + Na]+ Calcd for C22H45NO4SiNa 438.3010, 
Found 438.3010. 
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 (3R,6S,7R,E)-N-methoxy-N,4,6-trimethyl-3-((tri-ethylsilyl)oxy)-7-((triisopropylsilyl)oxy)non-4-
en-amide (S4).  
To a small, round bottom flask containing β-hydroxy amide 
S3 (79.0 mg, 0.190 mmol) under argon atmosphere in an ice-
water bath (0 °C) was added anhydrous dichloromethane (3.5 mL). The resulting clear solution 
was supplemented with 2,6-lutidine (89.0 μL, 0.761 mmol, 4.00 equiv.) and triethylsilyl 
trifluoromethanesulfonate (86.0 μL, 0.380 mmol, 2.00 equiv.). The reaction mixture was stirred 
at 0 °C for 2.5 h and quenched upon sequential addition of methanol (2 mL) and saturated, 
aqueous sodium bicarbonate solution (2 mL). The biphasic solution was warmed to ambient 
temperature and the layers were separated. The aqueous layer was extracted with 
dichloromethane (3 x 10 mL) and the combined organic fractions were dried over anhydrous 
sodium sulfate, filtered and concentrated under vacuum. The crude residue was purified by silica 
flash column chromatography (10-20% EtOAc/hexanes) producing the disilylether S4 as a 
transparent, clear oil (89.3 mg, 0.169 mmol, 89%). Rf = 0.58 (20% EtOAc/hexanes); []22
D
 = 9.7 
(c 1.00, CHCl3); 
1H NMR (400 MHz) δ 5.45 (d, J = 9.5 Hz, 1H), 4.59 (dd, J = 8.8, 4.5 Hz, 1H), 
3.70 (s, 3H), 3.61 (td, J = 6.5, 2.8 Hz, 1H), 3.16 (s, 3H), 2.99 – 2.80 (m, 1H), 2.60–2.50 (m, 1H), 
2.31 (dd, J = 13.9, 4.3 Hz, 1H), 1.64 (d, J = 1.1 Hz, 3H), 1.49–1.34 (m, 2H), 1.07 (s, 21H), 1.00 
(d, J = 6.9 Hz, 3H), 0.91 (t, J = 7.9 Hz, 9H), 0.82 (t, J = 7.4 Hz, 3H), 0.56 (q, J = 7.9 Hz, 6H); 
13C NMR (CDCl3, 100 MHz) δ 136.7, 128.2, 77.8, 75.6, 61.4, 39.5, 36.7, 32.1, 27.5, 18.5, 16.5, 
13.1. 11.4, 10.7, 6.9, 4.9 (missing amide carbonyl carbon); HRMS (ESI-TOF) m/z: [M + Na]+ 
Calcd for C28H59NO4Si2Na 552.3875, Found 552.3905. 
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 (5R,8S,9R,E)-6,8-dimethyl-5-((triethylsilyl)oxy)-9-((triiso-propylsilyl)oxy)undeca-1,6-dien-3-
one (S5).  
To a reaction vessel containing Weinreb amide S4 (37.6 mg, 0.0710 
mmol) under argon atmosphere was added anhydrous tetrahydrofuran 
(5 mL). The resulting clear solution was cooled with ice-water bath (0 °C). A solution of 
vinylmagnesium bromide (1.00 M) (0.224 mL, 0.224 mmol, 3.16 equiv.) was added to the stirred 
solution of starting material. After 3 h the reaction was quenched at 0 °C via addition of 
saturated, aqueous ammonium chloride solution (5 mL) and allowed to warm to ambient 
temperature. The biphasic solution was separated, and the aqueous layer was repeatedly 
extracted with ethyl acetate (3x 10 mL). The combined organic layers were dried over anhydrous 
sodium sulfate, filtered and concentrated under vacuum. Purification of the crude residue by 
silica flash column chromatography (5% EtOAc/hexanes) furnished the vinyl ketone as a clear, 
light yellow oil (32.7 mg, 0.658 mmol, 93%). Rf = 0.45 (5% EtOAc/hexanes); []22
D
 = 7.6 (c 1.00, 
CHCl3); 
1H NMR (400 MHz) δ 6.35 (dd, J = 17.6, 10.5 Hz, 1H), 6.19 (d, J = 17.6 Hz, 1H), 5.81 
(d, J = 10.5 Hz, 1H), 5.42 (d, J = 9.6 Hz, 1H), 4.55 (dd, J = 8.3, 4.7 Hz, 1H), 3.69 – 3.52 (m, 
1H), 2.94 (dd, J = 14.0, 8.4 Hz, 1H), 2.58–2.47 (m, 2H), 1.62 (s, 3H), 1.50–1.30 (m, 2H), 1.07 (s, 
21H), 0.99 (d, J = 6.9 Hz, 3H), 0.89 (t, J = 7.9 Hz, 9H), 0.81 (t, J = 7.4 Hz, 3H), 0.54 (q, J = 7.9 
Hz, 6H); 13C NMR (CDCl3, 100 MHz) δ 199.4, 137.6, 136.4, 128.4 (2), 77.8, 75.8, 46.9, 36.6, 
27.6, 18.4, 16.6, 13.2, 11.3, 10.6, 7.0, 4.9; HRMS (ESI-TOF) m/z: [M + Na]+ Calcd for 
C28H56NO3Si2Na 519.3660, Found 519.3674. 
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 (5R,8S,9R,E)-5,9-dihydroxy-6,8-dimethylundeca-1,6-dien-3-one (S6).  
Disilylether S5 (10.9 mg, 0.220 mmol) was transferred to a small 
polypropylene tube (15 mL, BD FalconTM)⁡and cooled via ice-water 
bath (0 °C). The diol was dissolved in acetonitrile (1 mL) and to the resulting clear solution was 
added a solution of 48% hydrofluoric acid in acetonitrile (11:89, 3.2 mL). The reaction mixture 
was placed in a refrigerator (4 °C) for 19 h and quenched via addition of an aqueous, saturated 
sodium bicarbonate solution until the mixture was neutralized (pH = 7). Extraction of the 
reaction mixture with ethyl acetate (4 x 15 mL), drying over anhydrous sodium sulfate, filtration 
and concentration under vacuum gave a crude product residue. Purification via flash column 
chromatography (50% EtoAc/hexanes) provided the desired diol as a cloudy, colorless oil (4.97 
mg, 0.220 mmol, quant.). Rf = 0.33 (50% EtOAc/hexanes); []21
D
 = 25.6 (c 0.87, CHCl3); 
1H 
NMR (400 MHz) δ 6.37 (dd, J = 17.6, 10.4 Hz, 1H), 6.26 (d, J = 17.6 Hz, 1H), 5.90 (d, J = 10.4 
Hz, 1H), 5.37 (d, J = 10.0 Hz, 1H), 4.53 (dd, J = 8.4, 4.0 Hz, 1H), 3.34–3.27 (m, 1H), 2.88 (dd, J 
= 8.4, 16.8 Hz, 1H), 2.80 (dd, J = 16.8, 4.4 Hz, 1H) 2.52 – 2.38 (m, 1H), 1.69 (s, 3H), 1.61–1.51 
(m, 1H), 1.43– 1.31(m, 1H), 0.97 (d, J = 6.8 Hz, 3H), 0.97 (t, J = 7.6 Hz, 3H); 13C NMR (CDCl3, 
100 MHz) δ 200.8, 137.4, 136.8, 129.5, 129.0, 77.1, 73.2, 44.7, 38.1, 27.2, 17.2, 12.6, 10.2; 
HRMS (ESI-TOF) m/z: [M + Na]+ Calcd for C13H22O3Na 249.1461, Found 249.1463. 
 
N-(2-(((5R,8S,9R,E)-5,9-dihydroxy-6,8-dimethyl-3-oxoundec-6-en-1-yl)thio)ethyl)acetamide 
(7a).  
To a small round bottom flask containing vinyl ketone S6 
(26.0 mg, 0.115 mmol) in anhydrous tetrahydrofuran (9 mL) 
under argon atmosphere was added N-acetylcysteamine 
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(14.6 μL, 0.138 mmol, 1.20 equiv.). A catalytic amount of cesium carbonate was added to the 
reaction mixture and the solution was stirred at ambient temperature for 11 h. The reaction was 
concentrated under vacuum and purified via silica flash column chromatography (10% 
MeOH/dichloromethane, 1 cm plug of Cu(II)SO4-silica on top) yielding the title compound as a 
colorless, cloudy oil (21.4 mg, 0.0620 mmol, 54%). Rf = 0.46 (10% MeOH/dichloromethane); 
[]22
D
 = 5.9 (c 0.59, CHCl3); 
1H NMR (400 MHz) δ 6.17 (s, 1H), 5.36 (d, J = 10.0 Hz, 1H), 4.48 
(dd, J = 8.1, 3.5 Hz, 1H), 3.43 (q, J = 6.3 Hz, 2H), 3.33–3.26 (m, 1H), 2.87 (br, 1H), 2.80 – 2.74 
(m, 4H), 2.74 – 2.58 (m, 4H), 2.49 – 2.38 (m, 1H), 1.99 (s, 3H), 1.81 (s, 1H), 1.65 (s, 3H), 1.61–
1.50 (m, 1H), 1.36 (dq, J = 14.1, 7.4 Hz, 1H), 0.96 (d, J = 7.4 Hz, 3H), 0.95 (t, J = 7.7 Hz, 3H); 
13C NMR (CDCl3, 100 MHz) δ 209.1, 170.5, 137.4, 128.9, 77.4, 73.2, 48.4, 43.6, 38.7, 38.0, 
32.2, 27.3, 25.2, 23.4, 17.3, 12.6, 10.2; HRMS (ESI-TOF) m/z: [M + Na]+ Calcd for 
C17H31NO4SNa 368.1866, Found 368.1873. 
 (R)-3-((4R,5R,E)-5-hydroxy-2,4-dimethylhept-2-enoyl)-4-isopropyloxazolidin-2-one (S7).  
This procedure is adapted from that of Hosokawa and coworkers.24 To 
a reaction vessel containing ent-1125 (0.720 g, 2.12 mmol, 1.50 equiv.) 
in anhydrous dichloromethane (42 mL) under argon atmosphere was 
added freshly distilled propionaldehyde22 (0.102 mL, 1.41 mmol, 1.00 equiv.). The resulting 
solution was cooled to -78 °C (acetone-dry ice). Titanium(IV) chloride (0.621 mL, 5.65 mmol, 
4.00 equiv.) was added, in one portion, to the chilled solution. The reaction mixture immediately 
developed a dark blue hue. The reaction was stirred at -78 °C for 17 h and quenched via addition 
saturated aqueous sodium bicarbonate solution (10 mL) and saturated aqueous potassium sodium 
tartrate (10 mL). The biphasic solution was warmed to ambient temperature, separated and the 
aqueous layer was extracted with dichloromethane (3 x 20 mL). The combined organic layers 
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were dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. Purification 
via flash column chromatography (30% EtOAc/hexanes) furnished aldol adduct S7 as a 
colorless, clear oil (0.344 g, 1.21 mmol, 86%). Rf = 0.26 (30% EtOAc/hexanes); []22
D
 = -65.2 (c 
1.00, CHCl3); 
1H NMR (400 MHz) δ 5.92 (d, J = 10.8 Hz, 1H), 4.56 (dt, J = 9.6, 5.0 Hz, 1H), 
4.33 (t, J = 9.0 Hz, 1H), 4.18 (dd, J = 8.9, 5.6 Hz, 1H), 3.55 (dt, J = 8.8, 4.2 Hz, 1H), 2.76 – 2.64 
(m, 1H), 2.40 – 2.27 (m, 1H), 1.94 (d, J = 1.3 Hz, 3H), 1.63–1.51 (m, 1H), 1.45 – 1.31 (m, 1H), 
1.03 (d, J = 6.8 Hz, 3H), 0.98 (t, J = 7.3 Hz, 3H), 0.93 (d, 5.5 Hz, 3H), 0.91 (d, 5.7 Hz, 3H); 13C 
NMR (CDCl3, 100 MHz) δ 171.9, 154.3, 142.5, 130.6, 77.4, 63.6, 58.3, 38.6, 28.5, 26.5, 18.0, 
15.3, 14.3, 13.9, 10.8; HRMS (ESI-TOF) m/z: [M + Na]+ Calcd for C15H25NO4Na 306.1678, 
Found 306.1680. 
 
(S)-3-((4S,5S,E)-5-hydroxy-2,4-dimethylhept-2-enoyl)-4-isopropyloxazolidin-2-one (ent-S7). 
The title compound was synthesized in an analogous matter to its enantiomer and was identical 
with respect to 1H-NMR and 13C-NMR spectra. []22
D
 = 66.0 (c 1.00, CHCl3); HRMS (ESI-TOF) 
m/z: [M + Na]+ Calcd for C15H25NO4Na 306.1678, Found 306.1682. 
 
 (R)-3-((4R,5R,E)-2,4-dimethyl-5-((triisopropylsilyl)oxy)-hept-2-enoyl)-4-isopropyloxazolidin-2-
one (S8).  
To a reaction flask containing aldol adduct S7 (0.260 g, 0.918 mmol) 
in anhydrous dichloromethane (10 mL) under argon atmosphere in 
ice-water bath (0 °C) was added diisopropylethylamine (0.192 mL, 
1.10 mmol, 1.20 equiv.) followed by triisopropylsilyl trifluoromethanesulfonate (0.296 mL, 1.10 
mmol, 1.20 equiv.). The reaction was stirred at 0 °C for 19 h and quenched upon addition of an 
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aqueous, saturated sodium bicarbonate solution (5 mL). The biphasic mixture was allowed to 
warm to ambient temperature and separated. The aqueous layer was extracted with 
dichloromethane (3x 20 mL) and the combined organic fractions were dried over anhydrous 
sodium sulfate, filtered and concentrated under vacuum. The crude residue was purified by flash 
column chromatography on silica gel (10% EtOAc/hexanes) affording the desired silyl ether as a 
colorless oil (0.373 mg, 0.848 mmol, 92%). Rf = 0.32 (10% EtOAc/hexanes); []22
D
 = -42.6 (c 
1.00, CHCl3); 
1H NMR (400 MHz) δ 6.04 (dd, J = 10.0, 1.4 Hz, 1H), 4.53 – 4.43 (m, 1H), 4.30 
(t, J = 8.8 Hz, 1H), 4.17 (dd, J = 8.9, 5.4 Hz, 1H), 3.75 (q, J = 5.2 Hz, 1H), 2.72 – 2.59 (m, 1H), 
2.46–2.34 (m, 1H), 1.92 (d, J = 1.4 Hz, 3H), 1.66 – 1.54 (m, 2H), 1.07 (s, 21H), 1.01 (d, J = 6.8 
Hz, 3H), 0.92 (d, J = 7.2 Hz, 3H), 0.90 (d, J = 7.0 Hz, 3H), 0.88 (t, 7.5 Hz, 3H); 13C NMR 
(CDCl3, 100 MHz) δ 172.2, 153.7, 142.3, 129.7, 76.2, 63.5, 58.6, 36.7, 28.3, 28.0, 18.4, 18.1, 
15.1, 14.1, 13.8, 13.1, 9.1; HRMS (ESI-TOF) m/z: [M + Na]+ Calcd for C24H45NO4SiNa 
462.3010, Found 462.2986. 
 
(S)-3-((4S,5S,E)-2,4-dimethyl-5-((triisopropylsilyl)oxy)hept-2-enoyl)-4-isopropyloxa-zolidin-2-
one (ent-S8).  
The title compound was synthesized in an analogous matter to its enantiomer and was identical 
with respect to 1H-NMR and 13C-NMR spectra. []22
D
 = 45.1 (c 1.00, CHCl3); HRMS (ESI-TOF) 
m/z: [M + Na]+ Calcd for C24H45NO4SiNa 462.3010, Found 462.3017. 
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 (4R,5R,E)-2,4-dimethyl-5-((triisopropylsilyl)oxy)hept-2-enal (S9).  
A round bottom flask containing acyl oxazolidinone S8 (0.373 g, 0.848 
mmol) dissolved in anhydrous dichloromethane (27 mL) under argon 
atmosphere was cooled to – 78 °C (dry ice-acetone). To the chilled reaction mixture was added a 
toluene solution of diisobutylaluminum hydride (1.49 M, 1.14 mL, 1.70 mmol, 2 equiv.) 
dropwise over two minutes. The reaction mixture was stirred at – 78 °C for 13 min and quenched 
upon sequential addition of methanol (10 mL) and saturated, aqueous potassium sodium tartrate 
solution (10 mL). The biphasic solution was allowed to warm to ambient temperature and 
separated. The aqueous layer was extracted with dichloromethane (3 x 15 mL) and the combined 
organic fractions were dried over anhydrous sodium sulfate, filtered and concentrated under 
vacuum. The crude product was purified via flash column chromatography (10% 
EtOAc/hexanes) to provide the aldehyde S9 as a clear and colorless oil (0.229 g, 0.733 mmol, 
86%). Rf = 0.56 (10% EtOAc/hexanes); []22
D
 = -17.7 (c 1.00, CHCl3); 
1H NMR (400 MHz) δ 
9.39 (s, 1H), 6.55 (d, J = 9.8 Hz, 1H), 3.79 (dt, J = 8.1, 4.4 Hz, 1H), 2.93 – 2.78 (m, 1H), 1.76 (s, 
3H), 1.72 – 1.49 (m, 2H), 1.10–1.04 (s, 24H), 0.89 (t, J = 7.5 Hz, 3H); 13C NMR (CDCl3, 100 
MHz) δ 195.8, 158.7, 137.9, 76.4, 37.3, 27.9, 18.4, 13.6, 13.1, 9.52, 9.46; HRMS (ESI-TOF) 
m/z: [M + Na]+ Calcd for C18H36O2SiNa 335.2377, Found 335.2396. 
 
(4S,5S,E)-2,4-dimethyl-5-((triisopropylsilyl)oxy)hept-2-enal (ent-S9).  
The title compound was synthesized in an analogous matter to its enantiomer and was identical 
with respect to 1H-NMR and 13C-NMR spectra. []23
D
 = 18.5 (c 1.00, CHCl3); HRMS (ESI-TOF) 
m/z: [M + Na]+ Calcd for C18H36O2SiNa 335.2377, Found 335.2375. 
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 (3S,6R,7R,E)-3-hydroxy-1-((R)-4-isopropyl-2-thioxo-thiazolidin-3-yl)-4,6-dimethyl-7-
((triisopropylsilyl)-oxy)non-4-en-1-one (S10). 
  
A reaction vessel containing acyl thiazolidinethione 16 (0.126 g, 
0.620 mmol, 1.70 equiv.) in anhydrous dichloromethane (2.3 mL) 
under argon atmosphere was cooled to -40 °C (dry ice-acetonitrile 
bath). The equilibrated solution was supplemented by titanium(IV) chloride (72.0 μL, 0.657 
mmol, 1.80 equiv.) and stirred for 30 min. To the reaction was slowly added freshly distilled 
diisopropylethylamine22 (0.114 mL, 0.657 mmol, 1.80 equiv.). The blood red reaction mixture 
was stirred for 2 h and transferred to dry ice-acetone bath (-78 °C). A dichloromethane (1.3 mL) 
solution of aldehyde S9 (0.114 g, 0.365 mmol, 1.00 equiv.) was slowly added to the cooled 
solution over 12 min. After stirring for 4 h at -78 °C the reaction was quenched via addition of 
ammonium chloride (5 mL). The biphasic mixture was warmed to ambient temperature and 
separated. The aqueous layer was extracted with dichloromethane (3 x 10 mL). Combined 
organic layers were dried over anhydrous sodium sulfate, filtered and concentrated under 
vacuum. The resulting crude oil was purified via flash chromatography (20% EtOAc/hexanes) to 
give both the aldol adduct S10 as a thick, bright yellow oil (99.3 mg, 0.192 mmol, 53%) and the 
dehydration product S11 as a viscous, yellow oil (44.4 mg, 0.0893 mmol, 24%). For S10: Rf = 
0.25 (20% EtOAc/hexanes); []22
D
 = -189.2 (c 1.00, CHCl3); 
1H NMR (400 MHz) δ 5.49 (d, J = 
9.6 Hz, 1H), 5.16 (t, J = 7.0 Hz, 1H), 4.56 (d, J = 9.3 Hz, 1H), 3.65 (dt, J = 6.6, 4.7 Hz, 1H), 3.53 
(dd, J = 7.7, 3.7 Hz, 1H), 3.51–3.47 (m, 1H), 3.40 (dd, J = 17.4, 9.6 Hz, 1H), 3.03 (d, J = 11.5 
Hz, 1H), 2.60–2.48 (m, 2H), 2.38 (app. sextet, J = 6.7 Hz, 1H), 1.67 (s, 3H), 1.61 – 1.46 (m, 2H), 
1.09–1.03 (m, 24H), 0.99 (d, J = 7.0 Hz, 3H), 0.96 (d, J = 0.68 Hz, 3H), 0.86 (t, J = 7.4 Hz, 3H); 
OH
Me Me Me
OTIPSO
NS
S
iPr
 98 
13C NMR (CDCl3, 100 MHz) δ 203.1, 173.1, 134.0, 131.4, 77.3, 73.6, 71.6, 44.2, 36.0, 31.0, 
30.8, 27.8, 19.2, 18.5, 18.0, 15.2, 13.2, 12.2, 9.4; HRMS (ESI-TOF) m/z: [M + Na]+ Calcd for 
C26H49NO3S2SiNa 538.2815, Found 538.2841. 
(2E,4E,6R,7R)-1-((R)-4-isopropyl-2-thioxothiazolidin-3-yl)-4,6-dimethyl-7-
((triisopropylsilyl)oxy)nona-2,4-dien-1-one (S11).  
For S11: Rf = 0.70 (20% EtOAc/hexanes); []
22
D
= -207.8 (c 
0.23, CHCl3); 
1H NMR (400 MHz) δ 7.37 (d, J = 15.2 Hz, 1H), 
7.32 (d, J = 15.3 Hz, 1H), 5.97 (d, J = 9.9 Hz, 1H), 5.07 (ddd, J = 8.2, 5.6, 2.6 Hz, 1H), 3.72 (dt, 
J = 6.9, 4.6 Hz, 1H), 3.50 (dd, J = 11.4, 8.1 Hz, 1H), 3.09 (dd, J = 11.4, 2.6 Hz, 1H), 2.74 – 2.64 
(m, 1H), 2.54 – 2.41 (m, 1H), 1.82 (d, J = 1.1 Hz, 3H), 1.64 – 1.47 (m, 2H), 1.09–1.03 (m, 24H), 
1.00 (d, J = 6.9 Hz, 6H), 0.86 (t, J = 7.5 Hz, 3H); 13C NMR (CDCl3, 100 MHz) δ 202.6, 167.5, 
150.4, 147.3, 132.5, 118.1, 72.4, 37.4, 30.9, 30.7, 28.0, 19.2, 18.5, 18.4, 17.4, 14.8, 13.2, 12.7, 
9.3; HRMS (ESI-TOF) m/z: [M + Na]+ Calcd for C26H47NO2S2SiNa 520.2710, Found 520.2713. 
 
  
D
22
Me Me Me
OTIPSO
NS
S
iPr
 99 
S-(2-acetamidoethyl) (3S,6R,7R,E)-3-hydroxy-4,6-di-methyl-7-((triisopropylsilyl)oxy)non-4-
enethioate (S12).  
To a small round bottom flask containing acyl thiazolidinethione 
S10 (50.5 mg, 0.0979 mmol) under argon atmosphere was added 
anhydrous dichloromethane (3 mL). A super-stoichiometric 
amount of imidazole (20.0 mg, 0.294 mmol, 3.00 equiv.) was added to the rapidly stirred, yellow 
mixture at ambient temperature. A slight excess of N-acetylcysteamine (11.5 μL, 0.108 mmol, 
1.10 equiv.) was added to the reaction solution. After stirring for 13.5 hr at ambient temperature, 
the mixture was concentrated under vacuum and purified by flash column chromatography (5% 
MeOH/dichloromethane, 1 cm thick CuSO4-SiO2) affording the desired thioester as a clear, 
colorless wax (32.3 mg, 0.682 mmol, 70%). Rf = 0.30 (5% MeOH/dichloromethane); [] = -2.5 
(c 1.00, CHCl3); 
1H NMR (400 MHz) δ 5.80 (br, 1H), 5.48 (d, J = 9.6 Hz, 1H), 4.48 (dd, J = 9.4, 
3.0 Hz, 1H), 3.64 (dt, J = 6.8, 4.7 Hz, 1H), 3.46 (app. dq, J = 6.6, 1.8 Hz, 1H), 3.06 (q, J = 6.3 
Hz, 1H), 2.84 (dd, J = 15.0, 9.5 Hz, 1H), 2.70 (dd, J = 15.0, 3.2 Hz, 1H), 2.56–2.46 (m, 1H), 
1.97 (s, 3H), 1.65 (d, J = 1.2 Hz, 3H), 1.62–1.41 (m, 2H), 1.06 (s, 21H), 0.95 (d, J = 6.8 Hz, 3H), 
0.85 (t, J = 7.4 Hz, 3H); 13C NMR (CDCl3, 100 MHz) δ 199.2, 170.5, 133.8, 131.7, 77.4, 74.5, 
49.7, 39.6, 36.0, 29.0, 27.8, 23.4, 18.5, 15.2, 13.2, 12.0, 9.3; HRMS (ESI-TOF) m/z: [M + Na]+ 
Calcd for C24H47NO4SSiNa 496.2887, Found 496.2887. 
 
S-(2-acetamidoethyl) (3S,6R,7R,E)-3,7-dihydroxy-4,6-dimethylnon-4-enethioate (6c).  
A polypropylene tube (15.0 mL, BD FalconTM) containing 
silylether S12 (32.3 mg, 0.682 mmol) dissolved in acetonitrile 
(3.40 mL) was placed in ice-water bath (0 °C) and allowed to 
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equilibrate. To the chilled reaction vessel was added a solution of 48% hydrofluoric acid in 
acetonitrile (11:89, 8.9 mL). The reaction mixture was transferred to a refrigerator (4 °C) for 48 
h and quenched at 0 °C via neutralization by saturated aqueous sodium bicarbonate solution. The 
resulting mixture was extracted with ethyl acetate (4 x 25 mL). The combined organic layers 
were dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The crude 
product residue was purified via silica flash column chromatography (10% 
MeOH/dichloromethane) furnishing the title compound as a clear, colorless oil (20.2 mg, 0.0630 
mmol, 93%). Rf = 0.26 (10% MeOH/dichloromethane); [] = 5.0 (c 1.47, CHCl3); 1H NMR 
(400 MHz) δ 6.23 (br, 1H), 5.35 (d, J = 9.7 Hz, 1H), 4.45 (dd, J = 7.8, 4.8 Hz, 1H), 3.41 (app. 
hept, J = 7.5 Hz, 2H), 3.34–3.28 (m, 1H), 3.08–2.95 (m, 2H), 2.82 (d, J = 8.2 Hz, 1H), 2.75 (d, J 
= 4.7 Hz, 1H), (dq, J = 12.8, 6.4 Hz, 1H), 1.95 (s, 3H), 1.65 (s, 3H), 1.56–1.43 (m, 1H), 1.35–
1.22 (m, 1H), 0.96 (d, J = 6.8 Hz, 3H), 0.92 (t, 7.4 Hz, 3H); 13C NMR (CDCl3, 100 MHz) δ 
198.7, 170.8, 135.7, 129.8, 77.2, 74.1, 49.8, 39.4, 37.8, 29.0, 27.1, 23.3, 15.7, 12.4, 10.6; HRMS 
(ESI-TOF) m/z: [M + Na]+ Calcd for C15H27NO4SNa 340.1553, Found 340.1547. 
S-(2-acetamidoethyl) (2E,4E,6R,7R)-4,6-dimethyl-7-((triisopropylsilyl)oxy)nona-2,4-
dienethioate (S13).  
To a round bottom flask containing acyl thiazolidinethione S11 
(44.2 mg, 0.0889 mmol) under argon atmosphere was added 
anhydrous dichloromethane (3 mL). To the resulting clear solution was added 4-
(dimethylamino)pyridine (32.6 mg, 0.267 mmol, 3.00 equiv.) followed by N-acetylcysteamine 
(10.4 μL, 0.098 mmol, 1.10 equiv.). The resulting mixture was stirred for 10 hr at ambient 
temperature and concentrated under vacuum. Purification of the crude residue via flash column 
chromatography (5% MeOH/dichloromethane) yielded the desired dienethiolate as a colorless 
365
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wax (23.1 mg, 0.0507 mmol, 57%). Rf = 0.38 (5% MeOH/dichloromethane); []23
D
= 7.6 (c 1.00, 
CHCl3); 
1H NMR (400 MHz) δ 7.25 (d, J = 15.3 Hz, 1H), 6.10 (d, J = 15.4 Hz, 1H), 6.01 (d, J = 
9.8 Hz, 1H), 5.94 (br, 1H), 3.72 (dt, J = 7.0, 4.6 Hz, 1H), 3.48 (app. q, J = 5.9 Hz, 2H), 3.12 (t, J 
= 6.3 Hz, 2H), 2.76–2.65 (m, 1H), 1.96 (s, 3H), 1.79 (s, 3H), 1.66 –1.46 (m, 2H), 1.08–1.04 (m, 
21H), 1.01 (d, J = 6.8 Hz, 3H), 0.87 (t, J = 7.5 Hz, 3H); 13C NMR (CDCl3, 100 MHz) δ 190.7, 
170.4, 148.9, 146.9, 131.4, 122.6, 40.2, 37.5, 28.5, 27.9, 23.4, 18.42, 18.37, 14.7, 13.1, 12.4, 9.3; 
HRMS (ESI-TOF) m/z: [M + Na]+ Calcd for C24H45NO3SSiNa 478.2781, Found 
 478.2780. 
 
S-(2-acetamidoethyl) (2E,4E,6R,7R)-7-hydroxy-4,6-dimethylnona-2,4-dienethioate (S14).  
A polypropylene tube (15.0 mL, BD FalconTM) containing 
silylether S13 (18.0 mg, 0.0395) dissolved in acetonitrile (4.15 
mL) was equilibrated in ice-water bath (0 °C). To the chilled starting material was added a 
solution 48% hydrofluoric acid in acetonitrile (11:89, 5.0 mL). The resulting acidified solution 
was stored at 4 °C for 48 h and quenched via addition of sodium sulfate at 0 °C. The reaction 
mixture was extracted with ethyl acetate (4 x 15 mL) and the combined organics were dried over 
anhydrous sodium sulfate. Filtration and concentration under vacuum gave the crude product 
residue that was purified by flash column chromatography (5% MeOH/dichloromethane) 
providing the desired alcohol as a cloudy, colorless oil (Scheme 3.1) (8.1 mg, 0.0271 mmol, 
69%). Rf = 0.28 (5% MeOH/dichloromethane); []22
D
= 37.5 (c 0.52, CHCl3); 
1H NMR (400 MHz) 
δ 7.26 (d, J = 15.5 Hz, 1H), 6.12 (d, J = 15.5 Hz, 1H), 5.94 (s, 1H), 5.87 (d, J = 10.1 Hz, 1H), 
3.47 (q, J = 6.0 Hz, 2H), 3.39 (ddd, J = 9.2, 6.5, 3.4 Hz, 1H), 3.11 (t, J = 6.3 Hz, 2H), 2.63 (dt, J 
= 10.1, 6.6 Hz, 1H), 1.96 (s, 3H), 1.81 (d, J = 0.9 Hz, 3H), 1.61–1.49 (m, 1H), 1.41–1.27 (m, 
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1H), 1.06 (d, J = 6.7 Hz, 3H), 0.95 (t, J = 7.4 Hz, 3H); 13C NMR (CDCl3, 100 MHz) δ 190.7, 
170.4, 146.8, 146.6, 132.6, 123.1, 77.0, 40.1, 39.6, 28.5, 27.9, 23.4, 15.8, 12.6, 10.4; HRMS 
(ESI-TOF) m/z: [M + Na]+ Calcd for C15H25NO3SSiNa 332.1447, Found 322.1447. Upon 
literature analysis we discovered that this compound had been synthesized through a different 
route by Cane, DE and co-workers.26 Our analytical data match that of the original report in all 
respects. 
 
 (3S,6S,7S,E)-3-hydroxy-1-((R)-4-isopropyl-2-thioxo-thiazolidin-3-yl)-4,6-dimethyl-7-
((triisopropylsilyl)-oxy)non-4-en-1-one (S15).  
To a reaction flask containing acyl thiazolidinethione 15 (88.8 
mg, 0.437 mmol, 1.70 equiv.) under argon atmosphere was 
added anhydrous dichloromethane (2.50 mL). The yellow 
solution was placed in dry ice-acetonitrile bath (- 40 °C) and allowed to equilibrate. To the 
chilled solution was added titanium(IV) chloride (50.7 μL, 0.463 mmol, 1.80 equiv.) and the 
resulting orange solution was stirred for 30 min. An aliquot of freshly distilled 
diisopropylethylamine22 (80.6 μL, 0.463 mmol, 1.80 equiv.) was slowly added to the reaction 
mixture and the blood red solution was stirred for an additional 2 hr at - 40 °C. The reaction was 
transferred to a dry ice-acetone bath (-78 °C) and supplemented with a dichloromethane solution 
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By utilizing the serendipitous byproduct S11, the result of dehydration during an aldol reaction, we were able 
to quickly produce the dehydration product S14. This dienethioate served as the product standard in LC-
MS/MS for the enzymatic dehydration reaction of 27. Additionally, the same compound was used as the 
product standard for TylDH3-catalyzed dehydration of 6d, as it is the enantiomer of the presumed product. 
 
S11
NACSH,
imid.
Me Me Me
OTIPSO
NACS HF
Me Me Me
OHO
NACS
S13 S14
69%57%
Scheme 3.1 Synthesis of dehydration product S14. 
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(0.400 mL) of aldehyde ent-S9 (80.3 mg, 0.257 mmol, 1.00 equiv.) in a dropwise fashion. The 
resulting reaction mixture was stirred at -78 °C for 1 h 45 min and quenched upon addition of 
aqueous saturated ammonium chloride (7.00 mL). The biphasic mixture was warmed to ambient 
temperature and separated. The aqueous layer was extracted with dichloromethane (3 x 15 mL) 
and the combined organic layers were dried over anhydrous sodium sulfate, filtered and 
concentrated under vacuum. The crude product residue was purified by flash column 
chromatography (20% EtOAc/hexanes) affording the aldol adduct S15 (0.102 g, 0.198 mmol, 
77%) as a bright yellow oil. Rf = 0.38 (20% EtOAc/hexanes); []22
D
= -199.5 (c 1.00, CHCl3); 
1H 
NMR (400 MHz) δ 5.50 (d, J = 9.6 Hz, 1H), 5.15 (d, J = 6.8 Hz, 1H), 4.55 (dd, J = 9.4, 2.2 Hz, 
1H), 3.68 (q, J = 4.8 Hz, 1H), 3.57–3.51 (m, 1H), 3.51–3.47 (m, 1H), 3.41 (dd, J = 17.4, 9.5 Hz, 
1H), 3.03 (d, J = 11.5 Hz, 1H), 2.58–2.48 (m, 1H), 2.39 (app. sextet, J = 6.8 Hz, 1H), 1.67 (s, 
3H), 1.61–1.49 (m, 2H), 1.10–1.03 (m, 24H), 0.99 (d, J = 6.9 Hz, 3H), 0.94 (d, J = 6.8 Hz, 3H), 
0.86 (t, J = 7.4 Hz, 3H); 13C NMR (CDCl3, 100 MHz) δ 203.1, 173.0, 134.1, 131.1, 77.3, 73.2, 
71.7, 44.3, 35.9, 31.0, 30.8, 27.9, 19.3, 18.4, 17.9, 15.1, 13.2, 12.7, 9.4; HRMS (ESI-TOF) m/z: 
[M + Na]+ Calcd for C26H49NO3S2SiNa 538.2815, Found 538.2830. 
 
S-(2-acetamidoethyl) (3S,6S,7S,E)-3-hydroxy-4,6-dimethyl-7-((triisopropylsilyl)oxy)non-4-
enethioate (S16).  
To a round bottom flask containing aldol adduct S15 (42.0 mg, 
0.0814 mmol) dissolved in anhydrous dichloromethane (3 mL) 
under argon atmosphere was added imidazole (17.0 mg, 0.250, 
3.07 equiv.). To the stirred reaction mixture was added N-acetylcysteamine (9.50 μL, 0.0893 
mmol, 1.10 equiv.) and the resulting solution was stirred at ambient temperature for 7 h. The 
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reaction mixture was quenched upon addition of a saturated, aqueous ammonium chloride 
solution (5 mL) and the biphasic solution was separated. The aqueous layer was extracted with 
dichloromethane (4 x 15 mL) and the combined organic layers were dried over anhydrous 
sodium sulfate, filtered and concentrated under vacuum. Crude product residues were purified by 
flash column chromatography (5% MeOH/dichloromethane) providing the title compound as a 
clear, colorless oil (35.3 mg, 0.746 mmol, 92%). Rf = 0.23 (5% MeOH/dichloromethane); []22
D
= 
-9.4 (c 1.00, CHCl3); 
1H NMR (400 MHz) δ 5.85 (br, 1H), 5.48 (d, J = 9.6 Hz, 1H), 4.47 (dd, J = 
9.0, 3.5 Hz, 1H), 3.76–3.60 (m, 1H), 3.45 (q, J = 6.2 Hz, 2H), 3.05 (dt, J = 5.3, 3.0 Hz, 2H), 2.82 
(dd, J = 15.0, 9.0 Hz, 1H), 2.73 (dd, J = 15.0, 3.7 Hz, 1H), 2.58–2.44 (m, 1H), 1.97 (s, 3H), 1.65 
(s, 3H), 1.60–1.46 (m, 2H), 1.06 (s, 21H), 0.92 (d, J = 6.8 Hz, 3H), 0.85 (t, J = 7.4 Hz, 3H); 13C 
NMR (CDCl3, 100 MHz) δ 199.1, 170.5, 133.9, 131.4, 77.4, 74.3, 49.8, 39.6, 35.9, 29.0, 27.8, 
23.4, 18.4, 15.1, 13.2, 12.2, 9.3; HRMS (ESI-TOF) m/z: [M + Na]+ Calcd for C24H47NO4SSiNa 
496.2887, Found 496.2881. 
 
S-(2-acetamidoethyl) (3S,6S,7S,E)-3,7-dihydroxy-4,6-dimethylnon-4-enethioate (6d).  
A large conical polypropylene tube (50 mL, BD FalconTM) 
containing silylether S16 (35.3 mg, 0.0746 mmol) dissolved in 
acetonitrile (3.75 mL) was placed in ice-water (0 °C) bath and 
allowed to equilibrate. To the chilled reaction vessel was added a solution of 48% hydrofluoric 
acid diluted in acetonitrile (11:89, 5.52 mL). The resulting clear solution was stored at 4 °C for 
23 h and neutralized via addition of an aqueous saturated sodium bicarbonate solution at 0 °C. 
The reaction mixture was extracted with ethyl acetate (4 x 15 mL) and the combined organic 
fractions were dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The 
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crude residue was purified via flash column chromatography (10% MeOH/dichloromethane) 
yielding the alcohol as a colorless oil (18.5 mg, 0.0583 mmol, 78%). Rf = 0.38 (10% 
MeOH/dichloromethane); []23
D
= -25.0 (c 0.62, CHCl3); 
1H NMR (400 MHz) δ 6.19 (br, 1H), 
5.36 (d, J = 9.7 Hz, 1H), 4.46 (dd, J = 8.2, 3.5 Hz, 1H), 3.42 (q, J = 6.1 Hz, 2H), 3.38–3.29 (m, 
1H), 3.09–2.95 (m, 2H), 2.83 (dd, J = 14.8, 8.6 Hz, 1H), 2.73 (dd, J = 14.8, 3.8 Hz, 1H), 2.48 
(dq, J = 13.3, 6.6 Hz, 1H), 1.95 (s, 3H), 1.65 (s, 3H), 1.58–1.47 (m, 1H), 1.32 (dq, J = 15.1, 7.8 
Hz, 1H), 0.94 (d, J = 6.9 Hz, 3H), 0.93 (t, J = 7.2 Hz, 3H); 13C NMR (CDCl3, 100 MHz) δ 198.8, 
170.8, 135.8, 129.7, 77.3, 74.2, 49.6, 39.4, 37.8, 29.0, 26.9, 23.3, 15.8, 12.5, 10.7; HRMS (ESI-
TOF) m/z: [M + Na]+ Calcd for C15H27NO4SNa 340.1553, Found 340.1556. 
 
 ()-S-(2-acetamidoethyl) 3-hydroxypentanethioate (()-26).  
The details for the synthesis of racemic diketide substrate 26 are currently 
pending publication in a separate manuscript21. 
 
S-(2-acetamidoethyl) (2E,4E,6S,7R)-7-hydroxy-4,6-di-methylnona-2,4-dienethioate (8).  
To a small polypropylene conical tube (15 mL) containing sterile 
deionized water (0.630 mL) was added a concentrated Tris 
buffer solution (0.500 M Tris-HCl, 1.50 M NaCl, pH 8.0, 0.500 mL). The clear solution was 
vortexed to mix and -hydroxy thioester 6b (3.17 mg, 0.0100 mmol) was added as a 50:50 
DMSO-water stock solution (100 mM, 100 μL) and mixed by inversion. Heterologously 
expressed TylDH3KR3 (2.53 mg/mL stock solution, 1.52 mL, 3.85 mg, 50.3 nmol). The reaction 
mixture was capped and incubated at ambient temperature with shaking (250 rpm) for 26 h. The 
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aqueous solution was extracted with ethyl acetate (3 x 10 mL) followed by drying over 
anhydrous sodium sulfate, filtration and concentration under vacuum. The crude product residue 
was purified via flash column chromatography (5% MeOH/dichloromethane) affording a cloudy, 
colorless oil (2.00 mg, 0.00667 mmol, 67%). Rf = 0.32 (5% MeOH/dichloromethane); Due to 
stability issues, an optical rotation was not obtained; 1H NMR (400 MHz, CDCl3) δ 7.29 (d, J = 
15.6 Hz, 1H), 6.12 (d, J = 15.5 Hz, 1H), 5.96 (d, J = 10.1 Hz, 1H), 5.91 (br, 1H), 3.52–3.39 (m, 
3H), 3.12 (t, J = 6.3 Hz, 2H), 2.72–2.60 (m, 1H), 1.96 (s, 3H), 1.82 (s, 3H), 1.54–1.49 (m, 1H), 
1.45–1.34 (m, 1H), 1.05 (d, J = 6.8 Hz, 3H), 0.96 (t, J = 7.4 Hz, 3H); 13C NMR (CDCl3, 100 
MHz) δ 190.7, 170.4, 146.6, 146.0, 133.5, 123.1, 77.0, 40.2, 39.2, 28.5, 27.8, 23.4, 17.0, 12.7, 
10.2; HRMS (ESI-TOF) m/z: [M + Na]+ Calcd for C15H25NO3SNa 322.1447, Found 322.1451. 
 
N-(2-(((4E,6E,8S,9R)-9-hydroxy-6,8-dimethyl-3-oxoundeca-4,6-dien-1-yl)thio)ethyl)acetamide 
(9).  
-Hydroxy ketone 7b (3.45 mg, 0.0100 mmol) was 
dehydrated in an analogous matter as the generation of 
dienethioate 8 resulting in dienone 9 (3.17 mg, 0.00969 mmol, 97%). Rf = 0.30 (5% 
MeOH/dichloromethane); Due to stability issues, an optical rotation was not obtained; 1H NMR 
(400 MHz) δ 7.17 (d, J = 16.7 Hz, 1H), 6.05 (d, J = 15.9 Hz, 1H), 5.89 (d, J = 10.0 Hz, 1H), 
3.43–3.35 (m, 3H), 2.87–2.80 (m, 2H), 2.80–2.74 (m, 3H), 2.66 – 2.54 (m, 3H), 1.94 (s, 3H), 
1.76 (s, 3H), 1.52–1.42 (m, 1H), 1.40–1.28 (m, 1H), 0.99 (d, J = 6.8 Hz, 3H), 0.90 (t, J = 7.4 Hz, 
3H); 13C NMR (CDCl3, 100 MHz) δ 198.8, 170.4, 148.7, 145.5, 133.9, 124.6, 77.0, 40.2, 39.2, 
38.7, 32.3, 27.8, 26.1, 23.4, 17.1, 12.7, 10.2; HRMS (ESI-TOF) m/z: [M + Na]+ Calcd for 
C17H29NO3SNa 350.1760, Found 350.1762. 
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General biology procedures.  
All chemical reagents were purchased from Sigma-Aldrich and were used directly 
without further purification.  E. coli BL21–AI cells were from Life Technologies. IPTG was 
acquired through Gold Biotechnology. L-(+)-Arabinose (≥99%) was purchased through Sigma 
Aldrich. His60 Ni Superflow resin was purchased from Clontech Laboratories, Inc. OD600 was 
measured on an Eppendorf BioPhotometer. Sonication was carried out by Branson Sonifier 450. 
Gel filtration purification was performed on HiLoad 16/600 Superdex 200 pg column (GE). 
Protein mass spectrometry was carried out using an Agilent 6250 QTOF LC/MS. Kinetic LC–
MS/MS was conducted with AB Sciex QTRAP 5500 mass spectrometer and Shimadzu LC 
system. 
The TylKR3-DH3 didomain was ordered as codon-optimized synthetic DNA from Life 
Technologies. The synthetic DNA encoded the region 957-1682 from the tylactone synthase 
module 3 polypeptide. The insert was cloned into pMCSG7 using ligation independent cloning 
(LIC). TylKr3-DH3 synthetic forward primer: 5’-TACTTCCAAT-
CCAATGCCCATCCGCTGCTGAGCG-3’; TylKr3-DH3 synthetic reverse primer: 5’-
TTATCCACTTCCAATGTTAGTTGGTATCTTCCGGTGTACCAGGCG-3’ (LIC-overhangs 
in bold; inserted stop codon underlined). The insert was confirmed via sequencing. 
Cloning and Expression of TylDH3-KR3 Construct 
Initial efforts to recombinantly express the mono-domain TylKR3 were hampered by 
with poor expression levels and protein aggregation. Strategies to alleviate these issues included 
an increase of rare tRNA codons (Rosetta cell line), optimization of codon selection (synthetic 
TylKR3 gene), toxic protein-compatible expression hosts (pLysS cell line), appending a fusion 
protein (attempted with SUMO, mOCR, and GST), chaperone coexpression (GroEL-GroES) and 
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truncations of both N- and C-termini. Disappointingly, these techniques failed to improve 
expression of soluble non-aggregated TylKR3 and forced us to abandon the expression of the 
mono-domain construct.  
 
The tylGII region encoding TylDH3-KR3 didomain comprising residues 957-1682 was 
cloned into a pMCSG7 vector and transformed into E. coli BL21-AI cells containing the pRARE 
plasmid. A large TB media culture (0.5 L in 2.8 L Fernbach flask) was inoculated with as small 
amount of overnight culture (5 mL) and incubated at 37 °C, shaking at 250 RPM until OD600 = 
1.00–1.20. The culture was cooled to 20 °C and incubated with shaking (250 RPM) for 1 h. Cells 
were induced upon addition of IPTG (0.100 mM) and L-arabinose (1.00 g) and allowed to shake 
(250 RPM) at 20 °C for 19 h. The cell pellet was collected after centrifugation (4 °C, 5,000 x G, 
30 min) and resuspended in lysis buffer (50 mM tricine, 50 mM ammonium sulfate, 100 mM 
urea, pH 8.5, 4 mL/g of pellet). The cells were lysed (3 x 2 min, 50% duty cycle, 40 % power, 4 
°C) and centrifuged (4 °C, 28,600 x G, 45 min). The soluble protein was purified by sequential 
metal-immobilized affinity chromatography and size exclusion chromatography to afford 
approximately 9 mg of purified protein (18 mg / L) that was greater than 90% pure as judged by 
SDS-PAGE (Fig. 3.3) and to be near the predicted calculated mass by mass spectrometry (Fig. 
3.4). 
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The ladder, cell lysate, insoluble pellet, soluble protein and serial nickel 
elution fractions are shown in lanes 1-9, respectively. The band corresponding 
to TylDH3-KR3 is boxed. 
 
Figure 3.4 Mass spectrometry analysis of TylDH3-KR3. 
The convoluted (raw) spectrum and deconvoluted are both displayed. TylDH3-KR3 was found to have a mass of 76,264 Da. 
The spectrum was obtained using 0.5 mg/mL of recombinant TylDH3-KR3 in 25% formic acid. 
 
Figure 3.3 SDS-PAGE image of TylDH3-KR3 purification. 
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Determination of TylDH3-KR3 Ketoreductase Activity (Data generated by Will Fiers) 
A small eppendorf tube (1.5 mL, 100 μL total volume) containing substrate 4 or 5 (1 
mM), heterologously expressed TylDH3-KR3 (5 μM), NADPH (2 mM), Tris (50 mM), NaCl  
(150 mM) at pH 8.0 was incubated at ambient temperature for 15 h. 60 µL of the diluted reaction 
solution was added to a HPLC vial and analyzed by LC-MS/MS (Table 3.1) employing a Kinetix 
reverse-phase C18 column (50 mm  2.1 mm, 2.6 µm, Phenomenex) operated at 0.4 mL min-1 
with a gradient between mobile phase A (H2O) and mobile phase B (MeCN). The gradient 
program was 0 min, 5% B; 2 min, 5% B; 7 min, 55% B; 8 min, 70% B; 9 min, 70% B; 10.5 min, 
5% B; 12 min, 5% B.  Co-injection of standards 6a, 6b, and 8 for substrate 4 confirmed the 
identity of product traces. The standards 7a, 7b, and 9 were used for the analysis of the 
incubation of substrate 5.  
 
Table 3.1 LC-MS/MS analysis of analytes 6a, 6b, 8, 7a, 7b, and 9. 
Analyte 
HPLC retention 
time (min) 
Transition 
6a 5.19 340→184 
6b 5.27 340→184 
8 6.17 300→181 
7a 
7b 
9 
5.24 
5.30 
6.00 
368→212 
368→212 
328→151 
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Analysis of TylDH3-KR3 Dehydratase Activity (Data generated by Will Fiers) 
Steady-State Analysis. 
The enzymatic reactions were carried out in a total volume of 50 µL under initial velocity 
conditions containing TylDH3-KR3 (1 µM), reaction buffer (50 mM Tris, 150 mM NaCl, pH 
8.0) and substrates 6b or 7b at variable concentrations (0.5, 1, 2, 3, 4, 6, 8 mM). The final 
DMSO concentration was held constant at 4%. After incubation at 25 °C for 8 min (the reaction 
found to be linear up to 10 min), 5 µL of the reaction mixture was added to 495 µL of 1:1 
MeCN–reaction buffer (100-fold dilution). The resulting solution was vortexed, centrifuged and 
analyzed by 60 µL of the diluted reaction solution was added to a HPLC vial with 10 µL of 
internal standard 3 (320 nM) and analyzed by LC-MS/MS (Table 3.1) employing a Kinetix 
reverse-phase C18 column (50 mm  2.1 mm, 2.6 µm, Phenomenex) operated at 0.4 mL min-1 
with a gradient between mobile phase A (H2O) and mobile phase B (MeCN). The gradient 
program was 0 min, 5% B; 2 min, 5% B; 7 min, 55% B; 8 min, 70% B; 9 min, 70% B; 10.5 min, 
5% B; 12 min, 5% B. Standard curves of enzymatic products 8 and 9 were generated by injecting 
the authentic standard at varying concentrations with a fixed concentration of an internal 
standard (8 for the standard curve of 9 and 9 for the standard curve of 8). The amount of 
enzymatic product formation at each time point was calculated by plotting the area ratio 
(analyte/internal standard) into the standard curve. Control reactions for each concentration of 
substrate were performed without the addition of enzyme. Each reaction was performed in 
duplicate. The specificity constants (KM/kcat) were determined by fitting the normalized v0 vs [S] 
plots to linear equations (Fig. 3.5A, B).  
 
 112 
Substrates 6c and 6d were analyzed in an analogous way using synthetic S14 as the product 
standard (Fig. 3.5C, D). The LC-MS/MS trace of S14 is provided in Fig 3.6. 
 
 
 
 
Figure 3.5 Linear regression analysis of TylDH3KR3 kinetic data with substrates 6b, 
7b, 6c, and 6d. 
The kinetic plots of thioester 6b, thioether 7b, thioester 6c and thioester 6d are shown in panels A, B, C and D, 
respectively. Represented data is the result of duplicate LC-MS/MS data normalized with controls lacking enzyme. 
Specificity constants (kcat/KM) for each substrate are displayed below the corresponding plot. 
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Results and discussion 
Thioether substrate syntheses 
The synthesis of tetraketide substrate mimic 7b for TylDH3 began with known 
vinylketene silyl N,O-acetal 11, obtained in two steps from commercially available trans-2-
methyl-2-pentenoic acid 10 (Scheme 3.2). The vinylogous Mukaiyama aldol reaction of 11 with 
propionaldehyde set the two distal stereogenic centers with excellent yield and 
diastereoselectivity (92%, >98 : 2 dr), illustrating the power of Kobayashi's methodology for 
synthesis of this triketide building block27. The relative and absolute stereochemistry was 
confirmed by comparison of its NMR spectral data and optical rotation value to the reported 
enantiomer23. The vinylogous aldol adduct 12 was subsequently protected as the triisopropylsilyl 
(TIPS) ether 13 in quantitative yield and reductive removal of the oxazolidinone auxiliary with 
diisobutylaluminum hydride (DIBAL-H) provided aldehyde 14. 
The synthetic compound S14 was used to confirm the identity of the 
dehydration products arising from thioesters 6c and 6d. A standard curve for 
quantitative determination of specificity constants was generated from the 
synthetic compound. 
 
Figure 3.6 LC-MS/MS trace of dienethiolate 
S14. 
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With the enal 14 in hand, we were 
poised to set the unknown stereochemistry of 
the TylKR3 reduction product. Utilization of 
Nagao's N-acetylthiazolidinethione 15 under 
titanium-catalyzed conditions developed by 
Vilarrassa, Urpí and coworkers furnished the d-
alcohol as the only detectable diastereomer in 
81% yield28-29. The thiazolidinethione chiral 
auxiliary of 16 was displaced with 
methyl(methoxy)amine to afford the 
corresponding Weinreb amide 1730. The newly 
formed β-hydroxyl group was protected as 
triethylsilyl (TES) ether 18. Due to susceptibility 
to α,β-elimination, the strength of base was crucial, as tertiary amines (TEA, DIPEA) yielded 
exclusively the conjugated dienamide, whereas 2,6-lutidine afforded the desired TES ether. The 
precise order of this two-step sequence (16 → 18) was critical as reversal led to a sterically 
encumbered, hydroxyl-protected thiazolidine resistant to displacement. Grignard addition of 
vinylmagnesium bromide to Weinreb amide 18 provided 19 that was globally deprotected with 
HF to afford 20. Regioselective Michael addition of N-acetylcysteamine (NAC) to the terminal 
enone of 20 produced TylDH3 substrate mimic 7b containing a two-carbon spacer. The l-alcohol 
diastereomer 7a was prepared in an analogous fashion from 14 employing the antipode of 15 
(Schemes 3.3, 3.4). 
Scheme 3.2 Exemplary synthesis of 
thioether 7b. 
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An asymmetric aldol reaction between key aldehyde 14 and Nagao’s chiral auxiliary ent-15 and displacement of the 
thiazoldinone with N-acetylcysteamine furnished thioester S2. Final deprotection with hydrogen fluoride afforded the 
desired diol substrate 6a. 
NS
S
iPr
O
Me
ent-15
14
ent-16, TiCl4,
 DIPEA
OH
Me Me Me
OTIPSO
NS
S
iPr
S1
NACSH, imid.
OH
Me Me Me
OTIPSO
NACS
S2
OH
Me Me Me
OHO
NACS
6a
HF
68% 97%
80%
Scheme 3.3 Synthetic route towards L-alcohol substrate 6a. 
Aldol adduct S1 was sequentially converted to the corresponding weinreb amide (S3) followed by protection with 
triethylsilyl trifluromethanesulfonate providing disilylether S4. Grignard addition and deprotection followed by 
Michael addition afforded thioether 7a. 
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Scheme 3.4 Chemical synthesis of thioether substrate 7a. 
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At the onset of the project we had planned to prepare the TylKR3 substrate mimic 5 from 
the corresponding TylDH3 substrate 7b through regioselective oxidation of the allylic alcohol 
over the distal secondary alcohol. Unfortunately, 7b and its precursor 20 proved recalcitrant to a 
variety of oxidants (MnO2, BaMnO4, Pd(OAc)2/O2, etc.), returning starting material or 
dehydration products under more forcing conditions31-33. In light of these results, we decided to 
chemoselectively remove the TES protecting group in 19 to provide 21 (Scheme 3.5A). A variety 
of common oxidants were then screened to affect the transformation of alcohol 21 to the desired 
β-diketone 22 including the Dess–Martin periodinane, TPAP/NMO, and SO3•pyr. Surprisingly, 
most common reagents led to quick decomposition of the starting material or unwanted hetero-
Michael additions to afford a tetrahydropyranone. A recently described β-hydroxyketone 
oxidation using iodoxybenzoic acid (IBX) as the oxidant was employed as a mild, neutral 
method34. This procedure afforded β-diketone 22 in near quantitative yields after simple filtration 
of the sparingly soluble oxidant from the products. Facile TIPS deprotection with aqueous HF 
provided 23, which was reacted with NAC to afford TylKR3 substrate 5. 
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Thioester product and substrate syntheses 
The NAC thioester TylKR3 and 
TylDH3 substrates 4 and 6b were 
synthesized in a straightforward approach 
from intermediates 16 and 24, respectively, 
prepared in Scheme 3.2. The 
thiazolidinethione in 16 was directly 
displaced with NAC yielding the β-
hydroxythioester 24 (Scheme 3.5B). TIPS 
deprotection with aqueous HF furnished the 
TylDH3 NAC thioester substrate mimic 6b. 
As anticipated, this compound displayed 
reasonable stability at room temperature and 
was stable for several months at 4 °C. The C-2 epimeric compound 6a could be synthesized in a 
similar manner (Scheme 3.4). Oxidation of β-hydroxythioester 24 would provide the required β-
ketothioester. Several reaction conditions were studied to effect this transformation and it was 
found, once again, that IBX afforded near quantitative yield of 25 (Scheme 3.5C). TIPS 
deprotection promoted by aqueous HF yielded TylKR3 NAC thioester substrate mimic 4. 
Expression of tylosin module 3 β-processing domains 
With TylKR3 substrate mimics 4 and 5 in hand, we sought to purify the KR and DH domains. 
By sequence alignment to structurally characterized domains16, 35-37, the sequence boundaries of 
the KR and DH were determined. The TylKR3 was recalcitrant to purification, so we constructed 
a plasmid encoding the TylDH3-KR3 didomain including a portion of linker between the KR and 
Scheme 3.5 Synthetic route to ketoreductase 
and thioester substrates 4, 5, and 6b. 
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ACP domains (residues 957-1682 of tylosin PKS module 3). The didomain was stable upon 
purification, and used in further analysis. The molecular weight of the recombinant proteins 
determined by SDS-PAGE was 76 kDa and found to be 76,265 Da by mass spectrometry, both 
consistent with the calculated value (76,511 Da). 
Enzymatic analysis of TylDH3-KR3 
We initially attempted to characterize the activity of the TylKR3 domain with substrates 
4 and 5 in the presence of NADPH using LC-MS/MS analysis with an internal standard for 
rigorous quantitation and synthetic standards for product identification. Overnight incubation of 
the TylDH3-KR3 didomain with 4 and 5 afforded the d-configured reduction products 6b and 7b 
in relatively minor amounts, consistent with the B-type KR domain, along with the dehydration 
products 8 and 9 as the major species (Scheme 3.6). NAC thioester 4 provided 6b : 8 in ratio of 
1 : 22 while NAC thioether 5 furnished 7b : 9 in a ratio of 1 : 102 (Figs. 3.7A, B). However, the 
KR acted very slowly, as the total conversion in each case was less than 2% of input substrate. 
The combination of slow KR conversion and low KR : DH product ratio suggests that the 
ketoreductase product can shuttle to the dehydratase in absence of ACP tethering. It further 
suggests that the chemically reversible dehydration reaction is unidirectional in the TylDH3  
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Overnight incubation conducted with KR substrates 4 (panel A) and 5 (panel B) and TylDH3-KR3 in the presence 
of NADPH. The identity of the β-hydroxy products (shown in blue) was confirmed by co-injection with authentic 
standards. Incubation with synthetic 7 (panel C) and 9 (panel D) resulted in sole formation of dehydration products 
10 and 11 (trace shown in red), respectively. Panels A and C blue trace represents MRM (m/z 368 → 212) red 
trace represents MRM (m/z 328 → 151). 
Figure 3.7 LC-MS/MS traces of in vitro ketoreduction and dehydration 
reactions. 
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Scheme 3.6 The chemoenzymatic synthesis of dienes 8 and 9 via 
TylDH3KR3-catalyzed dehydration. 
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since an unexpectedly high amount of dehydration product was formed from a freely diffusible 
reduction product. Unfortunately, we were unable to kinetically characterize TylKR3 due to the 
slow substrate turnover. 
We next examined the ability of TylDH3-KR3 to process DH substrates 6a, 6b, 7a, and 
7b. Each substrate (1 mM) was individually incubated overnight with 10 μM TylDH3-KR3 and 
the reactions were analyzed by LC-MS/MS as before. The d-alcohols 6b and 7b led to nearly 
quantitative formation of trans-olefin products 8 and 9, respectively (Figs. 3.7C, D) whereas l-
alcohols 6a and 7a were not turned over by the enzyme. This further corroborates the 
bioinformatic prediction that the preceding B-type TylKR3 should produce d-alcohols and is 
consistent with empirical observations that d-alcohols yield trans-olefins.7, 38 Based on the 
enhanced activity of TylDH3 relative to TylKR3 we performed a large-scale incubation of 6b 
and 7b and isolated 8 and 9 in 67 and 98% yield, respectively after flash chromatography. The 
product identities were unequivocally confirmed by NMR spectroscopy and exhibited nearly 
identical diagnostic 13C chemical shifts of ∼147 and ∼133 ppm and a 3 J HH coupling constant of 
∼16 Hz. 
The enhanced activity of TylDH3 domain enabled characterization by steady-state kinetic 
analysis. The velocity remained linear up to 10 minutes reaction time and was also linear with 
respect to TylDH3-KR3 concentration from 0.25 to 1 μM. The initial rates, v 0 at a given [S] 
were thus determined by single-time point stopped-time incubations at 8 minutes with 0.5 μM 
TylDH3-KR3. Due to the limited solubility of substrates 6b and 7b we were unable to reach 
saturation, consequently the plots of initial velocity versus [S] were fit by linear regression 
analysis to determine the specificity constants (k cat/K M). Thioester 6b and thioether 7b displayed 
specificity constants of 980 ± 30 and 410 ± 20 min–1 M–1, respectively (Fig. 3.5, Table 3.2).  
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The modest 2.5-fold difference in k cat/K M indicates thioethers are well tolerated, validating their 
use as stabilized forms of substrates otherwise prone to nonproductive, intramolecular 
cyclization. 
Table 3.2 Steady-state kinetic analysis of TylDH3 substrates 
To explore the impact of remote 
stereocenters on processing by TylDH3 
we synthesized full-length tetraketide 
NAC thioesters 6c and 6d, epimeric at 
the ε- and ζ-stereocenters, respectively 
(Schemes 3.7, 3.8). The specificity 
constant for 6c was 22 ± 2 min–1 M–1, 
which is 45-fold less than 6b (Table 
3.2). Although 6c only differs from 6b 
via inversion of the ε-methyl group, we 
expect the trisubstituted olefin may 
enhance the 1,3-allylic (A1,3) strain and 
more severely impact the side chain 
conformation, potentially contributing 
to the drastic attenuation in kcat/KM. 
Boddy and co-workers also invoked A1,3 strain to rationalize substrate tolerance in their work on 
PKS thioesterases39. We next evaluated the ζ-epimer 6d, whose specificity constant was 72 ± 6 
min–1 M–1, approximately 14-fold less than 6b. Since inversion of the ζ-stereocenter is not 
expected to significantly alter the substrate conformation, we speculate that the ζ-hydroxyl group 
may be important for substrate recognition that is otherwise dominated by hydrophobic  
Cmpd# DH substrate 
kcat/KM,  
min-1 M-1 
6a 
 
 
<10a 
6b 
 
 
980 ± 30 
7a 
 
 
<10a 
7b 
 
 
410 ± 20 
6c 
 
 
22 ± 2 
6d 
 
 
72 ± 6 
(±)-26 
 
<10a 
aBelow the limit of detection (LOD) of products in LC-MS/MS 
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Figure 3.7 Synthesis of TylDH3 substrate 6c. 
The outlined route closely parallels that of thioester 6b (Schemes 3.2 and 3.3 in manuscript). 
Notable differences include the use of the enantiomer of 11 (ent-11), the syn-selective vinylogous 
aldol promoted by excess titanium(IV) chloride, and the production of dehydration product S12 
due to an increased sensitivity of diastereomer S11 to prolonged aldol conditions. 
The enantiomer of aldehyde S9 (ent-S9) was submitted to an aldol reaction with 
Nagao’s acyl chiral auxiliary 15 to afford aldol adduct S15 as the only product. 
Interestingly, by decreasing the reaction time from 4 h to 1 h 45 min, we avoided 
the formation of elimination product with this diastereomer. Thiazolidinethione 
displacement followed by deprotection furnished the TylDH3 substrate 6d. 
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Scheme 3.8 Chemical preparation of substrate 6d. 
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interactions of this nonpolar substrate. To complete our substrate specificity studies, we also 
evaluated diketide (±)-26, but it was not processed, highlighting the significance of using full-
length substrates. 
 
Conclusion 
The use of full-length, diffusible tetraketide probes allowed for systematic analysis of the 
module 3 processing domains of tylosin: TylKR3 and TylDH3. The TylKR3 domain was weakly 
active and produced d-alcohols stereoselectively, further confirming the accuracy of existing 
bioinformatic approaches9, 15. In contrast, the TylDH3 domain proved robust in its production of 
trans-olefins allowing for the chemoenzymatic synthesis of dehydration products. Dehydratase 
substrate specificity in relation to each stereocenter was independently determined through 
steady-state kinetic analysis via LC-MS/MS detection revealing unpredicted biases for the native 
substrate. TylDH3 did not tolerate β-stereochemistry inversion, and epimerization of distal 
stereocenters attenuated the activity by 14–45 fold when compared to the native substrate. This 
finding was rationalized through recognition of allylic A1,3 strain within the molecule and the 
potential electrostatic and/or hydrogen bonding interactions of the distal hydroxyl moiety. The 
distant elements of the substrate were necessary for activity as truncated substrate (±)-26 was not 
dehydrated by TylDH3. Additionally, thioethers proved to be stable thioester surrogates. 
This work highlights the in vitro use of didomains in the study of cryptic processes as 
potential solutions for insoluble and/or unreactive domains. The ACP domain has been largely 
assumed to control the flow of intermediates throughout the reductive progression of domains 
towards the ultimate module product40-42. Unexpectedly, we discovered that tylosin module 3 
funnels diffusible substrates from ketoreductase to dehydratase independent of ACP tethering. 
The exact mechanism of this observed phenomenon remains to be determined and could involve 
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the proximity of the KR product exit and DH substrate entrance, thereby increasing the local 
concentration of DH substrate. Alternatively, a conformational change prior to or upon substrate 
release from the ketoreductase may draw the two catalytic sites together, leading to the observed 
shuttling process. Our results are consistent with structures of the pikromycin module 5 in which 
the ACP localization was determined by the tethered acyl group43-44.  
The finding that the distal stereochemical fidelity of preceding modules can be closely 
regulated by dehydratase activity via a stringently stereospecific process may have far-reaching 
implications in the fields of natural product isolation and synthetic biology. Specifically, this 
research directly supports the hypothesis that tightly controlled relative and absolute polyketide 
stereochemistry may not necessitate the action of exquisitely stereoselective domains but, 
instead, be the consequence of iterative, stereospecific checkpoints or gatekeeper domains. 
Stalled chain intermediates have been shown previously to be hydrolyzed by downstream TE 
domains, freeing a non-productive, immature polyketide acid and phosphopantetheine-ACP arm 
for productive product formation45-47. Interestingly, our work suggests that the dehydratase 
domain, which eliminates stereochemical information, can additionally enrich the final product 
optical purity. As the dehydratase-catalyzed syn-elimination of water is the only β-processing 
domain to require a specific, two-centered tetrahedral substrate conformation, it may be naturally 
sensitive to the local stereochemical features of the substrate. 
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Chapter 4. Vinylogous dehydration by a polyketide dehydratase domain in curacin 
biosynthesis 
 
This chapter is published: Fiers, W. D., Dodge, G. J., Sherman, D. H., Smith, J. L., & Aldrich, C. 
C. Vinylogous dehydration by a polyketide dehydratase domain in curacin biosynthesis. J Am 
Chem Soc 138, 16024-16036 (2016). 
 
Summary 
Polyketide synthase (PKS) enzymes continue to hold great promise as synthetic biology 
platforms for the production of novel therapeutic agents, biofuels and commodity chemicals. 
Dehydratase (DH) catalytic domains play an important role during polyketide biosynthesis 
through the dehydration of the nascent polyketide intermediate to provide olefins. Our 
understanding of the detailed mechanistic and structural underpinning of DH domains that 
control substrate specificity and selectivity remains limited, thus hindering our efforts to 
rationally re-engineer PKSs. The curacin pathway houses a rare plurality of possible double bond 
permutations containing conjugated olefins as well as both cis- and trans-olefins, providing an 
unrivaled model system for polyketide dehydration. All four DH domains implicated in curacin 
biosynthesis were characterized in vitro using synthetic substrates and activity was measured by 
LC-MS/MS analysis. These studies resulted in complete kinetic characterization of the all trans 
trienoate-forming CurK dehydratase, whose kcat of 72 s
−1 is more than three-orders of magnitude 
greater than any previously reported PKS DH domain. A novel stereospecific mechanism for 
diene formation involving a vinylogous enolate intermediate is proposed for the CurJ and CurH 
dehydratases based on incubation studies with truncated substrates. A synthetic substrate was co-
crystallized with a catalytically inactive Phe substitution in the His-Asp catalytic dyad of CurJ 
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DH to elucidate substrate-enzyme interactions. The resulting complex suggested the structural 
basis for dienoate formation and provided the first glimpse into the enzyme-substrate interactions 
essential for the formation of olefins in polyketide natural products. This examination of both 
canonical and non-canonical dehydration mechanisms reveals hidden catalytic activity inherent 
in some DH domains that may be leveraged for future applications in synthetic biology. 
Introduction 
Polyketide secondary metabolites are an exquisite example of Nature’s rich diversity, 
both in terms of molecular complexity and functionality. Small molecules from this natural 
product family cover a wide range of marketed medicinal agents, providing utility as 
hypolipodemic (lovastatin), antimicrobial (erythromycin), antineoplastic (ixabepilone), 
antifungal (amphotericin B), and immunosuppressive (FK-506) therapeutics. The variety in 
polyketide biological activity is largely attributed to their structural diversity arising from their 
assembly-line construction by polyketide synthases (PKSs). Type I PKSs consist of modular 
cassettes of megaenzymes with catalytic domains for extending, editing and transferring 
polyketide chains. The minimal components necessary for elongation of a polyketide 
intermediate include an acyl carrier protein (ACP), acyltransferase (AT), and ketosynthase (KS) 
domains. Each module may additionally house processing domains that alter the substituents and 
oxidation states at the α- and β-centers. These include C-methyltransferase (CMT), ketoreductase 
(KR), O-methyltransferase (OMT), dehydratase (DH), and enoyl reductase (ER) domains 
affording α-alkylated, β-hydroxy, β-methoxy, α,β-unsaturated or α,β-saturated products. Many of 
these transformations result in stereoselective formation of an optically enriched product. 
Subsequent elongation and processing steps by the downstream modules lead to the mature 
polyketide chain. Chain termination by a thioesterase (TE) domain results in lactonization or 
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hydrolysis to a macrolactone or carboxylic acid, respectively. The released polyketide is often 
subjected to tailoring events catalyzed by post-PKS tailoring enzymes that further diversify the 
natural product scaffold. 
Curacin A, a mixed polyketide-nonribosomal peptide natural product isolated from the 
cyanobacteria Moorea producens (formerly Lyngbya majuscula) is a potent antiproliferative 
agent that arrests mitosis through the inhibition of tubulin polymerization1. Curacin A is 
biosynthesized via a mixed nonribosomal peptide synthase-polyketide synthase pathway 
incorporating three malonyl-CoA units in a cyclopropyl moiety, one L-cysteine in a thiazolidine-
forming cyclization reaction, and seven units of malonyl-CoA through KS-catalyzed Claisen 
condensations. Both C-methyl and O-methyl substituents arise from two equivalents of S-
adenosylmethionine (SAM) during PKS processing steps. The curacin (Cur) biosynthetic 
pathway has provided a wealth of information about non-canonical enzymatic processes in 
polyketide biosynthesis including a GCN5-related N-acetyltransferase (GNAT)-like strategy for 
polyketide chain initiation, cyclopropane synthesis through β-branching and cryptic 
halogenation, as well as polyketide release via off-loading of a terminal alkene2-4. Moreover, the 
Cur pathway has yielded tremendous structural insight into this unprecedented PKS chemistry 
and three-dimensional structures of fourteen proteins in the Cur pathway have been published5-13.  
We selected the curacin biosynthesis as a platform for studying dehydratase activity in 
PKSs. The pathway uniquely produces nearly every possible type of olefin substitution pattern 
(mono-, di-, and trisubstituted) as well as both cis and trans geometric isomers (Fig. 4.1). 
Additionally, curacin B and C constitute geometric isomers of curacin A and suggest a degree of 
pathway flexibility in regards to olefin formation (Fig. 4.2)14. Bioinformatic analysis of the 
curacin gene cluster shows that PKS modules CurG and CurI are missing DH domains while 
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CurF contains an extraneous DH domain10, 15. Neighboring curacin modules could potentially 
accommodate for the missing DHs. This process, termed ‘domain stuttering’, involves direct 
transfer of an ACP-bound intermediate to the ACP of the next domain16. This product could be 
β-processed (dehydrated by a DH, in this case) then transferred back to the KS domain of the 
same module for a typical round of extension and β-processing. We hypothesized these non-
canonical dehydration events may occur through a simpler and more efficient process by an 
alternative mechanism. The Smith lab previously disclosed the structural characterization of all 
four excised DH domains from CurF, CurH, CurJ and CurK providing a solid structural 
foundation and a unique opportunity to capture a bound substrate10. The conserved, catalytic His-
Asp dyad residues necessary for syn-dehydration and the active site channels are surprisingly 
quite similar giving few clues on the identity of their native substrates17-18. This set the stage for 
our present study using synthetic substrates to probe the substrate specificity and dehydration 
mechanism. 
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Figure 4.2 Curacin A mixed NRPS-PKS biosynthetic pathway.  
The extraneous CurF dehydratase (DH) with no predicted function is highlighted in red. The absent DHs in CurG 
and CurI are shown with dashed lines in black and white. 
Figure 4.1 Natural geometric isomers of curacin. 
Both the Δ7,8 and Δ9,10 cis-isomers of curacin A have been 
isolated from Moorea producens. The biosynthetic origin of 
these isomerizations remains unknown. 
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Methods 
General chemistry procedures.  
All Chemical synthesis were performed by Will Fiers (U. Minnesota) 
All chemical reagents were used as provided unless indicated otherwise. Freshly distilled reagents 
were purified as reported19. Tetrahydrofuran (THF) and dichloromethane (CH2Cl2) were purified 
via passage through neutral alumina columns. All reactions were performed under an argon 
atmosphere using oven-dried (150 °C) glassware. Compounds were purified by flash 
chromatography using silica gel (300–400 mesh) in the indicated solvent system. TLC was 
performed using 250 μm, F254 silica gel plates and visualized by UV or through staining with 
para-anisaldehyde. Optical rotations were acquired on a polarimeter at the indicated temperature 
using the sodium D line (λ = 589 nm) unless otherwise specified and reported as follows: [α]
temp
D
 = rotation (c g/100 mL, solvent). 1H and 13C NMR spectra were recorded on a 400 MHz NMR 
spectrometer. Chemical shifts are reported in ppm based on an internal standard of residual CHCl3 
(7.26 ppm in 1H NMR and 77.16 in 13C NMR). Proton chemical data are reported in the following 
format: chemical shift (ppm), multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, quint = 
quintet, sext = sextet, sept = septet, m = multiplet, br = broad peak), coupling constant(s), and 
integration. High-resolution mass spectra (HRMS) were obtained on a time-of-flight (TOF) mass 
spectrometer using either PEG or PPG standards to calibrate the instrument.  
 
Ethyl (2E,4E)-2-methylhepta-2,4-dienoate (11) 
To a solution of triethyl 2-phosphonopropionate (2.81 mL, 13.1 mmol, 1.10 equiv) in 
THF (36 mL) at 0 °C was added sodium hydride (60% in oil, 0.595 g, 14.9 mmol, 1.25 equiv) 
l
Temp
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and the reaction stirred for 2 h. Freshly distilled 2-pentenaldehyde 920 (1.16 mL, 11.9 mmol, 1.00 
equiv) was then added dropwise over 20 min. After stirring at 0 °C for 5.5 h, the reaction was 
quenched with H2O (20 mL). The biphasic solution was separated, and the aqueous layer was 
extracted with Et2O (4 × 20 mL). The combined organic layers were dried (Na2SO4), filtered, and 
concentrated under reduced pressure. Purification by silica gel flash chromatography (95:5 
pentane–Et2O) afforded the title compound (2.00 g, quant.) as a transparent light yellow oil: Rf = 
0.22 (98:2 pentane–Et2O); 1H NMR (CDCl3, 400 MHz) δ 7.16 (d, J = 11.2 Hz, 1H), 6.33 (dd, J = 
14.8, 11.2 Hz, 1H), 6.11 (dt, J = 15.2, 6.4 Hz, 1H), 4.20 (q, J = 7.2 Hz, 2H), 2.21 (quint, J = 7.2 
Hz, 2H), 1.93 (s, 3H), 1.30 (t, J = 7.2 Hz, 3H), 1.05 (t, J = 7.6 Hz, 3H); 13C NMR (CDCl3, 100 
MHz) δ 168.8, 144.6, 138.7, 125.3, 125.2, 60.6, 26.5, 14.5, 13.3, 12.7; HRMS (ESI+) m/z calcd 
for C10H16O2Na
+ [M + Na]+ 191.1043, found 191.1039 (error 2.1 ppm). 
(2E,4E)-2-Methylhepta-2,4-dienal (13) 
To a solution of 11 (486 mg, 2.89 mmol, 1.00 equiv) in CH2Cl2 (13.0 mL) at 0 °C was 
slowly added diisobutylaluminum hydride (1.0 M in hexanes, 6.93 mL, 6.93 mmol, 2.40 equiv). 
After 40 min the reaction was quenched via successive addition of MeOH (3.5 mL) and saturated 
aqueous sodium potassium tartrate (10.0 mL). The resulting biphasic mixture was stirred 
vigorously at 23 °C for 14 h. The reaction mixture was partitioned between H2O (10.0 mL) and 
CH2Cl2 (10 mL). The biphasic mixture was separated, and the aqueous layer was extracted with 
CH2Cl2 (3 × 12 mL). The combined organic layers were dried (Na2SO4), filtered, and 
concentrated under reduced pressure to afford the allylic alcohol 12, which was carried onto the 
next reaction without further purification: Rf = 0.58 (8:2 hexanes–EtOAc). 
To a solution of the crude alcohol 12 prepared above in CH2Cl2 (15.0 mL) were 
sequentially added anhydrous MgSO4 (1.04 g, 8.67 mmol, 3.00 equiv) and MnO2 (88% 
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activated, 1.76 g, 20.2 mmol, 7.00 equiv). The resulting gray solution was vigorously stirred at 
23 °C for 24 h. The reaction mixture was filtered through a pad of Celite (2.00 cm) and the 
filtrate concentrated under reduced pressure. Purification by silica gel flash chromatography 
(98:2 pentane–Et2O) afforded the title compound (0.345 g, 96% over 2 steps) as a colorless oil: 
Rf = 0.43 (9:1 pentane–Et2O); 1H NMR (CDCl3, 400 MHz) δ 9.42 (s, 1H), 6.83 (d, J = 11.2 Hz, 
1H), 6.52 (ddt, J = 14.8, 11.2, 1.6 Hz, 1H), 6.28 (dt, J = 14.8, 6.4 Hz, 1H), 2.32–2.23 (m, 2H), 
1.84 (t, J = 0.8 Hz, 3H), 1.10 (t, J = 7.6 Hz, 3H); 13C NMR (CDCl3, 100 MHz) δ 195.3, 149.5, 
147.3, 136.2, 125.1, 26.7, 13.1, 9.5; HRMS (ESI+) m/z calcd for C8H12ONa
+ [M + Na]+ 
147.0780, found 147.0794 (error 9.5 ppm). 
(4R)-3-[(3S,4E,6E)-3-Hydroxy-4-methylnona-4,6-dienoyl]-4-isopropylthiazolidine-2-thione (15) 
To a solution of 14 (0.484 g, 2.38 mmol, 1.60 equiv) in CH2Cl2 (12.0 mL) at −40 °C was 
added TiCl4 (0.277 mL, 2.53 mmol, 1.70 equiv) whereupon the solution changed from bright 
yellow to orange-red. The solution was stirred for 30 min at −40 °C, then freshly distilled 
iPr2NEt (0.441 mL, 2.53 mmol, 1.70 equiv) was added dropwise. After 2.25 h the blood-red 
solution was cooled to −78 °C and aldehyde 13 (185.0 mg, 1.49 mmol, 1.00 equiv, dried 
overnight over 3 Å molecular sieves) was added over one min. The aldol reaction was stirred at 
−78 °C for 3.5 h and quenched with saturated aqueous NH4Cl (6.0 mL). The biphasic solution 
was separated, and the aqueous layer was extracted with CH2Cl2 (4 × 10 mL). The combined 
organics were dried (Na2SO4), filtered, and concentrated under reduced pressure. Purification by 
silica gel flash chromatography (7:3 hexane–EtOAc) afforded the title compound (0.230 g, 47%) 
as a viscous bright yellow oil: Rf = 0.41 (7:3 hexane–EtOAc); [α]24D = −246 (c 1.00, CHCl3); 
1H NMR (CDCl3, 400 MHz) δ 6.24 (dd, J = 14.8, 10.8 Hz, 1H), 6.09 (d, J = 10.8 Hz, 1H), 5.76 
(dt, J = 14.8, 6.8 Hz, 1H), 5.14 (t, J = 6.8 Hz, 1H), 4.61 (dd, J = 8.8, 0.8 Hz, 1H), 3.59–3.48 (m, 
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2H), 3.42 (dd, J = 17.2, 9.2 Hz, 1H), 3.03 (d, J = 11.6 Hz, 1H), 2.65 (br s, 1H), 2.37 (sext, J = 6.4 
Hz, 1H), 2.13 (pent, J = 7.2 Hz, 2H), 1.77 (s, 3H), 1.06 (d, J = 6.8, 3H), 1.02 (d, J = 7.4, 3H), 
0.99 (t, J = 8.8 Hz, 3H); 13C NMR (CDCl3, 100 MHz) δ 203.2, 172.9, 137.5, 135.2, 125.9, 124.9, 
73.0, 71.7, 44.1, 31.0, 30.8, 26.2, 19.2, 18.0, 13.8, 13.0; HRMS (ESI+) m/z calcd for 
C16H25NO2S2Na
+ [M + Na]+ 350.1219, found 350.1207 (error 3.4 ppm). 
S-(2-Acetamidoethyl) (S,4E,6E)-3-hydroxy-4-methylnona-4,6-dienethioate (1) 
A solution of aldol adduct 15 (15.0 mg, 0.0458 mmol, 1.00 equiv) in CH2Cl2 (3.00 mL) 
was treated with N-acetylcysteamine (5.0 μL, 0.050 mmol, 1.1 equiv) and imidazole (9.4 mg, 
0.14 mmol, 3.0 equiv) and stirred at 23 °C for 22 h. The reaction mixture was partitioned 
between H2O (5 mL) and EtOAc (5 mL) and the layers were separated. The aqueous layer was 
extracted with EtOAc (4 × 10 mL) and the combined organic fractions were dried (Na2SO4), 
filtered and concentrated under reduced pressure. The crude residue was purified by flash 
chromatography (95:5 CH2Cl2–MeOH) to afford the title compound (7.2 mg, 55%) as a colorless 
oil: Rf = 0.39 (95:5 CH2Cl2–MeOH); [α]24D = −21 (c 0.52, CHCl3); 1H NMR (CDCl3, 400 
MHz) δ 6.22 (dd, J = 15.2, 10.4 Hz, 1H), 6.07 (d, J = 10.8 Hz, 1H), 5.83 (br s, 1H), 5.76 (dt, J = 
15.2, 6.4 Hz, 1H), 4.53 (dd, J = 9.2, 3.6 Hz, 1H), 3.48–3.40 (m, 2H), 3.05 (app. sext, J = 8.0 Hz, 
2H), 2.84 (dd, J = 15.2, 8.8 Hz, 1H), 2.76 (dd, J = 14.8, 4.0 Hz, 1H), 2.48 (br s, 1H), 2.13 (app. 
quint, J = 7.2 Hz, 2H), 1.96 (s, 3H), 1.75 (s, 3H), 1.01 (t, J = 7.2 Hz, 3H); 13C NMR (CDCl3, 100 
MHz) δ 199.0, 170.6, 138.0, 134.9, 126.3, 124.7, 74.0, 49.6, 39.5, 29.0, 26.1, 23.4, 13.8, 12.6; 
HRMS (ESI+) m/z calcd for C14H23NO3SNa
+ [M + Na]+ 308.1291, found 308.1275 (error 5.2 
ppm). 
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(4R)-4-Benzyl-3-[(2S,3R,4E)-3-hydroxy-2-methylhept-4-enoyl]thiazolidine-2-thione (18) 
To a solution of thiazolidinethione 17 (0.250 g, 0.940 mmol, 1.00 equiv) in CH2Cl2 (4.00 
mL) at 0 °C was added TiCl4 (0.110 mL, 0.990 mmol, 1.05 equiv). The resulting bright orange, 
opaque solution was stirred for 9 min. Next, freshly distilled iPr2EtN (0.183 mL, 1.05 mmol, 
1.12 equiv) was added and the reaction was further stirred for 40 min at 0 °C. To the dark red 
mixture was slowly added freshly distilled 2-pentenaldehyde (0.138 mL, 1.41 mmol, 1.50 equiv) 
causing a color change to dark brown. After 2 h, the reaction was quenched with saturated 
aqueous NH4Cl (5 mL). The biphasic mixture was warmed to 23 °C and the layers separated. 
The aqueous layer was extracted with CH2Cl2 (3 × 10 mL) and the combined organic layers were 
dried (Na2SO4), filtered, and concentrated under reduced pressure. Purification by flash 
chromatography (8:2 hexanes–EtOAc) afforded the title compound (0.252 g, 72 %) as a viscous, 
yellow oil: Rf = 0.20 (8:2 hexanes–EtOAc); [α]22D = −191.6 (c 1.00, CHCl3); 1H NMR (CDCl3, 
400 MHz) δ 7.37–7.27 (m, 5H), 5.82 (ddt, J = 15.6, 6.4, 1.2 Hz, 1H), 5.50 (ddt, J = 15.2, 6.0, 1.2 
Hz, 1H), 5.39 (ddd, J = 10.6, 6.8, 4 Hz, 1H), 4.79 (dq, J = 6.8, 3.2 Hz, 1H), 4.59–4.54 (m, 1H), 
3.37 (dd, J = 11.6, 6.8 Hz, 1H), 3.24 (dd, J = 13.2, 4.0 Hz, 1H), 3.04 (dd, J = 13.2, 10.4 Hz, 1H), 
2.88 (d, J = 11.6 Hz, 1H), 2.74 (d, J = 2.8 Hz, 1H), 2.08 (app. quint, J = 7.2, 2H), 1.19 (d, J = 6.8 
Hz, 3H), 1.01 (t, J = 7.6 Hz, 3H); 13C NMR (CDCl3, 100 MHz) δ 201.8, 177.8, 136.6, 135.0, 
129.6, 129.1, 127.9, 127.4, 72.5, 69.1, 43.5, 37.1, 31.9, 25.5, 13.6, 11.6; HRMS (ESI+) m/z calcd 
for C18H23NO2S2Na
+ [M + Na]+ 372.1062, found 372.1087 (error 6.7 ppm). 
(4R)-4-Benzyl-3-[(2R,3R,4E)-3-hydroxy-2-methylhept-4-enoyl]thiazolidine-2-thione (19) 
To a solution of 17 (0.150 g, 0.566 mmol, 1.00 equiv) in anhydrous EtOAc (1.4 mL) 
were sequentially added anhydrous MgBr2•OEt2 (14.6 mg, 0.0566 mmol, 0.100 equiv), 2-
pentenaldehyde (60.9 μL, 0.623 mmol, 1.10 equiv), Et3N (0.158 mmol, 1.13 mmol, 2.00 equiv) 
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and Me3SiCl (0.108 mL, 0.849 mmol, 1.50 equiv), which all had been freshly distilled. The 
reaction mixture was stirred at 23 °C for 26 h, then filtered through a silica gel plug (2.00 cm), 
washing with Et2O (20 mL), and the filtrate was concentrated under reduced pressure. The crude 
residue was dissolved in a biphasic mixture of THF (10 mL) and aqueous hydrochloric acid (1 N, 
2 mL) and vigorously stirred at 23 °C for 2 h. The reaction was then quenched with saturated 
aqueous sodium bicarbonate (10 mL) and the biphasic solution was separated. The aqueous layer 
was extracted with EtOAc (3 × 15 mL) and the combined organic fractions were dried (Na2SO4), 
filtered, and concentrated under reduced pressure. Purification by silica gel flash 
chromatography (8:2 hexane–EtOAc) afforded the title compound (35.8 mg, 17%) as a viscous, 
yellow oil: Rf = 0.28 (8:2 hexane–EtOAc); [α]24D = −297.1 (c 1.00, CHCl3); 1H NMR (CDCl3, 
400 MHz) δ 7.37–7.27 (m, 5H), 5.79 (dt, J = 15.2, 5.6 Hz, 1H), 5.42 (ddt, J = 15.2, 7.2, 1.6 Hz, 
1H), 5.25 (ddd, J = 10.8, 6.8, 3.6 Hz, 1H), 4.34 (dq, J = 7.6, 6.8 Hz, 1H), 4.26 (t, J = 7.6 Hz, 
1H), 3.39 (dd, J = 11.2, 6.8 Hz, 1H), 3.26 (dd, J = 13.2, 3.6 Hz, 1H), 3.06 (dd, J = 12.8, 10.8 Hz, 
1H), 2.90 (d, J = 11.6 Hz, 1H), 2.16 (br, 1H), 2.06 (app. quint, J = 6.4, 2H), 1.22 (d, J = 6.8 Hz, 
3H), 1.00 (t, J = 7.2 Hz, 3H); 13C NMR (CDCl3, 100 MHz) δ 201.5, 178.2, 136.7, 136.3, 129.6, 
129.3, 129.0, 127.3, 76.7, 69.2, 45.2, 36.8, 32.8, 25.4, 14.9, 13.5; HRMS (ESI+) m/z calcd for 
C18H23NO2S2Na
+ [M + Na]+ 372.1062, found 372.1049 (error 3.5 ppm). 
S-(2-Acetamidoethyl) (2R,3R,4E)-3-hydroxy-2-methylhept-4-enethioate (3) 
To a solution of 19 (31.1 mg, 0.0890 mmol, 1.00 equiv) in CH2Cl2 (4.00 mL) was added 
imidazole (18.2 mg, 0.267 mmol, 3.00 equiv) and N-acetylcysteamine (10.4 μL, 0.0980 mmol, 
1.10 equiv). The reaction mixture was vigorously stirred at 23 °C for 21 h. The crude reaction 
mixture was concentrated under reduced pressure and directly purified by flash chromatography 
(95:5 CH2Cl2–MeOH) to afford the title compound (16.8 mg, 67%) as a light yellow, viscous oil: 
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Rf = 0.30 (95:5 CH2Cl2–MeOH); [α]24D = −34.5 (c 0.29, CHCl3); 1H NMR (CDCl3, 400 MHz) δ 
6.00 (br s, 1H), 5.76 (dt, J = 15.6, 6.0 Hz, 1H), 5.40 (ddt, J = 15.6, 6.4, 1.2 Hz, 1H), 4.19 (t, J = 
7.6 Hz, 1H), 3.55–3.37 (m, 2H), 3.13–2.98 (m, 2H), 2.76 (app. quint, J = 7.2 Hz, 1H), 2.42 (br s, 
1H), 2.06 (app. quint, J = 7.6 Hz, 2H), 1.94 (s, 3H), 1.11 (d, J = 6.8 Hz, 3H), 1.00 (t, J = 7.6 Hz, 
3H); 13C NMR (CDCl3, 100 MHz) δ 203.6, 170.6, 136.6, 128.8, 75.5, 54.5, 39.5, 28.7, 25.4, 
23.3, 15.1, 13.5; HRMS (ESI+) m/z calcd for C12H21NO3SNa
+ [M + Na]+ 282.1134, found 
282.1153 (error 6.7 ppm). 
 
 
(4S)-3-[ (3R,4E,6E)-3-Hydroxy-4-methylnona-4,6-dienoyl]-4-isopropylthiazolidine-2-thione 
(ent-15).  
The title compound was prepared from ent-14 and 13 following 
the procedure described for compound 15 and isolated (112.0 
mg, 75%) as a bright yellow oil, whose 1H and 13C NMR data 
were identical to its enantiomer: [] = +233.2 (c 1.00, CHCl3).  
 
S-(2-Acetamidoethyl) (3R,4E,6E)-3-hydroxy-4-methylnona-4,6-dienethioate (2).  
The title compound was prepared from ent-15 following the 
general thiazolidinethione displacement procedure and isolated 
(6.8 mg, 24%) as a yellow oil, whose 1H and 13C NMR data were 
identical to its enantiomer: [] = 17.1 (c 1.00, CHCl3). 
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(4S)-4-Benzyl-3-[(2R,3S,4E)-3-hydroxy-2-methylhept-4-enoyl)]thiazolidine-2-thione (ent-18).  
The desired aldol product was obtained an analogous method as the 
enantiomer, 18 and isolated (0.257 g, 78%) as a yellow oil: Rf  = 0.20 
(8:2 hexanes–EtOAc); [] 23
D
= +199.3 (c 1.00, CHCl3); 
1H NMR 
(CDCl3, 400 MHz) δ 7.38–7.27 (m, 5H), 5.82 (ddt, J = 15.6, 6.4, 1.2 Hz, 1H), 5.50 (ddt, J = 15.2, 
6.0, 1.2 Hz, 1H), 5.39 (ddd, J = 10.6, 6.8, 4 Hz, 1H), 4.79 (dq, J = 6.8, 3.2 Hz, 1H), 4.59–4.54 (m, 
1H), 3.37 (dd, J = 11.6, 6.8 Hz, 1H), 3.24 (dd, J = 13.2, 4.0 Hz, 1H), 3.04 (dd, J = 13.2, 10.4 Hz, 
1H), 2.88 (d, J = 11.6 Hz, 1H), 2.74 (d, J = 2.8 Hz, 1H), 2.08 (app. quint, J = 7.2, 2H), 1.19 (d, J 
= 6.8 Hz, 3H), 1.01 (t, J = 7.6 Hz, 3H); 13C NMR (CDCl3, 100 MHz) δ 201.8, 177.7, 136.5, 135.0, 
129.6, 129.1, 128.0, 127.4, 72.5, 69.1, 43.4, 37.1, 31.9, 25.5, 13.6, 11.5; HRMS (ESI+) m/z calcd 
for C18H23NO2S2Na
+ [M + Na]+ 372.1062, found 372.1081 (error 5.1 ppm). 
 
 
 
(4S)-4-Benzyl-3-[(2S,3S,4E)-3-hydroxy-2-methylhept-4-enoyl)]thiazolidine-2-thione (ent-19).  
The desired aldol product was obtained an analogous method as the 
enantiomer, 19, affording the product as a viscous yellow oil (20.6 
mg, 10%): Rf  = 0.28 (8:2 hexanes–EtOAc); []23
D
= +302.6 (c 1.00, 
CHCl3); 
1H NMR (CDCl3, 400 MHz) δ 7.37–7.24 (m, 5H), 5.79 (dt, J = 15.2, 5.6 Hz, 1H), 5.42 
(ddt, J = 15.2, 7.2, 1.6 Hz, 1H), 5.25 (ddd, J = 10.8, 6.8, 4 Hz, 1H), 4.34 (dq, J = 7.6, 6.8 Hz, 1H), 
4.26 (t, J = 7.6 Hz, 1H), 3.39 (dd, J = 11.2, 6.8 Hz, 1H), 3.26 (dd, J = 13.2, 3.6 Hz, 1H), 3.06 (dd, 
J = 12.8, 10.8 Hz, 1H), 2.90 (d, J = 11.6 Hz, 1H), 2.16 (br, 1H), 2.06 (app. quint, J = 6.4, 2H), 1.22 
(d, J = 6.8 Hz, 3H), 1.00 (t, J = 7.2 Hz, 3H); 13C NMR (CDCl3, 100 MHz) δ 201.5, 178.2, 136.7, 
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136.3, 129.6, 129.3, 129.0, 127.3, 76.7, 69.2, 45.2, 36.8, 32.8, 25.4, 14.9, 13.5; HRMS (ESI+) m/z 
calcd for C18H23NO2S2Na
+ [M + Na]+ 372.1062, found 372.1041 (error 5.6 ppm). 
 
S-(2-Acetamidoethyl) (2S,3R,4E)-3-hydroxy-2-methylhept-4-enethioate (4).  
To a solution of aldol adduct 18 (25.2 mg, 0.0721 mmol, 1.00 equiv) 
dissolved in CH2Cl2 (5.00 mL) was added with N-acetylcysteamine 
(8.43 μL, 1.10 equiv) and imidazole (14.7 mg, 0.216 mmol, 3.00 equiv). The reaction mixture was 
stirred at 23 °C for 21 h. The resulting solution was evaporated under nitrogen stream and the 
crude residue was purified by flash chromatography (95:5 CH2Cl2–MeOH), furnishing the title 
compound (16.9 mg, 0.0652 mmol, 90%) as a colorless, viscous oil: Rf  = 0.20 (95:5 CH2Cl2–
MeOH); [] = 27.6 (c 0.87, CHCl3); 1H NMR (CDCl3, 400 MHz) 5.79 (br, 1H), 5.77 (ddt, J = 
15.2, 6.4, 1.2 Hz, 1H), 5.44 (ddt, J = 15.2, 6.8, 1.6 Hz, 1H), 4.37 (br, 1H), 3.52–3.34 (m, 2H), 
3.10–2.96 (m, 2H), 2.84–2.75 (m, 1H), 2.06 (app. quint, J = 6.8 Hz, 2H), 1.96 (s, 3H), 1.22 (d, J = 
6.4 Hz, 3H), 0.99 (t, J = 7.2 Hz, 3H); 13C NMR (CDCl3, 100 MHz) δ 203.6, 170.5, 135.7, 128.0, 
73.6, 54.0, 39.6, 28.7, 25.4, 23.4, 13.5, 12.0; HRMS (ESI+) m/z calcd for C12H21NO3SNa
+ [M + 
Na]+ 282.1134, found 282.1136 (error 0.71 ppm). 
 
S-(2-Acetamidoethyl) (2R,3S,4E)-3-hydroxy-2-methylhept-4-enethioate (5).  
The thioester 5 was synthesized in an analogous manner to that of the 
thioester 4 yielding a colorless oil (14.5 mg, 63%): Rf  = 0.19 (95:5 
CH2Cl2–MeOH); [] = -24.1 (c 0.58, CHCl3); 1H NMR (CDCl3, 400 MHz) δ 5.91–5.67 (m, 2H), 
5.52–5.37 (m, 1H), 4.37 (br s, 1H), 3.54–3.35 (m, 2H), 3.10–2.95 (m, 2H), 2.87–2.75 (m, 1H), 
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2.06 (app. quint, J = 6.8 Hz, 2H), 1.96 (s, 3H), 1.22 (d, J = 7.2 Hz, 3H), 0.99 (t, J = 7.6 Hz, 3H); 
13C NMR (CDCl3, 100 MHz) δ 203.6, 170.5, 135.6, 128.0, 73.6, 54.0, 39.6, 28.7, 25.4, 23.4, 13.6, 
12.0; HRMS (ESI+) m/z calcd for C12H21NO3SNa
+ [M + Na]+ 282.1134, found 282.1152 (error 
6.4 ppm). 
 
S-(2-Acetamidoethyl) (2S,3S,4E)-3-hydroxy-2-methylhept-4-enethioate (6).  
The thioester 6 was synthesized in an analogous manner to that of the 
prior thioester 3 furnishing the desired product as a colorless oil (3.24 
mg, 42%): Rf  = 0.30 (95:5 CH2Cl2–MeOH); [] = 37.3 (c 0.35, CHCl3); 1H NMR (CDCl3, 400 
MHz) δ 5.88 (br s, 1H), 5.79 (dt, J = 15.6, 6.0 Hz, 1H), 5.40 (ddt, J = 15.6, 6.4, 1.2 Hz, 1H), 4.21 
(t, J = 7.6 Hz, 1H), 3.55–3.37 (m, 2H), 3.13–2.98 (m, 2H), 2.76 (app. quint, J = 7.2 Hz, 1H), 2.07 
(app. quint, J = 7.6 Hz, 2H), 1.96 (s, 3H), 1.13 (d, J = 6.8 Hz, 3H), 1.00 (t, J = 7.6 Hz, 3H); 13C 
NMR (CDCl3, 100 MHz) δ 203.7, 170.6, 136.8, 128.8, 75.6, 54.5, 39.7, 28.7, 25.4, 23.3, 15.2, 
13.5; HRMS (ESI+) m/z calcd for C12H21NO3SNa
+ [M + Na]+ 282.1134,found 282.1157 (error 8.2 
ppm). 
S-(2-Acetamidoethyl) 2-(diethoxyphosphoryl)propanethioate (S2).  
To a flask containing H2O (2.00 mL) was added triethyl 2-
phosphonopropionate (1.00 mL, 4.66 mmol, 1.00 equiv). The clear, 
colorless solution was cooled via ice water bath (0 °C). To the chilled 
mixture was slowly added a cooled (4 °C), aqueous NaOH solution (10.0 N, 0.490 ml, 4.90 mmol, 
1.05 equiv). The reaction mixture was allowed to slowly warm to 23 °C and stirred for 20 h. The 
reaction was quenched with aqueous HCl (1 N) until the pH was 1.00. The resulting solution was 
saturated with solid NaCl and extracted with CH2Cl2 (4  10 mL). The combined organic layers 
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were dried (Na2SO4), filtered and the solvent removed under reduced pressure. The crude residue 
was dissolved in CH2Cl2 (40 mL) and cooled by placing in an ice water bath (0 °C). To the chilled 
solution was added 4-dimethylaminopyridine (57.0 mg, 0.467 mmol, 0.100 equiv) and N,N’-
dicyclohexylcarbodiimide (1.01 g, 4.89 mmol, 1.05 equiv). After stirring for 2 min, N-
acetylcysteamine (0.644 mL, 6.06 mmol, 1.30 equiv) was added to the reaction mixture. The 
resulting solution was allowed to warm to 23 °C and stirred 22 h. The reaction mixture was diluted 
with Et2O (40 mL) and filtered to remove the urea precipitate. The filtrate was concentrated under 
reduced pressure and purified by flash chromatography (EtOAc) affording the title compound 
(1.36 g, 4.37 mmol, 94%) as a clear colorless oil: Rf  = 0.15 (EtOAc); 
1H NMR (CDCl3, 400 MHz) 
δ 6.30 (br, 1H), 4.21–4.09 (m, 4H), 3.54–3.37 (m, 2H), 3.29 (dq, J = 22.4, 7.2 Hz, 1H), 3.20–3.12 
(m, 1H), 3.04–2.95 (m, 1H), 1.96 (s, 3H), 1.45 (dd, J = 18.0, 7.2 Hz, 3H), 1.34 (t, J = 7.2 Hz, 6H); 
13C NMR (CDCl3, 100 MHz) δ 196.1, 196.0, 170.6, 63.34, 63.27, 63.0, 62.9, 49.2, 47.9, 39.2, 29.4, 
23.2, 16.54, 16.48, 12.51, 12.45; HRMS (ESI+) m/z calcd for C11H22NO5PSNa
+ [M + Na]+ 
334.0849, found 334.0847 (error 0.60 ppm). 
S-(2-Acetamidoethyl) (2E,4E)-2-methylhepta-2,4-dienethioate (8).  
To a solution of LiBr (0.132 g, 1.52 mmol, 3.16 equiv) in THF (6.00 
mL) was added the phophono-thioester S2 (0.150 g, 0.482 mmol, 1.00 
equiv). The solution was stirred vigorously at 23 °C for 10 min. To the reaction mixture was Et3N 
(0.212 mL, 1.52 mmol, 3.16 equiv) resulting in the formation of a cloudy, colorless solution that 
was stirred at 23 °C for 15 min. To the reaction vessel was added freshly distilled 2-pentenaldehyde 
919 (99.0 μL, 1.02 mmol, 2.11 equiv) in a drop wise fashion. After stirring for 24 h, the reaction 
mixture was quenched upon addition of H2O (30 mL). The biphasic solution was separated, and 
the aqueous layer was extracted with EtOAc (4  10 mL). The combined organic fractions were 
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dried (Na2SO4), filtered and concentrated under reduced pressure. The crude product residue was 
purified by wet-loading onto silica flash column (1:1 hexanes–EtoAc) yielding the title compound 
(49.5 mg, 0.205 mmol, 43%) as a cloudy oil: Rf  = 0.30 (95:5 CH2Cl2–MeOH); 1H NMR (CDCl3, 
400 MHz) δ 7.17 (d, J = 10.8 Hz, 1H), 6.35 (dd, J = 14.8, 11.2 Hz, 1H), 6.22 (dt, J = 5.6, 15.2 Hz, 
1H), 6.01 (br, 1H), 3.52–340 (m, 2H), 3.15–3.03 (m, 2H), 2.30–2.16 (m, 2H), 1.97 (s, 6H), 1.07 
(t, J = 6.8 Hz, 3H); 13C NMR (CDCl3, 100 MHz) δ 193.9, 170.8, 146.9, 138.5, 132.6, 124.8, 40.2, 
28.5, 26.7, 23.4, 13.2, 12.7; HRMS (ESI+) m/z calcd for C12H19NO2SNa
+ [M + Na]+ 264.1029, 
found 264.1043 (error 5.3 ppm). 
 
 
 
 (4S)-3-((5R,2E)-5-Hydroxy-2-methylhept-2-enoyl)-4-isopropyloxazolidin-2-one (S5).  
A solution of freshly distilled propionaldehyde19 (0.443 mL, 6.14 mmol, 
2.00 equiv) in CH2Cl2 (15.0 mL) was cooled via dry ice–acetone bath (-
78 °C). To the reaction mixture was added TiCl4 (0.338 mL, 3.07 mmol, 
1.00 equiv). To the resulting yellow reaction mixture was slowly added the N,O-silyl ketene acetal 
S421 (1.00 g, 3.07 mmol, 1.00 equiv) as a solution in CH2Cl2 (14.6 mL). The reaction mixture was 
transferred to an MeCN–dry ice bath (-40 °C) and stirred for 7 h. The reaction was halted via 
sequential addition of a saturated, aqueous potassium sodium tartrate (10 mL) and a saturated, 
aqueous NaHCO3 solution (10 mL). The resulting cloudy mixture was vigorously stirred at 23 °C 
for 1 h. The biphasic solution was separated, and the aqueous layer was extracted with CH2Cl2 (3 
 20 mL). The combined organic layers were dried (Na2SO4), filtered and concentrated under 
reduced pressure. The crude product residue was purified by flash chromatography (7:3 hexanes–
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EtOAc) affording the title compound (0.673 g, 2.49 mmol, 81%) as an amorphous white solid: Rf  
= 0.20 (7:3 hexanes–EtOAc); [] = 46.0 (c 1.00, CHCl3); 1H NMR (CDCl3, 400 MHz) δ 6.03 (t, 
J = 7.6 Hz, 1H), 4.56 (dt, J = 8.8, 4.8 Hz, 1H), 4.33 (t, J = 8.8 Hz, 1H), 4.9 (dd, J = 8.8, 5.2 Hz, 
1H), 3.70–3.60 (m, 1H), 2.53 (br, 1H), 2.43–2.26 (m, 3H), 1.94 (s, 3H), 1.65–1.47 (m, 2H), 0.98 
(t, J = 7.6 Hz, 3H), 0.92 (t, J = 6.8 Hz, 6H); 13C NMR (CDCl3, 100 MHz) δ 171.7, 154.4, 135.4, 
133.2, 72.2, 63.6, 58.3, 36.5, 29.9, 28.5, 18.0, 15.3, 13.9, 10.4, 7.3; HRMS (ESI+) m/z calcd for 
C14H23NO4Na
+ [M + Na]+ 292.1519, found 292.1529 (error 3.4 ppm). 
 
S-(2-Acetamidoethyl) (5R,2E)-5-hydroxy-2-methylhept-2-enethioate (21).  
A solution of imide S5 (0.190 g, 0.707 mmol, 1.00 equiv) dissolved in a 
THF–H2O (2:1, 6.43 mL) was vigorously stirred in ice water bath (0 °C). 
To the chilled reaction mixture was added H2O2 (30% in water, 0.219 mL, 1.93 mmol, 3.00 equiv) 
followed by LiOH•H2O (80.9 mg, 1.93 mmol, 3.00 equiv). The reaction mixture was vigorously 
stirred for 24 h, slowly warming to 23 °C. An additional aliquot of H2O2 (80.0 μL, 0.707 mmol, 
1.00 equiv) and LiOH•H2O (29.7 mg, 0.707 mmol, 1.00 equiv) were added to the reaction mixture 
at 0 °C. The reaction mixture was allowed to warm to 23 °C and stirred for 36 h. The crude solution 
was concentrated under reduced pressure and the resulting aqueous solution was portioned treated 
with aqueous, saturated NaHCO3 (1 mL) and washed with Et2O (2  10 mL). The aqueous fraction 
was acidified with aqueous HCl (2 M) to pH 2 and extracted with Et2O (4  10 mL). The combined 
organics were concentrated to dryness under reduced pressure and the crude colorless oil (0.112 
g) was submitted directly to the next reaction.  
 The crude acid S6 (82.2 mg, 0.520 mmol, 1.00 equiv) in DMF (2.73 mL) was cooled via 
ice–water bath (0 °C). To the chilled solution was sequentially added diphenylphophoryl azide 
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(0.168 mL, 0.780 mmol, 1.50 equiv) and Et3N (145 μL, 1.04 mmol, 2.00 equiv). The reaction 
mixture was stirred for 2 h at 0 °C. An aliquot of N-acetylcysteamine (55.3 μL, 0.520 mmol, 1.00 
equiv) was added to the reaction mixture at 0°C. The slightly yellow solution was allowed to 
gradually warm to 23 °C and stirred 5.5 h. The reaction mixture was quenched upon addition of 
H2O (3 mL) and EtOAc (10 mL) and the biphasic solution was separated. The aqueous layer was 
extracted with EtOAc (4  10 mL). The combined organic fractions were dried (Na2SO4), filtered 
and concentrated under reduced pressure. The crude product residue was purified by flash 
chromatography (95:5 to 9:1 CH2Cl2–MeOH) yielding the title compound (92.6 mg, 0.357 mmol, 
69% over 2 steps) as a clear, colorless oil: Rf  = 0.20 (95:5 CH2Cl2–MeOH); [] = –15.3 (c 1.00, 
CHCl3); 
1H NMR (CDCl3, 400 MHz) δ 6.86 (t, J = 7.2 Hz, 1H), 5.87 (br, 1H), 3.78–3.69 (m, 1H), 
3.45 (q, J = 6.0 Hz, 2H), 3.07 (t, J = 6.4 Hz, 2H), 2.47–2.32 (m, 2H), 1.97 (s, 3H), 1.91 (s, 3H), 
1.60–1.46 (m, 2H), 0.98 (t, J = 7.2, 3H); 13C NMR (CDCl3, 100 MHz) δ 194.0, 170.4, 138.0, 137.8, 
72,5, 39.9, 36.4, 30.3, 28.7, 23.4, 12.9, 10.0; HRMS (ESI+) m/z calcd for C12H21NO3SNa
+ [M + 
Na]+ 282.1134, found 282.1236 (error 0.71 ppm). 
The above compound matches that synthesized by another alternative and previously reported 
route in all respects22. 
 
 (4R)-3-((5S,2E)-5-Hydroxy-2-methylhept-2-enoyl)-4-isopropyloxazolidin-2-one (ent-S5).  
The target alcohol was synthesized from N, O-vinyl ketene acetal ent-
S4 via an analogous route to that of the enantiomer, S5: The product 
was produced as a clear, colorless oil (0.574 g, 88%). [] = -44.5 (c 
1.00, CHCl3). Additional properties matched those of the enantiomer S5. 
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S-(2-Acetamidoethyl) (5S,2E)-5-hydroxy-2-methylhept-2-enethioate (20).  
The thioenoate substrate 20 was synthesized in an analogous route to 
that of the enantiomer 21 starting from acyl oxazolidinone ent-S5. The 
desired SNAC-thioester was furnished as a clear, colorless oil (0.103 g, 69% over 2 steps): []
= -14.0 (c 1.00, CHCl3). All other properties matched those of the enantiomer, compound 21. 
 
 
 
General biology 
All chemical reagents were purchased from Sigma-Aldrich and were used directly 
without further purification. E. coli BL21(DE3) cells were from New England BioLabs. IPTG 
was acquired through Gold Biotechnology. His60 Ni Superflow resin was purchased from 
Clontech Laboratories, Inc. OD600 was measured on an Eppendorf BioPhotometer. Sonication 
was carried out with a Branson Sonifier 450. Gel filtration purification was performed on 
HiLoad 16/600 Superdex 200 pg column (GE Healthcare). The protein mass spectra data was 
obtained on a Bruker BioTOF II mass spectrometer. LC–MS/MS was conducted with an AB 
Sciex QTRAP 5500 mass spectrometer and Shimadzu LC system. 
Protein purification and crystallization 
DHs were purified as described previously10. For co-crystallization of substrates with 
inactive CurJ DH variants, the protein was pre-incubated 2 hr on ice in 5 mM substrate, and then 
crystallized at 20°C by sitting-drop vapor diffusion from a 1:1 mixture of protein stock (15 
mg/mL DH, 5 mM substrate, 50 mM Tris pH 7.5, 150 mM NaCl, 10% glycerol) with well 
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solution (18% polyethylene glycol (PEG) 3350, 5% 1,4-butanediol, 250 mM NaCl, 100 mM Bis-
Tris propane pH 6.5). Crystals were harvested directly from drops into liquid N2. 
Data collection and structure determination 
Data were collected at the Advanced Photon Source (APS, Argonne National Laboratory) 
on GM/CA beamline 23ID-D. CurJ H978F crystals diffracted to 2.4 Å in the presence of 5 mM 
substrate. The crystals were nearly isomorphous with the previously reported crystals of wild-
type CurJ DH10. Data were processed using XDS23. The structure was solved by molecular 
replacement in PHENIX24 using the wild-type CurJ (PDB 3KG8) as a search model. Refinement 
was accomplished in PHENIX and model building with coot25. Ligand restraint files were built 
using eLBOW26 in PHENIX. The structure was validated with MolProbity27; figures were 
generated with PyMOL28.  
Steady-state kinetic studies of CurK-DH 
Incubation and sample preparation  
Substrate 1 (0.25–6.0 mM) was incubated with recombinant CurK-DH (20 nM) and 
reaction buffer (50 mM Tris, 150 mM NaCl, pH 8.0) in a total volume of 50 μL at 23 °C. The 
reaction was quenched at 4 min by transfer of 5 μL of the reaction mixture into 495 μL of quench 
solution (1:1 MeCN–H2O). The quenched mixture was briefly vortexed and centrifuged (21,000 
× g, 5 min). A portion of the centrifuged supernatant (60 μL) was transferred to an HPLC vial 
containing the internal standard (10 μL of a 320 nM solution of diene 8), mixed, injected and 
analyzed by LC–tandem MS. 
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Instrumentation  
Reverse-phase liquid chromatography was conducted on a Shimadzu UFLC XR, SIL-
20AC autosampler and Prominence CTO-20A column oven. A SCIEX QTRAP 5500 
(Framingham, MA) was used for mass detection with an electrospray ionization source. All 
instrumentation was run using Analyst Software (1.5.2, AB SCIEX) 
Chromatography  
Reverse phase HPLC was conducted using a Kinetix reverse-phase C18 column (50 mm × 
2.1 mm, 2.6 μm, Phenomenex®, Torrance, CA) operated at 0.4 mL min−1 with a column 
temperature of 35 °C. The mobile phase A (0.1% formic acid in H2O) and mobile phase B 
(acetonitrile) were run at the following gradient program: 0 min, 5% B; 2 min, 5% B; 7 min, 
55% B; 8 min, 70% B; 9 min, 70% B; 10.5 min, 5% B; 12 min, 5% B, STOP. The injection 
volume was 10 μL. 
Mass spectrometry  
Analytes were analyzed by MS in positive ionization mode by Multiple Reaction 
Monitoring (MRM). Optimal MRM settings were determined by direct infusion of the analyte 
solution (10 nM, 1:1 H2O–MeCN with 0.1% formic acid) onto the MS by a syringe pump at a 
flow of 10 μL/min. The transitions and retention times are displayed in Table 4.1. 
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Table 4.1 LC-MS/MS transitions, parameters and retention times for 1-8, 20 and 21 
Cmpd Precursor Ion (m/z) Product Ion (m/z) DPa (V) CEa (V) CXPa (V) Retention Time (min) 
1, 2 
 
 
35 25 15 6.17 
7 
 
 
35 25 15 7.44 
3, 4, 5, 6 
 
 
35 30 15 
5.52 (3 and 6) 
5.24 (4 and 5) 
6 
  
35 30 15 6.80 
20, 21 
 
 
35 17 15 5.11 
aMass Spectrometry parameter abbreviations: DP = de-clustering potential, CE = collision energy, CXP = collision cell exit 
potential 
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Standard curve and data analysis  
A standard curve for the triene product 7 was generated by injecting the authentic 
standard at varying concentrations with a fixed concentration of internal standard 8 (Fig. 4.3). 
Transitions and retention times are given in Tables 4.2 and 4.3. Analyte and internals standard 
peak areas were calculated using MultiQuant software (version 2.0.2). Each analyte peak area 
was normalized to internal standard (8) peak area and converted to an analyte concentration 
using the standard curve equation. Each reaction was performed in duplicate. The calculated 
initial velocity at each substrate concentration was used to generate a Michaelis-Menten curve 
(eq.1, Fig.4.4 ) utilizing Prism 5 software (Version 5.0b) (Figure 4.4):  
(eq. 1) 
𝑣⁡ = ⁡
𝑉max[𝑆]
𝐾M + [𝑆]
 
where v is the reaction rate, Vmax is the maximum enzymatic reaction rate, [S] is the 
concentration of substrate and KM is the Michaelis-Menten constant. 
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Table 4.2 CurK DH standard curve data 
Conc. 3.7 
(nM) 
Transition 
(g/mol) 
Peak Area Area Ratio (3.7/4.6) 
0 268→ 121  7362.665 0.008408595 
0 242→ 95 875611.851  
20 268→ 121  22332.363 0.025029893 
20 242→ 95 892227.710  
40 268→ 121  31796.445 0.037390844 
40 242→ 95 850380.513  
80 268→ 121  59521.288 0.078705923 
80 242→ 95 756249.172  
160 268→ 121  107466.167 0.145652283 
160 242→ 95 737826.866  
320 268→ 121  228634.211 0.300539582 
320 242→ 95 760745.754  
640 268→ 121  425896.088 0.569489824 
640 242→ 95 747855.484  
1280 268→ 121  730462.476 1.025132203 
1280 242→ 95 712554.414  
 
 
Figure 4.3 LC-MS/MS standard curve of 7.  
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Each point is the result of an area ratio of 7 and internal standard 8. 
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Table 4.3 LC-MS/MS data for CurK DH substrate 1 
Conc. 
3.5 
(nM) 
Transition 
(g/mol) 
Peak Area Area 
Ratio 
(3.7/4.6) 
Conc. 
3.7 
(nM) 
Velocity 
(nM/min) 
100 
(dil.) 
Velocity 
(M/min) 
Blank 268→121 9949.448      
Blank 242→95 23056.428      
Blank 268→121 27593.916      
Blank 242→95 69868.674      
0.25 268→121 45799.656 0.0487 37.8 9.45 945.4 0.945 
0.25 242→95 940210.259      
0.25 268→121 51390.985 0.0558 46.6 11.7 1166.1 1.166 
0.25 242→95 920671.740      
0.50 268→121 153218.239 0.164 181.4 45.4 4535.9 4.536 
0.50 242→95 932404.409      
0.50 268→121 88632.4536 0.0973 98.2 24.5 2455.3 2.455 
0.50 242→95 910653.094      
1.00 268→121 154376.557 0.171 189.9 47.5 4746.6 4.747 
1.00 242→95 902209.734      
1.00 268→121 177808.667 0.186 208.7 52.2 5217.6 5.218 
1.00 242→95 954541.380      
2.00 268→121 359675.683 0.397 471.0 117.7 11774.6 11.775 
2.00 242→95 905047.196      
2.00 268→121 425682.053 0.452 539.4 134.9 13485.8 13.486 
2.00 242→95 940703.784      
3.00 268→121 587242.104 0.610 735.1 183.8 18378.3 18.378 
3.00 242→95 962612.388      
3.00 268→121 551492.214 0.607 732.2 183.0 18304.5 18.305 
3.00 242→95 907545.802      
6.00 268→121 1015127.87 1.03 1252. 313.0 31299.8 31.300 
6.00 242→95 989286.137      
6.00 268→121 900205.392 0.841 1022. 255.6 25557.8 25.558 
6.00 242→95 1070107.51      
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Overnight incubation of CurDHs with synthetic NAC substrates 
Incubations were carried out following a similar procedure to that of the kinetic analysis 
of CurK-DH. Briefly, substrates 1–6, 20–21, or product 8 (1 mM) were individually incubated 
with enzyme (5 μM) (CurF-DH, CurH-DH, CurJ-DH and CurK-DH) in reaction buffer (50 mM 
Tris, 150 mM NaCl, pH 8.0) at 23 °C for 14 h (or a set time period in the case of the CurK-DH 
time course experiment) in a total volume of 100 μL. Samples (5 μL) were quenched with 495 
μL quench solution (1:1 MeCN–H2O). The mixture was centrifuged, and the supernatant was 
directly analyzed by LC-MS/MS using the method described above. Chromatograms were 
generated by extraction of raw the LC-MS/MS data with Analyst software and plotted with 
Prism software (Fig. 4.4). 
 
 
Figure 4.4 Michaelis-Menten Analysis of CurK-DH with 
substrate 1. 
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Chemoenzymatic synthesis of 1 by CurK-DH. S-(2-Acetamidoethyl) (2E,4E,6E)-4-
methylnona-2,4,6-trienethioate (7) 
A solution sterile H2O (3.82 mL) and a small amount of 10× TRIS buffer solution (1.50 
M NaCl, 0.500M TRIS-HCl, pH 8.0) (0.600 mL) was briefly vortexed. To the buffered solution 
was added a DMSO– H2O (1:1) stock solution (50 mM) of the β-hydroxy thioester substrate 1 
(0.700 mL, 10.0 mg, 35.0 μmol). The mixture was vortexed to mix and the CurK dehydratase 
(8.19 mg/mL, 0.684 mL, 5.60 mg, 0.160 μmol) was added. The mixture was briefly inverted and 
covered with aluminum foil to shield from light. The reaction mixture was shaken (200 rpm) at 
23 °C in the dark for 14 h. The reaction mixture was extracted with EtOAc (4 × 10.0 mL) and the 
combined extracts were dried (Na2SO4), filtered and concentrated under reduced pressure. The 
crude extract was purified by flash chromatography (95:5 CH2Cl2–MeOH) affording the title 
compound (2.52 mg, 25%) as a transparent light yellow oil: Rf = 0.35 (95:5 CH2Cl2–MeOH); 1H 
NMR (CDCl3, 400 MHz) δ 7.30 (d, J = 15.6 Hz, 1H), 6.46 (d, J = 11.2 Hz, 1H), 6.40 (app. t, J = 
13.6 Hz, 1H), 6.15 (d, J = 15.2 Hz, 1H), 6.05 (dt, J = 13.6, 6.4 Hz, 1H), 5.98 (br, 1H), 3.48 (q, J 
= 6.0 Hz, 2H), 3.12 (t, J = 6.4 Hz, 2H), 2.22 (app. quint, J = 6.8 Hz, 2H), 1.97 (s, 3H), 1.87 (s, 
3H), 1.06 (t, J = 7.6 Hz, 3H); 13C NMR (CDCl3, 100 MHz) δ 190.5, 170.6, 146.5, 143.6, 141.6, 
131.2, 125.8, 122.8, 40.3, 28.5, 26.6, 23.4, 13.4, 12.5; HRMS (ESI+) m/z calcd for 
C14H21NO2SNa
+ [M + Na]+ 290.1185, found 290.1208 (error 7.9 ppm). 
  
 157 
Results 
Substrate design and synthesis 
We set out to synthesize potential substrates to profile the dehydratase activity of the four 
DH domains in the pathway (Fig. 4.5). The distal thiazoline and cyclopropyl moieties were 
eliminated to reduce molecular complexity and enhance solubility of the substrates. Synthesis of 
the truncated CurK-DH tetraketide 1 began with a Horner-Wadsworth-Emmons reaction between 
trans-2-pentenaldehyde (9) and triethyl 2-phosphonopropionate (10) to afford the trans-trans-
dienoate 11 in quantitative yield (Scheme 4.1). The dienoate was reduced with 
diisobutylaluminum hydride (DIBAL-H) and oxidized to aldehyde 13 employing MnO2. 
Asymmetric aldol reaction of 13 with Nagao’s D-valine-derived thiazolidinethione 14 provided 
alcohol 15 as a single diastereomer29. Facile displacement of the chiral auxiliary with N-
acetylcysteamine (NAC) furnished 1. The enantiomeric tetraketide 2 was prepared in an 
analogous fashion using the L-valine-derived thiazolidinethione. The CurK product 7 was 
obtained chemoenzymatically from 1 employing CurK-DH. 
The truncated CurJ triketide substrates were synthesized using Crimmins’ and Evans’ 
aldol chemistry that allows access to all four possible stereoisomers from common intermediate 
9 and the D-phenylalanine-derived thiazolidinethione 17 or its enantiomer by varying the Lewis 
acid and amine base (Scheme 4.1)30-31. The syn-aldol adduct 18 was obtained in a respectable 
72% yield and converted to the required NAC thioester 4 by treatment with N-acetylcysteamine 
(Scheme 4.1B). The anti-aldol adduct 19 was isolated in 17% yield and analogously elaborated 
to the NAC thioester 3 (Scheme 4.1C). We attribute the consistently poor yield of the anti-aldol 
transformation to a limitation of the Evans’ methodology when using aliphatic enals with an  
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Figure 4.5 CurJ and CurK truncated substrates and products. 
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aAbbreviations: DIBAL-H, diisobutylaluminum hydride; DIPEA, diisopropylethylamine; NAC, N-acetylcysteamine 
Scheme 4.1 Synthesis of CurK-DH substrate 1 and the CurJ substrates 3 and 4a. 
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exchangeable γ-proton that may polymerize under the reaction conditions. The 
enantiomers of 3 and 4 were synthesized in an analogous way utilizing L-phenylalanine-derived 
thiazolidinethione auxiliary to afford 6 and 5, respectively. Additionally, the truncated CurJ 
product 8 was synthesized through a Horner-Wadsworth Emmons reaction (Scheme 4.2)32-33.  
 
 
Biochemical characterization of Cur DHs with 1 and 2 
The four recombinant dehydratase domains (CurK-DH, CurJ-DH, CurH-DH, and CurF-
DH) were individually incubated overnight at 37 °C with NAC esters 1 and 2 and analyzed via 
LC-MS/MS. CurK-DH dehydrated its truncated substrate in a completely stereospecific fashion, 
selectively acting only on the D-alcohol 1 with no turnover for L-alcohol 2, whereas CurH-DH 
was unable to process either 1 or 2 (Figs. 4.6A, B). This matches the predicted stereospecificity 
of the CurK-KR containing the signature LDD motif for B-type ketoreductases34. Curiously, 
CurF-DH and CurJ-DH also turned over 1, but not 2, in a stereospecific fashion. While CurF-DH 
maintained comparable total conversions with that of CurK-DH (55% of CurK-DH), the CurJ-
DH was drastically deficient in its ability to catalyze the same transformation (7% of CurK-DH) 
(Fig. 4.6C). A single reaction product from 1 and CurK-DH was observed, which was isolated in 
25% overall yield from the overnight reaction mixture. The dehydrated substrate was analyzed 
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Scheme 4.2 Synthesis of diene 8. 
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via 1H and 13C NMR and confirmed as the all trans-trienoate 7. This result is consistent with the 
empirically based prediction that the enzymatic dehydration of D-alcohols affords E-olefins35-36. 
A time course study of the dehydration of 1 (1 mM) by CurK-DH (5 μM) revealed that the 
enzyme rapidly dehydrates nearly all of the substrate, reaching completion within 20 min (Fig. 
4.6D). Steady-state kinetic analysis of the CurK-DH catalyzed dehydration of 1 to 7 was 
quantified by LC-MS/MS under initial velocity (v0) conditions (Tables 4.2, 4.3, Figs. 4.3, 4.4). 
The resulting saturation curve (v0 versus [1]) was fit to the Michaelis-Menten equation to provide 
an apparent KM of 12.0 ± 4.7 mM and kcat of 72 ± 21 s
−1 resulting in a specificity constant 
(kcat/KM) of (6.00 ± 1.41) × 10
3 M−1 s−1. While the KM value is similar to other NAC thioester 
substrates with their cognate excised PKS DH domains, the kcat value is nearly three orders of 
magnitude greater than any previously characterized PKS DH domain37-38.  
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Extracted chromatograms of 14 h incubations of all curacin DH domains with substrates 1 (A) and 2 (B). CurF-DH, 
CurJ-DH, and CurK-DH all display stereospecificity for d-alcohol (1) over the l-alcohol (2). (C) Ratio of peak areas 
(7:1) for each curacin dehydratase enzyme subtracting negative control (no enzyme). CurF-DH and CurK-DH efficiently 
produce the triene 7, with a lesser amount produced by CurJ-DH. (D) Time course extracted chromatograms of CurK-
DH (5 μM) with substrate 1 (1 mM). The enzyme reaches equilibrium by 20 min. The transition m/z 268 → 121 was 
used to monitor both residual substrates (1 and 2) as well as product (7) formation for all extracted chromatograms due 
to spontaneous dehydration of the substrate under the MS ionization conditions. The recurring shoulder on compounds 1 
and 2 is believed to be minor trans,cis-isomers arising from isomerization during assay conditions. 
 
Figure 4.6 Incubation studies of synthetic CurK-DH substrates 1 and 2. 
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To probe the reaction mechanism and facilitate co-crystallization with substrates we 
prepared catalytically inactive point mutants His996Phe and Asp1169Asn of the His-Asp 
catalytic dyad in CurK-DH based on sequence alignment and the reported CurK-DH structure10. 
The His996Phe mutant was devoid of activity while the Asp1169Asn mutant retained small, but 
measurable activity showing 2–3% conversion of 1 to 7 after 12 hours. Crystal structures of both 
His996Phe and Asp1169Asn CurK-DH mutants were determined at 1.4 and 1.65 Å resolution, 
respectively (Tables 4.4 – 4.6, Figs. 4.7, 4.8)10. The structures of the mutant proteins were 
virtually identical to the wild type CurK-DH (RMSD of 0.11 Å for 509 Cα atoms) with no 
significant conformational changes in the active site. Co-crystallization trials of substrate 1 and 
either mutant of wild type CurK-DH resulted in no crystal growth under conditions that readily 
yielded crystals in absence of substrate. Crystal soaking experiments with 1 resulted in a rapid 
dissolution of the crystals, suggesting that substrate binding may induce a conformational change 
and destabilize the crystal form. 
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Table 4.4 Crystallographic summary for CurK DH 
Data CurK H996F CurK D1169N 
Space group P212121 P212121 
Unit cell a, b, c  (Å) 
38.11, 94.57, 152.00  
(90, 90, 90) 
38.22, 94.51, 151.70  
(90, 90, 90) 
Wavelength (Å) 1 1 
dmin (Å) 1.428 (1.479 - 1.428) 1.648 (1.707 - 1.648) 
      
Observations (#) 1,300,944 (96,298) 860, 172 (75,239) 
Unique reflections 100,090 (8,843) 67,404 (6,535) 
Mean I/σI 28.15 (2.74) 25.41 (2.07) 
Rmerge 0.04 (0.72) 0.05 (1.10) 
CC1/2 1 (0.83) 1 (0.70) 
CC* 1 (0.95) 1 (0.91) 
Completeness (%) 0.97 (0.87) 1 (0.99) 
Wilson B (Å2) 19.44 26.49 
Refinement     
Reflections (#) 100,088 (8,843) 67,401 (6,535) 
Rwork 0.20 (0.25) 0.20 (0.28) 
Rfree 0.22 (0.29) 0.23 (0.31) 
RMSD bonds (Å) 0.013 0.01 
RMSD angles (Å) 1.32 1.21 
Atoms (#)     
Protein 4,444 4436 
Solvent 168 46 
Ligand 0 0 
Avg B-factors (Å2)     
Protein 27.56 36.22 
Solvent 30 30.39 
Ligand n/a n/a 
Ramachandran     
Favored (%) 98 97.4 
Allowed (%) 1.64 2.6 
Outliers (%) 0.36 0 
 
* Values in parentheses refer to the outermost shell of data. 
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Figure 4.7 Ramachandran plots for CurK H996F 
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Figure 4.8 Ramachandran plots for CurK D1169N 
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Table 4.5 X-ray data statistics for CurK H996F 
Resolution N(obs)  N(uniq) Mult. Compl. <I/sigma> R-merge R-meas CC1/2 
47.31 - 3.08 131398  10759 12.21 99.84 61.9 0.033 0.034 1.000 
3.08 - 2.45 136117  10340 13.16 99.55 51.9 0.04 0.041 0.999 
2.45 - 2.14 135262  10199 13.26 99.23 42.8 0.049 0.051 0.999 
2.14 - 1.94 135359  10112 13.39 98.53 32.9 0.063 0.066 0.999 
1.94 - 1.80 132151  10013 13.2 98.39 21.3 0.098 0.102 0.997 
1.80 - 1.70 137670  9947 13.84 97.62 15.3 0.144 0.149 0.995 
1.70 - 1.61 129040  9955 12.96 97.8 9.9 0.22 0.229 0.987 
1.61 - 1.54 133388  9860 13.53 97.25 7.2 0.311 0.323 0.978 
1.54 - 1.48 130974  9799 13.37 96.83 4.7 0.472 0.491 0.952 
1.48 - 1.43 99064  8961 11.06 88.7 2.7 0.716 0.75 0.835 
47.28 - 1.43 1300423  99945 13.01 97.4 25.8 0.045 0.046 1.000 
 
 
 
 
 
Table 4.6 X-ray data statistics for CurK D1169N 
Resolution N(obs) N(uniq) Mult. Compl. <I/sigma> R-merge R-meas CC1/2 
47.28 - 3.55 82464 7100 11.61 99.87 65.1 0.029 0.031 1.000 
3.55 - 2.82 84857 6814 12.45 99.99 50.8 0.039 0.041 0.999 
2.82 - 2.46 89339 6773 13.19 100 34.8 0.063 0.066 0.999 
2.46 - 2.24 86684 6662 13.01 100 25.5 0.089 0.092 0.998 
2.24 - 2.08 87860 6709 13.1 100 18.5 0.128 0.133 0.996 
2.08 - 1.96 90476 6677 13.55 100 12.7 0.195 0.203 0.992 
1.96 - 1.86 84142 6643 12.67 100 7.1 0.345 0.359 0.974 
1.86 - 1.78 87274 6648 13.13 100 4.5 0.547 0.569 0.940 
1.78 - 1.71 88669 6607 13.42 100 3.2 0.784 0.815 0.881 
1.71 - 1.65 77926 6613 11.78 99.95 2 1.09 1.14 0.733 
44.59 - 1.65 859691 67246 12.78 99.98 22.8 0.053 0.056 1.000 
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CurK-DH and CurF-DH outcompete CurJ-DH in the dehydration of its predicted 
substrate 
We next evaluated the diastereomeric triketide substrates 3–6 with all four Cur DHs (Fig. 
4.3). Interestingly, only CurK-DH and CurF-DH were able to turn over the predicted CurJ-DH 
substrate 3, arising from the B1-type CurJ-KR, affording the conjugated trans-trans-dienoate 8 
(Fig. 4.9A)39. Neither of the syn-triketide substrates 4 and 5 nor the anti-triketide 6 were 
processed by any of the Cur DHs (Figs. 4.9B, C, D). This reaffirms the substrate specificity of 
CurF-DH and CurK-DH for D-configured alcohols at the β-position. The trans-olefin can only 
be formed through a syn-elimination of the α-proton and β-hydroxy group in 3 and thus provides 
the first confirmation for this mechanism for a PKS substrate lacking an α-substituent. From a 
biosynthetic perspective, the inability of CurJ-DH to process any of the truncated triketide 
substrates was unexpected, especially in light of the high activity of CurK-DH with its predicted 
truncated tetraketide substrate 1. This is in stark contrast to CurJ-DH’s ability to accommodate 
substrate 1, a D-alcohol lacking an α-substituent, albeit with marginal catalytic efficacy. 
Furthermore, these results rule out the classic “stuttered” dehydration pathway because the same 
substrate would be used for the second elimination. As both CurH and CurJ immediately follow 
modules without DH domains (i.e. CurG and CurI) we sought an alternative hypothesis for 
dehydration. 
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Figure 4.9 Overnight incubations of the putative triketide CurJ-DH substrates 
with all curacin PKS DHs. 
LC-MS/MS extracted ion chromatograms with diastereomers 3 (A), 4 (B), 5 (C), and 6 (D). In each panel, the 
LC-MS/MS extracted ion chromatograms are stacked with the traces for each enzyme color-coded: red for CurF, 
orange for CurH, blue for CurJ, and purple for CurK. The transition m/z 242 → 95 was used to monitor both 
remaining substrate as well as product formation due to spontaneous dehydration under the MS ionization 
conditions. The anti-triketide 3 (panel A) is the only substrate that showed turnover by the appearance of a peak 
at 6.8 min corresponding to the dehydration product (this was only observed with CurK-DH and CurF-DH). 
 170 
CurJ-DH and CurH-DH harbor vinylogous dehydration activity 
The simplest proposal is that the KR products from modules lacking dehydratases are 
carried through to the next module. After extension and reduction, the resulting β,δ-dihydroxy 
thioester could first be eliminated in the normal fashion (α, β) followed by a vinylogous 
elimination (γ, δ) yielding the diene (Fig. 4.11). Truncated δ-hydroxy-α,β -unsaturated thioester 
substrates 20 and 21 were synthesized to test this hypothesis (Fig. 4.10, Scheme 4.3). No 
dehydration products were observed upon incubation with the L-alcohol substrate 20 (Fig. 
4.11A). Overnight incubation with all four DH domains revealed that only CurH-DH and CurJ-
DH were able to stereospecifically process the D-alcohol substrate 21 to afford the trans-trans-
dienoate product 8 (Fig. 4.11B). Since the reaction is theoretically reversible, we next 
investigated the hydration reaction through incubation of trans-trans-dienoate 8 with each Cur 
DH domain. Consistent with the previous results, only CurH-DH and CurJ-DH were able to 
catalyze the reverse reaction, namely the regiospecific and stereospecific conversion of trans-
trans-dienoate 8 exclusively to 21 when compared to controls, albeit at a low total conversion 
(<1%) (Fig. 4.11C). Both the inability of the enzyme to reach a stable equilibrium and markedly 
slow reaction rate compared to the α,β-dehydration catalyzed by CurK indicate that the 
truncations of substrate 21 severely attenuate enzyme reactivity. The mechanism of this novel 
elimination was then probed through site-directed mutagenesis of the His-Asp catalytic dyad in 
both CurH-DH and CurJ-DH. In this case, the catalytic histidine was mutated to alanine and 
phenylalanine to afford CurH(H971A), CurH(H971F), CurJ(H978A), and CurJ(H978F) mutants. 
Similarly, the catalytic aspartate was mutated to asparagine yielding CurH(D1136N) and 
CurJ(D1156N). All mutants were completely devoid of activity towards 21 highlighting their 
critical role in this novel elimination reaction (Fig. 4.11D). 
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Figure 4.10 Proposed routes for elimination in the case of missing dehydratases. 
(A) Our proposed vinylogous elimination route in module J. The polyketide intermediate from CurI is 
loaded onto CurJ for normal extension, methylation, and ketoreduction. The CurJ-DH eliminates the β-
alcohol followed by a subsequent elimination of the δ-alcohol. (B) Classical stuttering mechanism based on 
predictions in other biosynthetic pathways. The polyketide intermediate from CurI is transferred directly 
onto the CurJ-ACP and dehydrated by the CurJ-DH. The ACP-bound intermediate is then transferred to the 
CurJ-KS for normal extension, methylation, and ketoreduction. A final dehydration by CurJ-DH furnishes 
the putative CurJ product. (C) Enantiomeric vinylogous CurJ-DH substrates 20 and 21. The design of the 
vinylogous substrates is based on the putative native substrate shown highlighted in violet in panel A. 
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Figure 4.11 Vinylogous elimination of δ-hydroxy-α,β-unsaturated thioester 
substrates by curacin DH domains. 
(A,B) LC-MS/MS extracted ion chromatograms obtained after overnight incubations of substrates 20 (A) and 21 
(B) with each Cur DH monitoring the transition at m/z 242 → 95 for product dienoate 8 (peak at 6.8 min) and 
m/z 260 → 141 (peak at 5.1 min) for the residual substrates. In each panel, the LC-MS/MS extracted ion 
chromatograms are stacked with the traces for each enzyme color-coded: red for CurF-DH, orange for CurH-DH, 
blue for CurJ-DH, and purple for CurK-DH. The l-alcohol substrate 20 shown in panel A is not a substrate for 
any of the Cur DHs, whereas the d-alcohol substrate 21 shown in panel B is converted to the corresponding 
dienoate 8 only by CurJ-DH and CurH-DH. (C) Hydration of dienoate 8. Compared to negative control (without 
8 or without CurJ-DH), only CurH-DH and CurJ-DH form 21 in the presence of 8. (D) Overnight incubation of 
the six CurJ-DH and CurH-DH catalytic dyad point mutants, scanning for the same transitions as previous 
panels. All mutants are devoid of activity, as evidenced by the absence of a peak at 6.8 min. 
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To visualize the binding of a vinylogous substrate to a DH, 21 was co-crystallized with 
the catalytically inactive H978F variant of the CurJ DH (Tables 4.7, 4.8, Fig. 4.12). Crystals 
grew more slowly in presence of compound (30 days compared to 2 days without substrate). In 
the 2.4-Å structure of the DH dimer, new density appeared in the active site of one monomer, 
adjacent to Asp1156 and within the hydrophobic substrate tunnel (Figs. 4.13, 4.14). Strong 
density was present for only the acyl portion of 21 and we assume that the polar N-
acetylcysteamine was hydrolyzed during the long crystal growth period. The substitution of Phe 
for the catalytic His978 resulted in no change to the protein backbone conformation. The best fit 
of hydrolyzed 21 to the new density placed the δ-OH group within hydrogen bonding distance of 
Asp1156, in the same position as a water molecule in the free-enzyme structure10. The acid 21 
was bound such that dehydration would proceed via the classic syn elimination mechanism of 
both PKS and FAS DHs. 
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Table 4.7 Crystallographic summary For CurJ DH 
Data CurJ H978F 
Space group P212121 
Unit cell a, b, c  (Å) 
47.55, 70.58, 176.02  
(90, 90, 90) 
Wavelength (Å) 1 
dmin (Å) 2.4 (2.486 - 2.4) 
    
Observations (#) 302,198 (30,140) 
Unique reflections 23,985 (2,331) 
Mean I/σI 18.08 (2.07) 
Rmerge 0.09 (1.44) 
CC1/2 0.99 (0.77) 
CC* 1 (0.93) 
Completeness (%) 1 (1) 
Wilson B (Å2) 62.41 
Refinement   
Reflections (#) 23,944 (2304) 
Rwork 0.188 (0.349) 
Rfree 0.242 (0.376) 
RMSD bonds (Å) 0.009 
RMSD angles (Å) 1.06 
Atoms (#)   
Protein 4587 
Solvent 22 
Ligand 11 
Avg B-factors (Å2)   
Protein 111.02 
Solvent 99.82 
Ligand 62.58 
Ramachandran   
Favored (%) 97.26 
Allowed (%) 2.2 
Outliers (%) 0.54 
 
* Values in parentheses refer to the outermost shell of data. 
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Figure 4.12 Ramachandran plots for CurJ H978F. 
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Table 4.8 X-ray data statistics for CurJ H978F 
Resolution N(obs) N(uniq) Mult. Compl. <I/sigma> R-merge R-meas CC1/2 
45.91 - 5.17 27490 2577 10.67 99.96 38.3 0.045 0.048 0.999 
5.17 - 4.10 29081 2446 11.89 100 36.5 0.055 0.058 0.999 
4.10 - 3.58 28639 2400 11.93 99.92 26.1 0.083 0.086 0.998 
3.58 - 3.26 31360 2406 13.03 100 20 0.124 0.129 0.997 
3.26 - 3.02 31547 2375 13.28 100 12.4 0.235 0.244 0.993 
3.02 - 2.85 29903 2359 12.68 99.96 8.1 0.371 0.387 0.985 
2.85 - 2.70 30720 2369 12.97 100 4.9 0.593 0.618 0.966 
2.70 - 2.59 31433 2359 13.32 100 3.3 0.837 0.87 0.925 
2.59 - 2.49 31885 2357 13.53 99.96 2.5 1.138 1.183 0.893 
2.49 - 2.40 30163 2339 12.9 100 1.9 1.44 1.499 0.775 
45.91 - 2.40 302221 23987 12.6 99.98 15.7 0.09 0.094 0.999 
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Figure 4.13 CurJ-DH H978F variant co-crystallized with 
the hydrolyzed form of compound 21. 
The δ-hydroxyl group of carboxylate 21 is within hydrogen bonding 
distance of Asp1156 (blue SA omit electron density contoured at 2.5σ). 
Hydrolyzed 21 (sticks with atom coloring: orange, C; red, O; white, H; only 
the pro-R H atom is shown) is within 4 Å of the Phe substitution for His978 
(sticks with cyan, C). 
Figure 4.14 CurJ DH H978F variant co-crystallized with 
hydrolyzed compound 21. 
SA omit density map around the carboxylate of 21 is shown in purple (2.5σ) and the 2Fo-Fc 
map is shown in cyan (1.0σ). In both maps, the hydrolyzed form of compound 21 fits the 
density well. 
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Discussion 
Enigmatic dehydration in polyketide synthases 
Curiously, there are numerous examples in the literature of missing DH domains when 
diene final products or intermediates are predicted. Notable cases come from the biosynthesis of 
columbamides, stigmatellin, epothilones, leinamycin, thuggacin, and the myxalamides (Fig. 
4.15).40-44 Unexpectedly, many of these anomalies involve the formation of a cis-alkene during 
the distal dehydration. The classic interpretations of these cases invoke either a trans-acting 
dehydratase, separate from the PKS pathway, or a stuttered dehydration process40, 45. Vinylogous 
dehydration of δ-hydroxy-α,β-unsaturated thioester substrates as described here provides an 
alternative mechanism. 
Alkenes arising from modules lacking a DH are highlighted in red. The subsequent module contains an active 
DH, possibly capable of vinylogous dehydration. 
Figure 4.15 Select examples of sequential dehydration with a missing 
dehydratase domain. 
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Crystal structures and substrate specificity 
The crystallization behavior of both CurK DH and CurJ DH in the presence of NAC-
linked substrates is suggestive of a conformational change in the protein at the entrance to the 
substrate tunnel. For both DHs, crystals either did not grow in the presence of substrate or grew 
only after thioester hydrolysis. Similarly, pre-grown DH crystals dissolved when presented with 
substrate. The structure of CurJ DH H978F with the hydrolyzed 21 reveals an ideal orientation 
for hydrogen bonding of the catalytic Asp1156 carboxylate with the substrate hydroxyl. The site 
is occupied by a water molecule in structures of the DH free enzyme10. We found that the best fit 
of hydrolyzed 21 to the experimental density was in a conformation that would yield a trans-cis 
dienoate. As CurJ DH produced the trans-trans dienoate from 21 (Fig. 4.11B), we assume that 
hydrolysis of the NAC thioester accounts for the predominant bound conformation. 
Mechanistic analogy to canonical eliminations in DH domains 
Vinylogous dehydration by DH domains closely parallels canonical dehydrations. 
Stereospecificity appears to be maintained between the two events in the module. Moreover, the 
empirical trend that D-alcohols form E-substituted olefins holds true in this distal elimination. 
The catalytic His-Asp dyad is essential for this novel, second transformation by the dehydratase 
domain as the respective point mutants are catalytically incompetent. Given these results, we 
predict the reaction is a net syn-elimination as previously established in α,β-dehydrations in PKS 
and FAS systems46-47. The proposed mechanism shares similarities to three reported biosynthetic 
enzymes: FabA, an isomerizing DH involved in corallopyronin A biosynthesis, and a recently 
characterized isomerase (Fig. 4.16)18, 48-49. The first step involves deprotonation of the γ–proton, 
pro-(R) in the case of FabA, by a general base (likely the catalytic His) to afford a vinylogous 
enolate.50 Until this point, the reaction mechanism mirrors that of a classic isomerase. Instead of 
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suprafacial protonation at the α-position, the subsequent elimination occurs with simultaneous 
protonation of the δ-hydroxyl group by the catalytic aspartic acid residue, forming the γ,δ-olefin. 
The dual activities would require that the substrate shift in the active site tunnel first to place the 
α-position by the catalytic His and the β-hydroxy by the catalytic Asp for the canonical 
dehydration, and then the γ-position by the catalytic His and δ-hydroxy by the catalytic Asp for 
the vinylogous dehydration. 
 
In the present study, we found that CurF-DH activity unexpectedly closely mirrors that of 
the CurK-DH in its stereospecific processing of 1 over 2. This seemingly nonsensical mimicry of 
dehydration activity is puzzling due to the fact that CurK-DH is predicted to process the longest 
dehydratase substrate in the Cur pathway, and CurF DH has no known function. By analyzing 
CurF polyketide cassette (ER-KS-AT-DH) against other possible pathways in the producing 
organism, we found that JamJ from the jamaicamide pathway has high homology (>72% 
identical) and the predicted action in its pathway matches that of the extra modules in CurF (i.e. 
Figure 4.16 FabA isomerization mechanism and proposed mechanism of vinylogous 
dehydration by curacin J and H dehydratases. 
The two events share a common intermediary vinylogous enolate and differ only in the final re-protonation or 
elimination. Site-directed mutagenesis of the catalytic dyad indicates that the canonical histidine and aspartic 
residues are the general base and acid, respectively. FabA (Escherichia coli β-hydroxydecanoyl thiol ester 
dehydrase) catalyzes elimination and bond isomerization in fatty acid biosynthesis. 
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a complete reductive processing sequence to form an alkane intermediate). The majority of the 
modules needed for jamaicamide synthesis appear to be vestigial in CurF, and vice versa. For 
example, the ER domain is responsible for cyclopropane formation in curacin biosynthesis, 
whereas the vestigial JamJ ER domain has no activity with the natural jamaicamide β,γ-olefin 
intermediate but has robust reductive activity with α,β-olefin substrates2. Additionally, there is an 
NRPS module set (PCP-A-Cy) for thiazoline production appended to the end of the vestigial 
CurF PKS module. Genetic analysis of several PKS biosynthetic clusters has recently revealed 
that analogous instances of surplus DH domains present in a pathway compared to a predicted 
activity is a more common occurrence than missing DH domains. This often arises due to two 
unique evolutionary pressures: The necessity to retain a hydroxyl group in the pathway for the 
final natural product or the duplication and insertion of a full or partial module cassette to fulfill 
another pathway role. In the former case, the DH domain is often catalytically inactivated by a 
knockout mutation in the catalytic region. Classic examples include rifamycin (DH2 and 5), 
amphotericin B (DH15, 17 and 18) and FK506 (DH3, 4 and 8)51-53. The latter case is often harder 
to interpret biosynthetically as the partial module harbors necessary activity for the natural 
product biosynthesis (i.e. CurF ER), but also a superfluous and active DH domain (i.e. CurF 
DH). Examples include rifamycin (DH6, 7 and 8), epothilone A and B (DH7 and 8) and FK506 
(DH2)25, 51, 53-54. Our results indicate this may be diagnosed by both sequence comparison to 
other modules in the organism and substrate-dehydratase interrogation, looking for high 
sequence identity and unexpected substrate selectivity, respectively. 
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Conclusion 
The curacin biosynthetic pathway continues to provide unique insight into non-canonical 
PKS enzymology. The present study focused on the mechanism and timing of DH-catalyzed 
processing in assembly of the polyketide segment introduced by the five Cur PKS monomodules 
CurG-CurK. Retrobiosynthetic analysis indicated five dehydrations are required; however, DH 
domains are missing in both CurG and CurI while an extraneous DH domain is present in CurF. 
To uncover the anomalous biosynthetic features of DH-catalysis in this segment of the 
polyketide, we employed diffusible small-molecule truncated NAC thioester substrates in 
conjunction with LC-MS/MS analysis, site-directed mutagenesis, and co-crystallization studies. 
We initially focused on the dehydration event in CurK using a tetraketide substrate and 
showed that CurK processed its predicted D-alcohol substrate 1 to the all trans-trienoate 7 more 
than three-orders of magnitude greater than any previously reported DH with its native 
substrate37-38, highlighting the high intrinsic activity of Cur DHs when presented with their native 
substrates. Therefore, the inability of the CurJ-DH, which is the DH domain in the preceding 
module, to turn over any of the four diastereomeric triketide substrates including 21, with the 
bioinformatically predicted 2R, 3S stereochemistry, suggested an alternative substrate. We 
hypothesized that CurJ may be responsible for a double dehydration of a β,δ-dihydroxy thioester 
substrate since the antecedent DH domain is absent in CurI. This would require a canonical 
dehydration to form a δ-hydroxy-α,β-unsaturated thioester intermediate, which would then 
undergo a second vinylogous elimination, at the same active site, to afford the trans-trans-
dienoate product. Using a synthetic triketide δ-hydroxy-α,β-unsaturated thioester substrate, we 
unequivocally demonstrated that CurJ can catalyze this novel vinylogous elimination as well as 
the reverse hydration reaction in a completely stereospecific and regiospecific manner. The 
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vinylogous elimination required the His-Asp catalytic dyad as point mutations to either of these 
residues completely abolished activity. CurH analogously lacks a DH domain in the preceding 
module and was also shown to catalyze a vinylogous elimination. By contrast, CurK does not 
catalyze the vinylogous elimination, but only the canonical dehydration as expected based on the 
collinear organization of CurJ and CurK, which both contain functional DH domains. 
Interestingly, the substrate specificity of CurF-DH mirrored that of CurK-DH, suggesting CurF-
DH is vestigial and may have evolutionary arisen from an earlier gene duplication event. 
To provide a structural framework for the novel vinylogous elimination, we co-
crystallized a mutagenized CurJ(H978F) with δ-hydroxy-α,β-unsaturated thioester 21. The 
binding pose shows that the catalytic Asp1156 side chain is positioned to hydrogen bond with a 
hydroxyl group - or water molecule, as in the free-enzyme structures - and that this could be 
either a β-hydroxy or a δ-hydroxy. 
The vinylogous elimination mechanism, catalyzed by both CurH-DH and CurJ-DH, 
compensates for the two modules lacking dehydratases (CurG and CurI) offering an alternative 
to the stuttered module hypothesis. The proposed mechanism closely resembles that of FabA in 
E. coli, which catalyzes α,β to γ,δ-isomerization of unsaturated fatty acids utilizing a His-Asp 
catalytic dyad. This discovery expands the growing number of known transformations carried 
out by the hotdog-fold family of enzymes. More broadly this new mechanism may be operative 
in other PKS systems missing DH domains. 
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Chapter 5. Molecular basis for olefin rearrangement in gephyronic acid polyketide 
synthase 
 
This chapter has been submitted: Dodge, G. J., Ronnow, D., Taylor, R. E., Smith, J. L. Molecular 
basis for olefin rearrangement in gephyronic acid polyketide synthase. ACS Chem. Biol. In 
Review.  
Summary 
Polyketide synthase (PKS) are a rich source of natural products of varied chemical 
composition and biological significance. Here, we report the characterization of an atypical 
dehydratase (DH) domain from the PKS pathway for gephyronic acid, an inhibitor of eukaryotic 
protein synthesis. Using a library of synthetic substrate mimics, the reaction course, 
stereospecificity, and tolerance to non-native substrates of GphF DH1 are probed via LC-MS 
analysis. Taken together, the studies establish GphF DH1 as a dual-function 
dehydratase/isomerase that installs an odd-to-even double bond and yields a product consistent 
with the structure of gephyronic acid. The studies also reveal an unexpected C2 epimerase 
function in catalytic turnover with the native substrate. A 1.55-Å crystal structure of GphF DH1 
guided mutagenesis experiments to elucidate the roles of key amino acids in the multi-step DH1 
catalysis, identifying critical functions for leucine and tyrosine side chains. The mutagenesis 
results were applied to add a secondary isomerase functionality to a non-isomerizing DH in the 
first successful gain-of-function engineering of a PKS DH. Our studies of GphF DH1 catalysis 
highlight the versatility of the DH active site and adaptation for a specific catalytic outcome with 
a specific substrate. 
 190 
Introduction 
Polyketide synthases (PKS) produce a plethora of bioactive and chemically diverse 
compounds. The bacterial modular type I PKS are among the most versatile, as each module 
contains a set of distinct catalytic domains individually responsible for a single step during the 
elongation and modification of polyketide intermediates. In so-called cis-AT pathways, each 
module includes a ketosynthase (KS), an acyltransferase (AT), and an acyl carrier protein (ACP) 
at a minimum, whereas in trans-AT pathways, a separate AT polypeptide delivers a common 
building block to all modules. A module may also contain one or more modification domains 
such as ketoreductase (KR), dehydratase (DH), O-methyltransferase (OMT), C-
methyltransferase (CMT), and enoylreductase (ER).  
 
The DH domain generates a 2-enoyl thioester intermediate via syn-elimination of a 3-
hydroxy group, resulting in the production of alkenes in even-to-odd positions in the final 
polyketide structure1-9. DHs are notable for a strict stereospecificity of the 3-hydroxy substrate, 
which is correlated with the geometry of the product double bond1-3, 10.  Despite high-resolution 
crystal structures of several type-I PKS DHs, the structural basis for substrate specificity and 
product selectivity remains unclear4, 11-14. While “A” and “B” sequence motifs within KR 
domains predict the sterochemical configuration of the 3-hydroxy group15, no such motifs have 
been identified in PKS DHs3.  To date, only DHs that act on A-type KR products have been 
shown to produce cis double bonds3, whereas B-type KR reduction followed by DH dehydration 
leads to trans double bonds in most cases1-2, 4-5, with notable exceptions4, 6, 16-17.  
Like other PKS enzymes, DH homologs exist in both type I and type II fatty acid 
synthase (FAS). The type II FAS of many bacteria, including Escherichia coli, employ two DHs, 
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FabA and FabZ18. FabZ catalyzes a general β-elimination reaction like PKS DHs, acting on a 
variety of fatty acyl chain lengths to produce a 2-enoyl intermediate that is subsequently reduced 
and subject to further elongation cycles. FabA is specific for decanoyl substrates, and initially 
produces a trans double bond ((E)-2-decenoyl, even-to-odd) in a manner analogous to PKS DHs 
and FabZ. However, FabA also catalyzes a subsequent double-bond migration to produce an 
odd-to-even olefin in the cis configuration ((Z)-3-decenoyl)7. The final products of type II FAS 
with FabA include fatty acids with a cis, odd-to-even alkene situated six carbons from the 
terminal methyl group. An analogous system from Enterococcus faecalis has been characterized 
in which FabN, a dehydratase more similar to FabZ than FabA, dehydrates and isomerizes a 3-
hydroxydecanoyl-ACP substrate to an odd-to-even (Z)-3-decenoyl product19. FabZ, FabA and 
PKS DHs possess conserved histidine and aspartate (or glutamate) catalytic amino acids and 
similar active site structures4, 11-14, 20-21. The catalytic groups presumably interact identically with 
the 3-hydroxy substrate in all these enzymes, but the structural basis for their differing activities 
is unknown. 
While many modular PKS pathways include DHs, the products of these pathways rarely 
contain odd-to-even unsaturated products. Nevertheless, a number of interesting natural products 
of unknown biosynthetic origin contain odd-to-even double bonds including the tedanolides, 
candidaspongiolides and myriaporones22-24. Two distinct mechanisms for generation of odd-to-
even unsaturation have been identified in trans-AT PKS. In the related pathways for chloronotil 
and anthracimycin, the formation of odd-to-even unsaturation has been attributed to 
multifunctional DHs25. In other pathways, DH-related enoyl isomerases (EIs) generate 3-enoyl 
intermediates from 2-enoyl substrates26-27. The best characterized is the EI from module 14 of the 
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bacillaene pathway (PksEI14), which catalyzes isomerization using only a catalytic histidine27, in 
stark contrast to FabA, where isomerization requires both the catalytic histidine and aspartate28. 
Olefin rearrangement has been characterized in only two cis-AT PKS systems8, 29. In the 
ansamitocin pathway, feeding studies implicated DH-containing module 3 in the formation of a 
conjugated 2,4-dienoyl product via a proposed vinylogous dehydration29. An interesting DH 
from the ambruticin pathway catalyzes a novel three-step reaction in which a 3,4-olefin is 
generated only after epimerization of a 4-methyl substituent8.  To date, no structures are 
available for any PKS DH predicted to catalyze both dehydration and isomerization.  
 Gephyronic acid (1) is a eukaryotic translation inhibitor produced by a cis-AT PKS in the 
myxobacterium Cystobacter violaceus30. An odd-to-even double bond in 1 is apparently installed 
by the first extension module of the Gph PKS (Fig. 5.1A). The GphF tri-module polypeptide 
includes module 1, which extends an isobutyryl starter unit from the loading module to produce 
an intermediate containing a 3-enoyl (odd-to-even) intermediate (Fig. 5.1A). In addition to the 
DH, module 1 contains CMT and KR modification domains, which act first and present to the 
DH a 2-methyl-3-hydroxy substrate31. Here we determine that the module 1 DH domain (GphF 
DH1) is the source of the odd-to-even unsaturation in gephyronic acid. Biochemical 
characterization and a crystal structure of GphF DH1 establish its role as a bifunctional 
dehydratase-isomerase and reveal an unexpected C2 epimerization activity. Additionally, we 
identify tyrosine and leucine amino acids that are key to the isomerase activity.  
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Figure 5.1 Domain architecture of GphF and substrate mimics used for assay. 
A: Domain architecture of GphF, the first gene in the gephyronic acid PKS. Gephyronic acid 1 contains an 
unusual odd-to-even double bond, apparently installed by module 1. B: Library of N-acetylcysteamine 
(NAC) substrate mimics used to assess the function of GphF DH1. The library was designed specifically to 
test the stereospecificity of the DH by sampling each diastereomer of the predicted substrates (2, 3, 4, 5). 
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Methods 
A. Chemical synthesis 
All synthesis experiments were run by Danialle Ronnow.  
Unless otherwise noted, all materials were used as received from a commercial supplier without 
further purification. All anhydrous reactions were performed using oven-dried or flame-dried 
glassware under an atmosphere of nitrogen or argon; unless otherwise indicated, all reactions 
where performed under anhydrous conditions. Tetrahydrofuran (THF), diethyl ether (Et2O), and 
dichloromethane (DCM), were filtered through activated alumina under nitrogen prior to use. All 
reactions were monitored by either E. Merck (Kenilworth, NJ, USA) analytical thin layer 
chromatography (TLC) plates (silica gel 60 GF, glass back) analyzed with 254 nm UV light 
and/or p-anisaldehyde/sulfuric acid or potassium permanganate treatment. Silica gel for column 
chromatography was purchased from E. Merck (Silica Gel 60, 230–400 mesh). All 1H and 13C 
NMR spectra were obtained either on a Bruker ADVANCE III HD 400 (operating at 400.130 
MHz for 1H and 100.613 MHz for 13C). Chemical shifts are reported as δ-values in parts per 
million (ppm) using residual CHCl3 as internal reference (
1H: δ = 7.27 ppm, 13C: δ = 77.23 ppm) 
and coupling constants (J) are reported in Hertz (Hz). Peak multiplicities are indicated as 
follows: s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet) and br (broad). Optical 
rotation data was obtained on a Perkin–Elmer polarimeter model 343 with a Na lamp.  
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A.1 (2R,3R)-3-hydroxy-2,4-dimethyl-pentanoyl-SNAc (2) 
 
To a stirred solution of  (2R,3R)-3-hydroxy-2,4-dimethyl-pentanoic acid32 (50 mg, 0.34 mmol)  
in  DCM (1.1 mL) was added N-acetylcyteamine (0.040 mL, 0.41 mmol) and DMAP (4.2 mg, 
0.030 mmol), followed by DCC (106 mg, 0.510 mmol) at 0 °C. The reaction was allowed to 
warm to RT and was stirred for 4 hours. The reaction was quenched with 10 ml of 1M aqueous 
HCl, filtered and the aqueous layer was extracted with DCM (3 x 10 ml). The combined DCM 
extracts were washed with aqueous 0.5 M HCl (10 ml), washed with saturated aqueous NaHCO3 
(10 ml) and finally washed with saturated aqueous NaCl (20 ml).  The organic layer was dried 
over Na2SO4 and then filtered and concentrated under reduced pressure. The residue was then 
purified by chromatography (3% MeOH/DCM) to yield (2R,3R)-3-hydroxy-2,4-dimethyl-
pentanoyl-SNAc (39 mg,0.17 mmol, 47 % yield). [α]20D = -12.7 (c = 0.49, CHCl3)  1H NMR 
(CDCl3, 400 MHz) δ ppm: 6.01 (br s, 1H), 3.49 – 3.35 (m, 3 H), 3.02 (m, 2H), 2.85 (qn, J = 7.3 
Hz, 1H), 2.21 (br s, 1H), 1.95 (s, 3H), 1.79 – 1.65 (m, 1H), 1.18 (d, J = 7.1 Hz, 3 H),  0.96 (d, J = 
6.8 Hz, 3H), 0.89 (d, J = 6.7 Hz, 3H); 13C NMR (CDCl3, 100 MHz) δ ppm 204.6, 170.5, 78.5, 
51.6, 39.4, 30.7, 28.6, 23.2, 19.9, 15.9, 15.5; HRMS (FAB) m/z (M+H)+ calcd for C11H21NO3S, 
248.1320; obsd 248.1295 
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 A.2 (2S,3S)-3-hydroxy-2,4-dimethylpentanoyl-SNAc (3) 
 
Synthesized via literature protocol 33 
A.3 (2S,3R)-3-hydroxy-2,4-dimethyl-pentanoyl-SNAc (4) 
  
To a stirred solution of  (2S,3R)-3-hydroxy-2,4-dimethyl-pentanoic acid (50 mg, 0.34 mmol)   in  
DCM (1.1 mL)  was added N-acetylcyteamine (0.045 mL, 0.41 mmol) and DMAP (4 mg, 0.030 
mmol), followed by  DCC (110 mg, 0.51 mmol) at 0 °C. The reaction was allowed to warm to 
RT and stirred for 4 hours. The reaction was quenched with 10 ml of 1M HCl and then filtered. 
The combined DCM extracts (3 x 30ml) were washed with 0.5 M HCl (10ml), washed with 
saturated aqueous NaHCO3 (10ml) and finally washed with 20ml saturated aqueous NaCl. The 
combined organic extracts were dried and then concentrated under reduced pressure. The residue 
is then purified by chromatography (3% MeOH/DCM) to yield  (2S,3R)-3-hydroxy-2,4-
dimethyl-pentanoyl-SNAc (21 mg, 0.09 mmol, 25 % yield).  Spectral data for compound 2 
matched the data previously reported in the literature.34  
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A.4 (2R,3S)-3-hydroxy-2,4-dimethylpentanoic acid  
 
 
To a solution of (3S)-3-benzyl-2-[(2R,3S)-3-hydroxy-2,4-dimethyl-
pentanoyl]cyclopentanone35 (590 mg, 1.95 mmol) in THF (9.8 mL) and water (1.2 
mL) was added H2O2 (1.17 ml, 11.7 mmol) followed by LiOH-H2O (163.9 mg, 3.9 mmol). 
The reaction mixture was stirred at 0 ˚C for 1hr and then a 0.5 M solution of Na2SO3 (270.5 
mg, 2.15 mmol) was added. After being buffered to pH 9 with aqueous NaHC03, the THF was 
removed with a rotary evaporator. The aqueous solution was washed with CH2Cl2.  After 
acidification to pH 6 with 10% HCl, the aqueous phase was extracted with EtOAc, the combined 
organics dried over MgSO4, filtered and concentrated in vacuo and used directly in the next step. 
A.5 (2R,3S)-3-hydroxy-2,4-dimethylpentanoyl-SNAc (5) 
  
To a stirred solution of  (2R,3S)-3-hydroxy-2,4-dimethyl-pentanoic acid (20 mg, 0.14 mmol)   in  
DCM (0.45 mL) was added  N-acetylcyteamine (0.020 mL, 0.16 mmol) and DMAP (2 mg, 0.01 
mmol), followed by DCC (42 mg, 0.21 mmol) at 0 °C. The reaction was allowed to warm to rt 
and stirred for 4 hours. The reaction was quenched with 10 ml of 1M aq. HCl and then filtered. 
The combined DCM extracts (3 x 10ml) were washed with aq. 0.5 M HCl (10ml), washed with 
saturated aqueous NaHCO3 (10ml) and finally washed with 20ml saturated aqueous NaCl. The 
combined organic extracts were dried and then concentrated under reduced pressure. The residue 
is then purified by chromatography (3% MeOH/DCM) to afford (2R,3S)-3-hydroxy-2,4-
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dimethylpentanoyl-SNAc (21 mg,0.084 mmol, 61% yield). [α]20D = -5.6 (c 0.5, CHCl3).  1H 
NMR (CDCl3, 400 MHz) δ ppm: 5.81 (br s, 1H), 3.58 (dd, J = 7.5, 3.7 1H), 3.46 (m, 2H), 3.02 
(m, 2H), 2.85 (m, 1H), 2.33 (br s, 1H), 1.95 (s, 3H), 1.72 – 1.63 (m, 1H), 1.20 (d, J = 7.0 Hz, 3 
H),  1.00 (d, J = 6.3 Hz, 3H), 0.88 (d, J = 6.8 Hz, 3H); 13C NMR (CDCl3, 100 MHz) δ ppm: 
204.5, 170.4, 77.3, 50.8, 39.5, 30.9, 28.6, 23.2, 19.2, 18.5, 10.8; HRMS (FAB) m/z (M+H)+ 
calcd for C11H21NO3S, 248.1320; obsd 248.1297 
A.6 (E)-2,4-dimethylpent-2-enoyl-SNAc (6) 
 
(E)-2,4-dimethylpent-2-enoic acid (105 mg, 0.820 mmol) was dissolved in DCM (3.12 mL)  and 
cooled to 0 ˚C before N-acetylcyteamine (0.100 mL, 0.980 mmol) was added followed by 
DMAP (10.0 mg, 0.0800 mmol) and EDC-HCl (236 mg, 1.23 mmol). The reaction was allowed 
to warm to RT and stirred for 4 hours.  Upon consumption of the starting material, saturated 
aqueous NH4Cl solution (5 ml) was added, and the organic phase was separated. The aqueous 
phase was extracted with diethyl ether (3 × 10 ml), and the combined organic phases were dried 
over anhydrous Na2SO4 and concentrated under reduced pressure. The residue was purified by 
silica gel column chromatography (60% EtOAc/hexane) to give (E)-2,4-dimethylpent-2-enoyl-
SNAc (154 mg, 0.672 mmol, 82.0 % yield).  1H NMR (CDCl3, 400 MHz) δ ppm: 6.57 (dq, J = 
9.5, 1.3 Hz, 1H), 5.90 (br s, 1H), 3.45 (q, J = 6.1 Hz, 2H), 3.06 (q, J = 6.2, 2H), 2.67 (m, 1H), 
1.97 (s, 3H), 1.88 (d, J =  1.3 Hz, 3H) 1.05 (6, J = 6.7 Hz, 6H); 13C NMR (CDCl3, 100 MHz) δ 
ppm: 194.3, 170.3, 148.4, 133.6, 39.8, 28.4, 28.1, 23.2, 21.8, 12.4; HRMS (FAB) m/z (M+H)+ 
calcd for C11H19NO2S, 230.1215; obsd 230.1220 
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A.7 t-butyl 2,4-dimethylpent-3-enoate  
 
In a glove box, LiHMDS (627 mg, 3.75 mmol) and [PdP(tBu)3Br]2 (29.0 mg, 0.038 mmol) was 
added to a 10-mL crimp cap vial containing a stir bar. The vial was crimped, Toluene (6.0 mL) 
was added, and the vial was taken out of the glove box and stirred at 22°C. t-butyl propionate 
(225 µl, 1.5 mmol) was added dropwise to the stirred solution. After 5 min, 1-bromo-2-
methylpropene (160 µl, 1.58 mmol) was added and stirred at 22°C for 3 h. The reaction mixture 
was diluted with ethyl acetate (5 ml), passed through a silica plug with ethyl acetate as eluent (20 
ml), and concentrated. The residue was purified by silica gel column chromatography (3% 
EtOAc/hexane) to afford t-butyl 2,4-dimethylpent-3-enoate (200 mg, 1.09 mmol, 74% yield). 
Spectral data for the compound 6 matched the data previously reported in the literature.36  
A.8 rac-2,4-dimethylpent-3-enoic acid  
 
TFA (0.69 mL, 9.0 mmol) was added dropwise to a solution of t-butyl 2,4-dimethylpent-3-enoate 
(55 mg, 0.30 mmol) in DCM (7.5 mL) at 0 ˚C.  The mixture was stirred at 0 ˚C for 30 mins 
before warming up to RT and stirred until starting material was consumed.  The reaction was 
then concentrated in vacuo, mixed with DCM and 1% aqueous NaOH and extracted with DCM.  
The DCM layer was discarded.  The aqueous layer was acidified with 10% HCl and extracted 3 
times with DCM.  The organic phase was dried over Na2SO4 and concentrated to afford 2,4-
dimethylpent-3-enoic acid (32mg,0.2497mmol, 83.653% yield) that was carried on crude to the 
next step.  Spectral data for the acid matched the data previously reported in the literature.37  
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A.9 2,4-dimethylpent-3-enoyl-SNAc (rac-7) 
 
To a stirred solution of  2,4-dimethylpent-3-enoic acid (14 mg, 0.11 mmol) in DCM (0.39 mL) 
was added  N-acetylcyteamine (14 µL, 0.13 mmol)  and DMAP (1.0 mg, 0.010 mmol), followed 
by DCC (34 mg, 0.16 mmol) at 0 °C. The reaction was allowed to warm to RT and stirred for 4 
hours. The reaction was quenched with 10 ml of 1M HCl and then filtered. The combined DCM 
extracts (3 x 5 ml) were washed with 0.5 M HCl (5 ml), washed with saturated aqueous NaHCO3 
(5 ml) and finally washed with 10 ml saturated aqueous NaCl. The combined organic extracts 
were dried and then concentrated under reduced pressure. The residue was purified by 
chromatography (60% EtOAc/hexanes) to afford S-(2-acetamidoethyl) 2,4-dimethylpent-3-
enethioate (15 mg, 0.067 mmol, 62 % yield) as a clear oil. 1H NMR (CDCl3, 400 MHz) δ ppm: 
5.86 (br s, 1H), 5.07 (dt, J = 9.4, 2.7 Hz, 1H), 3.45 (m, 1H), 3.39 (q, J = 6.2, 2H), 2.95 (t, J = 6.4 
Hz, 2H), 1.93 (s, 3H), 1.72 (d, J =  1.0 Hz, 3H) 1.66 (d, J = 1.1 Hz, 3H), 1.19 (d, J = 6.8 Hz, 3H); 
13C NMR (CDCl3, 100 MHz) δ ppm: 203.0, 170.2, 136.1, 123.2, 47.9, 39.8, 28.4, 25.8, 23.2, 
18.3, 18.1; HRMS (FAB) m/z (M+H)+ calcd for C11H19NO2S, 230.1215; obsd 230.1220 
A.10 (2R)-2,4-dimethylpent-3-enoyl-SNAc (8) 
 
 (2R)-2,4-dimethylpent-3-enoic acid38 (40 mg, 0.31 mmol) was dissolved in DCM (2.1 mL) and 
cooled to 0 ˚C before N-acetylcyteamine (0.040 mL, 0.37 mmol) was added followed by  DMAP 
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(3.8 mg, 0.030 mmol) and EDC-HCl (90 mg, 0.47 mmol). The reaction was allowed to warm to 
RT and stirred for 4 hours.  Upon consumption of the starting material, saturated aqueous NH4Cl 
solution (5 ml) was added, and the organic phase was separated. The aqueous phase was 
extracted with diethyl ether (3 × 5 ml), and the combined organic phases were dried over 
anhydrous Na2SO4 and concentrated under reduced pressure. The residue was purified by silica 
gel column chromatography (60% EtOAc/n-hexane) to give (2R)-2,4-dimethylpent-3-enoyl-
SNAc (58 mg,0.25  mmol, 81 % yield). ). [α]20D = -203.5 (c 1.0, CHCl3)1H NMR (CDCl3, 400 
MHz) δ ppm: 5.80 (br s, 1H), 5.09 (dt, J = 9.4, 1.3 Hz, 1H), 3.48 (m, 1H), 3.42 (q, J = 6.2, 2H), 
2.98 (t, J = 6.4 Hz, 2H), 1.95 (s, 3H), 1.75 (d, J =  1.0 Hz, 3H) 1.68 (d, J = 1.1 Hz, 3H), 1.22 (d, J 
= 6.9 Hz, 3H); 13C NMR (CDCl3, 100 MHz) δ ppm: 203.0, 170.2, 136.1, 123.2, 47.9, 39.8, 28.3, 
25.8, 23.2, 18.3, 18.1; HRMS (FAB) m/z (M+H)+ calcd for C11H19NO2S, 230.1215; obsd 
230.1216 
A.11 (3S)-3-hydroxy-4-methyl-pentanoyl-SNAc (9) 
  
To a stirred solution of (3S)-3-hydroxy-4-methyl-pentanoic acid39 (48.mg, 0.36mmol)  in DCM 
(1.2 mL) was added N-acetylcyteamine (0.05 mL, 0.44mmol) and DMAP (4 mg, 0.04mmol), 
followed by DCC (112 mg, 0.54mmol) at 0 °C. The reaction was allowed to warm to rt and 
stirred for 4 hours. The reaction was quenched with 5 ml of 1M aq. HCl and then filtered. The 
combined DCM extracts (3 x 10ml) were washed with aq. 0.5 M HCl (10ml), washed with 
saturated aqueous NaHCO3 (10ml) and finally washed with saturated aqueous NaCl (20 ml). The 
combined organic extracts were dried and then concentrated under reduced pressure. The residue 
is then purified by chromatography (3% MeOH/DCM) to afford (3S)-3-hydroxy-4-methyl-
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pentanoyl-SNAc (23 mg, 0.10 mmol, 27% yield).  [α]20D = 19.8 (c 1.0, CHCl3) . 1H NMR 
(CDCl3, 400 MHz) δ ppm: 5.31 (br s, 1H), 3.85 (m, 1H), 3.44 (m, 2H), 3.05 (m, 2H), 2.75 (dd, J 
= 15.4, 3.0 Hz, 1H), 2.68 (dd, J = 15.4, 9.3, 1H), 1.97 (s, 3H), 1.76 (br s, 1H), 1.71 (m. 1H), 0.95 
(d, J = 6.9 Hz, 3H), 0.93 (d, J = 6.9 Hz, 3H); 13C NMR (CDCl3, 100 MHz) δ ppm 200.0, 170.5, 
73.5, 48.3, 39.3, 33.4, 28.9, 23.2, 18.4, 17.6; HRMS (FAB) m/z (M+H)+ calcd for C10H19NO3S, 
234.1164; obsd 234.1131 
A.12 (E)-4-methylpent-2-enoyl-SNAc (10) 
  
(E)-4-methylpent-2-enoic acid (70 mg, 0.31 mmol) was dissolved in DCM (2.0 mL) and cooled 
to 0 ˚C before N-acetylcyteamine (0.040 mL, 0.37 mmol) was added followed by DMAP (3.8 
mg, 0.030 mmol) and EDC-HCl (89 mg, 0.46 mmol).  The reaction was allowed to warm to RT 
and stirred for 4 hours.  Upon consumption of the starting material, saturated aqueous NH4Cl 
solution (5 ml) was added, and the organic phase was separated. The aqueous phase was 
extracted with diethyl ether (3 × 5ml), and the combined organic phases were dried over 
anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified 
by silica gel column chromatography (60% EtOAc/n-hexane) to give (E)-4-methylpent-2-enoyl-
SNAc (55 mg, 0.128 mmol, 41.2 % yield).  Spectral data for compound 8 matched the data 
previously reported in the literature.37 
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A.13 4-methylpent-3-enoyl-SNAc (11) 
 
4-methylpent-3-enoic acid38 (100 mg, 0.880 mmol) was dissolved in DCM (3.00 mL) and cooled 
to 0 ˚C before N-acetylcyteamine (0.110 mL, 1.05 mmol) was added followed by DMAP (10.7 
mg, 0.0900 mmol) and EDC-HCl (252 mg, 1.31 mmol).  The reaction was allowed to warm to 
RT and stirred for 4 hours.  Upon consumption of the starting material, saturated aqueous NH4Cl 
solution (5 ml) was added, and the organic phase was separated. The aqueous phase was 
extracted with diethyl ether (3 × 5 ml), and the combined organic phases were dried over 
anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified 
by silica gel column chromatography (60% EtOAc/n-hexane) to give 4-methylpent-3-enoyl-
SNAc (103 mg, 0.478 mmol, 54.6 % yield).  1H NMR (CDCl3, 400 MHz) δ ppm: 5.85 (br s, 1H), 
5.26 (m, 1H), 3.43 (q, J = 6.2 Hz, 2H), 3.26 (d, J = 7.4, 2H), 3.00 (t, J = 6.4 Hz, 2H), 1.95 (s, 
3H), 1.76 (s, 3H) 1.66 (s, 3H); 13C NMR (CDCl3, 100 MHz) δ ppm: 199.1, 170.3, 137.8, 115.1, 
43.4, 39.7, 28.5, 25.8, 23.2, 18.1; HRMS (FAB) m/z (M+H)+ calcd for C10H17NO2S, 216.1058; 
obsd 216.1052 
A.14 (Z)-2,4-dimethylpent-2-enoyl-SNAc (12) 
 
(Z)-2,4-dimethylpent-2-enoic acid40 (61 mg, 0.48 mmol) was dissolved in DCM (1.5 mL) and 
cooled to 0 ˚C before N-acetylcysteamine (0.060 mL, 0.57 mmol) was added followed by DMAP 
(6.1 mg, 0.050 mmol) and EDC-HCl (137 mg, 0.71 mmol). The reaction was allowed to warm to 
RT and stirred for 4 hours.  Upon consumption of the starting material, saturated aqueous NH4Cl 
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solution (10 ml) was added, and the organic phase was separated. The aqueous phase was 
extracted with diethyl ether (3 × 10 ml), and the combined organic phases were dried over 
anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified 
by silica gel column chromatography (60% EtOAc/hexane) to give (Z)-2,4-dimethylpent-2-
enoyl-SNAc (65 mg,0.28 mmol, 60% yield).  1H NMR (CDCl3, 400 MHz) δ ppm: 5.98 (br s, 
1H), 5.49 (dq, J = 10.0, 1.4 Hz, 1H), 3.43 (q, J = 6.2, 2H), 3.05 (t, J = 6.4 Hz, 2H), 3.01 – 2.95 
(m,1H), 1.94 (s, 3H), 1.93 (d, J =  1.4 Hz, 3H), 0.96 (d, J = 6.8 Hz, 6H); 13C NMR (CDCl3, 100 
MHz) δ ppm: 194.9, 170.3, 146.2, 131.3, 39.8, 28.6, 28.4, 23.2, 22.7, 21.8, 20.7; HRMS (FAB) 
m/z (M+H)+ calcd for C11H19NO2S, 230.1215; obsd 230.1207 
A.15 (Z)-4-methylpent-2-enoyl-SNAc (13) 
 
 
 
(Z)-4-methylpent-2-enoic acid41 (50.mg, 0.4400mmol) was dissolved in DCM (1.5 mL) and 
cooled to 0 ˚C before N-(2-sulfanylethyl)acetamide (0.060 mL, 0.5300 mmol) was added 
followed by DMAP (2 mg, 0.0400mmol) and EDC-HCl (126 mg, 0.6600mmol).  The reaction 
was allowed to warm to RT and stirred for 4 hours.  Upon consumption of the starting material, 
saturated aqueous NH4Cl solution (10 ml) was added and the organic phase was separated. The 
aqueous phase was extracted with diethyl ether (3 × 10 ml), and the combined organic phases 
were dried over anhydrous Na2SO4 and concentrated under reduced pressure. The residue was 
purified by silica gel column chromatography (60% EtOAc/n-hexane) to give (Z)-4-methylpent-
2-enoyl-SNAc (65 mg,0.30 mmol, 68.916% yield) δH (CDCl3, 400 MHz) 6.89 (dd, 15.6, 6.6 Hz. 
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1H), 6.07 (dd, 15.6, 1.5 Hz, 1H), 5.91 (br s, 1H), 3.45 (q, 6.0 Hz, 2H), 3.08 (t, 6.4 Hz, 2H), 2.46 
(m, 1H), 1.96 (s, 3H), 1.05 (d, 6.8 Hz, 6H); 13C NMR (CDCl3, 100 MHz) δ ppm: 190.7, 170.3, 
152.6, 125.7, 39.8, 31.0, 28.3, 23.2, 21.1; HRMS (FAB) m/z (M+H)+ calcd for C10H17NO2S, 
216.1058; obsd 216.1051 
B. Biological protocols 
B.1 Cloning and expression 
A construct encoding amino acids 1697-1984 from GphF of the gephyronic acid PKS was codon 
optimized for expression in E. coli. Synthetic cDNA was cloned into a pMocr-based expression 
vector26 to create pGJD013. Cells of E. coli strain BL21(DE3) pRARE AI were transformed with 
pGJD013. The starter culture was transferred to a 2 L baffled flask containing 0.5 L 4% glycerol 
Terrific Broth media (BD) with 100 mg/L ampicillin and 50 mg/L spectinomycin, grown at 37°C 
to an OD600 of 1.5, cooled to 20°C, induced by addition of isopropyl β-D-1-
thiogalactopyranoside (IPTG) to 0.2 mM and 1 g solid (L)-arabinose, and incubated 18 hr. Cells 
were harvested via centrifugation, transferred to 50 mL falcon tubes and immediately frozen at -
20°C. Plasmids encoding CurK DH (wild type and P1005V) were expressed in E. coli as 
described previously.11 
B.2 Mutagenesis  
Site-directed mutagenesis of GphF DH1 and CurK DH was done via PCR of pGJD013 and 
pJRR19811, respectively, using primers designed with the QuikChange primer design tool 
website (Agilent) (Table 5.1). Forward and reverse primers are shown below with the mutated 
codons underlined. Sequences of the coding regions of all plasmids were confirmed by Sanger 
sequencing. 
 206 
 
Table 5.1 Primers for mutagenesis 
Mutant Primers (5' – 3') 
GphF DH1 H1735Q catcataaacccactgttcacccagatatgccgga 
tccggcatatctgggtgaacagtgggtttatgatg 
GphF DH1 D1898N cactgaaaacaggcattcagcagtgccggatgc 
gcatccggcactgctgaatgcctgttttcagtg 
GphF DH1 L1744P catttccagataggtaacacccggaacaacaattgcatcataaac 
gtttatgatgcaattgttgttccgggtgttacctatctggaaatg 
GphF DH1 Y1856F agacgcggaccaaaatagatgcgcatacgttcataa 
ttatgaacgtatgcgcatctattttggtccgcgtct 
CurK P1005V aatagcctgtggctacaaagagcaccttgttaaatacttggtg 
caccaagtatttaacaaggtgctctttgtagccacaggctatt 
 
B.3 Protein Purification 
All purification steps were performed at 4°C. Cells were resuspended in buffer A (50 mM Tris 
pH 7.5, 300 mM NaCl, 10% glycerol) with 15 mM imidazole (4 mL/g cell pellet), incubated 1 hr 
on ice in lysis buffer (Buffer A + 2 mM MgCl2, 0.5 mg/mL DNaseI, and 0.06 mg/mL lysozyme), 
and lysed by sonication. The lysate was cleared via centrifugation. The supernatant was filtered 
through a 0.2 μm filter, and loaded onto a 5 mL His Trap column (GE Healthcare). The column 
was washed with 10 volumes buffer A with 15 mM imidazole, and protein was eluted with a 
linear gradient from 15 mM to 400 mM imidazole. Peak fractions were pooled, and the His-Mocr 
tag was removed by overnight incubation with tobacco etch virus (TEV) protease (1:50 
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TEV:Mocr-GphF DH) with dialysis against Buffer A. The dialysate was re-loaded onto a His-
trap column, and the flow-through and wash fractions were pooled, concentrated, and loaded on  
a Superdex 16/60 S200 gel filtration column (GE Healthcare) equilibrated with buffer A.  GphF 
DH eluted as a monomer with an apparent molecular weight of 29 kDa (Calculated MW 32.6 
kDa).  Fractions with GphF DH1 were pooled, the protein was concentrated to 15 mg/mL, and 
flash frozen in liquid N2. 
B.4 Crystallography 
Crystals were grown by sitting-drop vapor diffusion in 1:1 mix of 15 mg/mL protein stock and 
crystallization solution (01.M trisodium citrate, 20% polyethylene glycol 4K, 22% 1,4-
butanediol, 10 mM Hepes pH 7.3). Crystals formed in 2-3 hours and were fully grown after 2 
days. Crystals were harvested directly from drops and flash-cooled in liquid N2. Data were 
collected at the Advanced Photon Source (APS, Argonne National Laboratory) on GM/CA 
beamline 23-ID-A. GphF DH crystals diffracted to 1.55 Å and were in orthorhombic space group 
P212121 with one polypeptide per asymmetric unit.  Data were processed using XDS
42. The 
structure was solved via molecular replacement in phaser43 using a search model generated using 
the chainsaw44 program in CCP445 based on a dehydratase in the curacin biosynthetic pathway 
(CurK DH11, PDB 3KG9). The CurK DH search model was truncated to the closest common 
carbon to the GphF DH. Refinement was done with PHENIX46, and model building in coot47.  
The refined model was validated with MolProbity48. The superior crystallization properties of 
DH1/P1711L are explained by a lattice contact of the Leu1711 side chain with an outward-facing 
Ala side chain on a helix in an adjacent molecule in the crystal lattice. 
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B.5 Enzyme Assay 
Reaction mixtures containing 200 μM substrate, 50 mM Hepes pH 7.5, 200 mM NaCl, 5% 
glycerol and GphF DH to a final concentration of 7.5 mg/mL (204.6 μM) in a total volume of 80 
μL were mixed by brief pipetting and incubated overnight at 37°C. Reactions were quenched by 
addition of 150 μL methanol. After precipitated proteins were removed via centrifugation, 0.5 μL 
of the supernatant from each reaction were analyzed by mass spectrometry on an Agilent 6250 
Q-TOF LC/MS. Separation was achieved using a Kinetix reverse-phase C18 column (50 mm x 
2.1 mm, 2.6 um, Phenomenex) with a gradient from 0-95% H20:acetonitrile. Serial dilution of 
authentic standards was used to determine the minimum sensitivity for each compound, standard 
curves were used for quantitation. Additionally, 10 μL of the same samples were separated by 
HPLC (Agilent 1200) and analyzed by ultraviolet absorbance at 225 nm. Separation was 
achieved using a Kinetix reverse-phase C18 column (50 mm x 2.1 mm, 2.6 um, Phenomenex) 
with a gradient of 0-95% acetonitrile in water. A225 values were quantitated from the peak areas 
based on extinction coefficients of standards, and LC/MS EIC values via standard curves of 
standards. CurK DH was assayed identically to the procedure used for GphF DH1, but with a 
final enzyme concentration of 10 mg/mL (313.68 μM) and a 30 hour incubation at 37°C. Chiral 
separation was achieved using a reverse-phase Lux cellulose 3 5 μm column (Phenomenex) with 
a gradient from 30-85% H2O:acetonitrile. 
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Results 
Synthesis of Gph1 DH substrate candidates 
All synthesis experiments were run by Danialle Ronnow  
To investigate both the reactivity and specificity of GphF DH1, we systematically 
examined features of both the native diketide and the potential intermediates crucial for 
recognition and processing (Fig. 5.1B). Four potential 2-methyl-3-hydroxy substrates (2-5), a 
potential (E)-2-methyl-2-enoyl dehydration product (6), and two potential 2-methyl-3-enoyl 
elimination products (rac-7, 8) were synthesized in an effort to explore the effect of 
stereochemistry on GphF DH function (Fig. 5.1B). To explore the importance of the 2-methyl 
group, a 3-hydroxy substrate (9), a potential (E)-2-enoyl dehydration product (10), and a 
potential 3-enoyl elimination product (11) were synthesized (Fig. 5.1B).   Finally, as some DHs 
can act on (Z) configured alkenes3, 10, (Z)-2-methyl-2-enoyl (12) and (Z)-2-enoyl (13) compounds 
were synthesized. All thioester analogs were synthesized by coupling the corresponding 
carboxylic acids to N-acetylcysteamine (NAC) except potential elimination product rac-7, which 
was synthesized in an expedient manner via a palladium-catalyzed alkenylation followed by 
routine conversion to the NAC thioester. All synthetic substrates had distinct retention times in 
chromatographic separation excepting the 2/3 , the 4/5 enantiomers and the E/Z regioisomers 
6/12 and 11/13 (Figs. 5.2, 5.3, 5.4, Table 5.2). 
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Distinct retention times are observed for all non-enantiomeric 
species. 
Figure 5.2 LCMS EICs for 2-13. 
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Figure 5.4 HPLC/UV traces of GphF substrate mimic 
standards. 
Standards of 6 (blue) and 7 (red) were analyzed separately and in a 2:1 ratio of 6:7 (black) by 
LCMS. The retention times observed in this experiment match those observed in the dehydration of 
2 and 3 by GphF DH1. 
Figure 5.3 LC separation of 6 and 7. 
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Table 5.2 LC/MS Retention Times 
C18 column  Chiral cellulose column 
Compound Retention Time  Compound Retention Time 
2 3.78  6 10.80 
3 3.78  8 10.21 
4 3.7  14 10.41 
5 3.7    
6 4.47    
rac-7 4.35    
8 4.35    
9 3.54    
10 & 11 4.23, 4.13    
12 4.47    
13 4.22    
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Catalytic assay 
Amino acids 1697-1984 of GphF were 
selected as the boundaries of the DH1 domain 
based on homology to PKS DH domains of known 
structure4, 11-14, and the excised DH was produced 
in E. coli. The purified, recombinant GphF DH1 
was monomeric in solution with an apparent 
molecular weight of 29 kDa by size-exclusion 
chromatography (calculated molecular weight 
32.6 kDa), in contrast to other module-embedded 
DH domains, which are dimeric in solution (Fig. 
5.5).4, 11-13 GphF DH1 was assayed using NAC-linked test substrates 2-13 (Fig. 5.1B). Following 
removal of protein by methanol precipitation, reaction mixtures were separated by HPLC and 
analyzed by both absorbance at 225 nm (Table 5.3) and mass spectrometry. Quantitation based 
on 2-13 authentic standards yielded highly consistent results with A225 and LC/MS analysis, but 
owing to the low ultraviolet absorbance of 2-13, the MS analysis had greater precision. Total ion 
counts (TIC) of the LC elution profiles of the test substrates and reaction mixes were monitored, 
and extracted ion chromatograms (EICs) were generated from individual peaks and used to 
quantitate the extent of catalysis. GphF DH1 catalyzed reactions with all compounds except 5 
and 8.  
  
Figure 5.5 Superdex S200 gel filtration 
profile of Purified GphF DH1. 
The apparent molecular weight of the excised 
domain is 29 kDa, indicating DH1 is monomeric in 
solution. The calculated molecular weight of GphF 
DH1 is 32.6 kDa. 
 
 214 
 
Table 5.3 GphF DH1 activity by UV absorbance 
 Distribution of substrate & products (%) 
3-hydroxy substrate 3-hydroxy  2-enoyl  3-enoyl 
2 70.3 ± 2.6* 27.7 ± 2.3 1.9 ± 7.4 
3 83.4 ± 4.1 14.5 ± 4.3 2 ± 17 
4 99.9 ± 4.5 0 0 
5 99.9 ± 3.4 0 0 
9 N.D.† 63.3 ± 1.3 36.7 ± 1.5 
Unsaturated Substrate 3-hydroxy  2-enoyl 3-enoyl 
6 0.4 ± 5.1 97.77 ± 0.04 1.81 ± 0.05 
rac-7 0 20.6 ± 0.7 79.4 ± 0.7 
8 0 0 99.9 ± 2.0 
10 & 11 N.D. 32.0 ± 4.0 67.9 ± 4.2 
12 0 99.9 ± 6.9 0 
13 N.D. 33.6 ± 4.3 66.4 ± 4.3 
 
 
 
  
* Quantitation of substrate/product distribution is based on HPLC separation 
and absorbance at 225 nm by comparison to authentic standards.  
†9 (rehydration product of 10, 11 or 13) does not absorb at 225 nm and cannot 
be detected in the UV absorbance assay. 
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Table 5.4 Activity of Wild-type GphF DH1 
Dehydratase activity  
Based on the biosynthetic pathway 
deduced from the gph gene cluster30 and on the 
established intermediates and products of 
homologous PKS modules, the GphF DH1 
natural substrate is predicted to be (2R,3R)-3-
hydroxy-2,4-dimethylpentanoyl-ACP, as the 
GphF CMT has been shown to act before the 
GphF KR131, and the “B-type” KR1 should 
produce an (R)-2-hydroxy product15 PKS DHs 
have been predicted to catalyze syn-elimination 
1-2, 49, as could occur with the (2R,3R)-2-methyl-
3-hydroxy substrate 2, or its enantiomer 3. This prediction is based on PKS DH similarity to FAS 
DHs, where syn-elimination has been demonstrated50-51, and on the activity of DH domains with 
2-methyl substituents 4, 49. Consistent with this prediction, recent studies on the stereospecificity 
of CMT domains from trans-AT PKS found that CMT domains installed (R)-2-methyl groups52. 
However, based on the structure of 1, the methyl group installed by GphF MT1 is predicted to be 
in the (S)-configuration30. Thus we investigated GphF DH1 reactivity with NAC-linked 
thioesters of all four diastereomers of the predicted natural substrate (2, 3, 4, 5) (Figs. 5.1B, 5.6, 
Table 5.4). Dehydrated products were detected for the enantiomers 2 and 3, which are competent 
for syn elimination, whereas only trace amounts of dehydrated product were detected with 4, and 
  Distribution of substrate & products (%) 
3-hydroxy substrate 3-hydroxy  2-enoyl  3-enoyl  
2 71.6 ± 0.5* 27.7 ± 0.5 0.6 ± 0.1 
3 81.6 ± 0.4 18.0 ± 0.3 0.3 ± 0.1 
4 99.9 ± 0.1 0.5 ± 0.1 < 0.01 
5 99.9 ± 0.1 < 0.01 < 0.01 
9 87.5 ± 0.2 5.4 ± 0.1 7.1 ± 0.1 
Unsaturated substrate 3-hydroxy  2-enoyl 3-enoyl 
6 1.3 ± 0.1 89.4 ± 0.1 9.3 ± 0.1 
rac-7 < 0.01 12.9 ± 0.2 
87.0 ± 0.2 
(37 + 50) 
8 < 0.01 < 0.01 99.9 ± 0.1 
10 & 11 (2:1) 5.9 ± 0.3  38 ± 2 56 ± 2 
12 0.3 ± 0.1 96.6 ± 0.1 3.1 ± 0.1 
13 6.3 ± 0.2 37.1 ± 0.4 56.7 ± 0.6 
* Quantitation of substrate/product distribution is 
based on LC/MS separation and extracted ion counts for 
each species, as described in Methods.  The starting 
substrate concentration in all assays was 200 M. 
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none with 5. Greatest activity was detected with 2 (28% conversion to 6), whereas 3 was less 
reactive (18% conversion to 6) under our assay conditions. This indicates that the natural 
substrate for GphF DH1 is likely (2R,3R)-3-hydroxy-2,4-dimethylpentanoyl-ACP and that GphF 
DH1 catalyzes a syn elimination.  
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Figure 5.6 Reaction of GphF DH1 with 
3-hydroxy substrates. 
EICs for the 3-hydroxy (270 for 2 and 3, 256 for 9) 
and the dehydrated 2-enoyl (EIC 252 for 2 and 3, 
238 for 9) demonstrate GphF DH1 catalyzed 
dehydration of 2, 3 and 9. 5 was not a substrate, 
and only trace amounts of dehydrated product were 
detected from 4. Two dehydrated species were 
observed that correspond to the retention times for 
the 2-enoyl (6, 10), and 3-enoyl (7, 11) standards, 
indicating GphF DH1 can both dehydrate and 
isomerize. 
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Isomerase activity  
Reaction of 2 or 3 with GphF DH1 resulted in two dehydrated products with retention 
times of 4.47 min for the major product, and 4.35 min for the minor product (Fig. 5.6, Table 5.4). 
The masses and elution times of these products exactly match those of authentic 6 and rac-7 
prepared independently (Fig. 5.4). Thus, GphF DH1 possesses both dehydration and 
isomerization activities, and dehydration of a 2-hydroxy substrate may be followed by 
isomerization of the resulting 2-enoyl 6 to 3-enoyl rac-7, similar to the catalytic route of FabA. 
The isomerase activity was easily detected, but less 3-enoyl than 2-enoyl product accumulated 
under our assay conditions. In the reaction of GphF DH1 with 4, we detected only trace amounts 
of the 2-enoyl product (retention time 4.47 min, Table 5.2) and the low turnover may have 
precluded detection of any 3-enoyl product.  
When exposed to an (E)-2-enoyl NAC substrate, the E. coli FAS DH FabA produced an 
equilibrium mixture of 68% 3-hydroxy, 29% (E)-2-enoyl and 3% (Z)-3-enoyl products7. In an 
analogous manner, we used 6 and rac-7 to assess the mixture of dehydration and isomerization 
products of GphF DH1 (Fig. 5.7, Table 5.4).  Incubation with 6 resulted in 9% conversion to the 
2-methyl-3-enoyl 7 (retention time 4.35 min), but only 1% re-hydration to substrate 2 or 3 
(retention time 3.78 min). Similarly, GphF DH1 isomerized 13% of 7 to 6, but 2/3 was not 
detected. These results provide additional support for a sequential mechanism of dehydration 
followed by isomerization and demonstrated strong forward equilibrium for the dehydration 
reaction, implying that the 2-methyl olefins 6 and 8/14 may have difficulty binding 
simultaneously with a water molecule in a manner competent for re-hydration. 
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Figure 5.7 Reaction of GphF DH1 with unsaturated intermediates and products. 
EICs are shown for both substrates and products. GphF DH1 was active on 6, 7, 12, 13, 
and a 2:1 mix of 10 & 11. These results establish that like FabA, GphF DH utilizes a two-
step mechanism in which the 2-enoly intermediate formed by dehydration is subsequently 
isomerized to give the final 3-enoyl product. Enantiomerically pure 8 is not turned over 
by DH1, while racemic 2-methyl-3-enoyl 7 is isomerized to 6.  
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Specificity at C2 and epimerase activity 
We used the (R)-configured 8 to assess GphF DH1 stereospecificity at C2 (Fig. 5.6, Table 
5.1). No products were detected in reactions of GphF DH1 with 8 (Fig. 5.7, 5.8, Table 5.4), 
indicating that isomerization of 6 yielded the (S)-2-methyl product 14.  This was confirmed by 
chiral-LC/MS analysis (Fig. 5.8, Table 5.2) The rac-7 standard was partially resolved into a 
species with an identical retention time to 8 (10.21 min) and a second species (10.41 min) 
corresponding to its enantiomer 14 (Fig. 5.8, Table 5.2). When incubated with 6, GphF DH1 
generated a product whose retention time matched that of 14, and co-injection of 8 with the 6 + 
GphF DH1 reaction mixture clearly demonstrated that the isomerization product was 14 and not 
8 (Fig. 5.8, Table 5.2) These results confirm a C2 epimerase function in the overall 
transformation of 2 to 14. The effective epimerization requires either different catalytic residues 
for dehydration and epimerization, or substrate rearrangement in the active site to position 6 with 
the pro-R face of C2 towards the presumed proton donor (His1735).  
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D 
Figure 5.8 Chiral-LC/MS analysis of GphF DH1 isomerization/epimerization reaction. 
EICs ([M + Na]+) are shown for unsaturated intermediates/products. The 2R and 2S enantiomers 8 and 14 
had distinct retention times (10.2 and 10.4 min, respectively). GphF DH1 selectively produced the 2S 
configured 14 from 6, confirming epimerization activity. 
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We also tested the tolerance of GphF DH1 for non-methylated substrates using 9, which 
resulted in products with retention times of 4.23 min and 4.13 min, identical to those of authentic 
standards for dehydration product 10 and elimination product 11, respectively, which were 
available as a 2:1 mixture (Figs. 5., 5.7 Table 5.4). Thus, the dual-functionality of GphF DH1 is 
not strictly dependent on the presence of a 2-methyl substituent. Nevertheless, GphF DH1 
preferred 2-methyl substrates: 9 was a poorer dehydration substrate than were 2 and 3 (13% 
dehydration for 9 vs. 28% for 2 and 18% for 3, Table 5.4). This is consistent with the 
demonstration that 2-methylation by GphF CMT precedes KR1 reduction31. While lower levels 
of dehydrated intermediate 10 accumulated with non-methylated substrate 9 (5% 10, compared 
to 28% 6 from methylated 2), the isomerization was more effective, as 9 yielded significant 
quantities of the 3-enoyl product 11 (7%, compared to <1% 7 from the methylated 2 or 3). 
Additionally, GphF DH1 converted the 67%:33% mixture of 10:11 to a 38%:56%:6% mixture of 
10:11:9 (Fig. 5.7, Table 5.4).  
E vs. Z selectivity 
To further explore the relaxed substrate selectivity, we also evaluated the tolerance of 
GphF DH1 for (Z)-2-enoyl substrates 12 and 13 (Fig. 5.7, Table 5.4). The (Z)-configured 13 was 
converted to a mixture of elimination product 10 (57%) and hydrated product 9 (6%).In contrast, 
GphF DH1 had very low activity with the (Z)-2-methyl substrate 12 (3% isomerized to 7, <1% 
hydrated to 2/3), illustrating again that a 2-methyl substituent is detrimental to isomerization and 
effectively blocks hydration of 2-enoyl substrates. Activity with a (Z)-configured substrate is 
additional evidence for the relaxed substrate specificity and intermediate regiospecificity of 
GphF DH1, although it is unlikely that the activity observed here represents a biologically 
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relevant function, as neither 12 nor 13 is predicted to be a native substrate or intermediate30. 
Some PKS DHs are predicted to produce a (Z)-2-enoyl product, and this has been demonstrated 
in one case3. 
GphF DH1 crystal structure 
Purified, recombinant GphF DH1 yielded single crystals that diffracted to 1.6 Å, but they 
were difficult to reproduce and grew slowly (Tables 5.5, 5.6, Figs. 5.10, 5.12A). A P1711L 
variant had identical activity to the wild type DH (Fig. 5.11) and resulted in reproducible growth 
of crystals of a different form that diffracted to 1.55 Å (Fig. 5.11, Tables 5.5, 5.7).GphF DH1 has 
the canonical double-hotdog fold of PKS DHs (Cα superposition results in RMSD values of 1.0 
– 2.1 Å, Fig. 5.12B)4, 11-14, but does not form a dimer in crystals, in agreement with the 
monomeric state in solution (Fig. 5.5). The active site, identified by the catalytic His1735 and 
Asp1898 side chains, is at the start of a hydrophobic substrate pocket (~7 Å wide and ~14 Å 
long) that extends from the catalytic His-Asp dyad along the central hotdog helix, and has a bi-
lobed shape that could accommodate the substrate terminal methyl groups. The GphF DH1 
pocket is shorter than the pockets of the curacin and erythromycin DHs, which have longer 
substrates11-12 (Fig. 5.13).  
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Table 5.5 Crystallographic summary for WT GphF DH1 and P1711L variant 
Diffraction data 
GphF DH1 
WT 
GphF DH1 
P1711L 
Space group P212121 P212121 
Unit cell a, b, c  (Å) 41.9, 74.42, 86.84 53.4, 71.6, 78.1 
Wavelength (Å) 1.033 1.033 
dmin (Å) 1.55 (1.605 – 1.55) 1.85 (1.91-1.85)* 
Observations (#) 209,337 (6,450) 181,621 (12,129) 
Unique reflections 
(#) 
37,411 (2,556) 26,020 (2,380) 
Mean I/σI 22.32 (1.99) 17.7 (1.67) 
Rmerge 0.044 (0.489) 0.076 (0.937) 
CC1/2 0.99 (0.62) 0.99 (0.56) 
CC* 1.00 1.00 
Completeness (%) 0.93 (0.65) 0.99 (0.92) 
Wilson B (Å2) 19.4 25.7 
Refinement   
Reflections (#) 37,374 26,014 
Rwork 0.19 0.18 
Rfree 0.22 0.22 
RMSD bonds (Å) 0.009 0.011 
RMSD angles (°) 1.27 1.33 
Atoms (#)   
Protein 2,241 2,266 
Solvent 271 1163 
Ligand n/a 19 
Avg B-factors (Å2)   
Protein 26.9 37.4 
Solvent 36.1 43.7 
Ligand  52.7 
Ramachandran   
Favored (%) 98.9 98.6 
Allowed (%) 1.1 1.4 
Outliers (%) 0 0 
 
* Values in parentheses refer to the outermost shell of data. 
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Table 5.6 X-ray data statistics for GphF DH1 WT 
Resolution N(obs) N(uniq) Mult. Compl. <I/sigma> R-merge R-meas R-pim CC1/2 
44.32 – 3.32 27,411 4,296 6.4 1.00 56.2 0.025 0.028 0.011 0.999 
3.32 – 2.64 27,084 4,130 6.6 1.00 40.9 0.033 0.035 0.014 0.999 
2.64 – 2.31 27,849 4,075 6.8 1.00 29.1 0.049 0.053 0.020 0.999 
2.31 – 2.09 24,957 4,008 6.2 0.99 21.4 0.073 0.080 0.032 0.996 
2.09 – 1.94 27,091 4,067 6.7 1.00 15.5 0.120 0.130 0.051 0.993 
1.94 – 1.83 25,431 3,966 6.4 0.99 9.6 0.204 0.223 0.089 0.982 
1.83 – 1.74 20,955 3,964 5.3 0.99 6.1 0.252 0.281 0.120 0.958 
1.74 – 1.66 13,541 3,553 3.8 0.88 3.5 0.335 0.387 0.187 0.905 
1.66 – 1.60 9,230 3,028 3.0 0.76 2.4 0.416 0.496 0.264 0.822 
1.60 – 1.54 6,143 2,506 2.5 0.63 1.7 0.503 0.629 0.368 0.614 
All 209,692 37,593 5.6 0.92 20.3 0.044 0.049 0.020 0.999 
 
Table 5.7 X-ray data statistics for GphF DH1 P1711L 
Resolution N(obs) N(uniq) Mult. Compl. <I/sigma> R-merge R-meas R-pim CC1/2 
44.10 – 3.99 18,806 2,782 6.8 1.00 47.3 0.028 0.031 0.012 0.999 
3.99 – 3.17 18,849 2,656 7.1 1.00 36.7 0.041 0.045 0.017 0.999 
3.17 – 2.77 18,925 2,615 7.2 1.00 22.6 0.071 0.076 0.028 0.998 
2.77 – 2.51 19,127 2,619 7.3 1.00 13.7 0.123 0.133 0.049 0.995 
2.51 – 2.33 19,006 2,594 7.3 1.00 9.9 0.176 0.189 0.070 0.992 
12.33 – 2.20 18,963 2,588 7.3 1.00 7.7 0.226 0.243 0.089 0.987 
2.20 – 2.09 18,961 2,589 7.3 1.00 5.7 0.315 0.339 0.124 0.978 
2.09 – 2.00 18,853 2,569 7.3 1.00 3.9 0.474 0.510 0.186 0.941 
2.00 – 1.92 18,005 2,566 7.0 1.00 2.4 0.756 0.817 0.305 0.882 
1.92 – 1.85 12,949 2,454 5.3 0.96 1.4 1.058 1.176 0.502 0.633 
All 182,444 26,032 7.0 1.00 15.5 0.071 0.077 0.029 0.999 
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Figure 5.9 Ramachandran plots for GphF DH1 
WT. 
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Figure 5.10 Ramachandran plots for GphF DH1 
P1711L. 
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The variant used to reproducibly generate crystals exhibits identical activity to WT GphF DH1 using both 2 and 6. 
Figure 5.11 GphF DH1/P1711L Assay. 
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Superposition of active site structures revealed distinct differences between PKS enzymes 
capable of isomerization (GphF DH1 and PksEI1427) and the non-isomerizing DHs4, 11-13 (Figs. 
5.12B). Like the FAS DHs, all these enzymes have a hydrogen bond from the catalytic His-N to 
a backbone carbonyl (Val1742), making the His-N atom available for acid-base chemistry. The 
most striking difference is a nearly 2 Å greater separation of the catalytic His and Asp functional 
groups in the isomerizing enzymes than in non-isomerizing PKS DHs4, 11-13,  
Figure 5.12 GphF DH1 structure. 
A: Overall structure. B: Superposition of GphF DH1 (green), PksEI14 (cyan), and several non-isomerizing PKS DHs 
(DEBS yellow, Rif tan, CurK red, CurH white, CurJ purple, AmbDH3 light green). The catalytic His of GphF DH1 and 
Pks EI is further from the catalytic Asp than in the non-isomerizing DHs, correlated with a branched-chain amino acid in 
lieu of Pro. Protrusion of the Leu or Val into the active site also influences the Asp position.  C. Superposition of WT 
GphF DH1 (Green) with L1744P GphF DH1 (Cyan). A modest shift in the position of the catalytic histidine is observed in 
the L1744P variant, reducing the distance between the catalytic His and Asp to 5.7 Å from 6.4 Å. Although this difference 
appears minor from a structural perspective, the L1744P variant is inactive as an isomerase, while retaining dehydration 
activity. D.  The active site architecture of PksEI with relevant amino acids shown as sticks. The active site of PKSEI is 
very similar to that of GphF DH1. E. Active site architecture of the CurK DH with relevant amino acids shown as sticks. 
CurK DH is representative of a typical monofunctional PKS DH. The catalytic His and Asp are much closer than in GphF 
DH1, and the distance between the catalytic Asp and a conserved Tyr is well outside of hydrogen-bond length. 
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Figure 5.13 Comparison of PKS DH 
structures and substrates. 
Active site entrances indicated by arrows, 
binding pockets shown as transparent surface. 
Comparison of these DHs highlights the 
similarity of the overall structure of PKS DHs, 
while active site renderings show how this 
fold is used as a scaffold to bind a variety of 
chemically diverse substrates. 
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and 1.3 Å longer than in FabA20 (Fig. 5.12C, D). The extended distance may be due to a 
branched-chain amino acid near the catalytic His (GphF DH1 Leu1744, PksEI14 Val27) (Figs. 
5.12C, D). As noted previously27, a branched amino acid exists at this position in most presumed 
isomerizing DHs, whereas it is proline in non-isomerizing PKS DHs (Fig. 5.14). To investigate 
the importance of Leu1744 to the active site structure, we solved a crystal structure of GphF 
DH1/L1744P (Figs. 5.12C, 5.14, Tables 5.8, 5.9). In this structure, the catalytic His1735 N is 
0.7 Å closer to Asp1898 than in the wild-type DH, but still further than in non-isomerizing DHs 
(Fig. 5.12E). Thus, the bulkier Leu side chain does not solely account for the longer distance 
between the catalytic side chains of GphF DH1.  
A second striking difference of GphF DH1 to the non-isomerizing DHs is a hydrogen 
bond from the conserved Tyr1856 hydroxy to the catalytic Asp1898 carboxylate, a unique 
feature of GphF DH1 (Figs. 5.12C, E). The hydroxy-carboxylate contact does not occur in the 
non-isomerizing DHs due to the position the Asp side chain, which in GphF DH1 is affected by 
the branched side chain at Leu1744. An analogous hydrogen bond does not exist in the PksEI14 
where the Asp is replaced with Asn and the Tyr with Trp (Figs. 5.12B, D 5.14)27. The Tyr1856 - 
Asp1898 hydrogen bond is especially interesting in light of the unusual GphF DH1 chemistry to 
affect an epimerization during sequential dehydration and isomerization reactions.  
Assessment of Dual-Enzyme Functionality 
We first tested the role of the His-Asp dyad in the dual DH activities. When the catalytic 
His1735 was substituted with Gln, no products were detected with 2, 6, 9, or 10 & 11, and 
substitution of the catalytic Asp1898 with Asn was similarly unreactive with 2 or 6. Thus, like 
FabA, both His1735 and Asp1898 are required for each of the dehydration and isomerization 
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reactions (Fig. 5.16)28. In contrast, the isomerase activity of the PksEI14 required only the 
catalytic His27.  
  
Figure 5.14 Sequence alignment of PKS DHs. 
Red stars denote catalytic His and Asp, yellow star denotes the differentially conserved Leu(Val)/Pro, blue star 
denotes the mostly conserved tyrosine. In most DHs predicted to catalyze olefin shifts, there is a conserved 
branched-chain amino acid found nine residues after the catalytic His. In standard DHs, this position contains a 
conserved Pro. 
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Table 5.8 Crystallographic summary for GphF DH1 L1744P 
Diffraction data 
GphF DH1 
P1711L, L1744P 
Space group P212121 
Unit cell a, b, c  (Å) 34.9, 53.3, 147.1 
Wavelength (Å) 1.033 
dmin (Å) 1.7 (1.76 – 1.70) 
Observations (#) 177,269 (8,583) 
Unique reflections 
(#) 
29,918 (2,268) 
Mean I/σI 11.61 (0.96) 
Rmerge 0.082 (0.879) 
CC1/2 0.988 (0.531) 
CC* 1.00 
Completeness (%) 0.95 (0.73) 
Wilson B (Å2) 25.7 
Refinement  
Reflections (#) 29,911 
Rwork 0.18 
Rfree 0.21 
RMSD bonds (Å) 0.013 
RMSD angles (°) 1.35 
Atoms (#)  
Protein 2,305 
Solvent 235 
Ligand n/a 
Avg B-factors (Å2)  
Protein 34.6 
Solvent 40.3 
Ligand  
Ramachandran  
Favored (%) 96.8 
Allowed (%) 3.2 
Outliers (%) 0.4 
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Table 5.9 X-ray data statistics for GphF DH1 P1711L, L1744P 
Resolution N(obs) N(uniq) Mult. Compl. <I/sigma> R-merge R-meas R-pim CC1/2 
43.20 – 3.65 20,073 3,365 6.0 0.99 26.4 0.053 0.058 0.023 0.997 
3.65 – 2.90 19,462 3,174 3.1 1.00 21.2 0.066 0.072 0.029 0.996 
2.90 – 2.53 20,154 3,160 6.4 1.00 14.9 0.095 0.104 0.041 0.994 
2.53 – 2.30 20,672 3,144 6.6 1.00 11.2 0.129 0.140 0.054 0.990 
2.30 – 2.14 20,246 3,093 6.5 1.00 8.2 0.175 0.191 0.074 0.986 
2.14 – 2.01 20,259 3,147 6.4 1.00 6.2 0.231 0.252 0.099 0.969 
2.01 – 1.91 20,410 3,065 6.7 1.00 3.9 0.353 0.384 0.148 0.934 
1.91 – 1.83 16,576 3,025 5.5 0.98 2.2 0.508 0.516 0.234 0.860 
1.83 – 1.76 11,595 2,668 4.3 0.86 1.4 0.669 0.758 0.347 0.745 
1.76 – 1.70 7,977 2,145 3.7 0.69 0.9 0.899 1.039 0.508 0.498 
All 177,424 29,986 5.9 0.95 10.0 0.083 0.091 0.036 0.998 
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Figure 5.15 Ramachandran plots for 
GphF DH1 P1711L, L1744P. 
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Figure 5.16 Mutagenesis of GphF DH1 catalytic residues. 
Substrate and product EICs shown 2, 6, 9, and 10 & 11. For both the H1735Q variant and 
the D1898N variant, neither dehydration nor isomerization are observed. This result 
contrasts with the Pks EI, which can isomerize a 2-enoyl intermediate using only a 
catalytic His.  
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Table 5.10 Activity of GphF DH1/L1744P 
We next investigated the role of the 
branched-chain amino acid near His1735. GphF 
DH1/L1744P had substantially increased 
dehydration activity relative to wild type DH1 
(Table 5.9), but it lacked detectable isomerase 
activity with any of the 2-methyl substrates (2, 3, 
6, rac-7, 12 ;Fig. 5.16; Table 5.10). In contrast, 
isomerase activity was retained with the 
substrates lacking a 2-methyl substituent (9, 10, 
11, 13). Thus, the effect of the branched side 
chain in the DH1 active site is specific to 2-
methyl substrates. Additionally, DH1/L1744P had greater rehydration activity with 6 (13% vs. 
1%) and with the 10/11 mixture (35% vs. 6%) than did the wild type. The increase in 
dehydration and rehydration with DH1/L1744P indicates that the branched side chain at position 
1744 enables isomerization at the cost of reduced dehydration and rehydration activities. 
 
  Distribution of substrate & products (%) 
3-hydroxy substrate 3-hydroxy 2-enoyl 3-enoyl 
2 51.4 ± 0.4 48.8 ± 0.4 < 0.01 
3 50.3 ± 0.6 49.6 ± 0.5 < 0.01 
4 95.4 ± 0.1 0.5 ± 0.1 < 0.01 
5 99.9 ± 0.1 < 0.01 < 0.01 
9 58.9 ± 0.1 39.1 ± 0.5 2.0 ± 0.1 
Unsaturated substrate 3-hydroxy 2-enoyl 3-enoyl 
6 12.9 ± 0.2 87.1 ± 0.2 < 0.01 
rac-7  < 0.01 < 0.01 99.9 ± 0.1 
8 < 0.01 < 0.01 99.9 ± 0.1 
10 & 11 (2:1) 35.1 ± 0.2 35.8 ± 0.8 29.1 ± 0.5 
12 4.3 ± 0.1 95.6 ± 0.1 < 0.01 
13 39.7 ± 0.6 40.7 ± 0.5 19.6 ± 0.2 
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Figure 5.17 Assay of GphF DH1/L1744P 
using 2, 6, and a 2:1 mix of 10 & 11. 
Substrate and product EICs are shown. DH1/L1744P 
dehydrated 2 and rehydrated 6 and 10 but did not form 
7 or perturb the ratio of 10:11. This demonstrates that 
for GphF DH1, Leu1744 is essential for isomerization 
activity, but plays no role in dehydration. 
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Table 5.11 Activity of GphF DH1/Y1856F 
 To investigate the role of Tyr1856, we generated 
a Phe substitution. Tyr is conserved at this 
position in most, but not all, PKS DHs but, 
uniquely in GphF DH1, the side chain hydroxy is 
hydrogen bonded to the catalytic Asp1898 
carboxylate (Figs. 5.12C, E 5.14, Table 5.11)4, 11-
12, 27. GphFDH1/Y1856F catalyzed dehydration 
at a comparable rate to the wild type, but lacked 
any detectable isomerase activity with the 2-
methyl substrates (2, 3, 6, rac-7, 12; Fig. 5.17; 
Table 5.11).  However, with substrates lacking a 
2-methyl substituent (9, 10, 11, 13), GphF DH1/Y1856F retained isomerase activity.  Thus, 
while Asp1898 is critical to both dehydratase and isomerase activity, Tyr1856 plays an essential 
role in isomerization of 2-methyl substrates.  
  
 
 Distribution of substrate & products (%) 
3-hydroxy substrate 3-hydroxy 2-enoyl 3-enoyl 
2 83.2 ± 0.6 16.1 ± 0.7 < 0.01 
3 80.5 ± 0.4 19.5 ± 0.4 < 0.01 
4 99.4 ± 0.1 0.6 ± 0.1 < 0.01 
5 99.9 ± 0.1 < 0.01 < 0.01 
9 61.4 ± 0.6 31.9 ± 0.5 6.6 ± 0.3 
Unsaturated substrate 3-hydroxy 2-enoyl 3-enoyl 
6 2.3 ± 0.3 97.7 ± 0.3 < 0.01 
7 (racemic) < 0.01 < 0.01 99.9 ± 0.1 
8 < 0.01 < 0.01 99.9 ± 0.1 
10 & 11 (2:1) 31.1 ± 0.3 38.5 ± 0.4 30.4 ± 0.2 
12 0.6 ± 0.1 99.3 ± 0.1 < 0.01 
13 33.8 ± 0.1 39.9 ± 0.2 26.3 ± 0.2 
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Figure 5.18 Assay of GphF DH1/Y1856F using 1, 3, 6, rac-7, 9, and a 2:1 
mix of 10 & 11. 
Substrate and product EICs are shown. DH1/Y1856F dehydrated 2 and 3, as well as hydrated 6 and 10. 
However, DH1/Y1856F was unable to form 7 or perturb the ratio of 10:11, demonstrating that 
Tyr1856 is essential for isomerase activity, but not for dehydration. 
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Engineering a curacin DH/isomerase 
Table 5.12 CurK DH activity 
To investigate the hypothesis that 
the His-proximal branched-chain amino 
acid is essential for isomerization activity, 
we created an analogous P1005V variant of 
the non-isomerizing CurK DH. The natural 
CurK DH substrate has a 4-methyl 
substituent but lacks a 2-methyl, so 9 was 
used as a surrogate substrate.  The wild-type CurK DH readily dehydrated 9, producing only the 
2-enoyl species 10. CurK DH/P1005V also dehydrated 9, but produced both the 2-enoyl species 
10, and the 3-enoyl 11 (Fig. 5.18, Table 5.12).  
  
 
 
 Distribution of substrate & products (%) 
 3-hydroxy 2-enoyl 3-enoyl 
Wild type    
3-hydroxy 9 49.1 ± 0.2 50.9 ± 0.2 < 0.01 
2-enoyl 10 & 3-enoyl 11 (2:1) 34.8 ± 0.3 34.9 ± 0.1 30.3 ± 0.3 
P1005V    
3-hydroxy 9 60.2 ± 0.3 38.4 ± 0.2 1.4 ± 0.2 
2-enoyl 10 & 3-enoyl 11 (2:1) 34.9 ± 0.3 36.9 ± 0.5 28.2 ± 0.7 
Left: 9 is a mimic of the acyl chain of the CurK DH substrate (top). Right: Assay of curK DH with 9. Dashed lines 
show EICs for wild-type (WT) CurK DH, solid lines show EICs for CurK DH/P1005V variant. Both WT and P1005V 
dehydrated 3, as shown by the production of 2-enoyl 10. A second peak corresponding to 3-enoyl 11 is observed in the 
product EIC for DH/P1005V, establishing that a single amino acid substitution is sufficient to impart isomerase 
activity.  
Figure 5.19 Engineering a dual-function PKS DH. 
 242 
Discussion: 
Multifunctional PKS dehydratases: 
Here, we describe the formation of an odd-to-even double bond by the GphF DH1 
through dual dehydratase and isomerase activities. The (S)-2,4-dimethyl-3-pentenoyl thioester 
product is consistent with the structure of gephyronic acid 1, the natural product of the Gph PKS 
pathway30. GphF DH1 had dehydratase activity only with compounds capable of syn elimination 
(2, 3 and 9), in agreement with previously characterized DHs. DH1 exhibited relaxed substrate 
selectivity for both the dehydration and isomerization reactions. It dehydrated both 2-methyl-3-
hydroxy enantiomers 2 and 3 as well as the non-methylated 9 to produce an (E)-2-enoyl product. 
DH1 was an isomerase for substrates with and without a 2-methyl substituent and even acted on 
(Z)-2-enoyl substrates. The FabA of bacterial fatty acid synthesis also catalyzes sequential 
dehydration and isomerization reactions, but it is specific for a 3-hydroxydecanoyl substrate and 
forms a (Z)-3-decenoyl product7.  
The crystal structure of GphF DH1, the first for an isomerizing PKS DH, offers clues to 
the basis for the dual catalytic activities. The active site His is assumed to be the sole catalytic 
base in all DH family members (FabA dual dehydratase/isomerase, PksEI14 and non-isomerizing 
DHs). As in other DHs, His1735 and Asp1898 together catalyze syn dehydration and therefore 
must be on the same face of the natural (2R,3R)-2-methyl-3-hydroxy substrate 2. The His-Asp 
catalytic dyad and Tyr1856 are all required for isomerization of the (E)-2-methyl-2-enoyl 
dehydration product 6. Thus, we propose that Asp1898 activates Tyr1856 to remove a C4 proton, 
creating a dienolate intermediate, and that His1735 re-protonates C2 to form the (S)-2-methyl-3-
enoyl product (enantiomer of 8) (Scheme 5.1). Tyr1856 is conserved in most PKS DHs (Fig. 
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5.14). Among those of known structure, only GphF DH1 Tyr1856 forms a hydrogen bond with 
catalytic Asp1898 and only GphF DH1 catalyzes isomerization4, 11-14. 
Despite the relaxed substrate selectivity of both the dehydratase and isomerase reactions, 
the mutagenesis data revealed a striking divergence of isomerase mechanism between substrates  
with a 2-methyl substituent (2, 3, 6, and rac-7) and those without (9, 10/11).  Whereas both the 
branched side chain of Leu1744 and the hydroxy group of Tyr1856 were essential to isomerase 
activity with any 2-methyl substrate, neither with the branched side chain nore the Tyr hydroxy 
was essential to isomerization of substrates lacking a 2-methyl. The Leu1744 side chain 
protrudes into the active site further than does a Pro side chain (Figs. 5.12B, C), and thus 
imposes greater conformational and positional constraints on binding of (E)-2-methyl-2enoyl 6 
than on the binding of (E)-2-enoyl 10. With the 2-methyl substrate, these constraints are 
evidently needed to position , the C4 appropriately for abstraction of a proton during the 
isomerization reaction. In contrast, the isomerase activity of GphF DH1/Y1856F with non-
methylated 10 may be due to C4 deprotonation by Asp1898, directly or through a water 
molecule. 
The importance of the branched side chain to substrate positioning for isomerization is 
clear from the data on CurK DH, a typical non-isomerizing DH with His, Asp, Pro and Tyr side 
chains in the active site and a substrate without a 2-methyl substituent. CurK DH dehydrated 9 
but had no detectable isomerase activity (Fig 5.18, Table 5.12). However, when the active-site 
Scheme 5.1 Proposed mechanism for GphF DH1 activity on substrates containing a 2-
methyl group. 
After dehydration, Asp1898 activates Tyr1856, which abstracts a proton from C4, generating a dienolate intermediate. 
His1735 then reprotonates C2, setting the methyl in the (S) configuration. 
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Pro1005 was replaced with the branched amino acid Val, the CurK DH acquired isomerase 
activity with 9 (Fig. 5.18, Table 5.12). 
Epimerization at C2 
We made the unexpected discovery that GphF DH1 acts as a 2-methyl epimerase through 
sequential dehydration and isomerization reactions. The preferred (and anticipated natural) 
substrate was (2R,3R)-2-methyl-3-hydroxy 2, although both 1 and the odd-to-even olefin product 
14 have an (S)-methyl at this position. Epimerization requires removal of the (2S)-proton in the 
dehydration step and addition of a (2R)-proton in the isomerization step, implying substantial re-
positioning of the substrate in the active site. While GphF DH1 epimerizes the C2 position of its 
substrate, FabA catalysis involves only the pro-2S proton50. Despite the similar overall 
structures, many details of the GphF DH1 and FabA active sites differ, which may explain the 
differences in the sterochemical course of reaction catalyzed by the two DHs. Notably, the 
analog of Tyr1856 is Pro in FabA, as is the analog of Leu1744. 
We note that several non-isomerizing PKS DH homologs function as C2 epimerases for 
2-methyl-3-keto substrates, which are not dehydration substrates53. These enzymes and GphF 
DH1 have the common problem of deprotonating and reprotonating opposite faces of the 
substrate C2 position. In all cases where epimerase activity has been reported, the DHs also have 
a Tyr analog of Tyr1856 in GphF DH1. While these DH homologs do not catalyze isomerization, 
they may use both His and Tyr for epimerization. In contrast, for the PksEI14, where the 
Asp1898 analog is Asn and the Tyr1856 analog is Trp, the acidity of the C4 proton is enhanced 
by a double bond to C5. No base was identified for deprotonation of the substrate C4 and it was 
concluded that the catalytic His is responsible for all proton transfers27.   
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Of the cis-AT DHs predicted to produce odd-to-even unsaturated final products, DH4 
from the ambruticin pathway catalyzes sequential dehydration, epimerization and isomerization 
reactions on a (3S,4S)-3-hydroxy-4-methyl substrate in which epimerization of the 4-methyl 
occurs after dehydration to a 4-methyl-2-enoyl intermediate and before double bond shift to the 
4-methyl-3-enoyl product (Scheme 5.2).8 The Amb DH4 is most similar to non-isomerizing DHs 
with His, Asp, Pro and Tyr amino acids in the active site (Fig. 5.14). It is tempting to speculate 
that the His and Tyr may be involved in the epimerization step. 
  
Scheme 5.2 Comparison of multifunctional DH reaction schemes. 
Each DH catalyzes an initial dehydration at the β position, but diverge in their secondary function. GphF 
isomerizes the 2-enoyl intermediate and resets the newly formed stereocenter to the (2S) configuration. 
FabA forms a (Z)-3-decenoyl final product and is highly specific for C10 substrates. Amb DH4 catalyzes an 
epimerization at C4 prior to isomerization, forming a 3-enoyl product that is subsequently methylated by a 
standalone MT. 
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Isomerase activity and pathway throughput 
In both GphF DH1 and FabA, the isomerization reaction is thermodynamically unfavorable as it 
shifts a double bond out of resonance with the thioester carbonyl. In biochemical assays, both 
enzymes produce low levels of the 3-enoyl elimination product7 (Table 5.4). While the level of 
the (Z)-3-decenoyl final product from FabA (3%) appears too low to support the critical 
biological requirement for unsaturated fatty acid biosynthesis, E. coli drives the equilibrium in 
the forward direction by co-expression of fabA with fabB, a gene encoding a specialized KS for 
elongation of a (Z)-3-decenoyl product54. We anticipate that the KS of GphF module 2 drives 
gephyronic acid biosynthesis in a similar manner. In contrast to GphF DH1 and FabA, the 
PksEI14 isomerization is more thermodynamically favorable, as the double bond shift forms a 
conjugated triene with double bonds at C5 and C7. 
Rational engineering in PKS DHs 
We conclude that GphF DH1 had a non-isomerizing DH ancestor that may have acted on a 2-
methyl substrate. Introduction of a branched side chain in the active site led to selective 2-methyl 
epimerization relative to the (2R,3R)-2-methyl-3-hydroxy product of the module KR.  
The presence of a branched-chain amino acid in the PKS DH active site is correlated with 
a capability for double-bond migration27, although the Amb DH4 is an exception8.  We show that 
substitution of a branched chain-amino acid at this position in a non-isomerizing DH from the 
curacin A PKS resulted in a 3-enoyl product. These experiments may represent a stepping-stone 
for PKS engineering. Attempts to engineer isomerization activity in bacterial FAS DHs required 
swapping large domains between FabZ and FabN (a FabZ homolog capable of isomerization)55. 
In contrast, the PKS DHs evolved a secondary isomerase function in a simpler manner, but at 
some expense to dehydration efficiency. If secondary isomerase activity is to be developed for 
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chemoenzymatic synthesis, then a scheme such as a capture enzyme may be needed to drive an 
unfavorable raction forward. 
In summary, GphF DH1 is a novel addition to the versatility of the DH and DH-like 
domains in PKS systems, expanding the repertoire of reactions catalyzed by these fascinating 
enzymes. The biochemical characterization and crystal structure together shed light on the 
molecular requirements for secondary function in PKS DHs. Both the substrate structure and the 
arrangement of Leu1744 and Tyr1856 adjacent to the His1735/Asp1898 catalytic dyad control 
isomerization subsequent to dehydration. The results of these experiments facilitated rational 
engineering of an isomerizing variant of the CurK DH, representing a step towards a more 
nuanced approach to PKS engineering. As the overall fold and general catalytic machinery of 
PKS DHs are highly conserved, we anticipate that additional secondary functions will be driven, 
in an analogous manner to GphF DH1, via subtle alterations to the active site that are specific to 
the natural DH substrate, as for the dehydratase-cyclase Amb DH314.  
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Chapter 6. AcpP-FabZ crystal structure elucidates differences in activity and substrate 
selectivity of E. coli dehydratases, FabA and FabZ 
 
Summary 
Fatty acid biosynthesis in α- and γ-proteobacteria requires two functionally distinct dehydratases 
(DHs), FabA and FabZ.  Here, mechanistic crosslinking facilitates the first structural 
characterization of a stable hexameric complex of E. coli FabZ with six AcpP acyl carrier 
proteins (ACP). The crystal structure sheds light on the divergent substrate selectivity of FabA 
and FabZ by revealing front and back “gating” residues along with distinct conformations of the 
binding pocket. Molecular dynamics simulations demonstrate differential biasing of substrate 
orientations within the active sites of FabA and FabZ such that FabZ is pre-organized to catalyze 
only dehydration, while FabA is primed for both dehydration and isomerization. 
 
Introduction 
In order to maintain membrane phospholipid homeostasis and modulate membrane 
fluidity, all organisms must regulate the synthesis of unsaturated fatty acids (UFAs).1-2 α- and γ-
proteobacteria, including Escherichia coli, Yersinia pestis, and Pseudomonas aeruginosa produce 
UFAs during de novo biosynthesis through the coordinated action of two dehydratases (DHs), 
FabA and FabZ.6-7 This system of UFA biosynthesis is unique to bacteria, and is of interest as an 
antibiotic target. FabA and FabZ are part of the type II fatty acid synthase (FAS), in which discrete 
enzymes synthesize fatty acids in a stepwise manner. Through this process the growing fatty acid 
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remains tethered to an acyl carrier protein (ACP), AcpP, for stability and transport (Figure 6.1A). 
Therefore, protein-protein interactions between AcpP and partner enzymes is essential to fatty acid 
synthesis. Both FabZ and FabA catalyze the dehydration of β-hydroxyacyl-AcpP, but they have 
varying substrate selectivity (C8-C12 substrates for FabA, and C6 and C12+ substrates for FabZ) 
(Figure 6.1B).7 FabA has an additional allylic-rearrangement activity that converts trans-dec-2-
enoyl-AcpP, the immediate product of dehydration, into cis-dec-3-enoyl-AcpP, the precursor to E. 
coli UFAs. FabZ is incapable of isomerization. While the activities of FabA and FabZ have been 
the subject of intense mechanistic study for decades,7-12 the structure-function relationships of 
these enzymes have not been established definitively. E. coli FabA and FabZ share 23% amino 
acid identity (41% similarity), but a crystal structure is available for only FabA.13 Crystal 
structures have been reported for both FabA and FabZ from Pseudomonas aeruginosa,14-15  but 
the similar active site pockets do not reveal the molecular basis for the selective activity of FabA 
as an isomerase, and the structures lack an associated acyl-AcpP. Recently, the crystal structure of 
a complex of phosphopantetheinyl-AcpP (holo-AcpP) and FabZ from Helicobacter pylori was 
described, but the ACP lacked an acyl group, limiting conclusions regarding the distinct activities 
and substrate preferences of FabA and FabZ.16 
The reason many structures are without an associated acyl-AcpP is that AcpP-partner 
protein interactions are fleeting. We previously circumvented the challenge of transient ACP-DH 
interactions by employing mechanism-based crosslinking probes to trap FabA in functional 
association with acyl-AcpP and solve the crystal structure (AcpP=FabA).5 Here, we apply this 
crosslinking strategy in combination with new fusion-protein methods to trap E. coli AcpP and 
FabZ (AcpP=FabZ), and report the crystal structure of the complex. The AcpP=FabZ and  
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A. Fatty acids are biosynthesized in an iterative fashion, with the growing substrate always tethered to the acyl carrier protein 
(ACP). In E. coli, the substrate is extended by two carbons by ketosynthase (KS) FabB or FabF, reduced by ketoreductase (KR) 
FabG, dehydrated by dehydratase (DH) FabA or FabZ, and reduced by enoyl reductase (ER) FabI. When at the optimal length, 
the substrate is transferred by acyl transferase (AT) PlsB and PlsC. B. FabA and FabZ have distinct substrate preferences. FabZ 
has much higher activity on C4 and C6 substrates than FabA, whereas FabA has a preference for intermediate chain lengths C8-
C12. Only FabA can perform the isomerization step to initiate the unsaturated fatty acid branch of the pathway. FabA and FabZ 
both have poor activity on C14 and C16 substrates, making it unclear which acts on those substrates. FabZ almost exclusively 
acts on C14:1. It was proposed that after the initial isomerization step by FabA, only FabZ can act on the unsaturated substrates 
C12:1-C16:1, but this has not been demonstrated experimentally for C12:1 or C16:1. 
Figure 6.1 Fatty acid biosynthesis and FabA/FabZ substrate preference. 
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AcpP=FabA structures enabled us to perform molecular dynamics (MD) simulations of the of 
acyl-AcpP•FabA and acyl-AcpP•FabZ complexes to evaluate the mechanisms of dehydration 
catalyzed  
by FabA and FabZ. Simulation results provide for the first time a structural rationale for the 
unique isomerase activity of FabA, accounting for the de novo synthesis of UFAs in E. coli. The 
simulations also recapitulated the established substrate preferences of FabA and FabZ. Together 
these findings reveal the molecular basis for the differential activity of FabA and FabZ, a critical 
component of bacterial phospholipid metabolism. 
Methods 
A. Chemical and biological protocols 
A.1. Cloning and protein expression 
FabZ: Previous reports indicated E. coli FabZ was soluble when expressed recombinantly with a 
C-terminal His tag17. For this work, an optimized construct encoding an N-terminal Mocr fusion 
protein18 and residues 2-150 of E. coli FabZ was cloned into a pMocr-based expression vector to 
create pGJD026 (Table 6.1). The insert was confirmed via sequencing. E. coli strain BL21 
pRARE AI was transformed with pGJD026. A 0.5 L culture in 4% glycerol Terrific Broth media 
(BD) with 100 mg/L ampicillin and 50 mg/L spectinomycin was grown at 37°C to an OD600 of 
1.5, cooled to 20°C, induced by the addition of isopropyl β-D-1-thiogalactopyranoside (IPTG) to 
0.2 mM and 1 g solid (L)-arabinose, and incubated 18 hr. Cells were harvested via 
centrifugation. Cell pellets were transferred to 50 mL falcon tubes, immediately frozen and 
stored at -20°C. 
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AcpP: E.coli AcpP was cloned into a pMCSG7-based expression vector to create pGJD042. The 
insert was confirmed via sequencing. E. coli strain BL21 pRARE AI was transformed with 
pGJD042. A 0.5 L culture in 4% glycerol Terrific Broth media (BD) with 100 mg/L ampicillin 
and 50 mg/L spectinomycin was grown at 37°C to an OD600 of 1.5, cooled to 20°C, induced by 
the addition of isopropyl β-D-1-thiogalactopyranoside (IPTG) to 0.2 mM and 1 g solid (L)-
arabinose, and incubated 18 hr. Cells were harvested via centrifugation. Cell pellets were 
transferred to 50 mL falcon tubes, immediately frozen and stored at -20°C. 
 Table 6.1 Primers for Cloning 
 
Primer Primer Sequence 5' to 3' 
fabz fwd 
LIC TACTTCCAATCCAATGCNACCACCAATACCCATACCTTACAGATTG 
fabz rev 
LIC TTATCCACTTCCAATGTTATTATCCACTTCCAATGTTA 
 
A.2. Protein purification 
FabZ: All steps were performed at 4°C. Cell pellets were resuspended in buffer A (50 mM Tris 
pH 7.5, 300 mM NaCl, 15 mM imidazole, 10% glycerol) with 2 mM MgCl2, 0.5 mg/mL DNase 
I, and 0.06 mg/mL lysozyme (4 mL per g cell pellet), incubated on ice for 1 hr, then sonicated. 
The lysate was cleared by centrifugation. The supernatant was passed through a 0.2 μm filter and 
loaded onto a 5 mL HisTrap column (GE Healthcare). The column was washed with 10 volumes 
buffer A, and protein was eluted with a linear gradient from 15 mM to 400 mM imidazole in 
buffer A. Peak fractions were pooled, concentrated, and loaded on a Superdex 16/60 S200 gel 
filtration column pre-equilibrated with buffer B (25 mM Tris pH 7.5, 150 mM NaCl, 10% 
glycerol). FabZ eluted as a hexamer, with an apparent molecular weight of 200 kDa (calculated 
MW 201 kDa). Peak fractions from were pooled and loaded onto a HiTrap Q column. The 
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column washed with 10 volumes buffer B, and protein was eluted with a linear gradient from 
150 mM to 1 M NaCl in buffer B. Peak fractions were pooled, concentrated, and loaded on a 
Superdex 16/60 S200 gel filtration column pre-equilibrated with buffer B. Peak fractions were 
pooled, concentrated to 15 mg/mL, flash cooled in liquid N2, and stored at -80°C. 
 
AcpP: All steps were performed at 4°C. Cell pellets were resuspended in buffer A (50 mM Tris 
pH 7.5, 300 mM NaCl, 15 mM imidazole, 10% glycerol) with 2 mM MgCl2, 0.5 mg/mL DNase 
I, and 0.06 mg/mL lysozyme (4 mL per g cell pellet), incubated on ice for 1 hr, then sonicated. 
The lysate was cleared by centrifugation. The supernatant was passed through a 0.2 μm filter, 
and loaded onto a 5 mL HisTrap column (GE Healthcare). The column was washed with 10 
volumes buffer A, and protein was eluted with a linear gradient from 15 mM to 400 mM 
imidazole in buffer A. Peak fractions were pooled, concentrated, and loaded on a Superdex 16/60 
S75 gel filtration column pre-equilibrated with buffer B (25 mM Tris pH 7.5, 150 mM NaCl, 
10% glycerol). Peak fractions were pooled, concentrated, and loaded on a Superdex 16/60 S200 
gel filtration column pre-equilibrated with buffer B. Peak fractions were pooled, concentrated to 
15 mg/mL, flash cooled in liquid N2, and stored at -80°C. 
 
A.3. One-pot AcpP modification and FabZ crosslinking 
 Apo-AcpP was prepared from a mixture of apo- and holo-AcpP according to a previously 
published protocol19.
 The one-pot loading reactions were performed as previously reported20. 
Briefly, the 1-mL reaction mix contained 8 mM ATP, 0.5 μM CoaA, 0.7 μM CoaD, 0.6 μM 
CoaE, 1.5 μM Sfp, 0.4 mM apo-AcpP, 500 μM DH6 probe in Buffer D (100 mM phosphate pH 
7.6, 100 mM NaCl, 10% glycerol). The mixture was rotated 24 hr at 37 °C. The formation of 
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crypto-AcpP was monitored by urea-PAGE gel and LCMS (ESI) analyses. The crypto-AcpP was 
purified by size exclusion (GE Healthcare Superdex S75) and concentrated using a 3-kDa ultra 
centrifugation filter (Amicon) and stored at -80°C until needed.  
 Crosslinking of His6-tagged crypto-DH6-AcpP and Mocr-tagged FabZ was carried out in 
a 1.5:1 molar ratio. A 1-mL crosslinking reaction in buffer D contained 150 μM (subunit) Mocr-
tagged FabZ, 225 μM His6-tagged crypto-DH6-AcpP, and 0.5 mg/mL TEV protease, and was 
rotated 8 hr at 37 °C. The formation of Mocr-tagged crosslinked complex and protease cleavage 
of the Mocr fusion partner were monitored by SDS-PAGE. Reaction mixtures were loaded 
directly onto a Superdex S200 gel filtration column equilibrated with Buffer B. Peak fractions 
were pooled, combined and concentrated to 10 mg/mL.  
 
A.4. Mocr-FabZ TEV protease cleavage turbidity 
 50 μM Mocr-FabZ was incubated in buffer C with TEV protease to a final concentration 
of 3.75 mg/mL in the presence of apo-AcpP at a final concentration of 0, 25, 50, 150, 300 or 500 
μM. Cleavage reaction mixtures were incubated at 25 °C for 1 hr and turbidity was determined 
by optical density (OD) at 600 nm. Concentrations of Mocr-FabZ refer to the monomer subunit. 
Experiments were performed in triplicate. 
 
A.5. Size exclusion chromatography with multi-angle light scattering  
 40 μM Mocr-FabZ was mixed with apo-AcpP to a final concentration of 200 (1:5), 400 
(1:10) or 800 (1:20) μM AcpP. 40 μM Mocr-FabZ was mixed with holo-AcpP to a final 
concentration of 200 (1:5) or 400 (1:10) μM AcpP.  20 μM Mocr-FabZ was mixed with holo-
AcpP to a final concentration of 200 (1:20) μM. All samples were incubated 1 hr at 25 °C. 50 μL 
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of each sample was loaded onto a KW-804 size exclusion column (Showdex) pre-equilibrated 
with buffer E (25 mM Tris pH 7.5, 100 mM NaCl) at a flow rate of 0.4 mL/min. The eluent was 
passed through both a DAWN HELEOS II multi-angle light scattering detector (Wyatt), and a T-
rEX differential refractive index detector (Wyatt) pre-configured with a β-amylase standard. 
Data were analyzed using ASTRA software package (Wyatt). Concentrations of Mocr-FabZ 
refer to the subunit. Experiments were performed in duplicate. 
 
A.6. Crystallography details 
 The AcpP-FabZ complex was crystallized at 20°C by hanging drop vapor diffusion in a 
1:1 mix of 9.5 mg/mL protein stock and reservoir solution (100 mM Bis-Tris pH 6.5, 200 mM 
MgCl2, 19% PEG 3350).  Crystals were harvested without additional cryoprotection and flash-
cooled in liquid N2.  
 Data were collected at the Advanced Photon Source (APS, Argonne National Laboratory) 
on GM/CA beamline 23-ID-D. Crystals diffracted to 2.5 Å and were in orthorhombic space 
group P212121 containing one AcpP=FabZ hexamer per asymmetric unit. Data were processed 
using XDS21. The AcpP-FabZ structure was solved by molecular replacement in phaser
22 using 
the P. aeruginosa FabZ as an initial search model (PDB: 1U1Z14). Six AcpPs were placed 
manually into electron density using the AcpP from the AcpP=FabA structure (PDB: 4KEH23) in 
coot24. The resulting atomic model was refined in PHENIX25. The refined model was validated 
with MolProbity26. Structure figures were generated in PyMOL27. Protein-protein interfaces were 
calculated using the PISA server28. 
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B. Molecular dynamic simulation protocols 
All simulations were carried out by Ashay Patel (UCSD) 
Initial coordinates were prepared using the structure of AcpP=FabZ structure reported 
herein and the crystal structure of crosslinked AcpP=FabA23. Note that while the AcpP•FabZ is 
hexameric, a DH dimer was simulated for reasons of computational tractability. The 
phosphopantetheinylated serine bearing the acyl substrates (or product) in each system was 
treated as a nonstandard residue. Partial atomic charges for the nonstandard residues were 
determined using the restrained electrostatic potential (RESP) methodology29. The potential was 
computed at the HF/6-31G(d) level of theory using Gaussian 0930. AMBER (ff14SB)
31 and 
GAFF32 type parameters were assigned to the atoms of these residues using ANTECHAMBER33. 
The protonation states of all systems were determined using the H++ webserver34-37, assuming an 
external dielectric constant of 80, salinity of 0.150 M, and at pH 7.4. The protonation states of all 
histidine residues were manually confirmed. All acyl-ACP•DH complexes were solvated with 
TIP3P38 water box large enough that no proteinogenic atom was within 12 Å of the box edge. 
Na+ and Cl– were added to the system to neutralize the anionic complex and to mimic the salt 
content of physiological systems (ca. 0.150 M). TLEAP was used to solvate and add counterions 
to these systems39. 
B1. Simulation details 
Gaussian accelerated molecular dynamics40-44 (GaMD) simulations were performed using 
Amber1439. The ff14SB
31 force field was employed in all simulation work. The SHAKE 
algorithm45 was used to constrain all nonpolar bond involving hydrogen atoms, and a 2 fs time-
step was used in the simulations. The Particle Mesh Ewald (PME) method46 was used to treat 
long-range electrostatic interaction using a 10.0 Å cutoff for nonbonded interactions. Before 
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simulations of the complexes were performed, all systems were subjected to a two-step 
minimization. In the first step, the solvent was allowed to relax, while the atoms in the solute 
were restraint using a harmonic potential (500 kcal mol–1 A–2). Subsequently, the entire system 
was minimized without constraints. After minimization, each system was slowly heated to 305 K 
over the course of a 3.5 ns canonical ensemble (NVT) MD simulation. These “heated” systems 
were subsequently equilibrated for 6 ns by performing unbiased isobaric-isothermal (NPT) 
simulations (at 305 K). In all simulations, temperature control was maintained using a Langevin 
thermostat ( = 1.0 ps–1)47.  For all NPT simulations, a Monte Carlo barostat was used. 
 Three independent 290 ns production-grade NPT GaMD simulations were performed of 
each acyl-AcpP•DH complex. The threshold energy was set to Vmax. A 16 ns unbiased NPT 
simulation was used collect data to determine the maximum (Vmax), minimum (Vmin), average 
(Vav), and the standard deviation (v) of the system potential. These data were not used in our 
analysis.  
B2. Data analysis and molecular visualization 
 Coordinate data were written to disk every 0.5 ps. Analysis was performed using 
PYTRAJ, a Python-based front-end for the CPPTRAJ48 software package, and MDTRAJ49. 
Gaussview 5,50 Avogadro,51 and PyMol v1.8.627 were used to prepare and visualize structures. 
PyMol was used to render the images shown herein27. Binding pockets were analyzed using 
POVME 3.3 
 
Results and discussion 
To compare catalytic selectivities and probe the structural basis of catalysis by natural 
FabA and FabZ partners, we sought to examine the E. coli FabZ in complex with AcpP. However, 
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unlike E. coli FabA, there are no reported structures of the E. coli FabZ, presumably due to the 
solubility challenges of FabZ. We produced highly pure, recombinant E. coli FabZ  as an N-
terminal fusion with the monomeric Mocr protein (Figure 6.2).18 The Mocr-FabZ fusion protein 
was purified to homogeneity in a stable and soluble form; the Mocr fusion did not interfere with 
the expected hexameric association of FabZ (Figure 6.2). After proteolytic cleavage of the Mocr 
fusion partner, FabZ remained soluble (as assessed by turbidity) only if the cleavage reaction 
included equimolar or greater concentrations of AcpP, implying that, like the H. pylori FabZ, the 
E. coli FabZ may have inherent affinity for its carrier protein (Table 6.2).52  
 
Table 6.2 Turbidity of Mocr-FabZ after TEV protease cleavage 
  Mocr-FabZ* + 25 μM 
apo-AcpP 
+ 50 μM 
apo-AcpP 
+ 150 μM 
apo-AcpP 
+ 300 μM 
apo-AcpP 
+ 500 μM 
apo-AcpP 
OD600 0.07 ± 0.02 0.04 ± 0.01 0.03 ± 0.01 0.01 ± 0.01 0.01 ± 0.01 0.01 ± 0.01 
 
We then used size exclusion chromatography (SEC) with multi-angle light scattering 
(MALS) to characterize the stoichiometry of complexes of Mocr-FabZ and holo-AcpP (with the 
A 
A: SDS PAGE, Lane 1: Total lysate from production of recombinant Mocr-FabZ; Lane 2: Soluble fraction; Lane 3: Pellet 
fraction; Lane 4: Histrap elution; Lane 5: Superdex S200 #1; Lane 6: IonX; Lane 7: Superdex S200 #2; Lane 8: 
Resolubilized precipitated protein following TEV protease treatment. B: Superdex S200 gel filtration profile. Mocr-FabZ 
elutes as a hexamer with an apparent molecular weight of 201 kDa. 
 
Figure 6.2 FabZ purification and solubilization. 
B 
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phosphopantetheine cofactor linked at Ser36) or apo-AcpP (lacking phosphopantetheine). All 
combinations of FabZ and AcpP resulted in complex formation with oligomeric states ranging 
from (AcpP1-FabZ6) to (AcpP6-FabZ6) (Figures 6.3A, 6.3B). The oligomer state was dependent on 
AcpP concentration, with a 20-fold molar excess of either apo- or holo-AcpP fully saturating  
Mocr-FabZ. The complexes had similar elution volumes to Mocr-FabZ in absence of AcpP, 
indicating a dynamic mixture of transient oligomeric states. This observation is consistent with a 
type II FAS system in which the AcpP must find and interact with each enzyme; should a tight, 
long lasting complex form with any one enzyme, FAS throughput would drop significantly. 
We then sought to generate a soluble AcpP=FabZ complex suitable for crystallography by 
crosslinking AcpP prior to proteolytic cleavage of the Mocr fusion partner. As previously reported, 
3-alkynyl-sulfone-pantethtine probes can be used to link AcpP and DHs.4-5 Here, we chose a six-
carbon probe (DH6) to mimic the optimal FabZ substrate, and appended it to AcpP (crypto-DH6-
AcpP, Figure 6.4B).7 Crosslinking trials with Mocr-FabZ and crypto-DH6-AcpP proceeded nearly 
to completion (Figures 6.3D, 6.4). In agreement with the previously reported substrate preference 
of FabZ,7 less than 10% crosslinked complex formed with a probe mimicking the least-favored 
substrate, crypto-DH10-AcpP (AcpP loaded with a 10-carbon probe, Figure 6.4A).  SEC-MALS 
analysis of DH6-AcpP=Mocr-FabZ indicated a stable complex with shorter retention time than the 
non-covalent complexes with apo-AcpP or holo-AcpP and a molecular weight corresponding to 
(AcpP6=Mocr-FabZ6) (Figures 6.2A, 6.2B). AcpP=FabZ was stable upon proteolytic cleavage of 
the Mocr fusion partner and had an apparent molecular weight of 160 kDa by SEC (Figure 6.5), 
again corresponding to an AcpP6=FabZ6 complex. 
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A. Schematic of FabZ and crypto-AcpP crosslinking reaction and TEV protease cleavage. FabZ is insoluble when 
released from the Mocr fusion partner, but solubility is rescued when FabZ is crosslinked to acidic AcpP.  
 
B. Denaturing gel (12% SDS) analysis of crosslinking reactions between AcpP and Mocr-FabZ. Lane 1: MW 
standards; Lane 2: apo-AcpP; Lane 3: Mocr-FabZ; Lane 4: apo-AcpP and Mocr-FabZ in crosslinking buffer; Lane 5: 
apo-AcpP and Mocr-FabZ in crosslinking buffer with TEV protease; Lane 6: crypto-DH6-AcpP and Mocr-FabZ 
crosslinking reaction; Lane 7: crypto-DH6-AcpP and Mocr-FabZ crosslinking reaction with TEV protease; 8: crypto-
DH10-AcpP and Mocr-FabZ crosslinking reaction; Lane 9: crypto-DH10-AcpP and 20 Mocr-FabZ crosslinking 
reaction with TEV protease.  
 
C, D. SEC-MALS traces of Mocr-FabZ and AcpP complexes. SEC elution profiles (differential refractive index) are 
shown in solid lines; MALS average molecular weight plots as dotted lines. C. SEC-MALS analysis of Mocr-FabZ in 
complex with apo-AcpP. Mocr-FabZ shown in purple, Mocr-FabZ=AcpP in black, 1:5 Mocr-FabZ:apo-AcpP in gold, 
1:10 Mocr-FabZ:apo-AcpP in red, 1:20 Mocr-FabZ:apo-AcpP in orange. D. SEC-MALS analysis of Mocr-FabZ in 
complex with holo-AcpP. Mocr-FabZ shown in purple, Mocr-FabZ=AcpP in black, 1:5 Mocr-FabZ:holo-AcpP in 
cyan, 1:10 Mocr-FabZ:holo-AcpP in teal, 1:20 Mocr-FabZ:holo-AcpP in dark green. In both C and D, an AcpP 
concentration-dependent increase in average MW is observed, fully saturating the available Mocr-FabZ at a 20-fold 
excess. Data generated by Kara Jaremko 
 
Figure 6.3 FabZ and AcpP crosslinking and biophysical analysis 
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Previously synthesized DH6 and DH10 probes 4 were loaded onto AcpP using “one-pot” methods, and the crypto-
AcpPs purified by size exclusion chromatography, and analyzed by HPLC-MS (ESI) in positive mode and the 
charge distribution deconvoluted. (A) Crypto-DH10-AcpP analysis, showing LC trace (left) and mass analysis of the 
t=7.33 min protein peak (right, m/z). (B) Crypto-DH6-AcpP analysis, showing LC trace (left) and mass analysis of 
the t=7.09 min protein peak (right, m/z). Data Generated by Kara Jaremko 
Figure 6.4 Crypto-DH6-AcpP and crypto-DH10-AcpP analysis. 
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Left: SDS PAGE, Lane 1: crypto-DH6-AcpP; Lane 2: Mocr-FabZ; Lanes 3-7: crosslinking reaction at several time 
points; Lane 8: Overnight crosslinking reaction with TEV protease; Lane 9: Overnight crosslinking reaction with TEV 
protease  after concentrating with a 100K Amicon filter (Millipore); Lanes 10-12: Peaks from S200 superdex gel 
filtration column. FabZ=AcpP remained soluble following gel filtration. Mocr and TEV were readily separated from 
AcpP=FabZ via size exclusion chromatography. Right: Superdex S200 gel filtration profile of crosslinking reaction 
mix. FabZ=AcpP can be readily separated from the other components. The FabZ=AcpP peak height exhibits low signal 
at 280 nm due to the low molar absorptivity of the both FabZ (calculated ε = 3,105) and AcpP (calculated ε = 1,490), 
compared to Mocr (calculated ε = 18,910) and TEV protease (calculated ε = 33,585). FabZ=AcpP elutes as a hexamer 
with an apparent molecular weight of 160 kDa. 
 
Figure 6.5 AcpP=FabZ purification and analysis. 
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We crystallized the AcpP6=FabZ6 complex and obtained a 2.5-Å crystal structure with six AcpPs 
crosslinked with the FabZ hexamer (Figures 6.6, 6.7, Tables 6.3, 6.4). The FabZ hexamer is a 
trimer of FabA-like dimers, consistent with structures of other bacterial FabZ enzymes14, 16, 53-55. 
In the hexamer, an AcpP is crosslinked to the catalytic His54 of each FabZ monomer and contacts 
both subunits of the FabZ “dimer” but makes no contacts with the other two “dimers” or with any 
other AcpP (Figure 6.8). 
 The surface of AcpP helix α2 contacts the surface of the FabZ β-sheet via an interface 
comprised of several hydrophobic contacts surrounded by ionic interactions (Figure 6.8As with 
FabA, acidic residues on AcpP contact basic residues on FabZ surrounding the active site 
entrance. Interestingly, the majority of protein-protein contacts occur between AcpP and the 
subunit of the FabZ “dimer” to which it is not crosslinked (AcpP subunit A to FabZ subunit B, 
and AcpP subunit B to FabZ subunit A). Nevertheless, the crosslinked subunit also contributes to 
the interface, which buries 16% (745 Å2) of the AcpP surface. The interface is significantly 
larger than the AcpP=FabA interface (~530 Å2)5, 56, in which AcpP has no contacts with the 
FabA monomer to which it is crosslinked (Figure 6.8). The six AcpP-FabZ interfaces are nearly 
identical, although two of the six AcpPs are shifted due to crystal contacts (Figure 6.9).  
The AcpP-interacting surface of E. coli FabZ is strictly analogous to the AcpP-interacting 
surface of H. pylori FabZ.16 However in contrast to our finding that the E. coli FabZ hexamer can 
interact productively with six AcpPs, a see-saw mechanism was proposed for the H. pylori FabZ 
in which only three AcpPs simultaneously engage the hexamer. The proposal was based on the 
crystal structure (FabZ6-AcpP3) where only one AcpP bound per dimer in the FabZ hexamer, 
together with analysis by SEC-MALS, small-angle X-ray scattering (SAXS) and micro-scale 
thermophoresis (MST)16. However, the H. pylori FabZ6-AcpP3 stoichiometry in the crystal  
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The central FabZ hexamer is composed of three dimers (dark and light shades of green, orange, and cyan). The six 
AcpPs are at the periphery (dark and light shades of red, pink, and dark blue), each crosslinked to a FabZ subunit. The 
FabZ catalytic His54 and DH6 crosslinker are rendered as sticks in atomic coloring (blue N, red O, yellow S, and C 
colored as the respective protein). 
Figure 6.6 Structure of AcpP=FabZ. 
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Table 6.3 Crystallographic summary 
Diffraction data FabZ=HisAcpP 
Space group P212121 
Unit cell a, b, c (Å) 65.1, 136.2, 152.2 
Wavelength (Å) 1.033 
dmin (Å) 2.5 (2.59 – 2.50)* 
Observations (#) 307,308 (29,936) 
Unique reflections (#) 47,665 (4,689) 
Mean I/σI 10.22 (1.12) 
Rmerge 0.150 (1.634) 
CC1/2 0.99 (0.479) 
CC* 0.99 (0.805) 
Completeness (%) 0.99 (0.99) 
Wilson B (Å2) 66.9 
Refinement  
Reflections (#) 47,645 
Rwork 0.208 
Rfree 0.253 
RMSD bonds (Å) 0.009 
RMSD angles (°) 1.27 
Atoms (#)   
Protein 10,369 
Solvent 58 
DH6 Probe 348 
Avg B-factors (Å2)   
Protein 84.2 
Solvent 64.3 
DH6 Probe 82.2 
Ramachandran   
Favored (%) 94.7 
Allowed (%) 5.1 
Outliers (%) 0.2 
# of TLS groups 82 
 
* Values in parentheses refer to the outermost shell of data. 
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Table 6.4 X-ray data statistics for AcpP=FabZ 
Resolution (Å) N(obs) N(uniq) Mult. Compl. (%) <I/sigma> R-merge R-meas R-pim CC1/2 
5.38 - 4.27 32,112 4,840 6.6 1.00 24.4 0.090 0.098 0.038 0.995 
4.27 - 3.73 31,186 4,807 6.5 1.00 17.7 0.145 0.158 0.062 0.991 
3.73 - 3.39 30,135 4,734 6.4 0.99 12.2 0.260 0.283 0.112 0.979 
3.39 - 3.15 29,779 4,736 6.3 1.00 7.3 0.363 0.396 0.158 0.698 
3.15 - 2.96 30,323 4,724 6.4 0.99 4.5 0.511 0.557 0.220 0.936 
2.96 - 2.82 31,768 4,715 6.7 1.00 3.1 0.732 0.795 0.307 0.885 
2.82 - 2.69 30,531 4,702 6.5 1.00 2.1 0.975 11.062 0.416 0.758 
2.69 - 2.59 31,703 4,698 6.7 1.00 1.6 1.334 1.448 0.557 0.592 
2.59 - 2.50 29,936 4,689 6.4 1.00 1.1 1.634 1.780 0.701 0.479 
All 307,308 47,665 6.4 1.00 10.2 0.150 0.164 0.065 0.997 
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Figure 6.7 Ramachandran plots for AcpP=FabZ. 
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The AcpP (cyan) is crosslinked to the dark green FabZ, but the protein-protein contacts with this subunit are limited to 
FabZ Arg100 and Lys102 (dark green sticks) and AcpP Asp35, Asp38, and Glu41 (cyan sticks). AcpP has far more 
contacts with the partner subunit (light green) of the FabZ dimer, where FabZ Lys119, Arg121, Arg122, Arg126, 
Leu124, Asp97 and Met144 (light green sticks) contact AcpP Leu37, Val40, Glu41, Val43, Met44 Glu47, Glu48, 
Asp56, Ala59 and Glu60). The reciprocal situation pertains to the AcpP crosslinked to the light green FabZ. 
 
 
Figure 6.8 The AcpP - FabZ interaction. 
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Shown in red, four of the six crosslinked AcpPs occupy similar positions. Shown in light and dark blue, the two 
remaining AcpPs are shifted about the DH6 crosslinker due to crystal packing. Non-crosslinked DH monomer shown in 
light green. DH6 crosslinker shown as red sticks. 
 
 
Figure 6.9 Position of crosslinked AcpP relative to the non-crosslinked DH monomer. 
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structure is more simply explained by crystal lattice contacts that block the three unoccupied 
AcpP sites. Previous surface plasmon resonance (SPR) characterization of the H. pylori FabZ – 
AcpP interaction indicated a single Kd of 120 nM,52 in contrast to the three weaker binding 
events deduced from MST data.16 In our SEC-MALS analysis of the E. coli FabZ-AcpP 
interaction, higher-order complexes existed with an excess of either apo- or holo-AcpP, and a 20-
fold excess AcpP fully saturated the Mocr-FabZ hexamer (Figure 6.3A, 6.3B). The crystal lattice 
of the H. pylori AcpP3-FabZ6 is incompatible with an equimolar complex, so it may be that a 
higher-order complex was missed in the study. Alternatively, the different oligomer states 
observed for the E. coli AcpP6-FabZ6 complex (this work) and the H. pylori ACP3-FabZ6 
complex16 may reflect a real difference in the two FabZ proteins, perhaps arising from distinct 
strategies for dehydration of β-hydroxyacyl-AcpPs during fatty acid biosynthesis. Indeed, the 
bacterial FAS DHs vary, for example the dual FabA – FabZ DH system exists in α- and γ- 
proteobacteria, whereas ε-proteobacteria such as H. pylori possess only FabZ and use a 
desaturase to synthesize unsaturated fatty acids.57-58  
  DHs possess a hydrophobic binding pocket that shields the fatty acyl substrate from 
solvent. In E. coli FabZ, the binding pocket abuts the central ‘hotdog’ helix (α3) and is bounded 
by amino acids in the α3-β3 loop (residues 85-90) and the α1-β1 loop.  Phe79 in the hotdog helix 
(α3), Leu85 in the α3-β3 loop and Leu17 form a hydrophobic surface at the innermost end of the 
pocket, where substrates with chain lengths of 12 carbons or greater can bind. The binding pocket 
broadens beyond the C6 position and could easily accommodate longer substrates with a cis double 
bond installed by FabA. In contrast, the FabA substrate-binding pocket is narrower and of length 
to accommodate C10 or shorter substrates.  These differences in pocket length and shape between 
FabA and FabZ are due to the structures and lengths of their α1-β1 and α3-β3 loops (Figures 6.10A, 
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6.10B, 6.11). The α1-β1 loop plays a much larger role in the substrate pocket of FabA, whereas 
the α3-β3 loop figures prominently in the FabZ pocket. 
The α3-β3 loop of FabZ connects the distal end of the pocket (Figure 6.10A, 6.10C) and 
conserved Tyr92 at the substrate entrance. Tyr92 was proposed as a FabZ “gating residue”  based 
on the reduced dehydration activity of an Ala substitution54 and on the “open” and “closed” 
conformations of the Tyr side chain in FabZ crystal structures (Figure 6.10C)14, 16, 53, 55, 59. In the  
closed conformation, the Tyr92 side chain blocks the entrance of the substrate binding pocket14, 53, 
55, 59. In the AcpP=FabZ complex, the Tyr92 gate is “open” in all six FabZ monomers, and the 
acylated phosphopantetheine extends into the binding pocket. 
 Interestingly, the α3-β3 loop is the least conserved region of FabZ and varies in length (7-
10 amino acids, Figure 6.11). In FabZ structures with shorter α3-β3 loops, the loop is often poorly 
ordered or disordered. However, the shorter α3-β3 loop in the E. coli FabZ is well ordered with 
identical conformations in all six subunits of the AcpP=FabZ complex, suggesting that FabZ 
interactions with AcpP or the acyl group may facilitate the ordering the α3-β3 loop and formation 
of the substrate pocket. How this may occur is not apparent from the structure. 
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A. FabZ (light and dark green) and AcpP (magenta) with an ordered α3-β3 loop (gray). The binding 
pocket (orange surface) is wide at the top with a narrow terminus and is long enough to for C14 
substrates. Important amino acids and the C6 crosslinkers shown as sticks.  
 
B. FabA (light and dark blue) and AcpP (magenta). The α1-β2 loop (gray) defines the end of the binding 
pocket (gray surface), which is optimal for C10 substrates. Important amino acids and the C10 
crosslinker are shown as sticks. 
 
C. Overlay of FabZ from E. coli (light/dark green) and P. aeruginosa (yellow/dark orange, PDB 1U1Z). 
In the AcpP=FabZ complex, the α3-β3 loop region (residues 85-90, gray) creates the distal end of the 
substrate pocket. The corresponding region of the P. aeruginosa FabZ is disordered in all subunits of the 
hexamer (dashed line). In absence of AcpP or a suitable ligand, the Tyr92 gate, which immediately 
follows the loop, blocks the entrance to the substrate pocket. The Tyr92 gate is open in the presence of 
acyl-ACP, which may order the loop and form the distal end of the substrate pocket. 
 
A B 
C 
Figure 6.10 Comparison of E. coli FabZ and FabA substrate binding pockets. 
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α-helical secondary structure denoted as red tubes, β-strands denoted by green arrows. 
Figure 6.11 Sequence alignment of FabZ and FabA from select biological sources. 
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We next used MD simulations to evaluate how the protein structure imparts the mechanistic 
differences and substrate selectivities of the two enzymes. As AcpP=FabZ and AcpP=FabA 
represent the most accurate approximations of natural binding events at the moment of catalysis, 
these structures are ideally suited for MD simulations with modeled alternate substrates. Gaussian 
accelerated molecular dynamics (GaMD)30 simulations of multiple [(R)--hydroxyhexanoyl-AcpP 
(C6), (R)--hydroxydecanoyl-acyl-AcpP (C10), α,β-trans-decenoyl-AcpP (trans-C10:1), β,γ-cis-
decenoyl-AcpP (cis-C10:1), (R)--hydroxytetradecanoyl-AcpP (C14), and (R)--
hydroxytetradec-7-cis-enoyl-AcpP (C14:1)] acyl-AcpP2•FabZ2 and acyl-AcpP2•FabA2 were 
performed and segregated into two mechanistic steps: β-hydroxy dehydration, as naturally 
catalyzed by both enzymes, and allylic rearrangement, as naturally catalyzed only by FabA. The 
β-hydroxy dehydration to form the trans-2-decenoate product can theoretically undergo 2 different 
mechanisms; a 2-step mechanism, where the conjugate base intermediate is stabilized by the 
carbonyl (E1cb), or a 1-step mechanism where no intermediates are formed (E2). Mechanistic 
studies of FabA support an E1cb-like mechanism (Scheme 6.1) ,8, 60 and a similar conclusion was 
reached on the basis of the crystal structure of P. aeruginosa FabA in complex with a substrate 
mimic.15 GaMD simulations of both β-hydroxydecanoyl-AcpP2•FabA2 and β-hydroxydecanoyl-
AcpP2•FabZ2 agree with the proposed E1cb dehydration. In both simulations, a clear bias for the 
60° Cα-Cβ dihedral was observed, which positions the substrate pro-R Hα and β-hydroxy group 
ideally for E1cb elimination (Figures 6.12A, 6.12B). The -60° Cα-Cβ dihedral, which would pose 
the substrate for E2 elimination was not observed in simulations of either FabA or FabZ.  
The production of cis-3-decenoyl-AcpP via allylic rearrangement has been unequivocally 
demonstrated to involve the intermediacy of trans-2-decenoyl-AcpP.8 NMR isotope studies 
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concluded that FabA abstracts the pro-R Hγ of trans-2-decenoyl-AcpP in order to produce cis-3-
decenoyl-AcpP.12 Consequently, we performed GaMD simulations of trans-2-decenoyl-
AcpP•FabA and trans-2-decenoyl-AcpP•FabZ and monitored the Cβ–C𝛾 dihedrals sampled in both 
enzymes. In the simulations, the substrate predominantly assumed one of four Cβ–C𝛾 rotameric 
states (Figure 6.13). In only one of the rotameric states sampled computationally, the (–) gauche 
conformer, is the pro-R H𝛾 suitably positioned within the active site to be abstracted by the active 
site catalytic His70 base to initiate the allylic rearrangement. While both FabA and FabZ sampled 
the same four conformers, FabA showed a distinct preference for the (–) gauche conformer 
compared to FabZ (Figure 6.13). Thus, FabA isomerization may be a consequence of 
preorganizing the allylic substrate for pro-R H𝛾 abstraction after dehydration. This analysis 
supports the critical influence of the shape and size of the FabA substrate pocket on the isomerase 
activity. 
To evaluate the origins of chain length preferences, we performed simulations of both β-
hydroxyhexanoyl-AcpP•FabA/Z and β-hydroxydecanoyl-AcpP•FabA/Z, the preferred substrates 
of FabZ (C6 and C14) and FabA (C10), respectively. Analysis of the simulation data demonstrated 
active site preorganization, as visualized by the distances between the catalytic His and substrate 
α carbon and between the catalytic Asp/Glu and the substrate β-hydroxy (Figures 6.14A, 6.14B). 
Throughout the simulation, FabZ maintained a hydrogen bond (d <  3.0 Å) between the carboxylate 
of Glu68 and the β-hydroxy substituent of β-hydroxyhexanoyl-AcpP, in agreement with the 
proposed Glu68 function as a general acid. In constrast, the FabA catalytic Asp84 formed a longer  
Scheme 6.1 Proposed mechanism of FabA-catalyzed 
dehydration of 3R-hydroxydecanoate NAC. 
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A: Newman projections along the Cɑ–Cβ bond of the (+) gauche (+60°), anti (180°), and (–) gauche (–60°) substrate 
rotamers of β-hydroxydecanoyl–AcpP. B: Left (orange): simulations of β-hydroxydecanol-AcpP•FabA. Right (blue): 
simulations of β-hydroxydecanol-AcpP•FabZ. Simulation data were written every 0.5 ps with a bin width of 5°. Data 
generated by Ashay Patel 
FabA FabZ 
A 
B 
Figure 6.12 Distribution of dihedral angles for the C(O)–Cɑ–Cβ–Cγ torsion sampled 
throughout the course of GaMD simulations of β-hydroxydecanoyl-AcpP. 
 281 
  
A.) Distribution of dihedral angles for the Cɑ–Cβ–Cγ–Cδ torsion of the trans-dec-2-enoyl substrate sampled throughout the course of 
GaMD simulations of trans-dec-2-enoyl-AcpP•FabA (left-hand panel, in orange) and trans-dec-2-enoyl-AcpP•FabZ (right-hand 
panel, in blue). Simulation data written every 0.5 ps were binned to prepare histograms using a bin width of 5°. B.) Representative 
structures of the four Cβ–Cγ rotamers sampled computationally. These structures were identified from the larger simulated ensemble 
of the trans-dec-2-enoyl-AcpP•FabA complex. Structures are oriented as Newman projections along the Cγ–Cβ bond of the trans-dec-
2-enoyl substrate (stick form with pale blue C, red O, blue N) within the active site of FabA (catalytic histidine and aspartate with 
white C). Large spheres indicate the portions of the substrate and catalytic residues omitted in the three-dimensional images. The 
smaller spheres found at Cγ show the pro-R (red) and pro-S (white) γ hydrogens;  the pro-R Hγ is abstracted in the isomerization 
reaction. A two-dimensional representation of each structure is shown on the left of each panel.   
 
B 
Figure 6.13 Analyis of MD simulations with trans-dec-2-enoyl-AcpP. 
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Distances of substrate atoms and catalytic amino acids during MD simulations. The 2D histograms were created by 
binning simulation data for the complexes of saturated β-hydroxyacyl-AcpP•DHs with C6 and C10 substrate chain 
lengths. The distance between the substrate β-hydroxy O atom and the carboxylate sidechain of Asp84 in FabA or Glu68 
in FabZ is represented on the horizontal axis, while the vertical axis depicts the distance between the substrate ɑ C atom 
and the imidazole moiety of the catalytic histidine. A) Data from simulations of β-hydroxyhexanoyl-Acp•FabA (left) 
and β-hydroxyhexanoyl-Acp•FabZ (right). B) Data from simulations of β-hydroxydecanoyl-AcpP•FabA (left) and β-
hydroxydecanoyl-AcpP•FabZ (right). Data generated by Ashay Patel. 
B 
A 
Figure 6.14 Distances between catalytic residues and key substrate positions during MD 
simulations. 
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hydrogen bond (3.0 Å < d <  3.5 Å) with the β-hydroxy substituent in the simulations of β-
hydroxyhexanoyl-AcpP•FabA.  While the Asp/Glu of FabA and FabZ could form a  hydrogen 
bond with the β-hydroxydecanoyl-AcpP, the FabA preferred substrate, the FabA active site 
histidine maintained contact with the substrate α-carbon throughout the simulation, whereas the 
FabZ catalytic histidine often disengaged (d > 6.0 Å) the substrate (Figure 6.14B). 
Further analysis of the substrate binding pockets was performed by evaluating the shape of 
the pockets sampled over the course of the MD simulations (Figures 6.15, 6.16). The 10 carbon 
substrates of decanoyl-AcpP, trans-2-decenoyl-AcpP, and cis-3-decenoyl-AcpP were all 
accommodated within the FabA binding pocket with minimal reorganization of the pocket and 
were of ideal length to occupy its entirety. When hexanoyl-AcpP was bound, the pocket was 
similar in size and shape to that sampled during simulations of the decanoyl-AcpP•FabA 
complexes; but the shorter 6 carbon alkyl chain, left a void in the binding cavity that may be 
responsible for its lower activity with FabA. In contrast, the 14 carbon substrates of tetradecanoyl-
AcpP and cis-7-tetradecanoyl-AcpP were too large for the FabA active site and not only forced the 
cavity to expand, but also increased the space between AcpP and FabA (Figure 6.15B, upper  
regions of the isosurfaces of tetradecanoy-AcpP•FabA and cis-7-tetradecanoyl AcpP•FabA), 
presumably reducing their affinity for one another. Analysis of simulation data for acyl-
AcpP•FabZ complexes demonstrated that the substrate binding pocket of FabZ was generally 
larger in volume and more dynamic than the FabA pocket (Figure 6.16). The relationship between 
simulated pocket volumes and substrate specificities is less obvious for FabZ than for FabA, as the 
preferred short6 carbon chain length substrate and intermediate 10 carbon chain length species 
(Figure 6.16B) occupied similar pockets during simulations. Interestingly, the simulations  
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Analysis of the FabA binding pocket size and shape for acyl substrates of varying length. Cavity volumes of the acyl-AcpP•FabA 
complexes were sampled computationally using POVME 33. A. Structure of the AcpP=FabA dimer5. B. Isosurfaces of the acyl-
AcpP•FabA complexes sampled via MD simulation. The views correspond to the blue acyl-AcpP in the lower image in A. The 
binding pocket is within the displayed volume in at least 10 percent of the simulation steps. The phosphantethiene prosthetic 
group and acyl substrate are shown as sticks (P atom as orange sphere). The computed cavities include unoccupied space (upper 
regions of isosurfaces) between AcpP and FabA. Data generated by Ashay Patel 
Figure 6.15 Analysis of binding pocket volume over the course of MD simulations with 
selected substrates for FabA. 
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Analysis of the FabZ binding pocket size and shape for acyl substrates of varying length. Cavity volumes of the acyl-
AcpP•FabZ complexes were sampled as in Figure 8. A. Structure of the AcpP=FabZ dimer. B. Isosurfaces of the acyl-
AcpP•FabZ complexes sampled via MD simulation. The views correspond to the blue acyl-AcpP in the lower image in 
A. The binding pocket is within the displayed volume in at least 37.5% of the simulation steps. The phosphantethiene 
and acyl substrate are as in Figure 8. Note that the computed cavities includes unoccupied space (upper regions of 
isosurfaces) between AcpP and FabZ. 
Figure 6.16 Analysis of binding pocket volume over the course of MD simulations with 
selected substrates for FabZ. 
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recapitulated the proposed FabZ reorganization of the substrate pocket when bound to longer-chain 
substrates (i.e, 14 carbon- acyl groups, Figure 6.16B).  
In conclusion, we present a 2.5-Å crystal structure of the E. coli AcpP=FabZ complex, the 
first structure of the E. coli FabZ, with six AcpPs in functional association with the FabZ hexamer. 
The E. coli AcpP=FabZ crystal structure used the power of small molecule inhibitor-based 
mechanistic crosslinking probes to trap the native interaction, clearly demonstrating that all six 
FabZ monomers can functionally and simultaneously interact with AcpP. The structure reveals a 
broad FabZ substrate pocket in contrast to the narrow and straight pocket of FabA. The α3-β3 loop 
of FabZ that lines the distal end of the substrate pocket is well-ordered, forming a hydrophobic 
cleft that may allow the dehydration of long-chain acyl substrates, especially those with cis-
unsaturation. By application of GaMD simulations to both the AcpP=FabZ and AcpP=FabA 
crosslinked structures, we corroborated these conclusions and recapitulated the known substrate 
preferences of both enzymes. GaMD further revealed how both enzyme pockets stabilize substrate 
rotamers to allow dehydration via an E1cb mechanism. Subsequently, simulations showed that 
only FabA stabilized the (–) gauche conformer of trans-2-decenoyl-AcpP for allylic 
rearrangement, in which the pro-R 𝛾 hydrogen is suitably positioned for abstraction to form cis-3-
decenoyl-AcpP. These structural findings shed light on the divergent substrate preferences of E. 
coli FabA and FabZ and provide clarity for how the structure of each enzyme dictates mechanistic 
specificity.  
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Chapter 7. Conclusions and future directions 
 
Substrate stereospecificity and product stereoselectivity of DHs 
Pikromycin DH2-KR2 
Studies on the DH2-KR2 di-domain from the pikromycin biosynthetic pathway represent 
the first steady-state kinetic analysis of a PKS DH domain1. The results of these studies 
identified unexpected extreme stereospecificity at the β, γ, and δ positions on a library of 
thioether chiral substrate mimics. Assay results agreed with the empirical observation that DHs 
in modules containing B-type KRs produce trans olefins. pH profiling of catalytic efficiency 
identified a critical general base with a pKa of 7.0, presumably His3611.  
The unexpected specificity of Pik DH2 hints at a role for DHs as stereochemical filters 
within PKS modules, a result that has since been echoed in the literature2-5. While intriguing 
from a functional standpoint, this unexpected stereospecificity adds a new layer of complication 
to PKS engineering efforts, as neither the amino acid sequence nor a homology model of Pik 
DH2 reveal any distinguishing characteristics. Site-directed mutagenesis guided by a homology 
model highlighted the importance of a hydrophobic patch comprising two Phe residues, one of 
which is usually a Tyr in a YGP motif in most DHs6. The feasibility of alkyne crosslinking 
probes as covalent substrate mimics for PKS DHs was tested using a 3-decynoyl-N-
acetylcysteamine. The probe inactivated PikDH2, implying that the crosslinking probes used to 
study substrate-protein interactions of FAS DHs7-8 may also be viable for PKS DHs. 
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Tylosin DH3-KR3 
 Studies on the DH3-KR3 di-domain from the tylosin biosynthetic pathway aimed to 
understand the stereochemical course of the reaction catalyzed by KR3 and the stereospecificity 
of DH3 using thioester and thioether substrate mimics4. These studies were the first in which a 
diffusible substrate probe bearing the native acyl moiety was used to characterize a PKS di-
domain. LC-MS/MS analysis showed strict stereospecificity of TylDH3 for the β-position, as 
well as at distal stereocenters. TylDH3 was also sensitive to the length of the substrate, 
exhibiting no dehydration activity on a truncated substrate mimic. These results agree with the 
PikDH2 studies mentioned above, and further reinforce the role of PKS DH as stereochemical 
filters within modules.  
A puzzling result from these experiments was the unexpectedly high rate of dehydration 
of diffusible substrates bearing a β-keto group. LC-MS/MS assay of overnight reactions showed 
KR3 was active, and produced a (R)-configured product consistent with its classification as a B-
type KR9. However, the ratio of β-hydroxy intermediate to α,β-unsaturated product was 1:22 for 
a thioester mimic and 1:102 for a thioether mimic. This unexpected distribution implies that KR3 
is capable of shuttling its product to DH3, even in the absence of an ACP. Two mechanisms 
were proposed to understand this phenomenon, one in which the KR active site exit and the DH 
entrance are proximal, and another in which a conformation change during catalysis brings the 
two active sites together – a similar KR conformational change has been observed in cryoEM 
studies of the full PikAIII module10. It is difficult to fully interpret this finding in the absence of 
any corresponding structural information. 
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Curacin DHs 
The curacin biosynthetic pathway is an example of a PKS pathway containing both cis 
and trans “orphan” double bonds11-14. Two sets of diffusible triketide substrate mimics were used 
to characterize each of the DH domains from this pathway to investigate this phenomenon5. 
CurK, CurF and CurJ DHs exhibited activity on a β-hydroxy diene triketide mimic of the native 
CurK substrate. CurF DH retained only 55% activity of CurK DH on the CurK substrate mimic, 
while CurJ maintained only 7% CurF DHs. Each of DHs were stereospecific for the D-alcohol, 
the expected product of a B-type KR.  
Curiously, only CurF DH and CurK DH were active upon a triketide substrate designed to mimic 
the CurJ native substrate, containing both an α-methyl and a β-hydroxy group. The 
stereochemistry of this substrate is consistent with β-reduction by a B-type KR and has the 
necessary configuration for syn elimination of the α-proton and the β-hydroxy group by a DH. 
The CurK DH does not encounter an α-methyl on its native substrate, yet was still specific for 
the (2S,3R) CurJ substrate, implying that this DH is indeed specialized for syn elimination of a 
B-type KR product. The inability for CurJ DH to dehydrate any of the β-hydroxy substrate 
mimics was unexpected, but led to the discovery of a non-canonical DH reaction discussed 
below. 
Gephyronic acid DH1 
The stereospecificity and regioselectivity of GphF DH1 was investigated using a library of 
diffusible substrate mimics that sampled all the possible enantiomers of the DHs native substrate 
and products15. As with the pikromycin, curacin, and tylosin DHs, GphF DH1 catalyzed syn 
elimination, but exhibited a degree of flexibility compared to most PKS DHs in that it 
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dehydrated either the (2S,3S) or (2R,3R) enantiomers of the native substrate. There was a slight 
(~10%) preference for the (2R,3R) which contained the proper β-hydroxy chirality predicted to 
be set by the B-type Gphf KR1. The regioselectivity of GphF DH1 was assayed using a set of (E) 
and (Z) configured α,β-unsaturated substrate mimics. Again, GphF DH1 showed a degree of 
flexibility in terms of substrate scope, as both the (E) and (Z) configured versions of its native 
product were rehydrated, with a 3:1 preference for the (E) regioisomer. The substrate scope of 
GphF DH1 was interrogated using a set of substrate and product mimics lacking an α-methyl 
group. Wild-type GphF DH1 had 5-fold reduced activity on a β-hydroxy substrate lacking an α-
methyl group. These results showed that like the PikDH2, TylDH3, and the Cur DHs, GphF DH1 
has specificity for the stereochemical configuration and composition of its native substrate. 
Non-canonical DH reactions 
Curacin DHs 
 CurJ DHs lack of activity on its native substrate mimic and the complete lack of activity 
of CurH DH prompted an expanded analysis of these domains5. Upon re-examination of the 
biosynthetic pathway, it became apparent that CurJ DH could encounter a β,δ-dihydroxy 
substrate as CurI lacks a DH. Using a δ-hydroxy-α,β-unsaturated triketide substrate, CurJ DH 
was demonstrated to stereospecifically catalyze a vinylogous δ-elimination as well as 
regiospecifically catalyze the reverse hydration. This novel reaction required the His-Asp 
catalytic dyad, as confirmed by mutagenesis. CurH DH also follows a module lacking a DH and 
was shown to catalyze vinylogous elimination in a manner identical to CurJ DH. The unexpected 
vinylogous dehydration activity uncovered by these experiments highlights the functional 
diversity of PKS DHs. From either sequence or structure analysis, there was no obvious 
distinction between CurJ or CurH DHs and any characterized “standard” PKS DHs. 
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 In an effort to better understand this novel activity structurally, a catalytically inactive 
variant of CurJ DH was co-crystallized with a thioester substrate mimic5. While only a portion of 
the density of the substrate was resolved, an obvious hydrogen bond between catalytic Asp1156 
and a hydroxyl of the substrate was observed, providing the first visualization of the Asp – 
hydroxyl interaction between a PKS DH and its substrate.  
GphF DH1 
 While there are examples of PKS DHs that catalyze multiple reactions2-3, 16-17, the 
molecular mechanisms behind their secondary functions are only beginning to be understood. 
We investigated the putative isomerization function of GphF DH1 using LC-MS assay, structure 
and mutagenesis. Secondary isomerization function was confirmed in our initial assay of GphF 
DH1, with both the (2R,3R) and (2S,3S) substrates generating both 2,3- (α,β-) and 3,4-(β,γ-) 
olefin products. While only minor amounts of the 3,4-olefin were observed from the 2-methyl-3-
hydroxy substrates, significant quantities were observed when GphF DH1 was assayed using the 
2,3-unsaturated intermediate directly. This result clearly demonstrated the GphF was a 
multifunctional DH/isomerase and agrees closely with results from E. coli FAS DH/isomerase 
FabA18. 
Isomerization was also assessed using the substrates lacking an α-methyl group. GphF 
DH1 exhibited reduced dehydration of these compounds compared to substrates bearing an α-
methyl group. Interestingly, GphF DH1 generated significantly higher quantities of isomerized 
β,γ-unsaturated final product from substrates without an α-methyl compared to those with an α-
methyl. This molecular basis for this result remains puzzling in the absence of a structure of an 
enzyme – substrate complex, but may imply that the α-methyl moiety of the native substrate 
imposes a barrier to isomerization, perhaps via a steric effect. 
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Interestingly, the chirality of the α-methyl of the preferred substrate (R), and the chirality 
of the corresponding methyl group on gephyronic acid (S) are enantiomers19. This led to the 
hypothesis that GphF DH1 harbors a cryptic third functionality as an epimerase. This was 
assessed using a 3,4-unsaturated product mimic containing the “incorrect” (R) configured α-
methyl group. No activity was observed using the (2R)-2-methyl-3,4-olefin, but significant 
isomerization of a racemic mixture of the (2R) and (2S) form of the 2-methyl-3,4-olefin was 
observed. This result showed that the (2S)-2-methyl-3,4-olefin was the final product of catalysis 
by GphF DH1, and that the enzyme had epimerized the α-methyl group in addition to the 
previously characterized dehydration and isomerization activity. 
Finally, structure-guided mutagenesis identified the catalytic machinery required for 
GphF DH1 function. A His1738-Asp1898 dyad was required for both dehydration and 
isomerization, in agreement with the experiments on the Cur, Tyl, and Pik DHs. Isomerization 
function was pinpointed to two positions adjacent to the catalytic dyad:  Leu1744 that is 
differentially conserved compared to most non-isomerizing DHs, where it is generally a Pro, and 
Tyr1856 that is repositioned in GphF DH1 to form a hydrogen bond with the catalytic Asp. 
Characterization of a Leu1744→Pro variant of GphF DH1 showed a drastic increase in 
dehydration efficiency at the cost of isomerization, while of a Tyr1856→Phe variant displayed 
no isomerization capacity, with wild-type levels of dehydration. These results facilitated a gain-
of-function experiment in which isomerization activity was engineered into the CurK DH via a 
Pro1005→Val substitution. This represented the first successful rational engineering of a PKS 
DH. 
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E.coli FabZ – AcpP complex 
 Here, the first structure of the E. coli FAS DH FabZ was determined, in a 1:1 crosslinked 
complex with its carrier protein AcpP. The complex was characterized biophysically by SEC-
MALS, which revealed that both apo-AcpP and holo-AcpP formed a 1:1 complex with FabZ, in 
agreement with crosslinking studies. Both the protein interaction surface between FabZ and 
AcpP and the position of the acyl moiety of the 6-carbon substrate mimic were visualized ina  
2.5Å crystal structure. The AcpP=FabZ and AcpP=FabA8 structures were used as starting 
models for GaMD simulations. These simulations revealed differences in preferred substrate 
chain length between FabA and FabZ and demonstrated that these FAS DHs differentially bias 
the conformations of substrate acyl chains. FabZ positioned substrates such that only dehydration 
could occur, while FabA biased the substrate towards conformations favorable for both 
dehydration and isomerization. 
Future directions 
PKS DH substrates and assay 
Clearly, N-acetylcysteamine truncated substrate mimics have proven to be useful tools for 
studying PKS DHs. As the NAC moiety fails to fully mimic the Ppant arm that would be present 
in a native DH – ACP complex within a module, it is possible that the results demonstrated here 
may be expanded by using Ppant tethered substrates. While the DHs reported in this work all 
displayed activity on NAC-linked substrates, there are reports in the literature of those that do 
not accept such compounds6. However, neither NAC-linked nor Ppant-linked substrates will 
recapitulate the protein-protein interactions between a productive DH – ACP complex, an area 
that is critically underexplored in PKS DHs. There are also reports of DHs that exhibit different 
stereospecificity on NAC-linked substrates than ACP-linked substrates20. When assayed using 
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NAC-linked, Ppant-linked, and AcpP-linked substrate mimics bearing identical acyl chains, 
FabA displayed significantly different activities for each class of substrate18. Future experiments 
must be designed with both DH – Ppant and DH – ACP interactions in mind. ACP – DH 
interaction studies would be particularly valuable in the case of GphF DH1, where both the 
(2S,3S) and (2R,3R) substrates are tolerated. For the α-proton and β-hydroxy group of these 
enantiomers to be properly positioned for elimination, they must bind in the same binding pocket 
rotated 180° relative to one another. One could imagine GphF ACP1 may bias substrate delivery 
such that only the native (2R,3R) substrate can bind correctly. 
DH substrate interactions 
 To date, there are no structures of a PKS DH in complex with a native substrate. The data 
reported here from the co-crystallization experiments with CurJ DH represent the first snapshot 
of a PKS DH interacting with a hydroxy-bearing truncated substrate fragment. A recently 
reported study of a DH from the phthiocerol dimycocerosate biosynthetic pathway (PpsC DH) 
utilized a catalytically inactive variant to trap PpsC DH in complex with both a C4:1 and C12:1 
acyl-CoA unsaturated product mimic21. While the PpsC DH structure revealed the first snapshot 
of a long chain product mimic in complex with a PKS DH, the compounds used for co-
crystallization contain relatively simple acyl chains compared to a typical PKS DH substrate. 
Thus, the structural basis for the extreme stereospecificity of the Pik, Tyl, Cur and Gph DHs 
remains unclear. As synthesis of PKS DH NAC- and Ppant-linked substrate mimics continues to 
improve, it may be worthwhile to screen libraries of compounds against DHs and catalytically 
inactive variants of DHs that behave well in crystallization. In the absence of a true enzyme – 
substrate complex structure, MD simulations may represent a viable alternative to generating 
meaningful data to further understand the structural determinants of PKS DH stereoselectivity. 
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DH ACP interactions 
 The E. coli FabZ studies here exemplify the use of chemical biology tools to study DH -
ACP interactions. As demonstrated with PikDH2, alkyne-based mechanistic inhibitors are active 
against PKS DHs1. As such, a scheme similar to that which generated the AcpP=FabZ and 
AcpP=FabA complex may facilitate the generation of ACP=DH complexes from PKS. There are 
obvious hurdles to this approach, most notably the differences between Type-I and Type-II 
biosynthetic schemes. As Type-II systems comprise a set of discrete enzymes, the catalytic 
machinery must harbor an affinity for the carrier protein. This is not the case in type-I systems, 
where the ACP is found in cis with the catalytic domains. To date, there are no reports on the 
affinity for excised type-I DHs and their cognate ACPs. In both the AcpP=FabA and AcpP=FabZ 
structures, a large portion of the protein interaction surface on AcpP comprises acidic residues. 
While these residues are conserved amongst type-II FAS ACPs, type-I PKS DHs are less 
acidic22, and thus may utilize different surfaces for protein interaction.  Due to the DH specificity 
reported here, efforts to develop crosslinking probes that better mimic the acyl groups of native 
substrates may be worthwhile to take advantage of any affinity for native acyl chains presented 
on an ACP. Additionally, crosslinking may be improved by targeting DHs with long-chain 
substrates, taking advantage of any hydrophobic stabilization afforded by the DH substrate 
binding pocket21, 23.  
Multi-domain and full module studies 
 While a number of structures of excised PKS DHs have been reported6, 12, 16, 20, there is 
only one reported multi-domain structure containing a DH from type-I PKS24. There are no 
structures of intact modules containing DHs. As the cost of synthetic DNA continues to decrease, 
crystallographic screening of libraries of PKS multi-domains will become more viable. Should 
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crosslinking methods be developed for trapping PKS DH – ACP complexes, these may be useful 
for generating stable complexes between excised PKS multi-domains containing DHs and their 
ACPs. With the rise of single particle cryo-electron microscopy (CryoEM), it has become easier 
to structurally characterize large, dynamic proteins, such as PKS and NRPS modules25-26. 
cryoEM studies of PKS modules containing DH domains could yield critical information in 
regard to protein-protein interactions between DHs and other domains within the module, as well 
as interactions between DHs and ACPs. 
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